Flavivirus inhibitors

Abstract

The invention relates to compounds that are inhibitors of Flavivirus NS2B-NS3 proteases and inhibit replication of flavivirus in cells. Compounds of this invention are useful alone or in combination with other agents for use in the treatment of infections caused by Flaviviruses, in particular by Dengue, West Nile, Zika, Japan Encephalitis viruses.

Description

[0001] FLAVIVIRUS INHIBITORS SUMMARY OF THE INVENTION The present invention relates to compounds that are inhibitors of Flavivirus NS2B-NS3 proteases and inhibit replication of flavivirus in cells. Compounds of this invention are useful alone or in combination with other agents for use in the treatment of infections caused by Flaviviruses, in particular by Dengue, West Nile, Zika, Japan Encephalitis viruses. The present invention also relates to pharmaceutical compositions containing said compounds. BACKGROUND The Flavivirus genus of the Flaviviridae family includes more than 70 related arthropod borne viruses. The most common and representative members are the dengue virus (DENV) with four serotypes (DENV-1, -2, -3, and -4), Zika (ZIKV), West Nile (WNV), Japanese-encephalitis (JEV), Yellow Fever (YFV), and tick-borne encephalitis (TBEV) viruses. These are the causative agents for viral haemorrhagic fever and encephalitis in human beings. These viruses are transmitted primarily by Aedes mosquitos. Infections with flaviviruses are a continuing public health threat The mosquito-borne dengue virus serotypes 1-4 (DENV1-4) are included in the National Institute of Allergy and Infectious Disease (NIAID) list of Category A, B, or C emerging human pathogens along with yellow fever virus (YFV), West Nile virus (WNV), and Japanese encephalitis virus (JEV). DENVs cause serious illnesses associated with considerable morbidity and mortality. According to World Health Organization estimates, globally over 50 million people suffer from the symptoms of dengue fever annually, and of these at least 250,000 cases develop into dengue hemorrhagic fever (DHF) or dengue shock syndrome (DSS) resulting in considerable mortality, particularly among children in South Asian Countries. The World Health Organization estimates that 2.5 billion people (~40% of the world’s population) live in areas that have an increased risk of contracting dengue virus infections. Frequent outbreaks occur in the Americas including the continental U.S., mainly in the Southern states as well as in Puerto Rico and Hawaii. Zika virus (ZIKV) has caused three major outbreaks in Pacific Ocean islands, Brazil, and other American countries, in which more than 1 million infections were reported and a large number of patients sought medical treatment. More seriously, Zika infection has been correlated with a 20- fold increased incidence of serious neurological disorders, including Guillain-Barre syndrome and more than 4,000 cases of microcephaly in newborns. Zika has quickly spread to 48 Pan-American countries and has recently been found to be transmitted through sex or body fluids. Inhibitors of two major steps of flaviviral entry have been reported: (i) molecules that block virus– receptor interaction; (ii) compounds that prevent conformational change of viral envelope protein during virus–host membrane fusion (ACS Infect. Dis.2015, 1, 9, 428–434). As such, a need exists for more effective compositions and methods for treating viral infections caused by flaviviruses. In addition to vaccine development and vector control, the search for antiviral agents that alleviate symptoms in patients are of considerable interest. WO2019 / 070709 provides compounds, compositions and methods related to the treatment and / or prevention of a flavivirus infection, such as a Zika virus infection, Dengue virus infection, West Nile virus infection, Yellow fever virus infection, Japanese encephalitis virus infection or St. Louis encephalitis virus infection. Flaviviruses share epidemiological, structural, and ecologic features and often different viruses can co-infect the same host. Therefore, the identification of broad- spectrum inhibitors is highly desirable either for known flaviviruses or for viruses that likely will emerge in the future. Strategies targeting both virus and host factors have been pursued to identify broad-spectrum antiflaviviral agents The Flavivirus genome consists of a positive-sense single-stranded RNA which is ~11 kb in length, consisting of a single long open reading frame (ORF). The single ORF encodes a polyprotein that is further processed by proteases from the host and the viral NS2B-NS3 complex. The flavivirus protease is highly conserved and essential for virus replication. The viral polyprotein is processed to three structural proteins (Capsid, pr-Membrane, and Envelope) and seven non-structural (NS) proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5). Three structural proteins form the virus shell, whereas seven NS proteins participate in the membrane- bound replication complex. Among these NS proteins, only NS3 and NS5 bear enzymatic function. (Pathogens 2022, 11293). Flaviviral replication depends on the NS3 protease, which is a 69 kDa protein with two domains that have different enzymatic functions: a trypsin-like serine protease domain located within the N-terminal region; while the C-terminal region has the activities of an RNA-helicase and an RNA-stimulated NTPase. Moreover, it is only entirely activated when associated with its cofactor, namely NS2B; forming an enzymatic complex, NS2B- NS3. Considering this, NS2B-NS3 proteases represent a valuable target for the development of new antiviral compounds, which act inhibiting their replication complex and leading to the flaviviral death. Flaviviral proteases share a high degree of structural similarity and substrate-recognition profile, which may facilitate a strategy towards development of pan-flaviviral protease inhibitors. However, the success of various drug discovery attempts during the last decade has been limited by the nature of the viral enzyme as well as a lack of robust structural templates. Small-molecular, structurally diverse protease inhibitors have been reported to reach affinities in the lower micromolar range. Peptide-based, substrate-derived compounds are often nanomolar inhibitors, however, with highly compromised drug-likeness. With some exceptions, the antiviral cellular activity of most of the reported compounds has been patchy and insufficient for further development. Recent progress has been made in the elucidation of inhibitor binding using different structural methods. This will hopefully lead to more rational attempts for the identification of various lead compounds that may be successful in cellular assays, animal models and ultimately translated to patients. W02021 / 175437 and W02021 / 175670 provide non-peptidic (4-phenoxy)-phenylglycine and (4- benzyloxy)-phenylglycine derivatives as inhibitors of the NS2B-NS3 serine protease for use in the treatment and prevention of flaviviruses infection. The present invention yields a novel series of drug-like, broadly active inhibitors of flavivirus proteases. SUMMARY OF THE INVENTION The present invention provides a series of compounds targeting the NS2B-NS3 protease. The compounds of the invention are sydnone imine derivatives thus having a mesoionic heterocyclic core properly substituted with a nitrogen derivative substituent at the imino nitrogen and with an alkyl-aromatic or heteroaromatic substituent. The chemotype discovered in the present invention results in extremely potent ZIKV NS2B-NS3 protease inhibitors, active also on the JEV, Dengue and WNV proteases. The compounds of the invention are capable of inhibiting replication of the above viruses in cells. It is therefore an object of the invention a compound of general Formula (I): wherein: n is 0, 1 or 2; R1and R2are independently selected from H and C1-6alkyl optionally substituted with one or more substituents selected from: hydroxy, OC1-3alkyl, halogen, NH2, NHCOC1-6alkyl, NHCOOC1- 6alkyl, NHC(=O)NHC1-6alkyl, NHSO2C1-6alkyl, NHC1-3alkyl, N(C1-3alkyl)2, or a cyclic amine selected from aziridine, azetidine, pyrrolidine, pyperidine, morpholine, piperazine, N- methylpyperazine; or R1and R2are linked together to form a C3-10-cycloalkyl ring or a C4-12-heterocycloalkyl ring; R3 is selected from: - saturated or unsaturated C3-10cycloalkyl ring, saturated or unsaturated C3- 10cycloheteroalkyl ring, each of said ring being optionally substituted with one or more substituents independently selected from halogen, hydroxy, NH2, NHC1-3alkyl, N(C1- 3alkyl)2, NHC1-3haloalkyl, N(C1-3alkyl)(C1-3haloalkyl), C1-6alkylNH2, C1-6alkylNHC1- 3alkyl, C1-6alkylN(C1-3alkyl)2, C1-6alkylNHC1-3haloalkyl, C1-6alkylC(O)OC1-3alkyl, NHCOC1-6alkyl, NHCOOC1-6alkyl, NHC(=O)NHC1-6alkyl, NHSO2C1-6alkyl, C1-6alkyl, C1-6haloalkyl, C1-6alkylOH, C(O)OH, C(O)OC1-3alkyl, C(O)NH2, C(O)NH(C1-3alkyl), C(O)N(C1-3alkyl)2, optionally substituted aziridine, optionally substituted azetidine, optionally substituted pyrrolidine, optionally substituted pyperidine, optionally substituted morpholine, optionally substituted piperazine, optionally substituted N-methylpyperazine, optionally substituted aryl, optionally substituted heteroaryl wherein each of said optional substituent is selected from halogen, methyl and trifluoromethyl; or - aromatic or heteroaromatic ring optionally substituted with one or more substituents independently selected from halogen, hydroxy, NH2, NHCOC1-6alkyl, NHCOOC1-6alkyl, NHC(=O)NHC1-6alkyl, NHSO2C1-6alkyl, NHC1-3alkyl, N(C1-3alkyl)2, C1-6alkyl, C1-6alkylC(O)OH, C1-6alkylC(O)OC1-3alkyl, hydroxyC1-6alkyl C3-6cycloalkyl, haloC1-6alkyl, C1-6alkoxy, cyano, aryl, heteroaryl wherein said aryl or heteroaryl ring are optionally substituted with one or more substituents each independently selected from halogen, hydroxy, cyano, NH2, NHCOC1-6alkyl, NHCOOC1-6alkyl, NHC1-3alkyl, N(C1-3alkyl)2, C3-6cycloalkyl, aziridine, azetidine, pyrrolidine, pyperidine, morpholine, piperazine, N- methylpyperazine, C1-6alkyl, C1-6alkoxy, wherein said C1-6alkyl, C1-6alkoxy are optionally substituted with one or more halogen, hydroxy, NH2, NHCOCH3, NHCOOC1-6alkyl, NHC1-3alkyl, N(C1-3alkyl)2, aziridine, azetidine, pyrrolidine, pyperidine, morpholine, piperazine and N-methylpyperazine; R4is selected from: a) a ring of formula (IIa) or (IIb): wherein - R6 is selected from NHC(O)R8, N(C1-6alkyl)C(O)R8, NHSO2R8, NH(C1-6alkyl), NH(C1- 6haloalkyl), hydroxy-C1-6alkyl, CN, C(O)OC1-6alkyl, C(O)NHR8, C2-6alkynyl, C1- 6alkylNHC(O)R8, C1-6alkylN(C1-6alkyl)C(O)R8, and - R6is H and R7is selected from NHC(O)R8, N(C1-6alkyl)C(O)R8, NHSO2R8, NH(C1-6alkyl), NH(C1-6haloalkyl), hydroxy-C1-6alkyl, CN, C(O)OC1-6alkyl, C(O)NHR8C2-6alkynyl, C1-6alkylNHC(O)R8, C1-6alkylN(C1-6alkyl)C(O)R8, and - R6 and R7 are H, with the proviso that when R6 and R7 are H, R3 is selected from saturated or unsaturated C3-10cycloalkyl ring, saturated or unsaturated C3-10heterocycloalkyl ring, each of said ring being optionally substituted with halogen, C1-6alkyl, haloC1-6alkyl, halogen, CN, OH, C1-6alkoxy, amine, optionally substituted aryl, optionally substituted heteroaryl; or when R6 and R7 are H, R3 is (4,6-dimethylpyrimidin-5-yl)pyridazin-3-yl; or - R6is OCH3or OH and R7is H, or R6is H and R7is OCH3or C(O)OCH3, or R6and R7are joined to form together with the ring of formula (IIa) a 8-(trifluoromethyl)quinoline-6-yl ring, with the proviso that R3 is 4-(4,6-dimethylpyrimidin-5-yl)phenyl; - R8is C1-6alkyl, C1-6haloalkyl, C1-6alkyl-aryl, C1-6alkyl-heteroaryl, C1-6alkyl-C3-10cycloalkyl, C1-6alkyl-C3-10heterocycloalkyl, C1-6haloalkyl-aryl, C1-6haloalkyl-heteroaryl, C1-6haloalkyl-C3-10cycloalkyl, C1-6haloalkyl-C3-10heterocycloalkyl, C1-6alkylSO2aryl, C1- 6alkylSO2heterocycloalkyl, C2-6alkynyl-aryl, aryl, heteroaryl, C3-10cycloalkyl ring, C3-10heterocycloalkyl ring, wherein each of said cycloalkyl and heterocycloalkyl ring is saturated or unsaturated and wherein each of said aryl, heteroaryl, cycloalkyl and herocycloalkyl ring is optionally substituted with one or more substituents independently selected from C1-6alkyl, C1-6alkoxy, C3-10cycloalkyl, C3-10heteroycloalkyl, amine, CN, C1-3alkyl-aryl, C1-3alkyl-heteroaryl, C1-3alkyl-C3-10cycloalkyl, C1-3alkyl-C3- 10heterocycloalkyl, C1-6alkylCOOH, C1-6alkylCOOCH3, C1-6alkylCONH2 COOH, C(O)OC1-3alkyl, NHC(O)C1-6alkyl, NHC(O)C3-6cycloalkyl, C1-6haloalkyl, halogen, C1- 6alkylamine, OH, optionally substituted C1-3alkylaryl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heteroaryloxy, optionally substituted aryloxy optionally substituted heteroaryl-alkoxy, heterocycloalkoxy, C1- 6alkyl-SO2NH2, C1-6alkyl-OC1-3alkylheteroaryl wherein said heteroaryl is optionally substituted with CH3, halogen or OH; - R9 is C1-6alkyl, halogen, C3-6cycloalkyl or C3-6heterocycloalkyl each of said cycloalkyl or heterocycloalkyl being optionally substituted with C1-3alkyl, haloC1-3alkyl, halogen; b) saturated or unsaturated C3-10cycloalkyl ring, saturated or unsaturated C3-10cycloheteroalkyl ring, each of said ring being optionally substituted with one or more substituents each independently selected from C1-6alkyl, haloC1-6alkyl, halogen, CN, OH, C1-6alkoxy, NHC(O)R8, N(C1-6alkyl)C(O)R8, NHSO2R8, NH(C1-6alkyl), NH(C1-6haloalkyl), hydroxy-C1-6alkyl, C(O)OC1-6alkyl, C(O)NHR8, C2-6alkynyl, C1-6alkylNHC(O)R8, C1-6alkylN(C1-6alkyl)C(O)R8, and; c) a ring of formula (III): wherein R10 is CF3, OCH3, t-butyl; and wherein when R4 is a ring of formula (III), R3 is selected from: - C3-10cycloalkyl ring, C3-10cycloalkenyl ring, C3-10cycloheteroalkyl ring, each of said ring being optionally substituted with halogen, C1-6alkyl, haloC1-6alkyl, halogen, CN, OH, C1- 6alkoxy, amine, optionally substituted aryl, optionally substituted heteroaryl; or - (1-methyl-1,2,3,4-tetrahydroquinolin-2-yl), 2-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl, (3-methylpyridazin-4-yl)phenyl, 4-(4-(trifluoromethyl)pyrimidin-5-yl)phenyl, 4-(4- methoxy-6-methylpyrimidin-5-yl)phenyl, 4-(1,4-dimethyl-1H-pyrazol-5-yl)phenyl, (2- methylthiazol-4-yl)phenyl, (3,5-dimethylisothiazol-4-yl)phenyl, (4-methylpyrimidin-5- yl)phenyl, (1,3-dimethyl-1H-pyrazol-4-yl)phenyl, 4-(4-methyl-1-(oxetan-3-yl)-1H- pyrazol-5yl)phenyl, 4-(4-methyl-1-(oxetan-3-yl)-1H-pyrazol-3-yl)phenyl, 4-(2- methylpyridin-3-yl)phenyl, 4-(2,5-dimethylthiazol-4-yl)phenyl, 4-(2-amino-4- methylpyrimidin-5-yl)phenyl, 4-(2,4-dimethylpyridin-3-yl)phenyl, 4-(pyrimidin-5- yl)phenyl, 4-(1,3,5-trimethyl-1H-pyrazol-4-yl)phenyl,4-(4,6-dimethylpyrimidin-5- yl)phenyl, 4-(4-Methyl-2-(oxetan-3-yl)pyrazol-3-yl]phenyl); and R5 is H, C1-6alkyl, C1-6haloalkyl or halogen; or a pharmaceutically acceptable salt, tautomer, solvate, or stereoisomer thereof. In a preferred embodiment, in the compound of formula (I) - n is 0 or 1; - R1 and R2 are H; and / or - R5is H; and / or - R9is cyclopropyl, methyl-cyclopropyl, trifluoromethyl-cyclopropyl, fluorocyclopropyl, difluorocyclopropyl, oxetane. Still preferably R3 is phenyl, pyridinyl, pyrazinyl, trifluoromethylphenyl, cyclobutyl, cyclohexyl, pyperidine, oxabicyclo[3.3.1]nonanyl, oxazepanyl, bicyclo[1.1.1]pentanyl, tetrahydroquinolinyl, bicyclo[2.2.1]heptanyl, tetrahydronaphtalenyl, azabicyclo[3.2.1]octane, 2-azaspiro[3.5]nonane, 3-azaspiro[5.5]undecane, 2-azaspiro[4.5]decane and 1,4-dioxaspiro[4.5]decane wherein each of said ring is optionally substituted with one or more substituents independently selected from optionally substituted heteroaryl, optionally substituted aryl, C1-3alkyl, halogen, hydroxy, isoindoline, NH2, NHCH3, N(CH3)2, N(C1-3alkyl)(haloC1-3alkyl), C1-3alkyl-NH2, C1-3alkyl- N(CH3)2, (1,3-dioxoisoindolin-2-yl)methyl, C1-3alkyl-NHCH3, C1-3alkyl-N(CH3)2, C1-3alkyl- NHC(O)CH3, COOH, C(O)NH2, C(O)NH(C1-3alkyl), C(O)N(C1-3alkyl)2, cycloamino-C(O) C1-3alkyl-C(O)O(C1-3alkyl), C1-3alkyl-OH, C(O)OC1-3alkyl, NHCH2CF3, CH2NHCH2CF3, C1-3alkyl- OH, haloC1-3alkyl, NH(CO)CF3. Still preferably, it is an object of the invention a compound of formula (I) wherein R4is a ring of formula (IIa) or (IIb): wherein - R6 is selected from NHC(O)R8, N(C1-3alkyl)C(O)R8, NHSO2R8, NH(C1-3alkyl), NH(C1- 3haloalkyl), hydroxy-C1-3alkyl, CN, C(O)OC1-3alkyl, C(O)NHR8, C2-6alkynyl, C1-3alkylNHC(O)R8, C1-3alkylN(C1-3alkyl)C(O)R8, and - R6 is H and R7 is selected from NHC(O)R8, N(C1-3alkyl)C(O)R8, NHSO2R8, NH(C1- 3alkyl), NH(C1-3haloalkyl), hydroxy-C1-3alkyl, CN, C(O)OC1-3alkyl, C(O)NHR8 C2- 6alkynyl, C1-3alkylNHC(O)R8, C1-3alkylN(C1-3alkyl)C(O)R8, and - R6and R7are H, with the proviso that when R6and R7are H, R3is selected from saturated or unsaturated C3-10cycloalkyl ring, saturated or unsaturated C3-10heterocycloalkyl ring, each of said ring being optionally substituted with halogen, C1-6alkyl, haloC1-6alkyl, halogen, CN, OH, C1-6alkoxy, amine, optionally substituted aryl, optionally substituted heteroaryl; or when R6and R7are H, R3is (4,6-dimethylpyrimidin-5-yl)pyridazin-3-yl; or - R6 is OCH3 or OH and R7 is H, or R6 is H and R7 is OCH3 or C(O)OCH3, or R6 and R7 are joined to form together with the ring of formula (IIa) a 8-(trifluoromethyl)quinoline-6-yl ring, with the proviso that R3is 4-(4,6-dimethylpyrimidin-5-yl)phenyl; R8 is C1-6alkyl, C1-6haloalkyl, C1-6alkyl-aryl, C1-3alkyl-heteroaryl, C1-3alkyl-C3-6cycloalkyl, C1- 3alkyl-C3-8heterocycloalkyl, C1-3haloalkyl-aryl, C1-3haloalkyl-heteroaryl, C1-3haloalkyl-C3-6cycloalkyl, C1-3haloalkyl-C3-8heterocycloalkyl, C1-3alkylSO2aryl, C1-3alkylSO2heterocycloalkyl, C2-6alkynyl-aryl, aryl, heteroaryl, C3-6cycloalkyl ring, C3-10heterocycloalkyl ring, wherein each of said cycloalkyl and heterocycloalkyl ring is saturated or unsaturated and wherein each of said aryl, heteroaryl, cycloalkyl and herocycloalkyl ring is optionally substituted with one or more substituents independently selected from C1-3alkyl, C1-3alkoxy, C3-6cycloalkyl, C3-8heteroycloalkyl, amine, CN, C1-3alkyl-aryl, C1-3alkyl-heteroaryl, C1-3alkyl-C3-6cycloalkyl, C1-3alkyl-C3-8heterocycloalkyl, C1-3alkylCOOH, C1-3alkylCOOCH3, C1-3alkylCONH2COOH, C(O)OC1-3alkyl, NHC(O)C1-3alkyl, NHC(O)C3-6cycloalkyl, C1-3haloalkyl, halogen, C1-3alkylamine, OH, optionally substituted C1-3alkylaryl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heteroaryloxy, optionally substituted aryloxy optionally substituted heteroaryl-alkoxy, heterocycloalkoxy, C1-3alkyl-SO2NH2, C1-3alkyl-OC1-3alkylheteroaryl wherein said heteroaryl is optionally substituted with CH3, halogen or OH; and wherein in said compound R9 is C3-6cycloalkyl or C3-6heterocycloalkyl each of said cycloalkyl or heterocycloalkyl being optionally substituted with C1-3alkyl, haloC1-3alkyl, halogen; preferably R9is cyclopropyl, methyl-cyclopropyl, trifluoromethyl-cyclopropyl, fluorocyclopropyl, difluorocyclopropyl, oxetane. Still preferably, it is an object of the invention a compound of formula (I) wherein R4is saturated or unsaturated C3-10cycloalkyl ring, saturated or unsaturated C3-10cycloheteroalkyl ring, each of said ring being optionally substituted with one or more substituents each independently selected from C1-6alkyl, haloC1-6alkyl, halogen, CN, OH, C1-6alkoxy, NHC(O)R8, N(C1-6alkyl)C(O)R8, NHSO2R8, NH(C1-6alkyl), NH(C1-6haloalkyl), hydroxy-C1-6alkyl, C(O)OC1-6alkyl, C(O)NHR8, C2-6alkynyl, C1-6alkylNHC(O)R8, C1-6alkylN(C1-6alkyl)C(O)R8; and wherein R9 is C3-6cycloalkyl or C3-6heterocycloalkyl each of said cycloalkyl or heterocycloalkyl being optionally substituted with C1-3alkyl, haloC1-3alkyl, halogen; preferably R9is cyclopropyl, methyl-cyclopropyl, trifluoromethyl-cyclopropyl, fluorocyclopropyl, difluorocyclopropyl, oxetane. Still preferably R3 is selected from: wherein each of the phenyl or heteroaromatic ring can be optionally further substituted by one or two substituents independently selected from methyl, CF3, halogen, cyclopropyl, methoxy, cyano. Even more preferably R3 is selected from and any stereoisomer thereof. Still preferably R4is selected from: and stereoisomers thereof. In a further preferred embodiment, the compound of formula (I) has formula (Ia) or formula (Ib) or formula (Ic) or formula (Id): Preferably the compound of general formula (I) is selected from the following list: - (3-(4-(2-Methoxy-4-methylpyrimidin-5-yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)((3- (2-phenylacetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - ((3-((Cyclohexylmethyl)sulfonamido)-5-(trifluoromethyl)phenyl)carbamoyl)(3-(4-(2- methoxy-4-methylpyrimidin-5-yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - ((3-Amino-5-(trifluoromethyl)phenyl)-carbamoyl)(3-(4-(2-methoxy-4- methylpyrimidin-5-yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - (3-((5-(2-(Aminomethyl)phenyl)pyridin-2-yl)methyl)-1,2,3-oxadiazol-3-ium-5- yl)((3-(2-phenylacetamido)-5-(trifluoromethyl)phenyl-)carbamoyl)amide - (3-((5-(1-Methyl-1H-imidazol-5-yl)pyridin-2-yl)methyl)-1,2,3-oxadiazol-3-ium-5- yl)((3-(2-phenylacetamido)-5-(trifluoromethyl)-phenyl)carbamoyl)amide - ((3-(2-Phenylacetamido)-5-(trifluoromethyl)-phenyl)carbamoyl)(3-(pyridin-2- ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - ((3-(2-Cyclohexylacetamido)-5-(trifluoro-methyl)phenyl)carbamoyl)(3-(4-(2- methoxy-4-methylpyrimidin-5-yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - (3-(4-(2-Methoxy-4-methylpyrimidin-5-yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)((3- (3-phenylpropanamido)-5-(trifluoro-methyl)phenyl)carbamoyl)amide - (3-(4-(2-Methoxy-4-methylpyrimidin-5-yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)((3- ((phenylmethyl)sulfonamido)-5-(trifluoro-methyl)phenyl)carbamoyl)amide - ((3-Acetamido-5-(trifluoromethyl)phenyl)-carbamoyl)(3-(4-(2-methoxy-4- methylpyrimidin-5-yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - (3-((5-Bromopyridin-2-yl)methyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- phenylacetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - (3-((5-(2-Methoxy-4-methylpyrimidin-5-yl)-pyridin-2-yl)methyl)-1,2,3-oxadiazol-3- ium-5-yl)((3-(2-phenylacetamido)-5-(trifluoromethyl)-phenyl)carbamoyl)amide - (3-((5-(Isoindolin-4-yl)pyridin-2-yl)methyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- phenyla-cetamido)-5-(trifluoromethyl)phenyl)carbamoyl)-amide - ((3-Benzamido-5-(trifluoromethyl)phenyl)-carbamoyl)(3-(4-(2-methoxy-4- methylpyrimidin-5-yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - (3-(4-(2-Methoxy-4-methylpyrimidin-5-yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)((3- (2-(4-methoxyphenyl)acetamido)-5-(trifluoromethyl)-phenyl)carbamoyl)amide - ((3-(2-(4-Chlorophenyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)(3-(4-(2- methoxy-4-methylpyrimidin-5-yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - ((3-(Cyclopentanecarboxamido)-5-(trifluoromethyl)phenyl)carbamoyl)(3-(4-(2- methoxy-4-methylpyrimidin-5-yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - (3-(4-(2-Methoxy-4-methylpyrimidin-5-yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)((3- (2-(pyridin-3-yl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - ((3-(2-(Benzo[d]isoxazol-3-yl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)(3- (4-(2-methoxy-4-methylpyrimidin-5-yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - ((3-(2-(2-Chlorophenyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)(3-(4-(2- methoxy-4-methylpyrimidin-5-yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - ((3-(2-(4-(Aminomethyl)phenyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)(3- (4-(2-methoxy-4-methylpyrimidin-5-yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - (R)-(3-(2-Amino-1-(4-(3,5-dimethylisoxazol-4-yl)phenyl)ethyl)-1,2,3-oxadiazol-3- ium-5-yl)((3-(2-phenylacetamido)-5-(trifluoromethyl)phenyl)-carbamoyl)amide - (S)-(3-(2-Amino-1-(4-(3,5-dimethylisoxazol-4-yl)phenyl)ethyl)-1,2,3-oxadiazol-3- ium-5-yl)((3-(2-phenylacetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - (3-((5-(2-Amino-4-methylpyrimidin-5-yl)pyridin-2-yl)methyl)-1,2,3-oxadiazol-3- ium-5-yl)((3-(2-phenylacetamido)-5-(trifluoromethyl)-phenyl)carbamoyl)amide - (3-((1R,3R)-3-Aminocyclobutyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- phenylacetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - ((3-(2-(4-(Aminomethyl)phenyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)(3- (pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - (3-Benzyl-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-phenylacetamido)-5- (trifluoromethyl)phenyl)-carbamoyl)amide - ((3-(1H-Benzo[d]imidazole-5-carboxamido)-5- (trifluoromethyl)phenyl)carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5- yl)amide - 5-(3-(3-(5-(Morpholinomethyl)furan-2-carboxamido)-5- (trifluoromethyl)phenyl)ureido)-3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium - ((3-(3-Phenoxybenzamido)-5-(trifluoromethyl)-phenyl)carbamoyl)(3-(pyridin-2- ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - ((3-(2-Phenylpropanamido)-5-(trifluoromethyl)-phenyl)carbamoyl)(3-(pyridin-2- ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - ((3-(2-(5-Methyl-2-phenyloxazol-4-yl)acetamido)-5-(trifluoromethyl)phenyl)- carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - ((3-(1-Phenyl-1H-pyrazole-5-carboxamido)-5-(trifluoromethyl)phenyl)carbamoyl)(3- (pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - ((3-(1-Benzyl-1H-pyrazole-4-carboxamido)-5-(trifluoromethyl)phenyl)carbamoyl)(3- (pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - ((3-(2-(1H-Pyrrolo[3,2-b]pyridin-3-yl)acetamido)-5-(trifluoromethyl)phenyl)- carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - ((3-(6-Cyanoimidazo[1,2-a]pyridine-2-carboxamido)-5-(trifluoromethyl)- phenyl)carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - (3-(Pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(4,5,6,7-tetrahydro-1H- indazole-7-carboxamido)-5-(trifluoromethyl)phenyl)-carbamoyl)amide - ((3-(5-Methyl-5,6-dihydro-4H-thieno[2,3-c]pyrrole-2-carboxamido)-5- (trifluoromethyl)phenyl)carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5- yl)amide - ((3-(2-(1-Methyl-1H-pyrazol-3-yl)acetamido)-5- (trifluoromethyl)phenyl)carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5- yl)amide - ((3-(2-(2-Methylthiazol-4-yl)acetamido)-5-(trifluoromethyl)phenyl)-carbamoyl)(3- (pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - ((3-(2-(6-Aminopyridin-3-yl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)(3- (pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - ((3-(2-(Phenylsulfonyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)(3-(pyridin- 2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - ((3-(Isoxazole-3-carboxamido)-5-(trifluoromethyl)-phenyl)carbamoyl)(3-(pyridin-2- ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - ((3-(Pyrazine-2-carboxamido)-5-(trifluoromethyl)-phenyl)carbamoyl)(3-(pyridin-2- ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - ((3-(3-Phenylpropiolamido)-5-(trifluoromethyl)-phenyl)carbamoyl)(3-(pyridin-2- ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - ((3-(Bicyclo[4.2.0]octa-1(6),2,4-triene-7-carboxamido)-5-(trifluoromethyl)phenyl)- carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - ((3-(1-Isopropyl-1H-pyrazole-3-carboxamido)-5- (trifluoromethyl)phenyl)carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5- yl)amide - ((3-(1-Methylazetidine-3-carboxamido)-5-(trifluoromethyl)phenyl)carbamoyl)(3- (pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - ((3-(2-Phenylcyclopropane-1-carboxamido)-5-(trifluoromethyl)phenyl)carbamoyl)(3- (pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - ((3-(3-(Methoxycarbonyl)bicyclo[1.1.1]pentane-1-carboxamido)-5- (trifluoromethyl)phenyl)-carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium- 5-yl)amide - ((3-(3-Carboxybicyclo[1.1.1]pentane-1-carboxamido)-5-(trifluoromethyl)phenyl)- carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - ((3-(Phenethylamino)-5-(trifluoromethyl)-phenyl)carbamoyl)(3-(pyridin-2-ylmethyl)- 1,2,3-oxadiazol-3-ium-5-yl)amide - ((3-(2-Cyclobutylacetamido)-5-(trifluoromethyl)phenyl)carbamoyl)(3-(pyridin-2- ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - (3-((1R3R)-3-(Dimethylamino)cyclobutyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- phenyl-acetamido)-5-(trifluoromethyl)phenyl)-carbamoyl)amide - (3-(4-(Aminomethyl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-phenylacetamido)-5- (trifluoromethyl)phenyl)carbamoyl)amide - ((3-Methyl-5-(2-phenylacetamido)phenyl)-carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3- oxadiazol-3-ium-5-yl)amide - ((3-Chloro-5-(2-phenylacetamido)phenyl)-carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3- oxadiazol-3-ium-5-yl)amide - (3-((1S,4S)-4-(Aminomethyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-phenyl- acetamido)-5-(trifluoromethyl)phenyl)-carbamoyl)amide - (3-((1S,4S)- 4-((1,3-Dioxoisoindolin-2-yl)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium- 5-yl)((3-(2-phenylacetamido)-5-(trifluoromethyl)-phenyl)carbamoyl)amide - (3-((1S,4S)- -4-((Dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5- yl)((3-(2-phenylacetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - (3-((1S,4S)-4-(Acetamidomethyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- phenylacetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - ((3-(2-(Bicyclo[2.1.1]hexan-2-yl)acetamido)-5- (trifluoromethyl)phenyl)carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5- yl)amide - ((3-(5,5-Dioxido-6,7-dihydro-4H-pyrazolo[5,1-c][1,4]thiazine-2-carboxamido)-5- (trifluoromethyl)phenyl)carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5- yl)amide - ((3-(2-(2-(Difluoromethyl)-1H-benzo[d]imidazol-1-yl)acetamido)-5- (trifluoromethyl)phenyl)carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5- yl)amide - ((3-(4-Hydroxybicyclo[2.2.1]heptane-1-carboxamido)-5-(trifluoromethyl)phenyl)- carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - ((3-(7-Methyl-2,3-dihydrobenzofuran-3-carboxamido)-5-(trifluoromethyl)phenyl)- carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - ((3-(3-Benzylcyclobutane-1-carboxamido)-5-(trifluoromethyl)phenyl)carbamoyl)(3- (pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - ((3-((1S,3S)-3-hydroxy-3-(pyridin-2-yl)cyclobutane-1-carboxamido)-5- (trifluoromethyl)phenyl)carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5- yl)amide - ((3-(1-((5-Methylfuran-2-yl)methyl)piperidine-4-carboxamido)-5- (trifluoromethyl)phenyl)-carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium- 5-yl)amide - ((3-(1-(3-Cyano-1H-pyrazol-1-yl)cyclopropane-1-carboxamido)-5- (trifluoromethyl)phenyl)carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5- yl)amide - ((3-(2-((4-Methyl-4H-1,2,4-triazol-3-yl)methoxy)acetamido)-5-(trifluoromethyl)- phenyl)carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - ((3-(3-(Cyclopentyloxy)propanamido)-5-(trifluoromethyl)phenyl)carbamoyl)(3- (pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - ((3-((1S,4R,5R)-4-(3-Methoxyphenyl)-2-oxabicyclo[2.1.1]hexane-5-carboxamido)-5- (trifluoromethyl)phenyl)carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5- yl)amide - ((3-(1-Cyclopropyl-1H-imidazole-5-carboxamido)-5-(trifluoromethyl)phenyl)- carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - ((3-(2,2-Difluoro-3-(pyrrolidin-1-yl)propanamido)-5-(trifluoromethyl)phenyl)- carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - ((3-(1-Cyclopropylazetidine-3-carboxamido)-5- (trifluoromethyl)phenyl)carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5- yl)amide - (3-(Pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(4-(1- sulfamoylethyl)benzamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - ((3-(2,3-Dihydrofuro[3,2-b]pyridine-5-carboxamido)-5-(trifluoromethyl)phenyl)- carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - (3-(Pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(5,6,7,8- tetrahydroimidazo[1,5-a]pyridine-7-carboxamido)-5-(trifluoromethyl) - phenyl)carbamoyl)amide - ((3-(3,4-Dihydro-1H-pyrrolo[2,1-c][1,4]oxazine-8-carboxamido)-5-(trifluoromethyl)- phenyl)carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - ((3-(5-(Piperidin-1-ylsulfonyl)pentanamido)-5- (trifluoromethyl)phenyl)carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5- yl)amide - ((3-(3-(4-Chlorophenoxy)oxetane-3-carboxamido)-5-(trifluoromethyl)phenyl)- carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - ((3-(2,6-Dioxaspiro[4.5]decane-7-carboxamido)-5- (trifluoromethyl)phenyl)carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5- yl)amide - ((3-(3,3-Difluorospiro[3.3]heptane-1-carboxamido)-5-(trifluoromethyl)phenyl)- carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - (3-(Pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-(3-(pyrrolidin-1- yl)oxetan-3-yl)acetamido)-5-(trifluoromethyl)phenyl) - carbamoyl)amide - (3-(Pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2,4,5,6- tetrahydrocyclopenta[c]pyrrole-1-carboxamido)-5-(trifluoromethyl)phenyl)- carbamoyl)amide - ((3-(4,4-Dioxido-1,4-oxathiane-2-carboxamido)-5- (trifluoromethyl)phenyl)carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5- yl)amide - ((3-Cyclopropyl-5-(2-phenylacetamido)phenyl)-carbamoyl)(3-(pyridin-2-ylmethyl)- 1,2,3-oxadiazol-3-ium-5-yl)amide - ((3-(2-(Benzylamino)-2-oxoethyl)-5-(trifluoromethyl)phenyl)carbamoyl)(3-(pyridin- 2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - (3-((1S,4S)-4-Aminocyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- phenylacetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - (3-((1R,4R)-4-Aminocyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- phenylacetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - (3-((1R,4R)-4-(Aminomethyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-phenyl- acetamido)-5-(trifluoromethyl)phenyl)-carbamoyl)amide - (3-((1R,4R)-4-((Dimethylamino)methyl)-cyclohexyl)-1,2,3-oxadiazol-3-ium-5- yl)((3-(2-phenylacetamido)-5-(trifluoromethyl)phenyl)-carbamoyl)amide - (3-((1S,4S)-4-(Dimethylamino)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- phenylacetamido)-5-(trifluoromethyl)phenyl)-carbamoyl)amide - (3-((1R,4R)-4-(dimethylamino)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- phenylacetamido)-5-(trifluoromethyl)phenyl)-carbamoyl)amide - (3-(4-(Methoxycarbonyl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- phenylacetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - ((3-(2-Phenylacetamido)-5-(trifluoromethyl)-phenyl)carbamoyl)(3-(piperidin-4-yl)- 1,2,3-oxadiazol-3-ium-5-yl)amide - (3-(1-Methylpiperidin-4-yl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-phenylacetamido)-5- (trifluoromethyl)phenyl)carbamoyl)amide - (3-(4-Carboxybenzyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-phenylacetamido)-5- (trifluoromethyl)-phenyl)carbamoyl)amide - (3-(4-(Hydroxymethyl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-phenylacetamido)- 5-(trifluoromethyl)phenyl)carbamoyl)amide - (3-(4-(Aminomethyl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-phenylacetamido)-5- (trifluoromethyl)phenyl)carbamoyl)amide - (3-(4-Carbamoylbenzyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-phenylacetamido)-5- (trifluoromethyl)phenyl)carbamoyl)amide - (3-((1-Methylpiperidin-2-yl)methyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- phenylacetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - (3-((1-Methylpiperidin-4-yl)methyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- phenylacetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - (3-(3-((1,3-Dioxoisoindolin-2-yl)methyl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- phenylacetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - (3-(3-(Aminomethyl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-phenylacetamido)-5- (trifluoromethyl)phenyl)carbamoyl)amide - (3-(4-(2-Methoxy-2-oxoethyl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- phenylacetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - ((3-(2-Phenylacetamido)-5-(trifluoromethyl)-phenyl)carbamoyl)(3-(piperidin-3- ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - (3-(4-(2-Hydroxyethyl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-phenylacetamido)- 5-(trifluoromethyl)phenyl)carbamoyl)amide - (3-(9-Amino-3-oxabicyclo[3.3.1]nonan-7-yl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- phenylacetamido)-5-(trifluoromethyl)phenyl)-carbamoyl)amide - (3-((5-(Methoxycarbonyl)pyridin-2-yl)methyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- phenylacetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - (3-(2-(Aminomethyl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-phenylacetamido)-5- (trifluoromethyl)phenyl)carbamoyl)amide - (3-((1,4-Oxazepan-2-yl)methyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- phenylacetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - (3-((5-(Hydroxymethyl)pyridin-2-yl)methyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- phenylacetamido)-5-(trifluoromethyl)phenyl)-carbamoyl)amide - (3-((1-Methylpiperidin-3-yl)methyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- phenylacetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - (3-((3-Aminocyclobutyl)methyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- phenylacetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - (3-((1S,4S)-4-(Aminomethyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-oxo-3- phenyl-pyrrolidin-1-yl)-5-(trifluoromethyl)phenyl)-carbamoyl)amide - ((3-(2-Phenylacetamido)-5-(trifluoromethyl)-phenyl)carbamoyl)(3-(piperidin-4- ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - (3-((5-(Isopropoxycarbonyl)pyridin-2-yl)methyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- phenylacetamido)-5-(trifluoromethyl)phenyl)-carbamoyl)amide - ((3-(2-Oxo-4-phenylpyrrolidin-1-yl)-5-(trifluoromethyl)phenyl)carbamoyl)(3- (pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - ((3-(2-(6-Oxo-1,6-dihydropyridin-3-yl)acetamido)-5-(trifluoromethyl)phenyl)- carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - ((3-(2-(1H-Benzo[d]imidazol-6-yl)acetamido)-5- (trifluoromethyl)phenyl)carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5- yl)amide - ((3-(2-Phenylacetamido)-5-(trifluoromethyl)-phenyl)carbamoyl)(3-(piperidin-2- ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - ((3-(2-(1H-Indazol-7-yl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)(3- (pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - ((3-Cyclopropyl-5-(2-phenylacetamido)phenyl)-carbamoyl)(3-((1-methylpiperidin-2- yl)methyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - ((3-Cyclopropyl-5-(2-phenylacetamido)phenyl)-carbamoyl)(3-((5- (methoxycarbonyl)pyridin-2-yl)methyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - ((3-Cyclopropyl-5-(2-phenylacetamido)phenyl)-carbamoyl)(3-((5- (hydroxymethyl)pyridin-2-yl)methyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - ((3-((1R,2R)-2-Methylcyclopropyl)-5-(2-phenylacetamido)phenyl)carbamoyl)(3- (pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - (3-(((1S,4S)-4-Aminocyclohexyl)methyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-oxo-3- phenylpyrrolidin-1-yl)-5-(trifluoromethyl)-phenyl)carbamoyl)amide - (3-(((1R,4R)-4-Aminocyclohexyl)methyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-oxo-3- phenylpyrrolidin-1-yl)-5-(trifluoromethyl)-phenyl)carbamoyl)amide - (3-(((1S,4S)-4-(Aminomethyl)cyclohexyl)-methyl)-1,2,3-oxadiazol-3-ium-5-yl)((3- (2-oxo-3-phenylpyrrolidin-1-yl)-5-(trifluoromethyl)-phenyl)carbamoyl)amide - (3-((3-(((5-Hydroxypyridin-2-yl)methyl)amino)-cyclobutyl)methyl)-1,2,3-oxadiazol- 3-ium-5-yl)((3-(2-phenylacetamido)-5-(trifluoromethyl)-phenyl)carbamoyl)amide - ((3-(2-Oxo-3-phenylpyrrolidin-1-yl)-5-(trifluoromethyl)phenyl)carbamoyl)(3- ((1S,4S)-4-(((2,2,2-trifluoroethyl)amino)methyl)-cyclohexyl)-1,2,3-oxadiazol-3-ium- 5-yl)amide - ((3-(2-Oxo-3-phenylpyrrolidin-1-yl)-5-(trifluoromethyl)phenyl)carbamoyl)(3- (((1s,4s)-4-((2,2,2-trifluoroethyl)amino)cyclohexyl)methyl)-1,2,3-oxadiazol-3-ium-5- yl)amide - ((3-(2-Oxo-3-phenylpyrrolidin-1-yl)-5-(trifluoromethyl)phenyl)carbamoyl)(3- (((1R,4R)-4-((2,2,2-trifluoroethyl)amino)-cyclohexyl)methyl)-1,2,3-oxadiazol-3-ium- 5-yl)amide - (3-((1S,4S)-4-((Dimethylamino)methyl)-cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3- (2-oxo-3-phenylpyrrolidin-1-yl)-5-(trifluoromethyl)-phenyl)carbamoyl)amide - ((3-(2-Oxo-3-phenylpyrrolidin-1-yl)-5-(trifluoromethyl)phenyl)carbamoyl)(3- (((1s,4s)-4-(((2,2,2-trifluoroethyl)amino)methyl)cyclohexyl)-methyl)-1,2,3- oxadiazol-3-ium-5-yl)amide - (3-((1-(2-Ethoxy-2-oxoethyl)piperidin-4-yl)methyl)-1,2,3-oxadiazol-3-ium-5-yl)((3- (2-phenylacetamido)-5-(trifluoromethyl)phenyl)-carbamoyl)amide - (3-((1-(2-Hydroxyethyl)piperidin-4-yl)methyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- phenylacetamido)-5-(trifluoromethyl)phenyl)-carbamoyl)amide - ((3-(2-Phenylacetamido)-5-(trifluoromethyl)-phenyl)carbamoyl)(3-((1-(2,2,2- trifluoroethyl)-piperidin-2-yl)methyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - (3-(((1R,4R)-4-Aminocyclohexyl)methyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-((R)-2- oxo-3-phenylpyrrolidin-1-yl)-5-(trifluoromethyl)-phenyl)carbamoyl)amide - ((3-((R)-2-Oxo-3-phenylpyrrolidin-1-yl)-5-(trifluoromethyl)phenyl)carbamoyl)(3- (((1r,4r)-4-((2,2,2-trifluoroethyl)amino)cyclohexyl)-methyl)-1,2,3-oxadiazol-3-ium- 5-yl)amide - ((3-((R)-2-Oxo-3-phenylpyrrolidin-1-yl)-5-(trifluoromethyl)phenyl)carbamoyl)(3- (((1R,4R)-4-(2,2,2-trifluoroacetamido)cyclohexyl)methyl)-1,2,3-oxadiazol-3-ium-5- yl)amide - (3-(((1R,4R)-4-(Methyl(2,2,2-trifluoroethyl)-amino)cyclohexyl)methyl)-1,2,3- oxadiazol-3-ium-5-yl)((3-((R)-2-oxo-3-phenylpyrrolidin-1-yl)-5- (trifluoromethyl)phenyl)carbamoyl)amide - (3-((1R,4R)-4-((Dimethylamino)methyl)-cyclohexyl)-1,2,3-oxadiazol-3-ium-5- yl)((3-(2-phenylacetamido)-5-(trifluoromethyl)phenyl)-carbamoyl)amide - (3-((1R,4R)-4-((Dimethylamino)methyl)-cyclohexyl)-1,2,3-oxadiazol-3-ium-5- yl)((3-(2-oxo-3-phenylpyrrolidin-1-yl)-5-(trifluoromethyl)-phenyl)carbamoyl)amide - (3-((5-(4,6-Dimethylpyrimidin-5-yl)pyridin-2-yl)methyl)-1,2,3-oxadiazol-3-ium-5- yl)((3-(2-phenylacetamido)-5-(trifluoromethyl)phenyl)-carbamoyl)amide - ((3-Cyclopropyl-5-(2-(phenylsulfonyl)-acetamido)phenyl)carbamoyl)(3-((1R,4R)-4- ((dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - (3-((1R,4R)-4-((Dimethylamino)methyl)-cyclohexyl)-1,2,3-oxadiazol-3-ium-5- yl)((3-(2-(phenylsulfonyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - (3-((1R,4R)-4-((Dimethylamino)methyl)-cyclohexyl)-1,2,3-oxadiazol-3-ium-5- yl)((3-(2-(3-methoxyphenyl)acetamido)-5-(trifluoromethyl)-phenyl)carbamoyl)amide - (3-((1R,4R)-4-((Dimethylamino)methyl)-cyclohexyl)-1,2,3-oxadiazol-3-ium-5- yl)((3-(2-(2-methoxyphenyl)acetamido)-5-(trifluoromethyl)-phenyl)carbamoyl)amide - ((3-(2-(Benzo[d][1,3]dioxol-5-yl)acetamido)-5- (trifluoromethyl)phenyl)carbamoyl)(3-((1R,4R)-4- ((dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - ((3-(2-(3-(Carboxymethyl)phenyl)acetamido)-5- (trifluoromethyl)phenyl)carbamoyl)(3-((1R,4R)-4- ((dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - ((3-(2-(4-Carboxyphenyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)(3- ((1R,4R)-4-((dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - (3-((1R,4R)-4-((Dimethylamino)methyl)-cyclohexyl)-1,2,3-oxadiazol-3-ium-5- yl)((3-(3-(1-methyl-1H-indol-3-yl)propanamido)-5- (trifluoromethyl)phenyl)carbamoyl)amide - (3-((1R,4R)-4-((Dimethylamino)methyl)-cyclohexyl)-1,2,3-oxadiazol-3-ium-5- yl)((3-(3-(pyrazin-2-yl)propanamido)-5-(trifluoromethyl-)phenyl)carbamoyl)amide - ((3-(2-(2-Carboxyphenyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)(3- ((1R,4R)-4-((dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - ((3-(2,2-Difluoro-3-(pyrrolidin-1-yl)propanamido)-5-(trifluoromethyl)phenyl)- carbamoyl)(3-((1R,4R)-4-((dimethylamino)-methyl)cyclohexyl)-1,2,3-oxadiazol-3- ium-5-yl)amide - (3-((1R,4R)-4-((dimethylamino)methyl)-cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3- (2-(1-methyl-1H-indol-3-yl)acetamido)-5-(trifluoro-methyl)phenyl)carbamoyl)amide - ((3-(2-(3-(2-Amino-2-oxoethyl)phenyl)-acetamido)-5-(trifluoromethyl)phenyl)- carbamoyl)(3-((1R,4R)-4-((dimethylamino)-methyl)cyclohexyl)-1,2,3-oxadiazol-3- ium-5-yl)amide - ((3-(2-(3-(Aminomethyl)phenyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)(3- ((1R,4R)-4-((dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - (3-((1R,4R)-4-((Dimethylamino)methyl)-cyclohexyl)-1,2,3-oxadiazol-3-ium-5- yl)((3-(2-phenylpropanamido)-5-(trifluoromethyl)phenyl)-carbamoyl)amide - (3-((1R,4R)-4-((Dimethylamino)methyl)-cyclohexyl)-1,2,3-oxadiazol-3-ium-5- yl)((3-(2-phenylbutanamido)-5-(trifluoromethyl)phenyl)-carbamoyl)amide - (3-((1R,4R)-4-((Dimethylamino)methyl)-cyclohexyl)-1,2,3-oxadiazol-3-ium-5- yl)((3-(trifluoromethyl)-5-(2-(2-(trifluoromethyl)- phenyl)acetamido)phenyl)carbamoyl)amide - (3-((1R,4R)-4-((Dimethylamino)methyl)-cyclohexyl)-1,2,3-oxadiazol-3-ium-5- yl)((3-(N-methyl-2-phenylpropanamido)-5-(trifluoro- methyl)phenyl)carbamoyl)amide - ((3-(2-(2-Chlorophenyl)acetamido)-5-(trifluoro-methyl)phenyl)carbamoyl)(3- ((1R,4R)-4-((dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - ((3-(2-(2,3-Difluorophenyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)(3- ((1R,4R)-4-((dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - (3-((1R,4S)-4-((Dimethylamino)methyl)-cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3- ((S)-2-phenylpropanamido)-5-(trifluoromethyl)-phenyl)carbamoyl)amide - (3-((1R,4R)-4-((Dimethylamino)methyl)-cyclohexyl)-1,2,3-oxadiazol-3-ium-5- yl)((3-(2-(o-tolyl)acetamido)-5-(trifluoromethyl)phenyl)-carbamoyl)amide - (3-((1R,4R)-4-((Dimethylamino)methyl)-cyclohexyl)-1,2,3-oxadiazol-3-ium-5- yl)((3-(N-methyl-2-phenylacetamido)-5-(trifluoromethyl)-phenyl)carbamoyl)amide - (3-((1R,3R)-3-(Dimethylamino)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- phenylacetamido)-5-(trifluoromethyl)phenyl)-carbamoyl)amide - (3-((1R,3S)-3-(Dimethylamino)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- phenyl-acetamido)-5-(trifluoromethyl)phenyl)-carbamoyl)amide - (3-((1R,4R)-4-((Dimethylamino)methyl)-cyclohexyl)-1,2,3-oxadiazol-3-ium-5- yl)((3-((R)-2-phenylpropanamido)-5-(trifluoromethyl)-phenyl)carbamoyl)amide - ((3-(2-(3-Chlorophenyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)(3- ((1R,4R)-4-((dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - (3-((1R,4R)-4-((Dimethylamino)methyl)-cyclohexyl)-1,2,3-oxadiazol-3-ium-5- yl)((3-(1,2,3,4-tetrahydronaphthalene-1-carboxamido)-5- (trifluoromethyl)phenyl)carbamoyl)amide - rac-(3-((1-Methyl-1,2,3,4-tetrahydroquinolin-2-yl)methyl)-1,2,3-oxadiazol-3-ium-5- yl)((2-(trifluoromethyl)pyridin-4-yl)carbamoyl)amide - (3-(((1S,4S)-4-(Pyrimidin-5-yl)cyclohexyl)-methyl)-1,2,3-oxadiazol-3-ium-5-yl)((3- (trifluoromethyl)phenyl)carbamoyl)amide - rac-(((3R,5S)-1,1-Difluorospiro[2.4]heptan-5-yl)carbamoyl)(3-((5-(4,6- dimethylpyrimidin-5-yl)pyridin-2-yl)methyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - rac-(3-((2-Methyl-1,2,3,4-tetrahydroisoquinolin -1-yl)methyl)-1,2,3-oxadiazol-3-ium- 5-yl)((2-(trifluoromethyl)pyridin-4-yl)carbamoyl)amide - (3-(((1S,4S)-4-(Pyrimidin-5-yl)cyclohexyl) methyl)-1,2,3-oxadiazol-3-ium-5-yl)((2- (trifluoro methyl)pyridin-4-yl)carbamoyl)amide - (3-((3-(Pyrimidin-5-yl)bicyclo[1.1.1]pentan-1-yl)methyl)-1,2,3-oxadiazol-3-ium-5- yl)((3-(trifluoromethyl)phenyl)carbamoyl)amide - (3-((6-(4,6-Dimethylpyrimidin-5-yl)pyridazin-3-yl)methyl)-1,2,3-oxadiazol-3-ium-5- yl)((3-(trifluoromethyl)phenyl)carbamoyl)amide - (3-((4-(Pyrimidin-5-yl)bicyclo[2.2.1]heptan-1-yl)methyl)-1,2,3-oxadiazol-3-ium-5- yl)((2-(trifluoromethyl)pyridin-4-yl)carbamoyl)amide - (3-(((1R,4R)-4-(Pyrimidin-5-yl)cyclohexyl) methyl)-1,2,3-oxadiazol-3-ium-5-yl)((3- (trifluoro methyl)phenyl)carbamoyl)amide - (3-(((1R,4R)-4-(Pyrimidin-5-yl)cyclohexyl)-methyl)-1,2,3-oxadiazol-3-ium-5-yl)((2- (trifluoromethyl)pyridin-4-yl)carbamoyl)amide - (3-(4-(3-Methylpyridazin-4-yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)((2- (trifluoromethyl)-pyridin-4-yl)carbamoyl)amide - ((2-(Trifluoromethyl)pyridin-4-yl)carbamoyl)(3-(4-(4-(trifluoromethyl)pyrimidin-5- yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - (3-(4-(4-Methoxy-6-methylpyrimidin-5-yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)((2- (trifluoromethyl)pyridin-4-yl)carbamoyl)amide - (3-((1R,4R)-4-((Dimethylamino)methyl)-cyclohexyl)-1,2,3-oxadiazol-3-ium-5- yl)((3-(2-(2-hydroxyphenyl)acetamido)-5-(trifluoromethyl)-phenyl)carbamoyl)amide - rac-(3-((2-Methyl-1,2,3,4-tetrahydro isoquinolin-1-yl)methyl)-1,2,3-oxadiazol-3-ium- 5-yl)((3-(2-phenylacetamido)-5-(trifluoromethyl) phenyl)carbamoyl)amide - ((2-(2-(2-Chlorophenyl)acetamido)-6-(trifluoromethyl)pyridin-4-yl)carbamoyl)(3- ((1R,4R)-4-((dimethylamino)methyl)-cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - (3-((1R,4R)-4-((Dimethylamino)methyl)-cyclohexyl)-1,2,3-oxadiazol-3-ium-5- yl)((3-(2-fluoro-2-(2-fluorophenyl)acetamido)-5- (trifluoromethyl)phenyl)carbamoyl)amide - ((3-(Bicyclo[4.2.0]octa-1(6),2,4-triene-7-carboxamido)-5-(trifluoromethyl)phenyl)- carbamoyl)(3-((1R,4R)-4-((dimethylamino-methyl)cyclohexyl)-1,2,3-oxadiazol-3- ium-5-yl)amide - (3-((1R,4R)-4-((Dimethylamino)methyl)-cyclohexyl)-1,2,3-oxadiazol-3-ium-5- yl)((3-(2-(6-hydroxypyridin-2-yl)acetamido)-5- (trifluoromethyl)phenyl)carbamoyl)amide - (3-((1R,4R)-4-((Dimethylamino)methyl)-cyclohexyl)-1,2,3-oxadiazol-3-ium-5- yl)((3-(2-(3,5-dimethylisoxazol-4-yl)acetamido)-5- (trifluoromethyl)phenyl)carbamoyl)amide - ((3-(2-(2-Chloro-6-fluorophenyl)acetamido)-5- (trifluoromethyl)phenyl)carbamoyl)(3-((1R,4R)-4- ((dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - ((3-(2-(2,6-Difluorophenyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)(3- ((1R,4R)-4-((dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - Rac-(3-((1,2,3,4-Tetrahydronaphthalen-1-yl)methyl)-1,2,3-oxadiazol-3-ium-5-yl)((2- (trifluoromethyl)pyridin-4-yl)carbamoyl)amide - (3-(4-(1,4-Dimethyl-1H-pyrazol-5-yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)((2- (trifluoromethyl)-pyridin-4-yl)carbamoyl)amide - (3-((1R,3S)-3-(Dimethylamino)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-(o- tolyl)acetamido)-5-(trifluoromethyl)phenyl)-carbamoyl)amide - (3-((1R,2R)-2-Hydroxycyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-(o- tolyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - (3-((1R,3S)-3-(Dimethylamino)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((2- (trifluoromethyl)-pyridin-4-yl)carbamoyl)amide - ((3-(2-(2-Chlorophenyl)propanamido)-5-(trifluoromethyl)phenyl)carbamoyl)(3- ((1R,4R)-4-((dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - (3-((1R,4R)-4-(2-Hydroxypropan-2-yl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3- (2-(o-tolyl)acetamido)-5-(trifluoromethyl)phenyl)-carbamoyl)amide - ((4-Cyano-3-(trifluoromethyl)phenyl)-carbamoyl)(3-(4-(4,6-dimethylpyrimidin-5- yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - (3-((1R,4R)-4-((Dimethylamino)methyl)-cyclohexyl)-1,2,3-oxadiazol-3-ium-5- yl)((3-(2-methyl-2-phenylpropanamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - (3-(4-(4,6-Dimethylpyrimidin-5-yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)((2- methoxypyridin-4-yl)carbamoyl)amide - (3-(4-(2-Methylthiazol-4-yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)((2- (trifluoromethyl)pyridin -4-yl)carbamoyl)amide - (3-(4-(3,5-Dimethylisothiazol-4-yl)benzyl)-1,2,3-oxadiazol-3-ium-5- yl)((2(trifluoromethyl)-pyridin-4-yl)carbamoyl)amide - (3-((1R,4R)-4-((Dimethylamino)methyl)-cyclohexyl)-1,2,3-oxadiazol-3-ium-5- yl)((3-(2-(2,3-dimethylphenyl)acetamido)- 5(trifluoromethyl)phenyl)carbamoyl)amide - (3-((1S,3R)-3-((Dimethylamino)methyl)-cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3- (2-(o-tolyl)acetamido)-5-(trifluoromethyl)phenyl) carbamoyl)amide - (3-((1R,3S)-3-Hydroxycyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-(o- tolyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - (3-((1R,3R)-3-Hydroxycyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-(o- tolyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - (3-((4-(4,6-Dimethylpyrimidin-5-yl)cyclohex-3-en-1-yl)methyl)-1,2,3-oxadiazol-3- ium-5-yl)((2-(trifluoromethyl)pyridin-4-yl)carbamoyl)amide - (3-(((1R,2R)-2Hydroxycyclohexyl)methyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-(o- tolyl)acetamido)-5-(trifluoromethyl)phenyl)-carbamoyl)amide - (3-(((1S,2R)-2-Hydroxycyclohexyl)methyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-(o- tolyl)acetamido)-5-(trifluoromethyl)phenyl)-carbamoyl)amide - (3-((1S,3S)-3-(Pyrimidin-5-yl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((2- (trifluoromethyl)pyridin -4-yl)carbamoyl)amide - (3-((1S,3R)-3-(Pyrimidin-5-yl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((2- (trifluoromethyl)-pyridin-4-yl)carbamoyl)amide - (3-((1S,3S)-3-(Pyrimidin-5-yl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-(o- tolyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - (3-((1S,3R)-3-(Pyrimidin-5-yl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-(o- tolyl)acetamido)-5-(trifluoromethyl)phenyl)-carbamoyl)amide - (3-((1R,3S)-3-(Methoxycarbonyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-(o- tolyl)acetamido)-5-(trifluoromethyl)phenyl)-carbamoyl)amide - (3-((1R,3R)-3-(Methoxycarbonyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-(o- tolyl)-acetamido)-5-(trifluoromethyl)phenyl)-carbamoyl)amide - (3-(4-(4-Methylpyrimidin-5-yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)((2- (trifluoromethyl)pyridin -4-yl)carbamoyl)amide - ((2-(tert-Butyl)pyridin-4-yl)carbamoyl)(3-(4-(4,6-dimethylpyrimidin-5-yl)benzyl)- 1,2,3-oxadiazol-3-ium-5-yl)amide - (3-((1R,4R)-4-(Methoxycarbonyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-(o- tolyl)-acetamido)-5-(trifluoromethyl)phenyl)carbamoyl) - amide - (3-((1R,4R)-4-(Hydroxymethyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-(o- tolyl)acetamido)-5-(trifluoromethyl)phenyl) carbamoyl)amide - (3-((1R,4R)-4-Carboxycyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-(o- tolyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - (3-((1R)-3-(Hydroxymethyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-(o- tolyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - (3-((1R,3R)-3-(Methylcarbamoyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-(o- tolyl)acetamido)-5-(trifluoromethyl)phenyl)-carbamoyl)amide - (3-((1R,3S)-3-(Methylcarbamoyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-(o- tolyl)acetamido)-5-(trifluoromethyl)phenyl)-carbamoyl)amide - (3-(4-(4,6-Dimethylpyrimidin-5-yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)(((1S,3S)-3- (trifluoromethyl)cyclopentyl)carbamoyl)amide - (3-((1R,3S)-3-(Dimethylcarbamoyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- (o-tolyl)-acetamido)-5-(trifluoromethyl)phenyl)-carbamoyl)amide - (3-((1R,3R)-3-Carbamoylcyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-(o- tolyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - (3-(4-(Pyrimidin-5-yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)((2- (trifluoromethyl)pyridin-4-yl)-carbamoyl)amide - (3-(4-(1,3-Dimethyl-1H-pyrazol-4-yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)((2- (trifluoromethyl)-pyridin-4-yl)carbamoyl)amide - ((4-Cyano-3-(trifluoromethyl)phenyl)-carbamoyl)(3-(4-(1,4-dimethyl-1H-pyrazol-5- yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - (3-((4-(4-Methyl-2-(oxetan-3-yl)pyrazol-3-yl]phenyl)methyl)oxadiazol-3-ium-5-yl)- ((2-(trifluoromethyl)pyridin-4-yl)carbamoyl)-azanide - (3-((1S,2R)-2-Hydroxycyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-(o- tolyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - (3-(((1R,4S)-4-(4-Methylpyrimidin-5-yl)cyclohexyl)methyl)-1,2,3-oxadiazol-3-ium- 5-yl)((2-(trifluoromethyl)pyridin-4-yl)carbamoyl)-amide - (3-(4-(1,4-Dimethyl-1H-pyrazol-5-yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)((2- (trifluoromethyl)-pyridin-4-yl)carbamoyl)amide - (3-((1R,4S)-4-((Dimethylamino)methyl)-cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3- ((S)-2-fluoro-2-(2-fluorophenyl)acetamido)-5- (trifluoromethyl)phenyl)carbamoyl)amide - rac-(3-((1R,2S)-2-(Dimethylamino)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- (o-tolyl)acetamido)-5-(trifluoromethyl)phenyl)-carbamoyl)amide - rac-(3-((1R,3S)-3-(Methylcarbamoyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- (o-tolyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - rac-(3-((1S,3R)-3-((Dimethylamino)methyl)-cyclohexyl)-1,2,3-oxadiazol-3-ium-5- yl)((3-(2-(o-tolyl)acetamido)-5-(trifluoromethyl)phenyl)-carbamoyl)amide - rac-(3-((1R,3S)-3-((Dimethylamino)methyl)-cyclohexyl)-1,2,3-oxadiazol-3-ium-5- yl)((3-(2-(o-tolyl)acetamido)-5-(trifluoromethyl)phenyl)-carbamoyl)amide - (3-((1R,4R)-4-(Dimethylcarbamoyl)-cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- (o-tolyl)acetamido)-5-(trifluoromethyl)phenyl)-carbamoyl)amide - (3-(4-(4,6-Dimethylpyrimidin-5-yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)((4-methoxy- 3-(trifluoromethyl)phenyl)carbamoyl)amide - (3-(4-(4-Methyl-1-(oxetan-3-yl)-1H-pyrazol-3-yl)benzyl)-1,2,3-oxadiazol-3-ium-5- yl)((2-(trifluoromethyl)pyridin-4-yl)carbamoyl)amide - rac-(3-((1R,4R)-4-(Methylcarbamoyl)-cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3- (2-(o-tolyl)acetamido)-5-(trifluoromethyl)phenyl)-carbamoyl)amide - rac-(3-((1R,3R)-3-(Methylcarbamoyl)-cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3- (2-(o-tolyl)-acetamido)-5-(trifluoromethyl)phenyl)-carbamoyl)amide - rac-(3-((1R,3S)-3-(Dimethylcarbamoyl)-cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3- (2-(o-tolyl)-acetamido)-5-(trifluoromethyl)phenyl)-carbamoyl)amide - (3-((1R,4R)-4-(Pyrrolidine-1-carbonyl)-cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3- (2-(o-tolyl)acetamido)-5-(trifluoromethyl)phenyl)-carbamoyl)amide - (3-((1R,3S)-3-Carbamoylcyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-(o- tolyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - (3-((4-(4,6-Dimethylpyrimidin-5-yl)phenyl)methyl)oxadiazol-3-ium-5-yl)-((rac- (1R,3R)-3-(trifluoromethyl)cyclopentyl)-carbamoyl)azanide - (3-((1R,4R)-4-(Dimethylamino)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-(o- tolyl)-acetamido)-5-(trifluoromethyl)phenyl)-carbamoyl)amide - (3-(4-(2-Methylpyridin-3-yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)((2- (trifluoromethyl)pyridin -4-yl)carbamoyl)amide - (3-(4-(2,5-Dimethylthiazol-4-yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)((2- (trifluoromethyl)pyridin -4-yl)carbamoyl)amide - (3-(4-(2-Amino-4-methylpyrimidin-5-yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)((2- (trifluoromethyl)pyridin-4-yl)carbamoyl)amide - (3-(4-(4,6-Dimethylpyrimidin-5-yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)((4-hydroxy- 3-(trifluoromethyl)phenyl)carbamoyl)amide - (3-(4-(4,6-Dimethylpyrimidin-5-yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)((4- (methoxy-carbonyl)-3-(trifluoromethyl)phenyl)carbamoyl) amide - (3-(4-(2,4-Dimethylpyridin-3-yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)((2- (trifluoromethyl)pyridin -4-yl)carbamoyl)amide - ((4-Acetamido-3-(trifluoromethyl)phenyl)-carbamoyl)(3-(4-(4,6-dimethylpyrimidin- 5-yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - (3-(3-(Hydroxymethyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-(o- tolyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - (3-(4-(Pyrimidin-5-yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)((2- (trifluoromethyl)pyridin-4-yl)carbamoyl)amide - (3-((1R,3R)-3-Carbamoylcyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-(o- tolyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - ((2-(Trifluoromethyl)pyridin-4-yl)carbamoyl)(3-(4-(1,3,5-trimethyl-1H-pyrazol-4- yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - (3-(4-(4-Methoxy-6-methylpyrimidin-5-yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)((2- (trifluoromethyl)pyridin-4-yl)carbamoyl)amide - ((2-(Trifluoromethyl)pyridin-4-yl)carbamoyl)(3-(4-(4-(trifluoromethyl)pyrimidin-5- yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - (3-((1R,4R)-4-((Dimethylamino)methyl)-cyclohexyl)-1,2,3-oxadiazol-3-ium-5- yl)((3-((R)-2-fluoro-2-(2-fluorophenyl)acetamido)-5- (trifluoromethyl)phenyl)carbamoyl)amide - (3-(4-(4,6-Dimethylpyrimidin-5-yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)((8- (trifluoromethyl)-quinolin-6-yl)carbamoyl)amide - (3-(4-(4,6-Dimethylpyrimidin-5-yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)((4-(methyl- carbamoyl)-3-(trifluoromethyl)phenyl)carbamoyl) amide - (3-(6-methyl-6-azabicyclo[3.2.1]octan-3-yl)-1,2,3-oxadiazol-3-ium-5-yl)((3-((S)-2- phenylpropanamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - (3-((1R,4R)-4-((dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3- (7-hydroxy-2-phenylhept-4-ynamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - ((3-((S)-2-phenylpropanamido)-5-(trifluoromethyl)phenyl)carbamoyl)(3-((1r,4S)-4- (pyrrolidin-1-yl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - (3-(2-methyl-2-azaspiro[4.5]decan-8-yl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-(o- tolyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - (3-((1R,4R)-4-((dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3- ((R)-3-methyl-2-phenylbutanamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - (3-((1R,4S)-4-((dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3- ((S)-3-methyl-2-phenylbutanamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - (3-((1R,4S)-4-(methyl(2,2,2-trifluoroethyl)amino)cyclohexyl)-1,2,3-oxadiazol-3- ium-5-yl)((3-((S)-2-phenylpropanamido)-5- (trifluoromethyl)phenyl)carbamoyl)amide - (S)-(3-(4-(dimethylamino)-4-(trifluoromethyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5- yl)((3-(2-phenylpropanamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - (3-((1S,4R)-4-(3,3-difluoroazetidin-1-yl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3- ((S)-2-phenylpropanamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - (S)-(3-(4-oxocyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-phenylpropanamido)-5- (trifluoromethyl)phenyl)carbamoyl)amide - 3-((1R,3S,4R)-4-(dimethylamino)-3-fluorocyclohexyl)-5-(3-(3-((S)-2- phenylpropanamido)-5-(trifluoromethyl)phenyl)ureido)-1,2,3-oxadiazol-3-ium - ((3-((S)-2-phenylpropanamido)-5-(trifluoromethyl)phenyl)carbamoyl)(3-((1s,4R)-4- ((1,1,1-trifluoropropan-2-yl)amino)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - (3-((1R,2S)-2-(dimethylamino)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-(o- tolyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - (3-((1R,4R)-4-((dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3- (6-hydroxy-2-phenylhex-4-ynamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - 5-(3-(3-((S)-2-phenylpropanamido)-5-(trifluoromethyl)phenyl)ureido)-3-((1r,4S)-4- ((2,2,2-trifluoroethyl)amino)cyclohexyl)-1,2,3-oxadiazol-3-ium - (S)-(3-(2-methyl-2-azaspiro[3.5]nonan-7-yl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- phenylpropanamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - (S)-(3-(1,4-dioxaspiro[4.5]decan-8-yl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- phenylpropanamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - (3-((1R,4R)-4-(dimethylamino)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-(o- tolyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - ((3-((S)-2-phenylpropanamido)-5-(trifluoromethyl)phenyl)carbamoyl)(3-((1r,4S)-4- ((1,1,1-trifluoropropan-2-yl)amino)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - (3-((1R,4R)-4-(pyrrolidin-1-yl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-(o- tolyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - (3-((1R,4S)-4-morpholinocyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-((S)-2- phenylpropanamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - (S)-(3-(4-(4,4-difluoropiperidin-1-yl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- phenylpropanamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - (3-(4-(methyl(1,1,1-trifluoropropan-2-yl)amino)cyclohexyl)-1,2,3-oxadiazol-3-ium- 5-yl)((3-((S)-2-phenylpropanamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - (3-((1R,4R)-4-((dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((4- (2-phenylacetamido)-3-(trifluoromethyl)phenyl)carbamoyl)amide - (3-((1S,4R)-4-(methyl(2,2,2-trifluoroethyl)amino)cyclohexyl)-1,2,3-oxadiazol-3- ium-5-yl)((3-((S)-2-phenylpropanamido)-5- (trifluoromethyl)phenyl)carbamoyl)amide - (3-((1R,4S)-4-(dimethylamino)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-((S)-2- phenylpropanamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - (3-((1R,4R)-4-((dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3- (3-phenyloxetane-3-carboxamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - (3-((1R,4S)-4-(3,3-difluoroazetidin-1-yl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3- ((S)-2-phenylpropanamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - (3-((1R,4S)-4-hydroxycyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-((S)-2- phenylpropanamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - ((3-(2-fluoro-2-(2-fluorophenyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)(3- ((1r,4r)-4-(2-hydroxypropan-2-yl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - ((3-((S)-2-fluoro-2-(2-fluorophenyl)acetamido)-5- (trifluoromethyl)phenyl)carbamoyl)(3-((1r,4S)-4-(2-hydroxypropan-2- yl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - ((3-((R)-2-fluoro-2-(2-fluorophenyl)acetamido)-5- (trifluoromethyl)phenyl)carbamoyl)(3-((1r,4R)-4-(2-hydroxypropan-2- yl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)amide. Preferably the compound according is an inhibitor of NS2B-NS3 protease of a Flavivirus, preferably an inhibitor of the NS2B-NS3 protease of Zika and / or Dengue and / or West Nile and / or Japan Encephalitis virus, thus inhibiting replication of the above viruses in cells. It is a further object if the invention a compound as defined above for medical use, preferably for use in treatment and / or prevention of a Flavivirus infection, preferably wherein the Flavivirus is selected from the group consisting of Dengue, West Nile, Zika and Japan Encephalitis virus. In one embodiment, the Flavivirus infection is dengue fever. In a further embodiment, the dengue fever is Dengue virus type 1 (DENV-1), type 2 (DENV-2), type 3 (DENV-3), or type 4 (DENV- 4). In one embodiment, the Flavivirus infection is West Nile fever. In one embodiment, Flavivirus infection is Yellow Fever. In one embodiment, the Flavivirus infection is from the Zika virus. It is a further object of the invention a pharmaceutical composition comprising the compound as defined above and at least one pharmaceutically acceptable excipient. Preferably the pharmaceutical composition is for use in the treatment and / or prevention of a flavivirus infection, preferably wherein the flavivirus is selected from the group consisting of Dengue, West Nile, Zika and Japan Encephalitis virus. In a preferred embodiment, said pharmaceutical composition comprises at least one further active compound selected from the group consisting of: antivirals, antibacterials, anti-inflammatory agents, anti-pain agents and antipyretic agents. It is a further object of the invention a method for the synthesis of the compound of general formula (I) as defined above. The present invention includes within its scope prodrugs of the compound of formula (I). In general, such prodrugs will be functional derivatives of the compound of formula (I) which are readily convertible in vivo into the required compound of formula (I). Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in "Design of Prodrugs", ed. H. Bundgaard, Elsevier, 1985. A prodrug may be a pharmacologically inactive derivative of a biologically active substance (the "parent drug" or "parent molecule") that requires transformation within the body in order to release the active drug, and that has improved delivery properties over the parent drug molecule. The transformation in vivo may be, for example, as the result of some metabolic process, such as chemical or enzymatic hydrolysis of a carboxylic, phosphoric or sulphate ester, or reduction or oxidation of a susceptible functionality. The present invention includes within its scope solvates of the compound of formula (I) and salts thereof, for example, hydrates. The compounds of the present invention may have asymmetric centers, chiral axes, and chiral planes (as described in: E.L. Eliel and S.H. Wilen, Stereochemistry of Carbon Compounds, John Wiley & Sons, New York, 1994, pages 1119-1190), and occur as racemates, racemic mixtures, and as individual diastereomers, with all possible isomers and mixtures thereof, including optical isomers, all such stereoisomers being included in the present invention. In addition, the compounds disclosed herein may exist as tautomers and all tautomeric forms are intended to be encompassed by the scope of the invention, even though only one tautomeric structure is depicted. Specific tautomeric forms of compounds of the invention are depicted below: The compounds may exist in different isomeric forms, all of which are encompassed by the present invention. When any variable occurs more than one time in any constituent, its definition on each occurrence is independent of every other occurrence. Also, combinations of substituents and variables are permissible only if such combinations result in stable compounds. It is understood that substituents and substitution patterns on the compounds of the instant invention can be selected by one of ordinary skill in the art to provide compounds that are chemically stable and that can be readily synthesized from readily available starting materials by techniques known in the art, as well as those methods set forth below. If a substituent is itself substituted with more than one group, it is understood that these multiple groups may be on the same carbon or on different carbons, so long as a stable structure results. The phrase “optionally substituted” should be taken to be equivalent to the phrase “unsubstituted or substituted with one or more substituents” and in such cases the preferred embodiment will have from zero to three substituents. More particularly, there are zero to two substituents. A substituent on a saturated, partially saturated or unsaturated heterocycle can be attached at any substitutable position. As used herein, "alkyl" is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms. For example, “C1-C6alkyl” is defined to include groups having 1, 2, 3, 4, 5 or 6 carbons in a linear or branched arrangement. For example, “C1-C6 alkyl” specifically includes methyl, ethyl, n-propyl, i-propyl, n-butyl, t-butyl, i-butyl, pentyl, hexyl, and so on. “Cycloalkyl” refers to a non-aromatic hydrocarbon ring system (monocyclic, bicyclic, or polycyclic), including cyclized alkyl and alkenyl groups. The term "Cn-m cycloalkyl" or “(Cn- Cm) cycloalkyl” refers to a cycloalkyl that has n to m ring member carbon atoms. Cycloalkyl groups can include mono- or polycyclic (e.g., having 2, 3, or 4 fused rings) groups and spirocycles. Cycloalkyl groups can have 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 ring-forming carbons (C3-14). In some embodiments, the cycloalkyl group has 3 to 14 members, 3 to 10 members, 3 to 6 ring members, 3 to 5 ring members, or 3 to 4 ring members. In some embodiments, the cycloalkyl group is monocyclic. In some embodiments, the cycloalkyl group is monocyclic or bicyclic. In some embodiments, the cycloalkyl group is a C3-6 monocyclic cycloalkyl group. Ring-forming carbon atoms of a cycloalkyl group can be optionally oxidized to form an oxo or sulfido group. Cycloalkyl groups also include cycloalkylidenes. In some embodiments, cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. Examples of cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptatrienyl, norbornyl, norpinyl, norcarnyl, bicyclo[1.1.1]pentanyl, bicyclo[2.1.1]hexanyl, and the like. In some embodiments, the cycloalkyl group is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. In some embodiments, cycloalkyl includes a single saturated carbocyclic ring of three to eight ring carbons, such as cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. Cycloalkyl may optionally be substituted with one or more substituents, such as one, two, or three substituents. In some embodiments, the cycloalkyl substituent is selected from the group consisting of (C1- C6)alkyl, hydroxy, (C1-C6)alkoxy, halo(C1-C6)alkyl, halo(C1-C6)alkoxy, halo, amino, mono- and di(C1-C6)alkylamino, hetero(C1- C6)alkyl, acyl, aryl, and heteroaryl. A cycloalkyl group can be unsubstituted or optionally substituted. When optionally substituted, one or more hydrogen atoms of the cycloalkyl group (e.g., from 1 to 4, from 1 to 2, or 1) may be replaced with a moiety as halogen, OH, cyano, methyl, trifluoromethyl, amino and the like. In some aspects, a substituted cycloalkyl group can incorporate an exo- or endocyclic alkene (e.g., cyclohex-2-en-1-yl). In some aspects, a cycloalkyl group is unsubstituted or not optionally substituted. "Alkoxy" represents an alkyl group of indicated number of carbon atoms attached through an oxygen bridge. “Alkoxy” therefore encompasses the definitions of alkyl above. Examples of suitable alkoxy groups include methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, s-butoxy and t- butoxy. The preferred alkoxy group is methoxy. The terms "haloC1-6alkyl" and "haloC1-6alkoxy" mean a C1-6alkyl or C1-6alkoxy group in which one or more (in particular, 1 to 3) hydrogen atoms have been replaced by halogen atoms, especially fluorine or chlorine atoms. Preferred are fluoroC1-6alkyl and fluoroC1-6alkoxy groups, in particular fluoroC1-3alkyl and fluoroC1-3alkoxy groups, for example, CF3, CHF2, CH2F, CH2CH2F, CH2CHF2, CH2CF3, OCF3, OCHF2, OCH2F, OCH2CH2F, OCH2CHF2 or OCH2CF3, and most especially CF3, OCF3and OCHF2. The term "hydroxyC1-6alkyl" means a C1-6alkyl group in which one or more (in particular, 1 to 3) hydrogen atoms have been replaced by hydroxy groups. Preferred are CH2OH, CH2CHOH and CHOHCH3. As used herein, "aryl" or “aromatic ring” is intended to mean any stable monocyclic or bicyclic carbon ring of 6 to 10 atoms, wherein at least one ring is aromatic. Examples of such aryl elements include phenyl, naphthyl, tetrahydronaphthyl, indanyl and tetrahydrobenzo[7]annulene. The preferred aryl group is phenyl or naphthyl, especially phenyl. As used herein, "heteroaryl" or “heteroaromatic ring” is intended to mean any stable monocyclic or bicyclic ring containing 1, 2, 3 or 4 heteroatoms independently selected from N, O and S, wherein at least one ring is aromatic. In particular the term heteroaryl includes 5 membered aromatic heterocycles containing 1, 2, 3 or 4 heteroatoms independently selected from N, O and S , but not more than one of which is O or S; 6 membered aromatic heterocycles containing 1, 2 or 3 nitrogen atoms; or a 7-13 membered aromatic heterocycle containing heteroatoms independently selected from N, O or S of 5 to 10 atoms, wherein at least one ring is aromatic. Heteroaryl ring also includes partially saturated bicyclic systems, such as indoline, isoindoline, 4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine; further included are tautomeric structures, such as for example hydroxypyrimidine and hydroxypyrimidones. Examples of particular heteroaryl of this invention are benzimidazolyl, benzofurandionyl, benzofuranyl, benzofurazanyl, benzopyrazolyl, benzotriazolyl, benzothienyl, benzoxazolyl, benzoxazolonyl, benzothiazolyl, benzothiadiazolyl, benzodioxolyl, benzoxadiazolyl, benzoisoxazolyl, benzoisothiazolyl, chromenyl, chromanyl, isochromanyl, carbazolyl, carbolinyl, cinnolinyl, epoxidyl, furanyl, furazanyl, imidazolyl, imidazothiazolyl, indolinyl, indolyl, indolizinyl, isoindolinyl, indazolyl, isobenzofuranyl, isoindolyl, isoquinolyl, isothiazolyl, isoxazolyl, naphthpyridinyl, oxadiazolyl, oxazolyl, oxazolinyl, oxoquinazolinyl isoxazolinyl, oxetanyl, purinyl, pyranyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridopyridinyl, pyridazinyl, pyridinyl, pyrimidinyl, triazinyl, tetrazinyl, pyrrolyl, quinazolinyl, quinolyl, quinoxalinyl, quinolizinyl, tetrazolyl, tetrazolopyridyl, thiadiazolyl, thiazolidinyl, thiazolyl, thienyl, triazolyl, imidazopyridinyl, phthalazinyl, naphthyridinyl, quinazolinyl, pteridinyl, pyrimidin-4(3H)-one and N-oxides thereof. Attachment of a heterocycle substituent can occur via a carbon atom or via a heteroatom. Biphenyl indicates a phenyl ring substituted with a further phenyl ring; phenyl-heteroaryl indicates a phenyl ring substituted with an heteroaromatic ring; bis heteroaryl indicates and heteroaryl substituted with a further heteroaromatic ring. The terms “heterocyclic ring”, “heterocycloalkyl ring” and “cycloheteroalkyl ring” are used interchangeably in the present invention in the present invention and refer to a non-aromatic ring radical, which consists of carbon atoms and at least one heteroatom of nitrogen, phosphorus, oxygen or sulfur. The heterocyclic ring may be a mono-, bi-, tri-, or tetracyclic ring system, which may include fused, bridged or spiro ring systems, and the nitrogen, phosphorus, carbon, oxygen, or sulfur atoms in the heterocyclic ring radical may be optionally oxidized to various oxidation states. In addition, the nitrogen atom may be optionally quaternized. Examples of particular heterocyclic rings of the invention are tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiopyranyl, tetrahydroisoquinolinyl, azetidinyl, 1,4-dioxanyl, hexahydroazepinyl, piperazinyl, piperidyl, pyridin-2-onyl, pyrrolidinyl, imidazolinyl, pyrazolinyl, pyrrolinyl, morpholinyl, thiomorpholinyl, dihydrobenzoimidazolyl, dihydrobenzofuranyl, dihydrobenzothiophenyl, dihydrobenzoxazolyl, dihydroimidazolyl, dihydroindolyl, dihydroisooxazolyl, dihydroisothiazolyl, dihydrooxadiazolyl, dihydrooxazolyl, dihydropyrazinyl, dihydropyrazolyl, dihydropyridinyl, dihydropyrimidinyl, dihydropyrrolyl, dihydroquinolinyl, dihydrotetrazolyl, dihydrothiadiazolyl, dihydrothiazolyl, dihydrothienyl, dihydrotriazolyl, dihydroazetidinyl, dihydroisochromenyl, dihydroimidazolonyl, dihydrotriazolonyl, dihydrobenzodioxinyl, dihydrothiazolopyrimidinyl, methylenedioxybenzoyl, tetrahydrofuranyl, tetrahydrothienyl, tetrahydroquinolinyl, thiazolidinonyl, imidazolonyl, isoindolinonyl, octahydroquinolizinyl, octahydroisoindolyl, azabicycloheptanyl, chromenonyl, triazolopyrimidinyl, dihydrobenzoxazinyl, thiazolotriazolyl, azoniabicycloheptanyl, azoniabicyclooctanyl. Attachment of a heterocyclyl substituent can occur via a carbon atom or via a heteroatom. Preferred and non-limitative examples of cycloheteroalkyl rings including a spiro ring system are: 2-azaspiro[4.5]decan-8-yl, 2-azaspiro[3.5]nonan-7-yl and 1,4-dioxaspiro[4.5]decan-8-yl, wherein each of said ring can be substituted with, for example, halogens (preferably fluorine atoms) and / or C1-3alkyl (preferably methyl) and / or C1-3haloalkyl (preferably trifluoromethyl). A preferred 4 membered saturated heterocycle is azetidine. A further preferred 4 membered saturated heterocycle is oxetane. A preferred 5 membered saturated heterocycle is tetrahydrofurane. Preferred 6 membered saturated or partially saturated heterocycles are pyrrolidinyl, piperidyl, piperazinyl, morpholinyl, thiomorpholinyl and thiazolidinyl. Preferred 5 membered heteroaryls are thienyl, thiazolyl, pyrazolyl, isoxazolyl, imidazolyl, thiadiazolyl, oxazolyl, triazolyl, tetrazolyl, furyl and oxadiazolyl. Preferred 6 membered heteroaryls are pyridinyl and pyrymidinyl. Preferred 8-10 membered heteroaryls are benzothienyl, indolyl, benzothiadiazolyl, benzoxadiazolyl, thiazolotriazolyl, dihydrobenzodioxinyl, dihydrothiazolopyrimidinyl, dihydrobenzoxazinyl, dihydrobenzofuranyl, benzothiazolyl, quinolinyl, isoquinolinyl, benzimidazolyl, benzofuranyl, dihydrobenzoxazolyl, dihydroindolyl, dihydroquinazolinyl, dihydrophthalazinyl, indazolyl, benzisoxazolyl, benzotriazolyl, dihydroisoindolyl, tetrahydronaphthyridinyl, triazolopyrimidinyl and tetrahydroquinolinyl. As used herein, the term 'halogen' refers to fluorine, chlorine, bromine and iodine, of which fluorine, chlorine and bromine are preferred. As used herein, the term “amine” refers to linear and cyclic amines, such as methylamine, dimethylamine, diethylamine, isopropylamine, pyrrolidine, pyperidine and the like. A substutuent referred generically as “amine” indicates that an amine radical is linked through its nitrogen to the specific residue. In some instances, it is herein used the term “C1-6alkylamine” which refers to an alkyl group substituted with an amino group, such as -CH2NH2, -CH2NHCH3, CH2NHCH2CH3, CH2-pyrrolidine, CH2-piperidine and the like. As used herein, unless differently specified, an optionally substituted aryl, heteroaryl, cycloalkyl, heterocycloalkyl refer to any of said ring systems as above defined being optionally substituted with groups such as halogen, hydroxy, methyl, trifluoromethyl, amino, methylamino, and the like. The pharmaceutically acceptable salts of the instant compounds can be synthesized from the compounds of this invention which contain a basic or acidic moiety by conventional chemical methods. Generally, the salts of the basic compounds are prepared either by ion exchange chromatography or by reaction of the free base with stoichiometric amounts or with an excess of the desired salt-forming inorganic or organic acid in a suitable solvent or various combinations of solvents. Similarly, the salts of the acidic compounds are formed by reactions with the appropriate inorganic or organic base. Thus, pharmaceutically acceptable salts of the compounds of this invention include the conventional non-toxic salts of the compounds of this invention as formed by reaction of a basic instant compound with an inorganic or organic acid. For example, conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like, as well as salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxy-benzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, trifluoroacetic and the like. Preferably, a pharmaceutically acceptable salt of this invention contains one equivalent of a compound of formula (I) and 1, 2 or 3 equivalents of an inorganic or organic acid. More particularly, pharmaceutically acceptable salts of this invention are the tartrate, trifluoroacetate or the chloride salts. When the compound of the present invention is acidic, suitable “pharmaceutically acceptable salts” refers to salts prepared form pharmaceutically acceptable non-toxic bases including inorganic bases and organic bases. Salts derived from inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic salts, manganous, potassium, sodium, zinc and the like. Particularly preferred are the ammonium, calcium, magnesium, potassium and sodium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as arginine, betaine, caffeine, choline, N,N1-dibenzylethylenediamine, diethylamine, 2- diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N- ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine tripropylamine, tromethamine and the like. The preparation of the pharmaceutically acceptable salts described above, and other typical pharmaceutically acceptable salts is more fully described by Berg et al., “Pharmaceutical Salts,” J. Pharm. Sci., 1977:66:1-19. It will also be noted that the compounds of the present invention are potentially internal salts or zwitterions, since under physiological conditions a deprotonated acidic moiety in the compound, such as a carboxyl group, may be anionic, and this electronic charge might then be balanced off internally against the cationic charge of a protonated or alkylated basic moiety, such as a quaternary nitrogen atom. The compounds of the invention find use in a variety of applications for human and animal health. The compounds of the invention are flavivirus inhibitors and can be used in the treatment and / or prevention of flavivirus infections. The compounds of this invention may be administered to mammals, preferably humans, either alone or in combination with pharmaceutically acceptable carriers, excipients or diluents, in a pharmaceutical composition, according to standard pharmaceutical practice. In one embodiment, the compounds of this invention may be administered to animals. The compounds can be administered orally or parenterally, including the intravenous, intramuscular, intraperitoneal, subcutaneous, rectal and topical routes of administration. The invention also provides pharmaceutical compositions comprising one or more compounds of this invention and a pharmaceutically acceptable carrier. The pharmaceutical compositions containing the active ingredient may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs. Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets. These excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, microcrystalline cellulose, sodium croscarmellose, corn starch, or alginic acid; binding agents, for example starch, gelatin, polyvinyl-pyrrolidone or acacia, and lubricating agents, for example, magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques to mask the unpleasant taste of the drug or delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a water-soluble taste masking material such as hydroxypropyl-methylcellulose or hydroxypropyl-cellulose, or a time delay material such as ethyl cellulose, cellulose acetate butyrate may be employed. Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water soluble carrier such as polyethyleneglycol or an oil medium, for example peanut oil, liquid paraffin, or olive oil. Aqueous suspensions contain the active material in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethyl-cellulose, sodium alginate, polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose, saccharin or aspartame. Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in mineral oil such as liquid paraffin. The oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavoring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an antioxidant such as butylated hydroxyanisol or alpha-tocopherol. Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example sweetening, flavoring and coloring agents, may also be present. These compositions may be preserved by the addition of an antioxidant such as ascorbic acid. The pharmaceutical compositions of the invention may also be in the form of an oil-in-water emulsion. The oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin or mixtures of these. Suitable emulsifying agents may be naturally occurring phosphatides, for example soybean lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate. The emulsions may also contain sweetening, flavoring agents, preservatives and antioxidants. Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative, flavoring and coloring agents and antioxidant. The pharmaceutical compositions may be in the form of a sterile injectable aqueous solution. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. The sterile injectable preparation may also be a sterile injectable oil-in-water microemulsion where the active ingredient is dissolved in the oily phase. For example, the active ingredient may be first dissolved in a mixture of soybean oil and lecithin. The oil solution may be then introduced into a water and glycerol mixture and processed to form a microemulsion. The injectable solutions or microemulsions may be introduced into a patient's blood stream by local bolus injection. The pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleaginous suspension for intramuscular and subcutaneous administration. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example as a solution in 1,3-butanediol. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables. Compounds of the invention may also be administered in the form of suppositories for rectal administration of the drug. These compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Such materials include cocoa butter, glycerinated gelatin, hydrogenated vegetable oils, mixtures of polyethylene glycols of various molecular weights and fatty acid esters of polyethylene glycol. For topical use, creams, ointments, jellies, solutions or suspensions, etc., containing the compound of the invention are employed. The compounds of the present invention can be administered in intranasal form via topical use of suitable intranasal vehicles and delivery devices, or via transdermal routes, using those forms of transdermal skin patches well known to those of ordinary skill in the art. To be administered in the form of a transdermal delivery system, the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen. Compounds of the present invention may also be delivered as a suppository employing bases such as cocoa butter, glycerinated gelatin, hydrogenated vegetable oils, mixtures of polyethylene glycols of various molecular weights and fatty acid esters of polyethylene glycol. When a compound according to this invention is administered into a human subject, the daily dosage regimen will normally be determined by the prescribing physician with the dosage generally varying according to the age, weight, sex and response of the individual patient, as well as the severity of the patient's symptoms. The instant compounds are also useful in combination with known therapeutic agents for simultaneous, separate or sequential administration. The term "administration" and variants thereof (e.g., "administering" a compound) in reference to a compound of the invention means introducing the compound or a prodrug of the compound into the system of the subject in need of treatment. When a compound of the invention or prodrug thereof is provided in combination with one or more other active agents (e.g., a cytotoxic agent, etc.), "administration" and its variants are each understood to include concurrent and sequential introduction of the compound or prodrug thereof and other agents. As used herein, the term "composition" is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts. The term "therapeutically effective amount" as used herein means that amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue, system, animal or human that is being sought by a researcher, veterinarian, medical doctor or other clinician. When a compound of the present invention is administered into a human subject, the daily dosage regimen will normally be determined by the prescribing physician, with the dosage generally varying according to the age, weight, and response of the individual patient, as well as the severity of the patient’s symptoms. In one exemplary application, oral dosages of the present invention will range between about 0.01 mg per kg of body weight per day (mg / kg / day) to about 100 mg / kg / day, preferably 0.01 to 10 mg / kg / day, and most preferably 0.1 to 5.0 mg / kg / day. It is a further object of the invention a method treating, ameliorating or preventing a Flavivirus infection and related conditions in a subject, preferably wherein the Flavivirus is selected from the group consisting of Dengue, West Nile, Zika and Japan Encephalitis virus, comprising administering to said subject a therapeutically effective amount of the compound as defined above. These and other aspects of the invention will be apparent from the teachings contained herein. Chemistry General The compounds, or pharmaceutically acceptable salts thereof, compositions, and methods described herein are further illustrated by the following non-limiting examples. As used herein, the following abbreviations have the following meanings. If an abbreviation is not defined, it has its generally accepted meaning. Boc2O: Di-tert-butyl decarbonate; DCM: Dichloromethane; DIPEA: N,N-Diisopropylethylamine; DMF: Dimethylformamide; DMSO: Dimethylsulfoxide; ES+: Electrospray Positive Ionisation; EtOAc: Ethyl acetate; EtOH: Ethanol; h: Hour; HATU: Hexafluorophosphate Azabenzotriazole Tetramethyl Uronium; HPLC: High Performance Liquid Chromatography; LiBH4: Lithium borohydride; LiOH: Lithium hydroxide; LCMS: Liquid Chromatography Mass Spectrometry; KOAc: Potassium acetate; K2CO3: Potassium carbonate; K3PO4: tripotassium phosphate; MeCN: Acetonitrile; MeOH: Methanol; min: Minute; NaH: Sodium Hydride; NH3: ammonium; NMP: N- Methylpyrrolidone; NMR: Nuclear Magnetic Resonance; NH2NH2: Hydrazine; NaCNBH3: Sodium cyanoborohydride; Pd(dppf)Cl2: (1,1'-Bis(diphenylphosphino)ferrocene)-palladium(II) dichloride; Pd(OAc)2: Palladium(II) acetate; PCy3: triclyclohexylphosphine; Py: pyridine; RP: Reverse Phase; tR: Retention time; rt: room temperature;tBuONO: tert-Butyl nitrite; TEA: Triethylamine; TIPS: Triisopropylsilyl ether; TFA: Trifluoroacetic acid; THF: Tetrahydrofurane; UPLC: Ultra High Performance Liquid Chromatography. General experimental details Solvents and reagents were obtained from commercial suppliers and were used without further purification. Flash chromatography purifications were performed on prepacked cartridges on a Biotage system. Purity of final compounds was determined using MS and UPLC. UPLC-MS analyses were performed on a Waters Acquity UPLCTM, equipped with a diode array and a ZQ mass spectrometer, using an X-Terra C18 column (5 μm, 4.6 x 50 mm) or a BEH C18 column (1.7 mm, 2.1 x 50 mm). Mobile phase comprised a linear gradient of binary mixtures of H2O containing 0.1% formic acid (A), and MeCN containing 0.1% formic acid (B). The linear gradient used is: (A): 90% (0.1 min), 90%-0% (2.6 min), 0% (0.3 min), 0%-90% (0.1 min) with a 0.5 mL / min flow. The purity of final compounds was ≥95%. All1H spectra were recorded on Bruker AV400 spectrometer at 400 MHz except where indicated. Chemical shift (δ) are reported in parts per million relative to TMS using CDCl3 as a solvent or relative to the residual solvent signal using DMSO-d6. Coupling costants (J) are reported in Hertz (Hz). Multiplicities are reported as singlet (s), broad (br), doublet (d), doublet of doublet (dd), doublet of doublet of doublet (ddd), triplet (t), doublet of triplet (dt), doublet of doublet of triplet (ddt), triplet of triplet (tt), quartet (q), doublet of quartets (dq) or multiplet (m). Unless indicated, spectra were acquired at 300 K. Temperatures are expressed in degrees Celsius (°C) and are uncorrected. Unless otherwise indicated, commercially available reagents and solvents (HPLC grade) were used without further purification. Where the synthesis of intermediates and starting materials is not described, these compounds are commercially available or can be made from commercially available compounds by standard methods or by extension of the Examples herein. During any of the synthetic sequences described herein it may be necessary and / or desirable to protect sensitive or reactive groups or any of the molecules concerned, this may be achieved by means of conventional protecting groups, such as those described in Protecting Groups in Organic Synthesis (3rdEdition, Greene, T.W. and Wuts, P.G.M.; Wiley Interscience, 1999) and Protecting Groups (Kocienski, P.J.; Thieme, 1994). Synthesis of Intermediates 1-9 Intermediate 1: N-(3-Amino-5-(trifluoromethyl)phenyl)-2-phenylacetamide Scheme 1 Step 1: N-(3-Nitro-5-(trifluoromethyl)phenyl)-2-phenylacetamide. A solution of 3-nitro-5-(trifluoromethyl)aniline (300 mg, 1.46 mmol) and HATU (830 mg, 2.18 mmol) in dry DMF (8 mL) was treated with DIPEA (0.77 mL, 4.37 mmol) followed by 2- phenylacetic acid (297 mg, 2.18 mmol) and the reaction mixture was stirred at rt for 18 h before being diluted with EtOAc (45 mL) and H2O (15 ml); the organic layer was separated, washed with brine and dried under reduced pressure to get a residue which was purified by flash chromatography on silica gel (eluting with 10-25% EtOAc in petroleum ether) to get the title compound as a yellow solid (387 mg, 82%).1H NMR (400 MHz, DMSO-d6) ^ 10.98 (s, 1H), 8.76 (br s, 1H), 8.39 (s, 1H), 8.16 (s, 1H), 7.36-7.28 (m, 5H), 3.73 (s, 2H). LCMS (ES+) m / z calculated for C15H11F3N2O3324.07, found 323 (M-H)-. HPLC tR 2.03 min. Step 2: N-(3-Amino-5-(trifluoromethyl)phenyl)-2-phenylacetamide (Intermediate 1). A solution of N-(3-nitro-5-(trifluoromethyl)phenyl)-2-phenylacetamide (387 mg, 1.19 mmol) in MeOH (14 mL) was treated with Pd (10% on C, 40 mg, 0.38 mmol) and stirred under an H2atmosphere at rt for 18 h. After removal of H2the reaction mixture was filtered on a pad of Celite and the solvent removed under reduced pressure to get a residue which was purified by RP chromatography on silica gel (eluting with 20-55% CH3CN in H2O) to get the title compound as a white solid (310 mg, 88%).1H NMR (400 MHz, DMSO-d6) ^ 10.15 (s, 1H), 7.33-7.32 (m, 4H), 7.28-7.23 (m, 1H), 7.10 (br s, 1H), 7.07 (br s, 1H), 6.53 (br s, 1H), 5.60 (br s, 2H), 3.61 (s, 2H).19F NMR (377 MHz, DMSO-d6) ^ -61.73 (s, 3F). LCMS (ES+) m / z calculated for C15H13F3N2O 294.10, found 293 1.66 min. Intermediate 2: N-(3-Isocyanato-5-(trifluoromethyl)phenyl)-2-phenylacetamide Scheme 2 Step 1: N-(3-Isocyanato-5-(trifluoromethyl)phenyl)-2-phenylacetamide (Intermediate 2). A solution of N-(3-amino-5-(trifluoromethyl)phenyl)-2-phenylacetamide (Intermediate 1, 78.19 mg, 0.27 mmol) and diphosgene (0.1 mL, 0.80 mmol) in dry dioxane (4 mL) was heated at 60 °C for 20 h. After cooling the solvent was removed under reduced pressure to get the title compound (85 mg, 99%) which was used in the next step without further purification. Intermediate 3: N-(3-Cyclopropyl-5-isocyanatophenyl)-2-phenylacetamide Scheme 3 Step 1: 3-Cyclopropyl-5-nitroaniline. A solution of 3-bromo-5-nitroaniline (500 mg, 2.3 mmol), PCy3(77 mg, 0.28 mmol), cyclopropylboronic acid (297 mg, 3.46 mmol), Pd(OAc)2 (26 mg, 0.12 mmol) and K3PO4 (978 mg, 4.61 mmol) in a degassed mixture of toluene (8 mL) and H2O (2 mL) was stirred at 100 °C for 2 h. After cooling the mixture was diluted with EtOAC, washed with brine, dried over Na2SO4, and concentrated under reduced pressure to get a residue which was purified by flash chromatography on silica gel (eluting with 0-20% EtOAc in petroleum ether) to get the title compound (206 mg, 40% pure, 20%) which was used without further purification. LCMS (ES+) m / z calculated for C9H10N2O2178.07, found 179 (M+H)+. HPLC tR 1.62 min. Step 2: N-(3-Cyclopropyl-5-nitrophenyl)-2-phenylacetamide. A solution of 3-cyclopropyl-5-nitroaniline (206 mg, 1.16 mmol) and HATU (659 mg, 1.73 mmol) in dry DMF (10 mL) was treated with DIPEA (448 mg, 3.47 mmol) followed by 2- phenylacetic acid (189 mg, 1.39 mmol) and the reaction mixture was stirred at rt for 12 h before being diluted with EtOAc; the organic phase was washed with NaHCO3(sat. aqueous solution), brine and dried under reduced pressure to get a residue which was purified by flash chromatography on silica gel (eluting with 0-25% EtOAc in petroleum ether) to get the title compound as a yellow solid (89.6 mg, 26%).1H NMR (400 MHz, DMSO-d6) ^ 10.56 (s, 1H), 8.39 (br t, J = 1.9 Hz, 1H), 7.63 (br d, J = 1.8 Hz, 2H), 7.34-7.33 (m, 4H), 7.29-7.25 (m, 1H), 3.68 (s, 2H), 2.12-2.06 (m, 1H), 1.08-1.03 (m, 2H), 0.76-0.72 (m, 2H). LCMS (ES+) m / z calculated for C17H16N2O3296.12, found 297 (M+H)+. HPLC tR1.94 min. Step 3: N-(3-Amino-5-cyclopropylphenyl)-2-phenylacetamide. A solution of N-(3-cyclopropyl-5-nitrophenyl)-2-phenylacetamide (85 mg, 0.29 mmol) and NH4Cl (38 mg, 0.72 mmol) in a mixture of EtOH (5 mL) and H2O (2 mL) was treated with iron (80.1 mg, 1.43 mmol) and heated at 100 °C for 3 h before being diluted with EtOAc; the organic phase was washed with NaHCO3 (sat. aqueous solution), brine and dried under reduced pressure to get the title compound (71.7 mg, 94%) which was used without further purification.1H NMR (400 MHz, DMSO-d6) ^ 9.75 (s, 1H), 7.32-7.31 (m, 4H), 7.28-7.21 (m, 1H), 6.70 (br s, 1H), 6.44 (br s, 1H), 5.99 (br s, 1H), 4.94 (br s, 2H), 3.56 (s, 2H), 1.71-1.65 (m, 1H), 0.86-0.82 (m, 2H), 0.52-0.49 (m, 2H). LCMS (ES+) m / z calculated for C17H18N2O 266.14, found 267 (M+H)+. HPLC 1.21 min. Step 4: N-(3-Cyclopropyl-5-isocyanatophenyl)-2-phenylacetamide (Intermediate 3). A solution of N-(3-amino-5-cyclopropylphenyl)-2-phenylacetamide (75 mg, 0.28 mmol) in dry dioxane (5 mL) was treated with diphosgene (0.1 mL, 0.84 mmol) and stirred at 60 °C for 18 h. After cooling the solvent was removed under reduced pressure to get the title compound (82 mg, 99%) which was used without further purification. Intermediate 4: 1-Isocyanato-3-nitro-5-(trifluoromethyl)benzene Scheme 4 Step 1: 1-Isocyanato-3-nitro-5-(trifluoromethyl)benzene (Intermediate 4). A mixture of 3-nitro-5-(trifluoromethyl)aniline (100 mg, 0.49 mmol) and diphosgene (0.17 mL, 1.46 mmol) in dry dioxane (30 mL) was heated at 60 °C for 16 h. After cooling the solvent was removed under reduced pressure to get the title compound (112 mg, 99%) which was used as such without further purification. Intermediate 5: tert-Butyl (tert-butoxycarbonyl)(3-isocyanato-5-(trifluoromethyl)phenyl)- Carbamate Scheme 5 Step 1: tert-Butyl (tert-butoxycarbonyl)(3-nitro-5-(trifluoromethyl)phenyl)carbamate. A solution of 3-nitro-5-(trifluoromethyl)aniline (500 mg, 2.43 mmol) in DCM (20 mL) was treated with TEA (0.33 mL, 2.43 mmol), DMAP (296 mg, 2.43 mmol) and Boc2O (2.12 g, 9.7 mmol) at 0 °C and stirred at rt for 15 h before being washed with H2O, NaHCO3(sat. aqueous solution) and brine, dried over Na2SO4, and evaporated under reduced pressure to get a residue which was purified by flash chromatography on silica gel (eluting with 30% EtOAc in petroleum ether) to get the title compound as a light yellow solid (844 mg, 86%).1H NMR (400 MHz, DMSO-d6) ^ 8.54 (br s, 1H), 8.47 (br s, 1H), 8.34 (br s, 1H), 1.40 (s, 18H). LCMS (ES+) m / z calculated for C17H21F3N2O6406.14, found 305 (M-H-Boc)-. HPLC tR2.48 min. Step 2: tert-Butyl (3-amino-5-(trifluoromethyl)phenyl)(tert-butoxycarbonyl)carbamate. A solution of tert-butyl (tert-butoxycarbonyl)(3-nitro-5-(trifluoromethyl)phenyl)carbamate (840 mg, 2.07 mmol) in a mixture of MeOH (10 mL) and EtOAc (10 mL) was treated with Pd / C (10% wt, 160 mg, 1.5 mmol) and stirred under H2atmosphere at rt for 12 h. After removal of H2the solution was filtered on a pad of Celite and the solvent removed under reduced pressure to get the title compound as a white solid (756 mg, 97%).1H NMR (400 MHz, DMSO-d6) ^ 6.59 (br s, 1H), 6.39 (br s, 1H), 6.36 (br s, 1H), 5.51 (br s, 2H), 1.20 (s, 18H). LCMS (ES+) m / z calculated for C17H23F3N2O4376.16, found 277 (M+H-Boc)+. HPLC tR2.29 min. Step 3: tert-Butyl (tert-butoxycarbonyl)(3-isocyanato-5-(trifluoromethyl)phenyl)carbamate (Intermediate 5). A mixture of tert-butyl (3-amino-5-(trifluoromethyl)phenyl)(tert-butoxycarbonyl)carbamate (120mg, 0.32 mmol) and diphosgene (0.06 mL, 0.48 mmol) in dry dioxane (10 mL) was heated at 60 °C for 12 h. After cooling the solvent was removed under reduced pressure to get the title compound (128 mg, 99%) which was used as such in the next reactions. Intermediate 6: 2-(3-(Aminomethyl)benzyl)isoindoline-1,3-dione hydrochloride Scheme 6 Step 1: tert-Butyl (3-((1,3-dioxoisoindolin-2-yl)methyl)benzyl)carbamate. A suspension of tert-butyl (3-(aminomethyl)benzyl)carbamate hydrochloride (300 mg, 1.10 mmol) in a mixture of H2O (15 mL) and THF (10 mL) was treated with ethyl 1,3- dioxoisoindoline-2-carboxylate (289 mg, 1.32 mmol) and Na2CO3 (350 mg, 3.3 mmol) and vigorously stirred at rt for 18 h before being treated with H2O (20 mL) and EtOAc. The organic phase was washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure to get the title compound as a white solid (340 mg, 84%) which was used without further purification. LCMS (ES+) m / z calculated for C21H22N2O4366.16. found 367 (M+H)+. HPLC tR 2.09 min. Step 2: 2-(3-(Aminomethyl)benzyl)isoindoline-1,3-dione hydrochloride (Intermediate 6). A solution of tert-butyl (3-((1,3-dioxoisoindolin-2-yl)methyl)benzyl)carbamate (199 mg, 0.54 mmol) in dioxane (5.0 mL) was treated with HCl (4 N in dioxane, 5.0 mL) and stirred at rt for 4 h before being concentrated under reduced pressure to get the title compound (164 mg, 99%) which was used without further purification.1H NMR (400 MHz, DMSO-d6) ^ 8.19 (br s, 3H), 7.94-7.87 (m, 4H), 7.40-7.35 (m, 4H), 4.80 (s, 2H), 3.99 (s, 2H). LCMS (ES+) m / z calculated for C16H14N2O2266.11, found 267 (M+H)+. HPLC tR 0.98 min. Intermediate 7: 2-(4-(Aminomethyl)benzyl)isoindoline-1,3-dione hydrochloride Scheme 7 Step 1: tert-Butyl (4-((1,3-dioxoisoindolin-2-yl)methyl)benzyl)carbamate. A solution of tert-butyl (4-(aminomethyl)benzyl)carbamate (500 mg, 2.12 mmol) and isobenzofuran-1,3-dione (345 mg, 2.33 mmol) in toluene (10 mL) was heated at reflux using a dean stark apparatus for 1 h. After cooling, the excess of solvent was removed under reduced pressure to give a residue which was dissolved in DMF (6.0 mL) and treated with HATU (802 mg, 2.11 mmol) and DIPEA (1.13 mL, 6.33 mmol) and stirred at rt for 20 h before being diluted with H2O and EtOAc. The organic phase was washed with brine, dried over Na2SO4, and evaporated under reduced pressure to get a residue which was purified by flash chromatography on silica gel (eluting with 0-100% EtOAc in petroleum ether) to get the title compound as a yellow solid (364 mg, 47%).1H NMR (400 MHz, CDCl3) ^ 7.87-7.84 (m, 2H), 7.74-7.72 (m, 2H), 7.42 (d, J=7.9 Hz, 2H), 7.28-7.24 (m, 3H), 4.85 (s, 2H), 4.29 (br d, J=5.0 Hz, 2H), 1.46 (s, 9H). LCMS (ES+) m / z calculated for C21H22N2O4366.16. HPLC tR 1.91 min. Step 2: 2-(4-(Aminomethyl)benzyl)isoindoline-1,3-dione hydrochloride (Intermediate 7). A solution of tert-butyl (4-((1,3-dioxoisoindolin-2-yl)methyl)benzyl)carbamate (364 mg, 0.99 mmol) in HCl (4 N in dioxane, 2.0 mL) was stirred at rt for 30 min. before being concentrated under reduced pressure to get the title compound as a yellow powder (300 mg, 99%) which was used without further purification. LCMS (ES+) m / z calculated for C16H14N2O2266.11, found 267 (M+H)+. HPLC tR 0.89 min. Intermediate 8: (1-(2,2,2-Trifluoroethyl)piperidin-2-yl)methanamine hydrochloride Scheme 8 Step 1: tert-Butyl ((1-(2,2,2-trifluoroethyl)piperidin-2-yl)methyl)carbamate. A solution of tert-butyl (piperidin-2-ylmethyl)carbamate (100 mg, 0.47 mmol) in CH3CN (2.3 mL) was treated with K2CO3 (194 mg, 1.4 mmol) and 2,2,2-trifluoroethyl trifluoromethanesulfonate (0.1 mL, 0.7 mmol) and heated at 75 °C for 5 h. After cooling, the reaction mixture was portioned between EtOAc and H2O, phases were separated, and the aqueous phase was extracted with EtOAc. Combined organics were washed with brine, dried over Na2SO4, and evaporated under reduced pressure to get a residue which was purified by flash chromatography on silica gel (eluting with 0-50% EtOAc in petroleum ether) to get the title compound (138 mg, 99%).1H NMR (400 MHz, DMSO-d6) ^ 6.74 (br s, 1H), 3.40-3.10 (m, 3H), 3.09-2.82 (m, 2H), 2.55-2.48 (m, 2H), 1.60-1.55 (m, 2H), 1.48-1.40 (m, 2H), 1.38 (s, 9H), 1.36- 1.25 (m, 2H).19F NMR (377 MHz, DMSO-d6) ^ -69.47 (s, 3F). LCMS (ES+) m / z calculated for C13H23F3N2O2296.17, found 297 2.05 min. Step 2: (1-(2,2,2-Trifluoroethyl)piperidin-2-yl)methanamine hydrochloride (Intermediate 8). A solution of tert-butyl ((1-(2,2,2-trifluoroethyl)piperidin-2-yl)methyl)carbamate (138 mg, 0.47 mmol) in HCl (4 N in dioxane, 1.5 mL) was stirred at rt for 18 h before being concentrated under reduced pressure to get the title compound as an off-white sticky powder (174.8 mg, 99%) which was used without further purification.19F NMR (377 MHz, DMSO-d6) ^ -69.57 (s, 3F). LCMS (ES+) m / z calculated for C8H15F3N2196.12, found 197 (M+H)+. Intermediate 9: Methyl 3-isocyanato-5-(trifluoromethyl)benzoate Scheme 9 Step 1: Methyl 3-isocyanato-5-(trifluoromethyl)benzoate (Intermediate 9). Triphosgene (34 mg, 0.11 mmol) was dissolved in DCM (0.5 mL). In a separate flask, methyl 3- amino-5-(trifluoromethyl)benzoate (50 mg, 0.23 mmol) was dissolved in a 1:1 mixture of saturated aqueous sodium bicarbonate and DCM (2.0 mL) and the mixture was cooled to 0 °C. Stirring was stopped and the triphosgene solution was added directly to the organic phase of the biphasic reaction mixture. The reaction was then stirred at 0 °C for 30 min, warmed to rt and stirred for 16 h. The reaction mixture was transferred to a separatory funnel and extracted with DCM (3 x 20 mL). The organic phase was washed with brine, dried over Na2SO4, filtered and evaporated under reduced pressure to get the title compound (65 mg, 65% pure, 76%) as a light- yellow powder which was used without further purification. Example 1: (3-(4-(2-Methoxy-4-methylpyrimidin-5-yl)benzyl)-1,2,3-oxadiazol-3-ium-5- yl)((3-(2-phenylacetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide Scheme 10 Step 1: 2-((4-Bromobenzyl)amino)acetonitrile (Intermediate 10). A suspension of 4-bromobenzylamine (10 g, 53.75 mmol) in CH3CN (65 mL) was treated with DIPEA (19 mL, 107.5 mmol) and 2-bromoacetonitrile (3.74 mL, 53.75 mmol) and stirred at rt for 24 h. Solvent was removed under reduced pressure and the residue treated with H2O and extracted with EtOAc. The organic phase was washed with brine, dried over Na2SO4, and evaporated under reduced pressure to get the title compound as a light orange oil (11.03 g, 91%).1H NMR (400 MHz, DMSO-d6) ^ 7.52 (d, J = 8.1 Hz, 2H), 7.29 (d, J = 8.1 Hz, 2H), 3.73 (br s, 2H), 3.59 (br s, 2H), 3.10 (br s, 1H). LCMS (ES+) m / z calculated for C9H9BrN2223.99, found 225-227 (M+H)+. HPLC tR1.19 min. Step 2: 5-Amino-3-(4-bromobenzyl)-1,2,3-oxadiazol-3-ium chloride (Intermediate 11). A solution of 2-((4-bromobenzyl)amino)acetonitrile (11 g, 48.87 mmol) in dry THF (25 mL) was treated with tert-butyl nitrite (17.5 mL, 146.61 mmol) and stirred at rt for 1 h before being treated with 4 N HCl in dioxane (36.2 mL, 305.43 mmol). The reaction mixture was stirred at rt for 18 h and then quenched with Et2O. After removal the solvent the title product was obtained as a white powder (8.2 g, 57%).1H NMR (400 MHz, DMSO-d6) ^ 9.77 (s, 2H), 8.16 (s, 1H), 7.68 (d, J = 8.3 Hz, 2H), 7.55 (d, J = 8.3 Hz, 2H), 5.91 (s, 2H). LCMS (ES+) m / z calculated for C9H9BrN3O 253.99, found 255-257 (M+H)+. HPLC tR0.92 min. Step 3: 3-(4-Bromobenzyl)-5-((tert-butoxycarbonyl)amino)-1,2,3-oxadiazol-3-ium (Intermediate 12). A solution of 5-amino-3-(4-bromobenzyl)-1,2,3-oxadiazol-3-ium chloride (2.3 g, 7.96 mmol) in a mixture of H2O (40 mL) and acetone (30 mL) was treated with Boc2O (10.4 g, 47.74 mmol). NaHCO3(0.8 g, 9.55 mmol) in H2O (15 mL) was slowly added to the reaction mixture and the solution was stirred at rt for 18 h before being extracted with EtOAc, washed with H2O and brine, dried over Na2SO4, filtered, and concentrated under reduced pressure to get the title compound as a white powder (2.3 g, 82%).1H NMR (400 MHz, DMSO-d6) ^ 8.06 (s, 1H), 7.67 (br d, J = 8.6 Hz, 2H), 7.52 (br d, J = 8.3 Hz, 2H), 5.76 (s, 2H), 1.39 (s, 9H). LCMS (ES+) m / z calculated for C14H16BrN3O3353.04, found 354-356 (M+H)+. HPLC tR1.57 min. Step 4: (tert-Butoxycarbonyl)(3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)-1,2,3- oxadiazol-3-ium-5-yl)amide (Intermediate 13). A solution of 3-(4-bromobenzyl)-5-((tert-butoxycarbonyl)amino)-1,2,3-oxadiazol-3-ium (1.7 g, 4.8 mmol), KOAc (1.4 g, 14.4 mmol), Pd(dppf)Cl2(356 mg, 0.48 mmol) and 4,4,5,5-tetramethyl- 2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane (1.8 g, 7.2 mmol) in dioxane (30 mL) was heated at 65 °C for 18 h before being diluted with EtOAc. The organic phase was washed with H2O, brine, dried over Na2SO4, filtered, and concentrated under reduced pressure to get the title compound (1.9 g, 99%) which was used without further purification.1H NMR (400 MHz, DMSO-d6) ^ 7.95 (s, 1H), 7.67 (d, J = 7.9 Hz, 2H), 7.47 (d, J = 7.9 Hz, 2H), 5.73 (s, 2H), 1.31 (s, 9H), 1.22 (s, 12H). LCMS (ES+) m / z calculated for C20H28BN3O5401.21, found 402 (M+H)+. HPLC tR 1.81 min. Step 5: (tert-Butoxycarbonyl)(3-(4-(2-methoxy-4-methylpyrimidin-5-yl)benzyl)-1,2,3-oxadiazol- 3-ium-5-yl)amide (Intermediate 14). A solution of (tert-butoxycarbonyl)(3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)- 1,2,3-oxadiazol-3-ium-5-yl)amide (1.7 g, 4.24 mmol), Pd(dppf)Cl2(315 mg, 0.42 mmol), 5- bromo-2-methoxy-4-methylpyrimidine (1.1 g, 5.51 mmol) and K3PO4 (2.7 g, 12.71 mmol) in a mixture of dioxane (40 mL) and H2O (4 mL) was stirred at 70 °C for 1 h. After cooling the solution was diluted with EtOAc. The organic phase was washed with H2O, brine, dried over Na2SO4, filtered, and concentrated under reduced pressure to get a residue which was purified by flash chromatography on silica gel (eluting with 10-100% EtOAc in petroleum ether) to get the title compound (835 mg, 50%). LCMS (ES+) m / z calculated for C20H23N5O4397.18, found 396 (M- H)-. HPLC tR1.41 min. Step 6: 5-Amino-3-(4-(2-methoxy-4-methylpyrimidin-5-yl)benzyl)-1,2,3-oxadiazol-3-ium 2,2,2- trifluoroacetate (Intermediate 15). A solution of (tert-butoxycarbonyl)(3-(4-(2-methoxy-4-methylpyrimidin-5-yl)benzyl)-1,2,3- oxadiazol-3-ium-5-yl)amide (835.0 mg, 2.1 mmol) in a mixture of TFA / DCM / H2O (1.0 mL / 8.5 mL / 0.5 mL) was treated with TIPS (400 mg, 2.1 mmol) and stirred at rt for 48 h. After removal of the solvent under reduced pressure the title compound was obtained (835 mg, 96%).1H NMR (400 MHz, DMSO-d6) ^ 9.34 (s, 2H), 8.25 (s, 1H), 7.93 (s, 1H), 7.52 (d, J = 8.1 Hz, 2H), 7.38 (d, J = 8.3 Hz, 2H), 5.79 (s, 2H), 3.79 (s, 3H), 2.23 (s, 3H). LCMS (ES+) m / z calculated for C15H16N5O2+298.13, found 298 (M+H)+. HPLC tR0.96 min. Step 7: (3-(4-(2-Methoxy-4-methylpyrimidin-5-yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- phenylacetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide (Example 1). A solution of N-(3-amino-5-(trifluoromethyl)phenyl)-2-phenylacetamide (Intermediate 1; 53.52 mg, 0.18 mmol) in THF (3 mL) at 0 °C was treated with TEA (0.05 mL, 0.36 mmol) and triphosgene (36.0 mg, 0.12 mmol) and stirred for 1 h. Diethyl ether (2 mL) was added and the mixture was stirred for 5 minutes before being filtered to afford a clear solution (A). In the meanwhile a solution of 5-amino-3-(4-(2-methoxy-4-methylpyrimidin-5-yl)benzyl)-1,2,3- oxadiazol-3-ium 2,2,2-trifluoroacetate (50.0 mg, 0.12 mmol) in THF (3.0 mL) at 0 °C was treated with NaH (60% in mineral oil; 5.8 mg, 0.24 mmol). Solution (A) was added dropwise, and the mixture stirred for 5 min. before being diluted with EtOAc. The organic phase was washed with H2O, brine, dried over Na2SO4, filtered, and concentrated under reduced pressure to get a residue which was purified by flash chromatography on silica gel (eluting with 1-6% MeOH in DCM) to get the title compound as a light orange solid (15 mg, 20%).1H NMR (400 MHz, DMSO-d6) ^ 10.34 (s, 1H), 9.67 (s, 1H), 8.35 (s, 1H), 8.14 (s, 1H), 7.91 (br s, 1H), 7.69 (br s, 1H), 7.62 (br d, J = 8.1 Hz, 2H), 7.46 (br d, J = 8.1 Hz, 2H), 7.26-7.23 (m, 5H), 7.20-7.16 (m, 1H), 5.78 (s, 2H), 3.87 (s, 3H), 3.57 (s, 2H), 2.32 (s, 3H).19F NMR (377 MHz, DMSO-d6) ^ -61.59 (s, 3F). LCMS (ES+) m / z calculated for C31H26F3N7O4617.20; found 616 (M-H)-. HPLC tR 2.00 min. Example 3: ((3-Amino-5-(trifluoromethyl)phenyl)carbamoyl)(3-(4-(2-methoxy-4- methylpyrimidin-5-yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)amide Scheme 11 Step 1: (3-(Bis(tert-butoxycarbonyl)amino)-5-(trifluoromethyl)phenyl)carbamoyl)(3-(4-(2- methoxy-4-methylpyrimidin-5-yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)amide (Intermediate 16). A solution of 5-amino-3-(4-(2-methoxy-4-methylpyrimidin-5-yl)benzyl)-1,2,3-oxadiazol-3-ium 2,2,2-trifluoroacetate (Intermediate 15) (50 mg, 0.12 mmol) in MeCN (2 mL) was treated with a solution of tert-butyl (tert-butoxycarbonyl)(3-isocyanato-5-(trifluoromethyl)phenyl)carbamate (Intermediate 5) (97 mg, 0.24 mmol) in THF (2 mL) followed by pyridine (0.04 mL, 0.49 mmol) and stirred at rt for 10 min. before being diluted with EtOAc and H2O. The phases were separated, and the organic phase was washed with H2O and brine, dried over Na2SO4, filtered, and concentrated under reduced pressure to get the title compound (84.8 mg, 99%) which was used in the next step without further purification. LCMS (ES+) m / z calculated for C33H36F3N7O7699.26, found 698 (M-H)-. HPLC tR 2.59 min. Step 2: (3-Amino-5-(trifluoromethyl)phenyl)carbamoyl)(3-(4-(2-methoxy-4-methylpyrimidin-5- yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)amide (Example 3). A solution of ((3-(bis(tert-butoxycarbonyl)amino)-5-(trifluoromethyl)phenyl)carbamoyl)(3-(4- (2-methoxy-4-methylpyrimidin-5-yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)amide (Intermediate 16) (50 mg, 0.07 mmol) in a mixture of TFA / DCM / H2O (1.0 mL / 8.5 mL / 0.5 mL) was treated with TIPS (catalytic amount) and stirred at rt for 12 h before being diluted with EtOAc and washed with NaHCO3(sat. aqueous solution), H2O, and brine. After removal of the solvent under reduced pressure the title compound was obtained after purification by automated RP-HPLC using water (+ 0.1% TFA) and CH3CN (+ 0.1% TFA) as eluents (C18 column). Fractions containing product were lyophilized to give the title compound as a yellow solid (25.9 mg, 59%).1H NMR (400 MHz, DMSO-d6) ^ 9.48 (s, 1H), 8.43 (s, 1H), 8.22 (s, 1H), 7.69 (br d, J = 8.3 Hz, 2H), 7.53 (br d, J = 8.3 Hz, 2H), 7.33 (br s, 1H), 7.09 (br s, 1H), 6.49 (br s, 1H), 5.85 (s, 2H), 3.94 (s, 3H), 2.39 (s, 3H).19F NMR (377 MHz, DMSO-d6) ^ -61.60 (s, 3F). LCMS (ES+) m / z calculated for C23H20F3N7O3499.16, found 498 1.74 min. General procedures A and B for the synthesis of Examples 8-11, 15-22 Scheme 12: Synthesis of Examples 8-11, 15-22 General procedure A. Step 1. A solution of ((3-amino-5-(trifluoromethyl)phenyl)carbamoyl)(3-(4-(2-methoxy-4- methylpyrimidin-5-yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)amide (Example 3) (5.0 mg, 0.01 mmol, 1 eq.) and HATU (5.7 mg, 0.015 mmol, 1.5 eq.) in dry DMF (1.0 mL) was treated with DIPEA (0.01 mL, 0.03 mmol, 3 eq.) followed by the corresponding carboxylic acid (0.015 mmol, 1.5 eq.) and the reaction mixture was stirred at rt for 16 h. The title compound was obtained after purification by automated RP-HPLC using water (+ 0.1% TFA) and MeCN (+ 0.1% TFA) as eluents (C18 column). Fractions containing product were lyophilized to give the desired compound. General procedure B. Step 2. A solution of ((3-amino-5-(trifluoromethyl)phenyl)carbamoyl)(3-(4-(2-methoxy-4- methylpyrimidin-5-yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)amide (Example 3) (5.0 mg, 0.01 mmol, 1 eq.) and the corresponding acid chloride or sulphonyl chloride (0.02 mmol, 2 eq.) in dry THF (1.5 mL) was treated with TEA (0.004 mL, 0.03 mmol, 3 eq.) and the reaction mixture was stirred at rt for 16 h. The title compound was obtained after purification by automated RP-HPLC using water (+ 0.1% TFA) and CH3CN (+ 0.1% TFA) as eluents (C18 column). Fractions containing product were lyophilized to give the desired compound. The following examples were synthesized according to the above procedure (Scheme 12) by reaction using the appropriate starting materials. Example 8: (3-(2-Cyclohexylacetamido)-5-(trifluoromethyl)phenyl)carbamoyl)(3-(4-(2- methoxy-4-methylpyrimidin-5-yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)amide. The title compound was obtained as a white solid by using 2-cyclohexylacetic acid (Method A). LCMS (ES+) m / z calculated for C31H32F3N7O4623.25, found 624 (M+H)+. HPLC tR2.27 min. Example 9: (3-(4-(2-Methoxy-4-methylpyrimidin-5-yl)benzyl)-1,2,3-oxadiazol-3-ium-5- yl)((3-(3-phenylpropanamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide. The title compound was obtained as a white solid by using 3-phenylpropanoic acid (Method A). LCMS (ES+) m / z calculated for C32H28F3N7O4631.22, found 632 (M+H)+. HPLC tR2.13 min. Example 10: (3-(4-(2-Methoxy-4-methylpyrimidin-5-yl)benzyl)-1,2,3-oxadiazol-3-ium-5- yl)((3-((phenylmethyl)sulfonamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide. The title compound was obtained as a white solid by using phenylmethanesulfonyl chloride (Method B). LCMS (ES+) m / z calculated for C30H26F3N7O5S 653.17, found 652 (M-H)-. HPLC tR 2.05 min. Example 11: (3-Acetamido-5-(trifluoromethyl)phenyl)carbamoyl)(3-(4-(2-methoxy-4- methylpyrimidin-5-yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)amide. The title compound was obtained as a white solid by using acetyl chloride (Method B). LCMS (ES+) m / z calculated for C25H22F3N7O4541.17, found 542 1.76 min. Example 15: (3-Benzamido-5-(trifluoromethyl)phenyl)carbamoyl)(3-(4-(2-methoxy-4- methylpyrimidin-5-yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)amide. The title compound was obtained as a white solid by using 3-phenylpropanoic acid (Method A). LCMS (ES+) m / z calculated for C30H24F3N7O4603.18, found 604 (M+H)+. HPLC tR2.09 min. Example 16: (3-(4-(2-Methoxy-4-methylpyrimidin-5-yl)benzyl)-1,2,3-oxadiazol-3-ium-5- yl)((3-(2-(4-methoxyphenyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide. The title compound was obtained by using 2-(4-methoxyphenyl)acetic acid (Method A). LCMS (ES+) m / z calculated for C32H28F3N7O5647.21, found 648 (M+H)+. HPLC tR 2.06 min. Example 17: (3-(2-(4-Chlorophenyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)(3-(4- (2-methoxy-4-methylpyrimidin-5-yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)amide. The title compound was obtained by using 2-(4-chlorophenyl)acetic acid (Method A). LCMS (ES+) m / z calculated for C31H25ClF3N7O4651.16, found 652 (M+H)+. HPLC tR2.21 min. Example 18: (3-(Cyclopentanecarboxamido)-5-(trifluoromethyl)phenyl)carbamoyl)(3-(4-(2- methoxy-4-methylpyrimidin-5-yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)amide. The title compound was obtained by using cyclopentanecarboxylic acid (Method A). LCMS (ES+) m / z calculated for C29H28F3N7O4595.22, found 596 (M+H)+. HPLC tR2.12 min. Example 19: (3-(4-(2-Methoxy-4-methylpyrimidin-5-yl)benzyl)-1,2,3-oxadiazol-3-ium-5- yl)((3-(2-(pyridin-3-yl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide. The title compound was obtained by using 2-(pyridin-3-yl)acetic acid (Method A). LCMS (ES+) m / z calculated for C30H25F3N8O4618.20, found 617 (M-H)-. HPLC 1.47 min. Example 20: (3-(2-(Benzo[d]isoxazol-3-yl)acetamido)-5-(trifluoromethyl)phenyl)carba- moyl)(3-(4-(2-methoxy-4-methylpyrimidin-5-yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)amide. The title compound was obtained by using 2-(benzo[d]isoxazol-3-yl)acetic acid (Method A). LCMS (ES+) m / z calculated for C32H25F3N8O5658.19, found 659 (M+H)+. HPLC tR 2.06 min. Example 21: ((3-(2-(2-Chlorophenyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)(3- (4-(2-methoxy-4-methylpyrimidin-5-yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)amide. The title compound was obtained by using 2-(2-chlorophenyl)acetic acid (Method A). LCMS (ES+) m / z calculated for C31H25ClF3N7O4651.16, found 650 (M-H)-. HPLC tR2.13 min. Example 22: (3-(2-(4-(Aminomethyl)phenyl)acetamido)-5-(trifluoromethyl)phenyl)- carbamoyl)(3-(4-(2-methoxy-4-methylpyrimidin-5-yl)benzyl)-1,2,3-oxadiazol-3-ium-5- yl)amide. The title compound was obtained as a white solid by using 2-[4-[(tert- butoxycarbonylamino)methyl]phenyl]acetic acid (Method A - crude material was treated with TFA in DCM before HPLC purification). LCMS (ES+) m / z calculated for C32H29F3N8O4646.23, found 645 1.49 min. Example 4: (3-Methyl-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-phenylacetamido)-5-(trifluoro- methyl)phenyl)carbamoyl)amide Scheme 13 Step 1: (3-Methyl-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-phenylacetamido)-5-(trifluoromethyl)- phenyl)carbamoyl)amide (Example 4). A solution of 5-amino-3-methyl-1,2,3-oxadiazol-3-ium chloride (Intermediate 17) prepared as reported in the synthesis of Example 1 (Scheme 10 steps 1 and 2) (30 mg, 0.22 mmol) and N-(3- Isocyanato-5-(trifluoromethyl)phenyl)-2-phenylacetamide (Intermediate 2) (141 mg, 0.44 mmol) in THF (4 mL) was treated with pyridine (0.07 mL, 0.88 mmol) at 0 °C and stirred at rt for 1 h before being diluted with EtOAc. The organic phase was washed with NaHCO3 (sat. aqueous solution) and brine, dried over Na2SO4, filtered, and concentrated under reduced pressure. The title compound was obtained after purification by automated RP-HPLC using water (+ 0.1% TFA) and CH3CN (+ 0.1% TFA) as eluents (C18 column). Fractions containing product were lyophilized to give the title compound as a white powder (49.0 mg, 53%).1H NMR (400 MHz, DMSO-d6) ^ 10.24 (s, 1H), 9.50 (s, 1H), 7.89 (s, 1H), 7.80 (s, 1H), 7.57 (s, 1H), 7.51 (s, 1H), 7.15- 7.14 (m, 4H), 7.09-7.04 (m, 1H), 4.04 (s, 3H), 3.47 (s, 2H).19F NMR (377 MHz, DMSO-d6) ^ - 61.57 (s, 3F). LCMS (ES+) m / z calculated for C19H16F3N5O3419.12, found 420 (M+H)+. HPLC tR1.73 min. Example 12: (3-((5-Bromopyridin-2-yl)methyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- phenylacetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide Scheme 14 The above example was prepared following procedure reported for the synthesis of Example 1 (Scheme 10, steps 1, 2) using (5-bromopyridin-2-yl)methanamine dihydrochloride in step 1 and followed by reaction with intermediate 2 (as reported for the synthesis of Example 4). The title compound was obtained as an orange solid (2.2 mg, 44%).1H NMR (400 MHz, DMSO-d6) ^ 10.42 (s, 1H), 9.75 (s, 1H), 8.76 (br d, J = 2.2 Hz, 1H), 8.21 (dd, J1 = 8.4 Hz, J2 = 2.3 Hz, 1H), 8.15 (s, 1H), 7.99 (br s, 1H), 7.75 (br s, 1H), 7.70 (br s, 1H), 7.65 (br d, J = 8.3 Hz, 1H), 7.33 (br d, J = 4.4 Hz, 4H), 7.27-7.24 (m, 1H), 5.94 (s, 2H), 3.65 (s, 2H).19F NMR (377 MHz, DMSO-d6) ^ -61.58 (s, 3F). LCMS (ES+) m / z calculated for C24H18BrF3N6O3574.06, found 575-577 (M+H)+. HPLC tR1.92 min. Example 13: (3-((5-(2-Methoxy-4-methylpyrimidin-5-yl)pyridin-2-yl)methyl)-1,2,3- oxadiazol-3-ium-5-yl)((3-(2-phenylacetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide. Scheme 15 A solution of (3-((5-bromopyridin-2-yl)methyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- phenylacetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide (Example 12; 20.0 mg, 0.035 mmol, 1 eq), appropriate boronic ester (0.035 mmol, 1 eq), Pd(dppf)Cl2 (2.87 mg, 0.0035 mmol, 0.1 eq) and K3PO4(22.14 mg, 0.105 mmol, 3 eq) in a mixture of dioxane (1 mL) and H2O (0.1 mL) was heated at 75 °C for 1 h before being cooled at rt and filtered on a pad of solca flock. After removal of solvent under reduced pressure the title compound was obtained after purification by automated RP-HPLC using water (+ 0.1% TFA) and CH3CN (+ 0.1% TFA) as eluents (C18 column). Fractions containing product were lyophilized to give the desired compound. The title compound was obtained as a white solid by using 2-methoxy-4-methyl-5-(4,4,5,5-tetramethyl- 1,3,2-dioxaborolan-2-yl)pyrimidine.1H NMR (400 MHz, DMSO-d6) ^ 10.42 (s, 1H), 9.76 (s, 1H), 8.68 (d, J = 1.8 Hz, 1H), 8.50 (s, 1H), 8.22 (s, 1H), 8.05 (dd, J1 = 8.0 Hz, J2 = 2.3 Hz, 1H), 8.00 (br s, 1H), 7.78 (d, J = 8.3 Hz, 1H), 7.75 (br s, 1H), 7.70 (br s, 1H), 7.33 (d, J = 4.4 Hz, 4H), 7.28- 7.24 (m, 1H), 6.02 (s, 2H), 3.95 (s, 3H), 3.65 (s, 2H), 2.41 (s, 3H).19F NMR (377 MHz, DMSO- d6) ^ -61.59 (s, 3F). LCMS (ES+) m / z calculated for C30H25F3N8O4618.20, found 619 (M+H)+. HPLC tR 1.77 min. The following examples were synthesized according to the above procedure (Scheme 15) by reaction using the appropriate starting materials. Example 5: (3-((5-(2-(Aminomethyl)phenyl)pyridin-2-yl)methyl)-1,2,3-oxadiazol-3-ium-5- yl)((3-(2-phenylacetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide. The title compound was obtained as a white solid by using tert-butyl (2-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)benzyl)carbamate and treating the crude material with HCl (4.0 M in 1,4- dioxane) before HPLC purification.1H NMR (400 MHz, DMSO-d6) ^ 10.43 (s, 1H), 9.77 (s, 1H), 8.64 (s, 1H), 8.22 (s, 1H), 8.13 (br s, 3H), 8.02-7.95 (m, 2H), 7.81-7.79 (m, 2H), 7.67-7.65 (m, 2H), 7.59-7.49 (m, 2H), 7.40-7.38 (m, 1H), 7.33 (d, J = 4.4 Hz, 4H), 7.27-7.23 (m, 1H), 6.03 (s, 2H), 3.99-3.95 (m, 2H), 3.65 (s, 2H).19F NMR (377 MHz, DMSO-d6) ^ -61.58 (s, 3F). LCMS (ES+) m / z calculated for C31H26F3N7O3601.20, found 602 1.39 min. Example 6: (3-((5-(1-Methyl-1H-imidazol-5-yl)pyridin-2-yl)methyl)-1,2,3-oxadiazol-3-ium- 5-yl)((3-(2-phenylacetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide. The title compound was obtained as a white solid by using 1-methyl-5-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)-1H-imidazole. LCMS (ES+) m / z calculated for C28H23F3N8O3576.18, found 577 (M+H)+. HPLC tR 1.30 min. Example 14: (3-((5-(Isoindolin-4-yl)pyridin-2-yl)methyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- phenylacetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide. The title compound was obtained as a white solid by using tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)isoindoline-2-carboxylate and treating the crude material with HCl (4.0 M in 1,4-dioxane) before HPLC purification.1H NMR (400 MHz, DMSO-d6) ^ 10.42 (s, 1H), 9.76 (s, 1H), 9.45 (br s, 2H), 8.76 (s, 1H), 8.22 (s, 1H), 8.08 (br d, J = 8.3 Hz, 1H), 8.00 (s, 1H), 7.82 (s, 1H), 7.79 (br s, 1H), 7.67 (br s, 1H), 7.65-7.59 (m, 1H), 7.58-7.52 (m, 4H), 7.33 (d, J = 4.4 Hz, 4H), 7.28-7.24 (m, 1H), 6.03 (s, 2H), 4.68-4.64 (m, 2H), 4.62-4.58 (m, 2H), 3.65 (s, 2H).19F NMR (377 MHz, DMSO-d6) ^ -61.59 (s, 3F). LCMS (ES+) m / z calculated for C32H26F3N7O3613.20, found 614 (M+H)+. HPLC tR 1.35 min. Example 25: (3-((5-(2-Amino-4-methylpyrimidin-5-yl)pyridin-2-yl)methyl)-1,2,3-oxadiazol- 3-ium-5-yl)((3-(2-phenylacetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide. The title compound was obtained as a yellow solid by using 4-methyl-5-(4,4,5,5-tetramethyl- 1,3,2-dioxaborolan-2-yl)pyrimidin-2-amine.1H NMR (400 MHz, DMSO-d6) ^ 10.43 (s, 1H), 9.75 (s, 1H), 8.62 (s, 1H), 8.19 (s, 1H), 8.13 (s, 1H), 7.99 (s, 1H), 7.96 (br d, J = 8.1 Hz, 1H), 7.75-7.73 (m, 1H), 7.71 (br s, 1H), 7.60-7.48 (m, 2H), 7.33 (d, J = 4.4 Hz, 4H), 7.28-7.24 (m, 1H), 6.76 (s, 2H), 5.98 (s, 2H), 3.65 (s, 2H), 2.26 (s, 3H).19F NMR (377 MHz, DMSO-d6) ^ -61.58 (s, 3F). LCMS (ES+) m / z calculated for C29H24F3N9O3603.20, found 604 (M+H)+. HPLC tR 1.57 min. Example 28: (3-Benzyl-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-phenylacetamido)-5-(trifluoro- methyl)phenyl)carbamoyl)amide Scheme 16 Step 1: (3-Benzyl-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-phenylacetamido)-5-(trifluoromethyl)- phenyl)carbamoyl)amide (Example 28). A solution of 5-amino-3-benzyl-1,2,3-oxadiazol-3-ium chloride (Intermediate 18) (prepared as reported in the synthesis of Example 1 (Scheme 10 steps 1 and 2) (50 mg, 0.28 mmol) and N-(3- Isocyanato-5-(trifluoromethyl)phenyl)-2-phenylacetamide (Intermediate 2) (136 mg, 0.43 mmol) in THF (10 mL) was treated with pyridine (0.02 mL, 0.28 mmol) at 0 °C and stirred at rt for 1 h before being diluted with EtOAc. The organic phase was washed with NaHCO3(sat. aqueous solution) and brine, dried over Na2SO4, filtered, and concentrated under reduced pressure. The title compound was obtained after purification by automated RP-HPLC using water (+ 0.1% TFA) and CH3CN (+ 0.1% TFA) as eluents (C18 column). Fractions containing product were lyophilized to give the title compound as a yellow powder (9.2 mg, 7%).1H NMR (400 MHz, DMSO-d6) ^ 11.25 (s, 1H), 1.51 (s, 1H), 10.32 (s, 1H), 7.97 (s, 1H), 7.78 (s, 1H), 7.74 (s, 1H), 7.59-7.57 (m.1H), 7.52 (s, 1H), 7.49-7.46 (m, 2H), 7.36-7.31 (m, 6H), 7.30-7.24 (m, 4H), 4.96 (s, 2H), 3.66 (s, 2H).19F NMR (377 MHz, DMSO-d6) ^ -61.77 (s, 3F). LCMS (ES+) m / z calculated for C25H20F3N5O3495.15, found 496 (M+H)+. HPLC tR1.94 min. Example 7: ((3-(2-Phenylacetamido)-5-(trifluoromethyl)phenyl)carbamoyl)(3-(pyridin-2- ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide Scheme 17 Step 1: 2-((Pyridin-2-ylmethyl)amino)acetonitrile (Intermediate 19). A suspension of pyridin-2-ylmethanamine dihydrochloride (500 mg, 4.62 mmol) in MeCN (5 mL) was treated with DIPEA (3.3 mL, 18.49 mmol) and 2-bromoacetonitrile (0.3 mL, 4.62 mmol) and stirred at 60 °C for 4 h. After cooling the reaction mixture was treated with H2O and extracted with EtOAc. The organic phase was washed with brine, dried over Na2SO4, and evaporated under reduced pressure to get the title compound as a brown oil (750 mg, 85% pure, 94%) which was used without further purification.1H NMR (400 MHz, CDCl3) ^ 10.40 (br s, 1H), 8.53 (d, J = 4.4 Hz, 1H), 7.65 (br t, J = 7.7 Hz, 1H), 7.27 (d, J = 7.7 Hz, 1H), 7.19-7.16 (m, 1H), 4.00 (br s, 2H), 3.63 (br s, 2H). Step 2: N-(Cyanomethyl)-N-(pyridin-2-ylmethyl)nitrous amide (Intermediate 20). A solution of 2-((pyridin-2-ylmethyl)amino)acetonitrile (750 mg, 4.23 mmol) in THF (5 mL) was treated with tert-butyl nitrite (1.5 mL, 12.69 mmol) and stirred at rt for 1 h before being treated with H2O and extracted with EtOAc. The organic phase was washed with brine, dried over Na2SO4, and evaporated under reduced pressure to get the title compound as a brown oil (667 mg, 90%) which was used without further purification.1H NMR (400 MHz, CDCl3) ^ 8.54 (d, J = 4.4 Hz, 1H), 7.75-7.70 (m, 1H), 7.33 (d, J = 7.7 Hz, 1H), 7.28-7.23 (m, 1H), 5.54 (s, 2H), 4.47 (s, 2H). LCMS (ES+) m / z calculated for C8H8N4O 176.07, found 177 (M+H)+. HPLC tR0.78 min. Step 3: 5-Amino-3-(pyridin-1-ium-2-ylmethyl)-1,2,3-oxadiazol-3-ium chloride (Intermediate 21). A solution of N-(cyanomethyl)-N-(pyridin-2-ylmethyl)nitrous amide (667 mg, 3.79 mmol) in MeCN (7 mL) was treated with 4 N HCl in dioxane (1.9 mL, 7.57 mmol). The reaction mixture was stirred at rt for 5 min. and then treated with trimethylsilyl trifluoromethanesulfonate (2.1 mL, 11.36 mmol) and stirred at rt for further 5 min. before being treated with H2O (20 mL). After removal of the solvent by lyophilization the title product was obtained as a yellow powder (2.0 g, 46% pure, 97%) and used without further purification.1H NMR (400 MHz, DMSO-d6) ^ 9.49 (s, 2H), 8.60 (d, J = 4.0 Hz, 1H), 8.07 (s, 1H), 7.95 (br t, J = 7.8 Hz, 1H), 7.67 (d, J = 7.9 Hz, 1H), 7.48 (dd, J1 = 7.1 Hz, J2 = 5.4 Hz, 1H), 6.05 (s, 2H). Step 4: (3-(2-Phenylacetamido)-5-(trifluoromethyl)phenyl)carbamoyl)(3-(pyridin-2-ylmethyl)- 1,2,3-oxadiazol-3-ium-5-yl)amide (Example 7). A solution of 5-amino-3-(pyridin-1-ium-2-ylmethyl)-1,2,3-oxadiazol-3-ium chloride (100 mg, 0.20 mmol) and N-(3-isocyanato-5-(trifluoromethyl)phenyl)-2-phenylacetamide (Intermediate 2) (77 mg, 0.24 mmol) in MeCN (2 mL) was treated with pyridine (0.13 mL, 1.63 mmol) and stirred at rt for 5 min. before being diluted with DCM and H2O. The phases were separated, and the organic phase was washed with H2O and brine, dried over Na2SO4, filtered, and concentrated under reduced pressure. The title compound was obtained after purification by automated RP- HPLC using water (+ 0.1% TFA) and CH3CN (+ 0.1% TFA) as eluents (C18 column). Fractions containing product were lyophilized to give the title compound as a white solid (11.0 mg, 11%).1H NMR (400 MHz, DMSO-d6) ^ 10.31 (s, 1H), 9.64 (s, 1H), 8.50 (br d, J = 4.0 Hz, 1H), 8.04 (s, 1H), 7.88 (s, 1H), 7.82 (br t, J = 7.8 Hz, 1H), 7.61 (br d, J = 10.7 Hz, 2H), 7.54 (br d, J = 7.9 Hz, 1H), 7.35 (dd, J1 = 7.2 Hz, J2 = 5.3 Hz, 1H), 7.22-7.21 (m, 4H), 7.17-7.11 (m, 1H), 5.84 (s, 2H), 3.54 (s, 2H).19F NMR (377 MHz, DMSO-d6) ^ -61.58 (s, 3F). LCMS (ES+) m / z calculated for C24H19F3N6O3496.15, found 497 1.72 min. Synthesis of Examples 29-51, 54, 64-80, 82-86, 88.

[0002] Scheme 18 Step 1: (3-Nitro-5-(trifluoromethyl)phenyl)carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3- ium-5-yl)amide (Intermediate 22). A solution of 5-amino-3-(pyridin-1-ium-2-ylmethyl)-1,2,3-oxadiazol-3-ium chloride (Intermediate 21, 800.0 mg, 3.74 mmol) in dry THF (20 mL) was treated with a solution of 1- isocyanato-3-nitro-5-(trifluoromethyl)benzene (Intermediate 4, 1.3 g, 5.62 mmol) in THF (7.0 mL) followed by pyridine (0.91 mL, 11.23 mmol) and the reaction mixture was stirred at rt for 10 min.before being diluted with EtOAc. The organic phase was washed with H2O and brine, dried over Na2SO4, filtered, and concentrated under reduced pressure. The title compound was obtained after purification by flash chromatography on silica gel (eluting with 30-100% EtOAc in petroleum ether) to get the title compound as a yellow solid (800 mg, 52%).1H NMR (400 MHz, DMSO-d6) ^ 10.21 (s, 1H), 8.84 (s, 1H), 8.61 (br d, J = 4.8 Hz, 1H), 8.41 (s, 1H), 8.30 (s, 1H), 7.97 (s, 1H), 7.94 (br t, J = 7.7 Hz, 1H), 7.66 (br d, J = 7.9 Hz, 1H), 7.47 (br t, J = 6.1 Hz, 1H), 5.97 (s, 2H).19F NMR (377 MHz, DMSO-d6) ^ -61.74 (s, 3F). LCMS (ES+) m / z calculated for C16H11F3N6O4408.08, found 409 1.74 min. Step 2: (3-Amino-5-(trifluoromethyl)phenyl)carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol- 3-ium-5-yl)amide (Intermediate 23). A solution of ((3-nitro-5-(trifluoromethyl)phenyl)carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3- oxadiazol-3-ium-5-yl)amide (Intermediate 22, 500.0 mg, 1.22 mmol) and NH4Cl (327.5 mg, 6.12 mmol) in a mixture of EtOH (15 mL) and H2O (7 mL) was treated with iron (683.9 mg, 12.25 mmol) and heated at 100 °C for 2 h before being diluted with EtOAc, the organic phase was washed with H2O, brine and dried under reduced pressure to get the title compound (463 mg, 99%) which was used without further purification.1H NMR (400 MHz, DMSO-d6) ^ 9.40 (s, 1H), 8.61 (br d, J = 4.2 Hz, 1H), 8.10 (s, 1H), 7.93 (br t, J = 7.7 Hz, 1H), 7.65 (br d, J = 7.7 Hz, 1H), 7.46 (dd, J1 = 7.5 Hz, J2 = 4.8 Hz, 1H), 7.23 (s, 1H), 7.03 (s, 1H), 6.41 (s, 1H), 5.92 (s, 2H), 5.42 (br s, 2H).19F NMR (377 MHz, DMSO-d6) ^ -61.56 (s, 3F). LCMS (ES+) m / z calculated for C16H13F3N6O2378.11, found 379 1.30 min. Step 3: Coupling amide. General procedure: A solution of ((3-amino-5-(trifluoromethyl)phenyl)carbamoyl)(3-(pyridin-2- ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide (20.0 mg, 0.05 mmol, 1 eq.) and HATU (30.2 mg, 0.08 mmol, 1.5 eq.) in dry DMSO (0.8 mL) was treated with DIPEA (20.5 mg, 0.16 mmol, 3 eq.) followed by the appropriate carboxylic acid (0.06 mmol, 1.2 eq.) and the reaction mixture was stirred at rt for 18 h. The title compound was obtained after purification by automated RP-HPLC using water (+ 0.1% TFA) and CH3CN (+ 0.1% TFA) as eluents (C18 column). Fractions containing product were lyophilized to give the desired compound. The following examples were synthesized according to the above procedure (Scheme 18) by reaction using the appropriate starting materials in Step 3. Example 29: ((3-(1H-Benzo[d]imidazole-5-carboxamido)-5-(trifluoromethyl)phenyl)- carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide. The title compound was obtained by using 1H-benzo[d]imidazole-5-carboxylic acid. LCMS (ES+) m / z calculated for C24H17F3N8O3522.14, found 523 (M+H)+. HPLC 1.31 min. Example 30: (3-(5-(Morpholinomethyl)furan-2-carboxamido)-5-(trifluoromethyl)phenyl)- carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide. The title compound was obtained by using 5-(morpholinomethyl)furan-2-carboxylic acid. LCMS (ES+) m / z calculated for C26H24F3N7O5571.18, found 572 1.17 min. Example 31: (3-(3-Phenoxybenzamido)-5-(trifluoromethyl)phenyl)carbamoyl)(3-(pyridin- 2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide. The title compound was obtained by using 3-phenoxybenzoic acid. LCMS (ES+) m / z calculated for C29H21F3N6O4574.16, found 575 (M+H)+. HPLC tR 2.08 min. Example 32: (3-(2-Phenylpropanamido)-5-(trifluoromethyl)phenyl)carbamoyl)(3-(pyridin- 2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide. The title compound was obtained by using 2-phenylpropanoic acid. LCMS (ES+) m / z calculated for C25H21F3N6O3510.16, found 511 (M+H)+. HPLC tR 1.89 min. Example 33: (3-(2-(5-Methyl-2-phenyloxazol-4-yl)acetamido)-5-(trifluoromethyl)phenyl)- carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide. The title compound was obtained by using 2-(5-methyl-2-phenyloxazol-4-yl)acetic acid. LCMS (ES+) m / z calculated for C28H22F3N7O4577.17, found 578 (M+H)+. HPLC tR 1.91 min. Example 34: (3-(1-Phenyl-1H-pyrazole-5-carboxamido)-5-(trifluoromethyl)phenyl)- carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide. The title compound was obtained by using 1-phenyl-1H-pyrazole-5-carboxylic acid. LCMS (ES+) m / z calculated for C26H19F3N8O3548.15, found 549 (M+H)+. HPLC tR 1.74 min. Example 35: (3-(1-Benzyl-1H-pyrazole-4-carboxamido)-5-(trifluoromethyl)phenyl)- carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide. The title compound was obtained by using 1-benzyl-1H-pyrazole-4-carboxylic acid. LCMS (ES+) m / z calculated for C27H21F3N8O3562.17, found 563 (M+H)+. HPLC tR 1.74 min. Example 36: (3-(2-(1H-pyrrolo[3,2-b]pyridin-3-yl)acetamido)-5-(trifluoromethyl)phenyl)- carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide. The title compound was obtained by using 2-(1H-pyrrolo[3,2-b]pyridin-3-yl)acetic acid. LCMS (ES+) m / z calculated for C25H19F3N8O3536.15, found 537 (M+H)+. HPLC tR1.13 min. Example 37: (3-(6-Cyanoimidazo[1,2-a]pyridine-2-carboxamido)-5-(trifluoromethyl)- phenyl)carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide. The title compound was obtained by using 6-cyanoimidazo[1,2-a]pyridine-2-carboxylic acid. LCMS (ES+) m / z calculated for C25H16F3N9O3547.13, found 548 (M+H)+. HPLC tR1.61 min. Example 38: (3-(Pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(4,5,6,7-tetrahydro-1H- indazole-7-carboxamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide. The title compound was obtained by using 4,5,6,7-tetrahydro-1H-indazole-7-carboxylic acid. LCMS (ES+) m / z calculated for C24H21F3N8O3526.17, found 527 (M+H)+. HPLC tR 1.54 min. Example 39: (3-(5-Methyl-5,6-dihydro-4H-thieno[2,3-c]pyrrole-2-carboxamido)-5-(trifluo- romethyl)phenyl)carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide. The title compound was obtained by using 5-methyl-5,6-dihydro-4H-thieno[2,3-c]pyrrole-2- carboxylic acid. LCMS (ES+) m / z calculated for C24H20F3N7O3S 543.13, found 544 (M+H)+. HPLC tR0.89 min. Example 40: (3-(2-(1-Methyl-1H-pyrazol-3-yl)acetamido)-5-(trifluoromethyl)phenyl)- carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide. The title compound was obtained by using 2-(1-methyl-1H-pyrazol-3-yl)acetic acid. LCMS (ES+) m / z calculated for C22H19F3N8O3500.15, found 501 (M+H)+. HPLC tR1.43 min. Example 41: ((3-(2-(2-Methylthiazol-4-yl)acetamido)-5-(trifluoromethyl)phenyl)- carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide. The title compound was obtained by using 2-(2-methylthiazol-4-yl)acetic acid. LCMS (ES+) m / z calculated for C22H18F3N7O3S 517.11, found 518 (M+H)+. HPLC 1.52 min. Example 42: (3-(2-(6-Aminopyridin-3-yl)acetamido)-5-(trifluoromethyl)phenyl)- carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide. The title compound was obtained by using 2-(6-aminopyridin-3-yl)acetic acid. LCMS (ES+) m / z calculated for C23H19F3N8O3512.15, found 513 (M+H)+. HPLC tR 1.11 min. Example 43: (3-(2-(Phenylsulfonyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)(3- (pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide. The title compound was obtained by using 2-(phenylsulfonyl)acetic acid. LCMS (ES+) m / z calculated for C24H19F3N6O5S 560.11, found 561 (M+H)+. HPLC 1.61 min. Example 44: (3-(Isoxazole-3-carboxamido)-5-(trifluoromethyl)phenyl)carbamoyl)(3- (pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide. The title compound was obtained by using isoxazole-3-carboxylic acid. LCMS (ES+) m / z calculated for C20H14F3N7O4473.11, found 474 (M+H)+. HPLC tR1.57 min. Example 45: (3-(Pyrazine-2-carboxamido)-5-(trifluoromethyl)phenyl)carbamoyl)(3- (pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide. The title compound was obtained by using pyrazine-2-carboxylic acid. LCMS (ES+) m / z calculated for C21H15F3N8O3484.12, found 485 1.53 min. Example 46: (3-(3-Phenylpropiolamido)-5-(trifluoromethyl)phenyl)carbamoyl)(3-(pyridin- 2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide. The title compound was obtained by using 3-phenylpropiolic acid. LCMS (ES+) m / z calculated for C25H17F3N6O3506.13, found 507 1.88 min. Example 47: (3-(Bicyclo[4.2.0]octa-1(6),2,4-triene-7-carboxamido)-5-(trifluoromethyl)- phenyl)carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide. The title compound was obtained by using bicyclo[4.2.0]octa-1(6),2,4-triene-7-carboxylic acid. LCMS (ES+) m / z calculated for C25H19F3N6O3508.15, found 509 (M+H)+. HPLC 1.82 min. Example 48: (3-(1-Isopropyl-1H-pyrazole-3-carboxamido)-5-(trifluoromethyl)phenyl)- carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide. The title compound was obtained by using 1-isopropyl-1H-pyrazole-3-carboxylic acid. LCMS (ES+) m / z calculated for C23H21F3N8O3514.17, found 515 1.59 min. Example 49: (3-(1-Methylazetidine-3-carboxamido)-5-(trifluoromethyl)phenyl)- carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide. The title compound was obtained by using 1-methylazetidine-3-carboxylic acid. LCMS (ES+) m / z calculated for C21H20F3N7O3475.16, found 476 (M+H)+. HPLC tR 1.07 min. Example 50: (3-(2-Phenylcyclopropane-1-carboxamido)-5-(trifluoromethyl)phenyl)- carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide. The title compound was obtained by using 2-phenylcyclopropane-1-carboxylic acid. LCMS (ES+) m / z calculated for C26H21F3N6O3522.16, found 523 (M+H)+. HPLC tR1.93 min. Example 51: (3-(2-(Bicyclo[2.1.1]hexan-2-yl)acetamido)-5-(trifluoromethyl)phenyl)- carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide. The title compound was obtained by using 2-(bicyclo[2.1.1]hexan-2-yl)acetic acid. LCMS (ES+) m / z calculated for C24H23F3N6O3500.18, found 501 (M+H)+. HPLC tR1.93 min. Example 54: (3-(2-Cyclobutylacetamido)-5-(trifluoromethyl)phenyl)carbamoyl)(3-(pyridin- 2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide. The title compound was obtained as a beige solid by using 2-cyclobutylacetic acid.1H NMR (400 MHz, DMSO-d6) ^ 10.09 (s, 1H), 9.72 (s, 1H), 8.61 (br d, J = 3.7 Hz, 1H), 8.13 (s, 1H), 7.95 (br s, 2H), 7.72 (br d, J = 10.9 Hz, 2H), 7.66 (br d, J = 7.9 Hz, 1H), 7.48-7.45 (m, 1H), 5.95 (s, 2H), 2.71-2.63 (m, 1H), 2.43 (br d, J = 7.9 Hz, 2H), 2.10-2.01 (m, 2H), 1.87-1.79 (m, 2H), 1.76-1.69 (m, 2H).19F NMR (377 MHz, DMSO-d6) ^ -61.53 (s, 3F). LCMS (ES+) m / z calculated for C22H21F3N6O3474.16, found 475 (M+H)+. HPLC tR1.78 min. Example 64: (3-(5,5-Dioxido-6,7-dihydro-4H-pyrazolo[5,1-c][1,4]thiazine-2-carboxamido)- 5-(trifluoromethyl)phenyl)carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5- yl)amide. The title compound was obtained by using 6,7-dihydro-4H-pyrazolo[5,1-c][1,4]thiazine-2- carboxylic acid 5,5-dioxide. LCMS (ES+) m / z calculated for C23H19F3N8O5S 576.12, found 577 (M+H)+. HPLC tR 1.46 min. Example 65: (3-(2-(2-(Difluoromethyl)-1H-benzo[d]imidazol-1-yl)acetamido)-5- (trifluoromethyl)phenyl)carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5- yl)amide. The title compound was obtained by using 2-(2-(difluoromethyl)-1H-benzo[d]imidazol-1- yl)acetic acid. LCMS (ES+) m / z calculated for C26H19F5N8O3586.15, found 587 (M+H)+. HPLC tR 1.67 min. Example 66: (3-(4-Hydroxybicyclo[2.2.1]heptane-1-carboxamido)-5-(trifluoromethyl)- phenyl)carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide. The title compound was obtained by using 4-hydroxybicyclo[2.2.1]heptane-1-carboxylic acid. LCMS (ES+) m / z calculated for C24H23F3N6O4516.17, found 517 (M+H)+. HPLC tR 1.40 min. Example 67: (3-(7-Methyl-2,3-dihydrobenzofuran-3-carboxamido)-5-(trifluoromethyl)- phenyl)carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide. The title compound was obtained by using 7-methyl-2,3-dihydrobenzofuran-3-carboxylic acid. LCMS (ES+) m / z calculated for C26H21F3N6O4538.16, found 539 (M+H)+. HPLC tR 1.89 min. Example 68: (3-(3-Benzylcyclobutane-1-carboxamido)-5-(trifluoromethyl)phenyl)- carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide. The title compound was obtained by using 3-benzylcyclobutane-1-carboxylic acid. LCMS (ES+) m / z calculated for C28H25F3N6O3550.19, found 551 (M+H)+. HPLC tR 2.08 min. Example 69: (3-((1S,3S)-3-Hydroxy-3-(pyridin-2-yl)cyclobutane-1-carboxamido)-5- (trifluoromethyl)phenyl)carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5- yl)amide. The title compound was obtained by using (1S,3S)-3-hydroxy-3-(pyridin-2-yl)cyclobutane-1- carboxylic acid. LCMS (ES+) m / z calculated for C26H22F3N7O4553.17, found 554 (M+H)+. HPLC tR 1.18 min. Example 70: (3-(1-((5-Methylfuran-2-yl)methyl)piperidine-4-carboxamido)-5- (trifluoromethyl)phenyl)carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5- yl)amide. The title compound was obtained by using 1-((5-methylfuran-2-yl)methyl)piperidine-4-carboxylic acid. LCMS (ES+) m / z calculated for C28H28F3N7O4583.22, found 584 (M+H)+. HPLC tR1.23 min. Example 71: (3-(1-(3-Cyano-1H-pyrazol-1-yl)cyclopropane-1-carboxamido)-5- (trifluoromethyl)phenyl)carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5- yl)amide. The title compound was obtained by using 1-(3-cyano-1H-pyrazol-1-yl)cyclopropane-1- carboxylic acid. LCMS (ES+) m / z calculated for C24H18F3N9O3537.15, found 538 (M+H)+. HPLC tR1.71 min. Example 72: (3-(2-((4-Methyl-4H-1,2,4-triazol-3-yl)methoxy)acetamido)-5-(trifluoro- methyl)phenyl)carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide. The title compound was obtained by using 2-((4-methyl-4H-1,2,4-triazol-3-yl)methoxy)acetic acid. LCMS (ES+) m / z calculated for C22H20F3N9O4531.16, found 532 (M+H)+. HPLC tR1.23 min. Example 73: (3-(3-(Cyclopentyloxy)propanamido)-5-(trifluoromethyl)phenyl)- carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide. The title compound was obtained by using 3-(cyclopentyloxy)propanoic acid. LCMS (ES+) m / z calculated for C24H25F3N6O4518.19, found 519 (M+H)+. HPLC tR 1.83 min. Example 74: (3-((1R,4S,5S)-4-(3-methoxyphenyl)-2-oxabicyclo[2.1.1]hexane-5-carbo- xamido)-5-(trifluoromethyl)phenyl)carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3- ium-5-yl)amide. The title compound was obtained by using (1R,4S,5S)-4-(3-methoxyphenyl)-2- oxabicyclo[2.1.1]hexane-5-carboxylic acid. LCMS (ES+) m / z calculated for C29H25F3N6O5 594.18, found 595 (M+H)+. HPLC 1.86 min. Example 75: (3-(1-Cyclopropyl-1H-imidazole-5-carboxamido)-5-(trifluoromethyl)phenyl)- carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide. The title compound was obtained by using 1-cyclopropyl-1H-imidazole-5-carboxylic acid. LCMS (ES+) m / z calculated for C23H19F3N8O3512.15, found 511 1.23 min. Example 76: (3-(2,2-Difluoro-3-(pyrrolidin-1-yl)propanamido)-5-(trifluoromethyl)phenyl)- carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide. The title compound was obtained by using 2,2-difluoro-3-(pyrrolidin-1-yl)propanoic acid. LCMS (ES+) m / z calculated for C23H22F5N7O3539.17, found 540 1.15 min. Example 77: (3-(1-Cyclopropylazetidine-3-carboxamido)-5-(trifluoromethyl)phenyl)- carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide. The title compound was obtained by using 1-cyclopropylazetidine-3-carboxylic acid. LCMS (ES+) m / z calculated for C23H22F3N7O3501.17, found 502 (M+H)+. HPLC 1.09 min. Example 78: (3-(Pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(4-(1-sulfamoylethyl)- benzamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide. The title compound was obtained by using 4-(1-sulfamoylethyl)benzoic acid. LCMS (ES+) m / z calculated for C25H22F3N7O5S 589.14, found 590 (M+H)+. HPLC 1.51 min. Example 79: (3-(2,3-Dihydrofuro[3,2-b]pyridine-5-carboxamido)-5-(trifluoromethyl)- phenyl)carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide. The title compound was obtained by using 2,3-dihydrofuro[3,2-b]pyridine-5-carboxylic acid. LCMS (ES+) m / z calculated for C24H18F3N7O4525.14, found 526 (M+H)+. HPLC 1.77 min. Example 80: (3-(Pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(5,6,7,8-tetrahydro- imidazo[1,5-a]pyridine-7-carboxamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide. The title compound was obtained by using 5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-7-carboxylic acid. LCMS (ES+) m / z calculated for C24H21F3N8O3526.17, found 527 (M+H)+. HPLC tR1.10 min. Example 82: (3-(5-(Piperidin-1-ylsulfonyl)pentanamido)-5-(trifluoromethyl)phenyl)- carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide. The title compound was obtained by using 5-(piperidin-1-ylsulfonyl)pentanoic acid. LCMS (ES+) m / z calculated for C26H30F3N7O5S 609.20, found 610 (M+H)+. 1.73 min. Example 83: (3-(3-(4-Chlorophenoxy)oxetane-3-carboxamido)-5-(trifluoromethyl)phenyl)- carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide. The title compound was obtained by using 3-(4-chlorophenoxy)oxetane-3-carboxylic acid. LCMS (ES+) m / z calculated for C26H20ClF3N6O5588.11, found 589 (M+H)+. HPLC 1.94 min. Example 84: (3-(2,6-Dioxaspiro[4.5]decane-7-carboxamido)-5-(trifluoromethyl)phenyl)- carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide. The title compound was obtained by using 2,6-dioxaspiro[4.5]decane-7-carboxylic acid. LCMS (ES+) m / z calculated for C25H25F3N6O5546.18, found 547 1.68 min. Example 85: (3-(3,3-Difluorospiro[3.3]heptane-1-carboxamido)-5-(trifluoromethyl)- phenyl)carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide. The title compound was obtained by using 3,3-difluorospiro[3.3]heptane-1-carboxylic acid. LCMS (ES+) m / z calculated for C24H21F5N6O3536.16, found 537 (M+H)+. HPLC 1.95 min. Example 86: (3-(Pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-(3-(pyrrolidin-1- yl)oxetan-3-yl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide. The title compound was obtained by using 2-(3-(pyrrolidin-1-yl)oxetan-3-yl)acetic acid. LCMS (ES+) m / z calculated for C25H26F3N7O4545.20, found 546 1.08 min. Example 88: (3-(4,4-Dioxido-1,4-oxathiane-2-carboxamido)-5-(trifluoromethyl)phenyl)- carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide. The title compound was obtained by using 1,4-oxathiane-2-carboxylic acid 4,4-dioxide. LCMS (ES+) m / z calculated for C21H19F3N6O6S 540.10, found 541 (M+H)+. HPLC tR 1.44 min. Example 110: ((3-(2-Phenylacetamido)-5-(trifluoromethyl)phenyl)carbamoyl)(3-(piperidin- 3-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide Scheme 19 Step 1: tert-Butyl((1-((4-nitrophenyl)sulfonyl)piperidin-3-yl)methyl)carbamate (Intermediate 24). A solution of tert-butyl (piperidin-3-ylmethyl)carbamate (410 mg, 1.91 mmol) in DCM (19 mL) was treated with TEA (0.8 mL, 5.74 mmol) and 4-nitrobenzenesulfonyl chloride (424 mg, 1.91 mmol) and stirred at 0 °C for 5 min. before being diluted with DCM and washed with H2O (3x), brine, dried over Na2SO4, filtered and concentrated under reduced pressure to afford the title compound as a light yellow powder (680 mg, 88%) which was used without further purification.1H NMR (400 MHz, DMSO-d6) ^ 8.24 (d, J = 8.8 Hz, 2H), 7.77 (d, J = 8.8 Hz, 2H), 6.75-6.70 (m, 1H), 3.39-3.33 (m, 1H), 2.69-2.62 (m, 2H), 2.54-2.47 (m, 1H), 2.15-2.09 (m, 1H), 1.85-1.80 (m, 1H), 1.50-1.47 (m, 1H), 1.40-1.36 (m, 2H), 1.20-1.16 (m, 1H), 1.18 (s, 9H), 0.72-0.66 (m, 1H). HPLC tR 1.87 min. Step 2: (1-((4-Nitrophenyl)sulfonyl)piperidin-3-yl)methanamine hydrochloride (Intermediate 25). A solution of tert-butyl (1-((4-nitrophenyl)sulfonyl)piperidin-3-yl)methyl)carbamate (Intermediate 24, 680 mg, 1.70 mmol) in HCl (4 N in dioxane, 6.4mL, 25.53 mmol) was stirred at rt for 1 h. After removal of the solvent under reduced pressure the title compound was obtained as a yellow solid (560 mg, 97%) which was used without further purification.1H NMR (400 MHz, DMSO-d6) ^ 8.47 (d, J = 8.8 Hz, 2H), 8.01 (d, J = 8.8 Hz, 2H), 3.72 (br d, J = 11.4 Hz, 1H), 3.56- 3.52 (m, 1H), 3.33-3.30 (m, 1H), 3.05-2.90 (m, 2H), 2.71-2.66 (m, 1H), 2.40-2.33 (m, 1H), 2.19- 2.13 (m, 1H), 1.84-1.66 (m, 3H), 1.51-1.43 (m, 1H), 1.02-0.94 (m, 1H). LCMS (ES+) m / z calculated for C12H17N3O4S 299.09, found 300 (M+H)+. HPLC tR0.86 min. Step 3: 2-(((1-((4-Nitrophenyl)sulfonyl)piperidin-3-yl)methyl)amino)acetonitrile (Intermediate 26). The title compound was prepared according to the procedure reported in the synthesis of Example 1 (Scheme 10) in step 1 and obtained as a white powder (541 mg, 94%) which was used without further purification. LCMS (ES+) m / z calculated for C14H18N4O4S 338.10, found 339 (M+H)+. HPLC tR 1.23 min. Step 4: 5-Amino-3-((1-((4-nitrophenyl)sulfonyl)piperidin-3-yl)methyl)-1,2,3-oxadiazol-3-ium chloride (Intermediate 27). The title compound was prepared according to the procedure reported in the synthesis of Example 1 (Scheme 10) in step 2 & 3 and obtained as a brown oil (538 mg, 82%) which was used without further purification. LCMS (ES+) m / z calculated for C14H18N5O5S+368.10, found 368 (M+H)+. HPLC tR 0.99 min. Step 5: (3-((1-((4-Nitrophenyl)sulfonyl)piperidin-3-yl)methyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- phenylacetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide (Intermediate 28). The title compound was prepared according to the procedure reported in the synthesis of Example 1 (Scheme 10) in step 7 and obtained as a white powder (25 mg, 11%). LCMS (ES+) m / z calculated for C30H28F3N7O7S 687.17, found 688 (M+H)+. HPLC tR 1.99 min. Step 6: (3-(2-Phenylacetamido)-5-(trifluoromethyl)phenyl)carbamoyl)(3-(piperidin-3-ylmethyl)- 1,2,3-oxadiazol-3-ium-5-yl)amide (Example 110). A suspension of (3-((1-((4-nitrophenyl)sulfonyl)piperidin-3-yl)methyl)-1,2,3-oxadiazol-3-ium-5- yl)((3-(2-phenylacetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide (14 mg, 0.02 mmol) and K2CO3 (2.8 mg, 0.02 mmol) in CH3CN (1.8 mL) was treated with benzenethiol (0.01 mL, 0.10 mmol) and stirred at rt for 2 h. The excess of solvent was removed under reduced pressure to give a residue which was purified by automated RP-HPLC using water (+ 0.1% TFA) and CH3CN (+ 0.1% TFA) as eluents (C18 column). Fractions containing product were lyophilized to give the title compound as a white powder (3.8 mg, 37%).1H NMR (400 MHz, DMSO-d6) ^ 10.42 (s, 1H), 9.77 (s, 1H), 8.69 (br d, J = 9.7 Hz, 1H), 8.34 (br d, J = 9.7 Hz, 1H), 8.22 (s, 1H), 8.01 (br s, 1H), 7.83 (br s, 1H), 7.63 (br s, 1H), 7.34-7.33 (m, 4H), 7.29-7.24 (m, 1H), 4.57-4.55 (m, 2H), 3.65 (s, 2H), 3.25 (br t, J = 13.2 Hz, 2H), 2.82-2.72 (m, 2H), 2.45-2.37 (m, 1H), 1.85-1.78 (m, 2H), 1.66- 1.59 (m, 1H), 1.36-1.24 (m, 1H).19F NMR (377 MHz, DMSO-d6) ^ -61.60 (s, 3F). LCMS (ES+) m / z calculated for C24H25F3N6O3502.19, found 503 (M+H)+. HPLC 1.22 min. The following compounds were prepared according to the procedure described above (Scheme 19) using the appropriate reagents in the first step. Example 99: ((3-(2-phenylacetamido)-5-(trifluoromethyl)phenyl)carbamoyl)(3-(piperidin- 4-yl)-1,2,3-oxadiazol-3-ium-5-yl)amide The title compound was obtained as a white powder (2.6 mg, 16%).1H NMR (300 MHz, DMSO- d6) δ 10.52 (s, 1H), 10.45 (s, 1H), 8.93-8.81 (m, 1H), 8.78 (s, 1H), 8.66-8.41 (m, 1H), 8.04 (s, 1H), 7.78 (s, 1H), 7.71 (s, 1H), 7.40-7.12 (m, 5H), 5.35-5.16 (m, 1H), 3.66 (s, 2H), 3.55-3.35 (m, 2H), 3.27-3.01 (m, 2H), 2.50-2.45 (m, 2H), 2.41-2.15 (m, 2H). LCMS (ES+) m / z calculated for C23H23F3N6O3488.18; found 489 (M+H)+.HPLC tR 2.50 min. Example 105: (3-((1-Methylpiperidin-2-yl)methyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- phenylacetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide. The title compound was obtained as a white powder.1H NMR (400 MHz, DMSO-d6) ^ 10.42 (s, 1H), 9.81 (s, 1H), 8.33 (s, 1H), 8.02 (s, 1H), 7.85 (s, 1H), 7.62 (s, 1H), 7.34 (br d, J = 4.2 Hz, 4H), 7.29-7.24 (m, 1H), 5.09-4.95 (m, 2H), 3.86-3.76 (m, 1H), 3.65 (s, 2H), 2.95 (br s, 3H), 2.90-2.84 (m, 2H), 1.84-1.70 (m, 3H), 1.67-1.48 (m, 3H).19F NMR (377 MHz, DMSO-d6) ^ -61.61 (s, 3F). LCMS (ES+) m / z calculated for C25H27F3N6O3516.21, found 517 (M+H)+. HPLC 1.23 min. Example 106: (3-((1-Methylpiperidin-4-yl)methyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- phenylacetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide. The title compound was obtained as a white powder.1H NMR (400 MHz, DMSO-d6+TFA) ^ 10.45 (s, 1H), 9.89 (s, 1H), 8.29 (s, 1H), 8.01 (s, 1H), 7.81 (s, 1H), 7.65 (s, 1H), 7.33 (br d, J = 4.2 Hz, 4H), 7.29-7.23 (m, 1H), 4.57 (br d, J = 6.8 Hz, 2H), 3.66 (s, 2H), 3.47-3.44 (br m, 2H), 2.96- 2.88 (m, 3H), 2.76-2.75 (m, 3H), 2.30-2.20 (m, 1H), 1.91-1.86 (m, 2H), 1.52-1.43 (m, 2H).19F NMR (377 MHz, DMSO-d6) ^ -61.59 (s, 3F). LCMS (ES+) m / z calculated for C25H27F3N6O3 516.21, found 517 (M+H)+. HPLC 1.22 min. Example 115: (3-((1,4-oxazepan-2-yl)methyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-phenyl- acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide. The title compound was obtained as a white powder. LCMS (ES+) m / z calculated for C24H25F3N6O4518.19, found 519 (M+H)+. HPLC tR 1.31 min. Example 120: (3-(2-Phenylacetamido)-5-(trifluoromethyl)phenyl)carbamoyl)(3-(piperidin- 4-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide. The title compound was obtained as a white powder.1H NMR (400 MHz, DMSO-d6) ^ 10.35 (s, 1H), 9.69 (s, 1H), 8.47 (br d, J = 9.0 Hz, 1H), 8.12 (br s, 2H), 7.93 (s, 1H), 7.75 (s, 1H), 7.56 (s, 1H), 7.26 (br d, J = 4.2 Hz, 4H), 7.21-7.15 (m, 1H), 4.48 (br d, J = 6.6 Hz, 2H), 3.58 (s, 2H), 3.25- 3.22 (m, 2H), 2.85-2.76 (m, 2H), 2.30-2.22 (m, 1H), 1.74 (br d, J = 13.1 Hz, 2H), 1.39-1.31 (m, 2H).19F NMR (377 MHz, DMSO-d6) ^ -61.60 (s, 3F). LCMS (ES+) m / z calculated for C24H25F3N6O3502.19, found 503 (M+H)+. HPLC 1.28 min. Example 121: (3-(2-Phenylacetamido)-5-(trifluoromethyl)phenyl)carbamoyl)(3-(piperidin- 2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide. The title compound was obtained as a white powder.1H NMR (400 MHz, DMSO-d6) ^ 10.36 (s, 1H), 9.72 (s, 1H), 8.65-8.56 (br m, 2H), 8.18 (br s, 1H), 7.95 (s, 1H), 7.76 (s, 1H), 7.55 (s, 1H), 7.26 (br d, J = 4.4 Hz, 4H), 7.22-7.16 (m, 1H), 4.80-4.76 (m, 1H), 4.60 (br dd, J1 = 14.4 Hz, J2 = 8.7 Hz, 1H), 3.58 (s, 2H), 3.28 (br d, J = 12.3 Hz, 1H), 2.88-2.79 (m, 2H), 1.93-1.84 (m, 1H), 1.76-1.65 (m, 2H), 1.50-1.41 (m, 3H).19F NMR (377 MHz, DMSO-d6) ^ -61.61 (s, 3F). LCMS (ES+) m / z calculated for C24H25F3N6O3502.19, found 503 1.30 min. Example 127: (3-Cyclopropyl-5-(2-phenylacetamido)phenyl)carbamoyl)(3-((1-methyl- piperidin-2-yl)methyl)-1,2,3-oxadiazol-3-ium-5-yl)amide. The title compound was obtained as a light-yellow powder.1H NMR (400 MHz, DMSO-d6) ^ 9.98 (s, 1H), 9.32 (br s, 1H), 8.27 (s, 1H), 7.70 (s, 1H), 7.33 (br d, J = 4.2 Hz, 4H), 7.29-7.23 (m, 1H), 7.08 (s, 1H), 6.92 (s, 1H), 5.10-4.86 (m, 2H), 3.60 (s, 2H), 3.31-3.24 (br m, 1H), 3.11-3.05 (m, 1H), 2.95 (br s, 3H), 2.89-2.81 (m, 1H), 2.05-2.02 (m, 1H), 1.85-1.74 (m, 3H), 1.67-1.46 (m, 3H), 0.95-0.86 (m, 2H), 0.56-0.53 (m, 2H).19F NMR (377 MHz, DMSO-d6) ^ -74.10 (s, 3F). LCMS (ES+) m / z calculated for C27H32N6O3488.25, found 489 (M+H)+. 1.17 min. Example 117: (3-((1-Methylpiperidin-3-yl)methyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- phenylacetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide Scheme 20 Step 1: (3-((1-Methylpiperidin-3-yl)methyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-phenylacetamido) -5-(trifluoromethyl)phenyl)carbamoyl)amide (Example 117). A suspension of ((3-(2-phenylacetamido)-5-(trifluoromethyl)phenyl)carbamoyl)(3-(piperidin-3- ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide (Example 110, 26 mg, 0.05 mmol) in MeOH (0.5 mL) was treated with formaldehyde (5.0 uL, 0.18 mmol) followed by NaOAc (7.1 mg, 0.05 mmol) and the mixture was stirred at rt for 30 min. before being treated with NaCNBH3(10.0 mg, 0.10 mmol) and stirred at rt for 1 h. The reaction mixture was filtered through a pad of cellulose and the filtrate was concentrated under reduced pressure to get a residue which was purified by automated RP-HPLC using water (+ 0.1% TFA) and CH3CN (+ 0.1% TFA) as eluents (C18 column). Fractions containing product were lyophilized to give the title compound as a white powder (8.2 mg, 21%).1H NMR (400 MHz, DMSO-d6) ^ 10.42 (s, 1H), 9.77 (br s, 1H), 9.33 (br s, 1H), 8.23 (s, 1H), 8.02 (br s, 1H), 7.83 (br s, 1H), 7.62 (br s, 1H), 7.34-7.33 (m, 4H), 7.29-7.24 (m, 1H), 4.62-4.50 (m, 3H), 3.65 (s, 2H), 3.40 (br d, J = 11.4 Hz, 2H), 2.86-2.77 (m, 4H), 2.46- 2.41 (m, 1H), 1.93-1.89 (m, 1H), 1.83-1.80 (m, 1H), 1.70-1.63 (m, 1H), 1.28-1.21 (m, 1H).19F NMR (377 MHz, DMSO-d6) ^ -61.60 (s, 3F). LCMS (ES+) m / z calculated for C25H27F3N6O3516.21, found 517 (M+H)+. HPLC 1.25 min. The above procedure was used for the preparation of the following examples from the appropriate starting materials: Example 96: (3-((1R,4R)-4-(Dimethylamino)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- phenylacetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide The title compound was prepared from Example 92 and obtained as white powder (1.8 mg, 57%).1H NMR (300 MHz, DMSO-d6+TFA) δ 10.51 (s, 1H), 10.37 (br s, 1H), 9.80-9.40 (m, 1H), 8.74 (s, 1H), 8.02 (s, 1H), 7.80 (s, 1H), 7.69 (s, 1H), 7.36-7.32 (m, 4H), 7.31-7.20 (m, 1H), 5.03-4.87 (m, 1H), 3.67 (s, 2H), 3.34- 3.18 (m, 1H), 2.79 (d, J = 4.9 Hz, 6H), 2.48-2.34 (m, 3H), 2.27-1.99 (m, 3H), 1.80-1.61 (m, 2H). LCMS (ES+) m / z calculated for C26H29F3N6O3530.23; found 531 (M+H)+.HPLC tR 2.58 min. Example 100: (3-(1-Methylpiperidin-4-yl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- phenylacetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide The title compound was prepared from Example 99 and obtained as white powder (3.4 mg, 81%).1H NMR (300 MHz, DMSO-d6 +TFA) δ 10.50 (s, 1H), 10.42-10.20 (m, 1H), 10.00-9.56 (m, 1H), 8.94-8.55 (m, 1H), 8.02 (s, 1H), 7.87-7.77 (m, 1H), 7.70 (br s, 1H), 7.43-7.15 (m, 5H), 5.33-5.03 (m, 1H), 3.74-3.57 (m, 4H), 3.54-3.37 (m, 1H), 3.34-3.10 (m, 2H), 2.85 (s, 2H), 2.69-2.55 (m, 2H), 2.46-2.20 (m, 2H).19F NMR (282 MHz, DMSO-d6) δ -62.04 (s, 3F). LCMS (ES+) m / z calculated for C24H25F3N6O3502.19; found 503 (M+H)+.HPLC tR 2.52 min. Example 138: (3-((1S,4S)-4-((Dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5- yl)((3-(2-oxo-3-phenylpyrrolidin-1-yl)-5-(trifluoromethyl)phenyl)carbamoyl)amide The title compound was prepared from example 119 and obtained as white powder (1.5 mg, 80%). LCMS (ES+) m / z calculated for C29H33F3N6O3570.26; found 571 (M+H)+.HPLC tR2.69 min. Example 89: ((3-Cyclopropyl-5-(2-phenylacetamido)phenyl)carbamoyl)(3-(pyridin-2- ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide Scheme 21 Step 1: (3-Cyclopropyl-5-(2-phenylacetamido)phenyl)carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3- oxadiazol-3-ium-5-yl)amide (Example 89). A solution of 5-amino-3-(pyridin-1-ium-2-ylmethyl)-1,2,3-oxadiazol-3-ium chloride (Intermediate 21, 40 mg, 0.19 mmol) and N-(3-cyclopropyl-5-isocyanatophenyl)-2- phenylacetamide (Intermediate 3, 82 mg, 0.28 mmol) in THF (12 mL) was treated with pyridine (0.05 mL, 0.56 mmol) at 0 °C and stirred at rt for 1 h before being diluted with EtOAc. The organic phase was washed with NaHCO3(sat. aqueous solution) and brine, dried over Na2SO4, filtered, and concentrated under reduced pressure. The title compound was obtained after purification by automated RP-HPLC using water (+ 0.1% TFA) and CH3CN (+ 0.1% TFA) as eluents (C18 column). Fractions containing product were lyophilized to give the title compound as a light beige powder (24.0 mg, 27%).1H NMR (400 MHz, DMSO-d6) ^ 10.01 (s, 1H), 9.360 (s, 1H), 8.61 (s, 1H), 8.21 (s, 1H), 7.93 (s, 1H), 7.64 (s, 1H), 7.47 (s, 1H), 7.32-7.24 (br m, 5H), 7.02 (s, 1H), 5.97 (s, 2H), 3.60 (s, 2H), 1.79-1.77 (m, 1H), 0.90 (s, 2H), 0.54 (s, 2H). LCMS (ES+) m / z calculated for C26H24N6O3468.19, found 469 1.57 min. The above procedure was used for the preparation of the following examples: Example 57: ((3-Methyl-5-(2-phenylacetamido)phenyl)carbamoyl)(3-(pyridin-2-ylmethyl)- 1,2,3-oxadiazol-3-ium-5-yl)amide (trifluoroacetate salt) The title compound was prepared from N-(3-isocyanato-5-methylphenyl)-2-phenylacetamide (prepared from 3-methyl-5-nitroaniline following procedure reported in the synthesis of Intermediate 3 in which step 3 is performed using H2on Pd / C in EtOAc) and 5-amino-3-(pyridin- 1-ium-2-ylmethyl)-1,2,3-oxadiazol-3-ium chloride (Intermediate 21), final compound was obtained as a yellow powder (16.6 mg, 13%).1H NMR (400 MHz, DMSO-d6) ^ 9.93 (s, 1H), 9.24 (s, 1H), 8.54 (d, J= 4.6 Hz, 1H), 8.02 (s, 1H), 7.86 (br t, J= 7.7 Hz, 1H), 7.61 (s, 1H), 7.58 (br d, J = 7.9 Hz, 1H), 7.39 (dd, J1 = 7.1 Hz, J2 = 5.2 Hz, 1H), 7.26-7.24 (m, 4H), 7.21-7.14 (m, 1H), 7.05 (s, 1H), 6.97 (s, 1H), 5.87 (s, 2H), 3.53 (s, 2H), 2.11 (s, 3H). LCMS (ES+) m / z calculated for C24H22N6O3442.18, found 443 (M+H)+. HPLC tR 1.46 min. Example 58: ((3-Chloro-5-(2-phenylacetamido)phenyl)carbamoyl)(3-(pyridin-2-ylmethyl)- 1,2,3-oxadiazol-3-ium-5-yl)amide (trifluoroacetate salt) The title compound was prepared from N-(3-chloro-5-isocyanatophenyl)-2-phenylacetamide (prepared from 3-chloro-5-nitroaniline following procedure reported in the synthesis of Intermediate 3 in which step 3 is performed using H2on Pd / C in EtOAc) and 5-amino-3-(pyridin- 1-ium-2-ylmethyl)-1,2,3-oxadiazol-3-ium chloride (Intermediate 21) final compound was obtained as a white powder (30.2 mg, 28%).1H NMR (400 MHz, DMSO-d6) ^ 10.28 (s, 1H), 9.60 (s, 1H), 8.61 (d, J= 4.6 Hz, 1H), 8.09 (s, 1H), 7.93 (br t, J= 7.7 Hz, 1H), 7.71 (s, 1H), 7.65 (br d, J= 7.9 Hz, 1H), 7.48-7.45 (m, 2H), 7.39 (s, 1H), 7.33-7.32 (m, 4H), 7.28-7.23 (m, 1H), 5.95 (s, 2H), 3.63 (s, 2H). LCMS (ES+) m / z calculated for C23H19ClN6O3462.12, found 463 (M+H)+. HPLC tR 1.62 min. Example 98: (3-(4-(Methoxycarbonyl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-phenyl- acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide The above example was prepared following the procedure reported for Example 4 (Scheme 13) using Intermediate 2 and 5-amino-3-(4-(methoxycarbonyl)benzyl)-1,2,3-oxadiazol-3-ium chloride (prepared as described in the synthesis of Example 1, scheme 10, in step 1 and 2 from methyl 4-(aminomethyl)benzoate). The title compound was obtained after purification by automated RP-HPLC using water (+ 0.1% TFA) and CH3CN (+ 0.1% TFA) as eluents (C18 column). Fractions containing product were lyophilized to give the title compound as a white solid (1.8 mg, 44%).1H NMR (400 MHz, DMSO-d6) ^ 10.42 (s, 1H), 9.76 (s, 1H), 8.20 (s, 1H), 8.04 (d, J = 8.3 Hz, 2H), 7.98 (s, 1H), 7.75 (s, 1H), 7.70 (br d, J = 8.1 Hz, 3H), 7.33 (br d, J = 4.4 Hz, 4H), 7.29-7.23 (m, 1H), 5.90 (s, 2H), 3.87 (s, 3H), 3.65 (s, 2H).19F NMR (377 MHz, DMSO-d6) ^ -61.59 (s, 3F). LCMS (ES+) m / z calculated for C27H22F3N5O5553.16, found 554 (M+H)+. HPLC tR 1.92 min. Example 130: ((3-((1R,2R)-2-Methylcyclopropyl)-5-(2-phenylacetamido)phenyl)- carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide (trifluoroacetate salt) The title compound was prepared from N-(3-isocyanato-5-((1R,2R)-2- methylcyclopropyl)phenyl)-2-phenylacetamide (prepared from 4,4,5,5-tetramethyl-2-((1R,2R)-2- methylcyclopropyl)-1,3,2-dioxaborolane following procedure reported in the synthesis of Intermediate 3) and 5-amino-3-(pyridin-1-ium-2-ylmethyl)-1,2,3-oxadiazol-3-ium chloride (Intermediate 21) in CH3CN as solvent and obtained as a beige powder (43.0 mg, 38%).1H NMR (400 MHz, DMSO-d6) ^ 10.00 (br s, 1H), 9.35 (br s, 1H), 8.61 (br s, 1H), 8.20 (br s, 1H), 7.94 (br t, J= 6.9 Hz, 1H), 7.67-7.62 (m, 2H), 7.47 (br s, 1H), 7.33-7.32 (m, 4H), 7.27-7.23 (m, 1H), 6.98 (br d, J= 8.8 Hz, 2H), 5.96 (br s, 2H), 3.59 (br s, 2H), 1.49-1.45 (m, 1H), 1.12 (br d, J= 5.0 Hz, 3H), 0.95-0.89 (m, 1H), 0.76-0.68 (m, 2H). LCMS (ES+) m / z calculated for C27H26N6O3482.21, found 483 (M+H)+. HPLC tR1.69 min. Example 102: (3-(4-(Hydroxymethyl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-phenyl- acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide Scheme 22 Step 1: (3-(4-(Hydroxymethyl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-phenylacetamido)-5- (trifluoromethyl)phenyl)carbamoyl)amide (Example 102). A solution of (3-(4-(methoxycarbonyl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- phenylacetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide (Example 98, 20mg, 0.04 mmol) in a mixture of EtOH (1.0 mL) and DMSO (0.5 mL) was treated with LiBH4(3.2 mg, 0.14 mmol) and stirred at rt for 30 min before being diluted with H2O and EtOAc. The phases were separated, and the organic phase was washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure. The title compound was obtained after purification by automated RP-HPLC using water (+ 0.1% TFA) and CH3CN (+ 0.1% TFA) as eluents (C18 column). Fractions containing product were lyophilized to give the title compound as a white solid (3.0 mg, 16%).1H NMR (400 MHz, DMSO-d6) ^ 10.39 (s, 1H), 9.71 (br s, 1H), 8.05 (s, 1H), 7.96 (br s, 1H), 7.68 (br d, J = 8.6 Hz, 2H), 7.51 (br d, J = 7.9 Hz, 2H), 7.38 (br d, J = 7.7 Hz, 2H), 7.30 (br d, J = 4.0 Hz, 4H), 7.25-7.20 (m, 1H), 5.74 (s, 2H), 4.50 (s, 2H), 3.62 (s, 2H).19F NMR (377 MHz, DMSO- d6)^^ -61.59 (s, 3F). LCMS (ES+) m / z calculated for C26H22F3N5O4525.16, found 526 (M+H)+. HPLC tR1.65 min. Example 101: (3-(4-Carboxybenzyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-phenylacetamido)-5- (trifluoromethyl)phenyl)carbamoyl)amide Scheme 23 Step 1: (3-(4-Carboxybenzyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-phenylacetamido)-5-(trifluoro- methyl)phenyl)carbamoyl)amide (Example 101) A solution of (3-(4-(methoxycarbonyl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- phenylacetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide (Example 98, 25 mg, 0.05 mmol) in THF (0.25 mL) and H2O (0.25 mL) was treated with lithium hydroxide hydrate (5.0 mg, 0.11 mmol) and stirred for 2 h at rt before being diluted with H2O and EtOAc. The phases were separated, and the aqueous phase was acidified to pH 5 with HCl (1N) and extracted with EtOAc. The organic phase was washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure. The title compound was obtained after lyophilization as a yellow solid (17.8 mg, 72%).1H NMR (400 MHz, DMSO-d6) ^ 10.48 (s, 1H), 9.81 (br s, 1H), 8.23 (s, 1H), 8.07 (br d, J = 8.1 Hz, 2H), 8.04 (br s, 1H), 7.78 (br d, J = 14.5 Hz, 2H), 7.71 (br d, J = 8.1 Hz, 2H), 7.39 (br d, J = 4.4 Hz, 4H), 7.33-7.29 (m, 1H), 5.94 (s, 2H), 3.71 (s, 2H).19F NMR (377 MHz, DMSO- d6)^^ -61.59 (s, 3F). LCMS (ES+) m / z calculated for C26H20F3N5O5539.14, found 540 (M+H)+. HPLC tR1.66 min. . Example 104: (3-(4-Carbamoylbenzyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-phenylacetamido)- 5-(trifluoromethyl)phenyl)carbamoyl)amide Scheme 24 Step 1: (3-(4-Carbamoylbenzyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-phenylacetamido)-5- (trifluoromethyl)phenyl)carbamoyl)amide (Example 104). A solution of (3-(4-carboxybenzyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-phenylacetamido)-5- (trifluoromethyl)phenyl)carbamoyl)amide (Example 101, 15 mg, 0.03 mmol) in DMF (0.5 mL) was treated with TBTU (13 mg, 0.04 mmol) followed by NH3 (0.5 M in dioxane, 0.46 mL, 0.14 mmol) and the resulting solution was stirred at rt for 2 h. Solvent was removed under reduced pressure and the residue dissolved in MeOH and passed through a SiCO3 cartridge (2.0 g). Solvent was removed under reduced pressure and the title compound was obtained after purification by automated RP-HPLC using water (+ 0.1% TFA) and CH3CN (+ 0.1% TFA) as eluents (C18 column). Fractions containing product were lyophilized to give the title compound as a white solid (7.3 mg, 48%).1H NMR (400 MHz, DMSO-d6) ^ 10.23 (s, 1H), 9.56 (br s, 1H), 7.97 (s, 1H), 7.84 (br s, 1H), 7.79 (s, 1H), 7.74 (br d, J = 8.3 Hz, 2H), 7.52 (br d, J = 16.0 Hz, 2H), 7.44 (br d, J = 8.3 Hz, 2H), 7.27 (br s, 1H), 7.14 (br d, J = 4.4 Hz, 4H), 7.09-7.03 (m, 1H), 5.66 (s, 2H), 3.45 (s, 2H).19F NMR (377 MHz, DMSO-d6)^^ -61.59 (s, 3F). LCMS (ES+) m / z calculated for C26H21F3N6O4538.16, found 539 1.57 min. Example 109: (3-(4-(2-Methoxy-2-oxoethyl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- phenylacetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide The above example was prepared following the procedure reported for Example 4 (Scheme 13) using Intermediate 2 and 5-amino-3-(4-(2-methoxy-2-oxoethyl)benzyl)-1,2,3-oxadiazol-3-ium chloride (prepared as described in the synthesis of Example 1, scheme 10, in step 1 and 2 from methyl 2-(4-(aminomethyl)phenyl)acetate hydrochloride). The title compound was obtained after purification by flash chromatography on silica gel (eluting with 10-100% EtOAc in petroleum ether) as a yellow solid (8.0 mg, 48%).1H NMR (400 MHz, DMSO-d6) ^ 10.42 (s, 1H), 9.73 (s, 1H), 8.10 (s, 1H), 7.98 (br s, 1H), 7.73 (br s, 1H), 7.70 (br s, 1H), 7.53 (d, J = 8.1 Hz, 2H), 7.36 (br d, J = 8.3 Hz, 2H), 7.33 (br d, J = 4.4 Hz, 4H), 7.28-7.23 (m, 1H), 5.77 (s, 2H), 3.73 (s, 2H), 3.65 (s, 2H), 3.62 (s, 3H).19F NMR (377 MHz, DMSO-d6) ^ -61.58 (s, 3F). LCMS (ES+) m / z calculated for C28H24F3N5O5567.17, found 568 (M+H)+. HPLC tR1.88 min. Example 111: (3-(4-(2-Hydroxyethyl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-phenyl- acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide The above example was prepared following the procedure reported for Example 102 (scheme 22) using Example 109 in EtOH at 40 °C for 30 min. The title compound was obtained after purification by automated RP-HPLC using water (+ 0.1% TFA) and CH3CN (+ 0.1% TFA) as eluents (C18 column). Fractions containing product were lyophilized to give the title compound as a white solid (5.2 mg, 96% pure, 21%).1H NMR (400 MHz, DMSO-d6) ^ 10.36 (s, 1H), 9.68 (s, 1H), 8.04 (s, 1H), 7.92 (br s, 1H), 7.67 (br s, 1H), 7.64 (br s, 1H), 7.42 (d, J = 8.1 Hz, 2H), 7.28-7.24 (m, 6H), 7.22-7.17 (m, 1H), 5.68 (s, 2H), 3.59 (s, 2H), 3.54 (t, J = 6.6 Hz, 2H), 2.68 (t, J = 6.8 Hz, 2H).19F NMR (377 MHz, DMSO-d6) ^ -61.59 (s, 3F). LCMS (ES+) m / z calculated for C27H24F3N5O4539.18, found 540 1.68 min. Example 113: (3-((5-(Methoxycarbonyl)pyridin-2-yl)methyl)-1,2,3-oxadiazol-3-ium-5- yl)((3-(2-phenylacetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide The above example was prepared following the procedure reported for Example 4 (Scheme 13) using Intermediate 2 and 5-amino-3-((5-(methoxycarbonyl)pyridin-2-yl)methyl)-1,2,3-oxadiazol- 3-ium (prepared as described in the synthesis of Example 1, scheme 10, in step 1 and 2 from methyl 6-(aminomethyl)nicotinate hydrochloride). The title compound was obtained after purification by flash chromatography on silica gel (eluting with 0-100% EtOAc in petroleum ether) as a yellow solid (2.6 mg, 46%).1H NMR (400 MHz, DMSO-d6) ^ 10.43 (s, 1H), 9.76 (s, 1H), 9.09 (s, 1H), 8.42 (br d, J = 8.3 Hz, 1H), 8.20 (s, 1H), 7.98 (br s, 1H), 7.79 (br d, J = 8.3 Hz, 1H), 7.75 (br s, 1H), 7.70 (br s, 1H), 7.33 (br d, J = 4.2 Hz, 4H), 7.28-7.23 (m, 1H), 6.07 (s, 2H), 3.90 (s, 3H), 3.65 (s, 2H).19F NMR (377 MHz, DMSO-d6) ^ -61.59 (s, 3F). LCMS (ES+) m / z calculated for C26H21F3N6O5554.15, found 555 (M+H)+. HPLC tR1.83 min. Example 116: (3-((5-(Hydroxymethyl)pyridin-2-yl)methyl)-1,2,3-oxadiazol-3-ium-5-yl)((3- (2-phenylacetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide The above example was prepared following the procedure reported for Example 102 (scheme 22) using Example 113 in EtOH at rt for 30 min. The title compound was obtained after purification by automated RP-HPLC using water (+ 0.1% TFA) and CH3CN (+ 0.1% TFA) as eluents (C18 column). Fractions containing product were lyophilized to give the title compound as a white solid (6.5 mg, 34%).1H NMR (400 MHz, DMSO-d6) ^ 10.43 (s, 1H), 9.75 (s, 1H), 8.55 (s, 1H), 8.10 (s, 1H), 7.99 (br s, 1H), 7.85 (br d, J = 7.5 Hz, 1H), 7.72 (br d, J = 6.1 Hz, 2H), 7.63 (br d, J = 7.9 Hz, 1H), 7.33 (br d, J = 4.2 Hz, 4H), 7.28-7.23 (m, 1H), 5.92 (s, 2H), 4.56 (s, 2H), 3.65 (s, 2H).19F NMR (377 MHz, DMSO-d6) ^ -61.58 (s, 3F). LCMS (ES+) m / z calculated for C25H21F3N6O4 526.16, found 527 (M+H)+. HPLC 1.49 min. Example 108: (3-(3-(Aminomethyl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-phenyl- acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide Scheme 25 Step 1: (3-(3-(Aminomethyl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-phenylacetamido)-5- (trifluoromethyl)phenyl)carbamoyl)amide (Example 108). A solution of (3-(3-((1,3-dioxoisoindolin-2-yl)methyl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- phenylacetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide (prepared according to the procedure reported for the synthesis of Example 2 starting from 2-(3- (aminomethyl)benzyl)isoindoline-1,3-dione hydrochloride (Intermediate 6); 30.0 mg, 0.05 mmol) in a mixture of EtOH (3.0 mL) and CHCl3(5.0 mL) was treated with hydrazine hydrate (11.5 mg, 0.23 mmol) and stirred at rt at 80 °C for 4 h, After removal of solvent under reduced pressure the title compound was obtained after purification by automated RP-HPLC using water (+ 0.1% TFA) and CH3CN (+ 0.1% TFA) as eluents (C18 column). Fractions containing product were lyophilized to give the title compound as a white powder (7.0 mg, 29%).1H NMR (400 MHz, DMSO-d6) ^ 10.41 (s, 1H), 9.75 (s, 1H), 8.12 (br s, 4H), 8.00 (br s, 1H), 7.78 (br s, 1H), 7.63 (br s, 2H), 7.57-7.54 (m, 3H), 7.34-7.33 (m, 4H), 7.28-7.24 (m, 1H), 5.82 (s, 2H), 4.09-4.05 (m, 2H), 3.65 (s, 2H).19F NMR (377 MHz, DMSO-d6) ^ -61.59 (s, 3F). LCMS (ES+) m / z calculated for C26H23F3N6O3524.18, found 525 (M+H)+. HPLC 1.34 min. The following compounds were prepared according to the procedure described above using the appropriate starting amine prepared as reported for the synthesis of Intermediate 7 (Example 56) or Intermediate 8 (Example 142). Example 114: (3-(2-(Aminomethyl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-phenyl- acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide. The title compound was obtained as a white powder. LCMS (ES+) m / z calculated for C26H23F3N6O3524.18, found 525 (M+H)+. HPLC 1.40 min. Example 118: (3-((3-Aminocyclobutyl)methyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-phenyl- acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide. The title compound was obtained as a white powder.1H NMR (400 MHz, DMSO-d6) ^ 10.42 (s, 1H), 9.75 (s, 1H), 8.15 (d, J = 9.4 Hz, 1H), 7.99 (br s, 3H), 7.89 (br s, 1H), 7.81 (br s, 1H), 7.65 (s, 1H), 7.34 (br d, J = 4.4 Hz, 4H), 7.28-7.24 (m, 1H), 4.72 (br d, J = 7.9 Hz, 1H), 4.59 (br d, J = 6.6 Hz, 1H), 3.65 (s, 2H), 3.05-2.96 (m, 1H), 2.76-2.70 (m, 1H), 2.39-2.32 (m, 1H), 2.28-2.18 (m, 2H), 1.99-1.90 (m, 1H).19F NMR (377 MHz, DMSO-d6) ^ -61.58 (s, 3F). LCMS (ES+) m / z calculated for C23H23F3N6O3488.18, found 489 (M+H)+. HPLC tR 1.22 min. Example 56: (3-(4-(Aminomethyl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- phenylacetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide. The title compound was obtained as a white powder.1H NMR (400 MHz, DMSO-d6) ^ 10.42 (s, 1H), 9.74 (s, 1H), 8.14 (br s, 3H), 8.09 (s, 1H), 7.99 (s, 1H), 7.77 (s, 1H), 7.65-7.63 (m, 3H), 7.54 (br d, J = 7.9 Hz, 2H), 7.33 (br d, J = 4.4 Hz, 4H), 7.29-7.23 (m, 1H), 5.81 (s, 2H), 4.09-4.05 (m, 2H), 3.65 (s, 2H).19F NMR (377 MHz, DMSO-d6) ^ -61.60 (s, 3F). LCMS (ES+) m / z calculated for C26H23F3N6O3524.18, found 523 (M-H)-. 1.32 min. Example 142: ((3-(2-Phenylacetamido)-5-(trifluoromethyl)phenyl)carbamoyl)(3-((1-(2,2,2- trifluoroethyl)piperidin-2-yl)methyl)-1,2,3-oxadiazol-3-ium-5-yl)amide (trifluoroacetate salt) The above example was prepared following the procedure reported for Example 4 (a mixture of CH3CN and DMSO was used as solvent) using Intermediate 2 and 5-amino-3-((1-(2,2,2- trifluoroethyl)piperidin-2-yl)methyl)-1,2,3-oxadiazol-3-ium chloride (prepared as described in the synthesis of Example 1 in step 1 and 2 from Intermediate 8; step 1 was performed at 60 °C). The title compound was obtained after purification by automated RP-HPLC using water (+ 0.1% TFA) and CH3CN (+ 0.1% TFA) as eluents (C18 column). Fractions containing product were lyophilized to give the title compound as a pale orange solid (15.5 mg, 92% pure, 4%).1H NMR (400 MHz, DMSO-d6) ^ 10.23 (s, 1H), 9.51 (s, 1H), 7.99 (s, 1H), 7.78 (s, 1H), 7.59 (s, 1H), 7.48 (s, 1H), 7.14-7.13 (br m, 5H), 7.08-7.03 (m, 1H), 4.70-4.65 (m, 1H), 4.45-4.41 (m, 1H), 3.45 (s, 2H), 3.28-3.12 (m, 3H), 2.85-2.79 (m, 1H), 2.46-2.39 (m, 1H), 1.52-1.38 (m, 2H), 1.35-1.14 (m, 4H).19F NMR (377 MHz, DMSO-d6) ^ -61.59 (s, 3F), -70.95 (s, 3F). LCMS (ES+) m / z calculated for C26H26F6N6O3584.20, found 585 (M+H)+. HPLC tR 2.11 min. Example 112: (3-(9-Amino-3-oxabicyclo[3.3.1]nonan-7-yl)-1,2,3-oxadiazol-3-ium-5-yl)((3- (2-phenylacetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide. The title compound was obtained as a white powder. LCMS (ES+) m / z calculated for C26H27F3N6O4544.20, found 545 1.22 min. Example 140: ((3-(Benzylcarbamoyl)-5-(trifluoromethyl)phenyl)carbamoyl)(3-((1-(2- ethoxy-2-oxoethyl)piperidin-4-yl)methyl)-1,2,3-oxadiazol-3-ium-5-yl)amide (trifluoroacetate salt) Scheme 26 Step 1: (3-(Benzylcarbamoyl)-5-(trifluoromethyl)phenyl)carbamoyl)(3-((1-(2-ethoxy-2-oxo- ethyl)piperidin-4-yl)methyl)-1,2,3-oxadiazol-3-ium-5-yl)amide (trifluoroacetate salt) (Example 140). A suspension of ((3-(benzylcarbamoyl)-5-(trifluoromethyl)phenyl)carbamoyl)(3-(piperidin-4- ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide (Example 120, 78 mg, 0.16 mmol) in MeOH (1.5 mL) was treated with ethyl 2-oxoacetate (0.22 mL, 0.54 mmol) followed by NaOAc (21 mg, 0.16 mmol) and the mixture was stirred at rt for 30 min. before being treated with NaCNBH3(29 mg, 0.47 mmol) and stirred at rt for 1 h. The mixture was then filtered on a pad of solca flok and concentrated under reduced pressure. The title compound was obtained after purification by automated RP-HPLC using water (+ 0.1% TFA) and CH3CN (+ 0.1% TFA) as eluents (C18 column). Fractions containing product were lyophilized to give the title compound as a white solid (4.4 mg, 4%).1H NMR (400 MHz, DMSO-d6) ^ 10.42 (s, 1H), 9.91 (br s, 1H), 9.77 (br s, 1H), 8.21 (s, 1H), 8.00 (s, 1H), 7.83 (s, 1H), 7.63 (s, 1H), 7.34-7.32 (m, 4H), 7.29-7.23 (m, 1H), 4.55 (br d, J = 5.7 Hz, 2H), 4.27-4.16 (m, 4H), 3.65 (s, 2H), 3.55-3.51 (br m, 2H), 3.05-2.97 (m, 2H), 2.29-2.22 (m, 1H), 1.89 (br d, J = 15.6 Hz, 2H), 1.65-1.59 (m, 2H), 1.25 (br t, J = 6.9 Hz, 3H).19F NMR (377 MHz, DMSO-d6)^^ -61.60 (s, 3F). LCMS (ES+) m / z calculated for C28H31F3N6O5 588.23, found 589 (M+H)+. HPLC 1.36 min. Example 141: ((3-(Benzylcarbamoyl)-5-(trifluoromethyl)phenyl)carbamoyl)(3-((1-(2- hydroxyethyl)piperidin-4-yl)methyl)-1,2,3-oxadiazol-3-ium-5-yl)amide (trifluoroacetate salt) Scheme 27 Step 1: ((3-(Benzylcarbamoyl)-5-(trifluoromethyl)phenyl)carbamoyl)(3-((1-(2-hydroxyethyl)- piperidin-4-yl)methyl)-1,2,3-oxadiazol-3-ium-5-yl)amide (trifluoroacetate salt) (Example 141). A solution of ((3-(benzylcarbamoyl)-5-(trifluoromethyl)phenyl)carbamoyl)(3-((1-(2-ethoxy-2- oxoethyl)piperidin-4-yl)methyl)-1,2,3-oxadiazol-3-ium-5-yl)amide (Example 140, 19mg, 0.03 mmol) in a mixture of EtOH (4 mL) and DMSO (1 mL) was treated with LiBH4(42 mg, 1.95 mmol) and stirred at rt for 1 h and at 40 °C for 3 h before being cooled to rt and diluted with EtOAc and H2O. The organic phase was washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure. The title compound was obtained after purification by automated RP-HPLC using water (+ 0.1% TFA) and CH3CN (+ 0.1% TFA) as eluents (C18 column). Fractions containing product were lyophilized to give the title compound as a white solid (6.7 mg, 26%).1H NMR (400 MHz, DMSO-d6) ^ 10.51 (s, 1H), 9.86 (br s, 1H), 9.19 (br s, 1H), 8.30 (s, 1H), 8.10 (s, 1H), 7.92 (s, 1H), 7.72 (s, 1H), 7.43-7.41 (m, 4H), 7.39-7.34 (m, 1H), 4.64 (br d, J = 6.1 Hz, 2H), 3.84-3.79 (m, 2H), 3.75 (s, 2H), 3.63-3.59 (br m, 2H), 3.23-3.20 (m, 2H), 3.09-3.00 (m, 2H), 2.39-2.35 (m, 1H), 2.01-1.93 (m, 2H), 1.71-1.62 (m, 2H).19F NMR (377 MHz, DMSO-d6)^^ -61.59 (s, 3F). LCMS (ES+) m / z calculated for C26H29F3N6O4546.22, found 547 1.25 min. Intermediate 32: 5-Amino-3-((1R,4R)-4-((1,3-dioxoisoindolin-2-yl)methyl)cyclohexyl)-1,2,3- oxadiazol-3-ium chloride Scheme 28 Step 1: tert-Butyl ((1R,4R)-4-((1,3-dioxoisoindolin-2-yl)methyl)cyclohexyl)carbamate (Intermediate 29) A suspension of tert-butyl ((1R,4R)-4-(aminomethyl)cyclohexyl)carbamate (520 mg, 2.28 mmol) in H2O (10 mL) was treated with Na2CO3 (133 mg, 1.25 mmol) and N- carbethoxyphthalimide (549 mg, 2.51 mmol) and stirred at rt for 18 h. H2O (20 mL) was added to the reaction mixture and the product was extracted with EtOAc. The organic phase was washed with HCl (1N), brine, dried over Na2SO4, filtered and concentrated under reduced pressure to afford the title compound as a white powder (411 mg, 50%).1H NMR (400 MHz, DMSO-d6) δ 7.96-7.72 (m, 4H), 6.66 (br d, J = 8.2 Hz, 1H), 3.42 (d, J = 6.8 Hz, 2H), 3.24-3.03 (m, 1H), 1.88- 1.46 (m, 5H), 1.37 (s, 9H), 1.13-0.89 (m, 4H). LCMS (ES+) m / z calculated for C20H26N2O4358.19; found 359 (M+H)+. HPLC tR 2.09 min. Step 2: 2-(((1R,4R)-4-Aminocyclohexyl)methyl)isoindoline-1,3-dione hydrochloride (Intermediate 30) A solution of tert-butyl((1R,4R)-4-((1,3-dioxoisoindolin-2-yl)methyl)cyclohexyl)carbamate (Intermediate 29, 411 mg, 1.15 mmol) in HCl (4 N in 1,4-dioxane; 2.0 mL) was stirred at rt for 1 h before being treated with Et2O. A powder formed which was filtered and dried to afford the title compound as an off-white powder (309 mg, 92%).1H NMR (400 MHz, DMSO-d6) δ 8.02-7.69 (m, 7H), 3.44 (d, J=6.8 Hz, 2 H), 3.07-2.85 (m, 1H), 2.03-1.84 (m, 2H), 1.80-1.52 (m, 3H), 1.37- 1.16 (m, 2H), 1.16-0.98 (m, 2H). LCMS (ES+) m / z calculated for C15H18N2O2258.14; found 259 1.05 min. Step 3: 2-(((1R,4R)-4-((1,3-dioxoisoindolin-2-yl)methyl)cyclohexyl)amino)acetonitrile (Intermediate 31) The title compound was prepared following the procedure described for the synthesis of Example 173 in Step 1 and obtained as an off-white powder (287 mg, 92%) which was used without further purification.1H NMR (400 MHz, DMSO-d6) δ 8.10-7.64 (m, 4H), 3.60 (br d, J = 4.4 Hz, 2H), 3.44 (d, J = 6.7 Hz, 2H), 2.48-2.35 (m, 2H), 1.85 (br d, J = 11.5 Hz, 2H), 1.73-1.53 (m, 3H), 1.12- 0.81 (m, 4H). LCMS (ES+) m / z calculated for C17H19N3O2297.15; found 298 (M+H)+. HPLC tR1.09 min. Step 4: 5-amino-3-((1R,4R)-4-((1,3-Dioxoisoindolin-2-yl)methyl)cyclohexyl)-1,2,3-oxadiazol-3- ium chloride (Intermediate 32) A solution of 2-(((1R,4R)-4-((1,3-dioxoisoindolin-2-yl)methyl)cyclohexyl)amino)acetonitrile (Intermediate 31, 287 mg, 0.97 mmol) in THF / DMSO mixture (4.0 mL / 0.5 mL) was treated with isopentyl nitrite (0.39 mL, 2.9 mmol) and stirred at rt for 18 h. The reaction mixture was diluted with H2O (2mL) and extracted with DCM. The organic phase was washed (3x) with small amounts of H2O and finally with brine; then was dried over Na2SO4, filtered and concentrated in vacuo to yield a solid yellowish product that was treated with HCl (4 N, 2.1 mL). The white suspension was stirred at rt for 30 min and then diluted with Et2O (3 mL). A precipitated formed which was filtered and dried to get the title compound (310 mg, 98%).1H NMR (400 MHz, DMSO-d6) δ 9.45 (s, 2H), 8.03 (s, 1H), 7.92-7.79 (m, 4H), 5.03-4.64 (m, 1H), 3.50 (d, J = 6.5 Hz, 2H), 2.34-2.12 (m, 2H), 2.00-1.77 (m, 5H), 1.38-1.11 (m, 2H). LCMS (ES+) m / z calculated for C17H19N4O3+327.15; found 327 (M+H)+. HPLC tR1.22 min. Example 149: ((3-Cyclopropyl-5-(2-(phenylsulfonyl)acetamido)phenyl)carbamoyl)(3- ((1R,4R)-4-((dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)amide (trifluoroacetate salt) Scheme 29 Step 1: N-(3-Cyclopropyl-5-nitrophenyl)-2-(phenylsulfonyl)acetamide (Intermediate 33) A solution of 3-cyclopropyl-5-nitroaniline (100 mg, 0.56 mmol) and HATU (320 mg, 0.84 mmol) in dry DMF (1.2 mL) was treated with DIPEA (218 mg, 1.68 mmol) and 2-(phenylsulfonyl)acetic acid (169 mg, 0.84 mmol) and the solution was stirred at rt for 1 h before being concentrated under reduced pressure. The obtained oily residue was dissolved in EtOAc and treated with a NaHCO3(sat. aqueous solution). The organic layer was washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo to give a crude material which was triturated with EtOAc to afford the title compound as a yellow powder (142 mg, 70%). LCMS (ES+) m / z calculated for C17H16N2O5S 360.08, found 361 1.74 min. Step 2: N-(3-Amino-5-cyclopropylphenyl)-2-(phenylsulfonyl)acetamide (Intermediate 34) A degassed solution of N-(3-cyclopropyl-5-nitrophenyl)-2-(phenylsulfonyl)acetamide (Intermediate 33, 141 mg, 0.39 mmol) in dry THF (3.9 mL) was treated with Pd (10% on C, 12.5 mg, 0.12 mmol) and stirred under an H2atmosphere at rt for 18 h. After removal of H2the reaction mixture was filtered on a pad of Celite and the solvent removed under reduced pressure to get the title compound as a white solid (120 mg, 88%). LCMS (ES+) m / z calculated for C17H18N2O3S 330.10, found 331 (M+H)+. HPLC tR1.11 min. Step 3: ((3-Cyclopropyl-5-(2-(phenylsulfonyl)acetamido)phenyl)carbamoyl)(3-((1R,4R)-4-((1,3- dioxoisoindolin-2-yl)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)amide (Intermediate 35) A solution of N-(3-amino-5-cyclopropyl-phenyl)-2-(benzenesulfonyl)acetamide (Intermediate 34, 64 mg, 0.19 mmol) and DIPEA (50 mg, 0.39 mmol) in dry THF (0.7 mL) was treated with triphosgene (29 mg, 0.10 mmol) and stirred at rt for 1 h before being added dropwise to a stirring suspension of 5-amino-3-((1R,4R)-4-((1,3-dioxoisoindolin-2-yl)methyl)cyclohexyl)-1,2,3- oxadiazol-3-ium chloride (Intermediate 32, 35 mg, 0.10 mmol) in dry THF (1 mL) followed by the addition of DIPEA (49.9 mg, 0.39 mmol) at 0 °C. The mixture was stirred at this temperature for 5 minutes before being diluted with H2O and extracted with EtOAc (2x). The collected organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo to get a residue which was purified by flash chromatography on silica gel (eluting with 0-100% EtOAc in petroleum ether) to get the title compound as a yellow solid (18 mg, 27%). LCMS (ES+) m / z calculated for C35H34N6O7S 682.22, found 683 (M+H)+. HPLC 1.78 min. Step 4: (3-Cyclopropyl-5-(2-(phenylsulfonyl)acetamido)phenyl)carbamoyl)(3-((1R,R)-4- ((dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)amide (Example 149). A solution of ((3-cyclopropyl-5-(2-(phenylsulfonyl)acetamido)phenyl)carbamoyl)(3-((1R,4R)-4- ((1,3-dioxoisoindolin-2-yl)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)amide (Intermediate 35, 17 mg, 0.025 mmol) in dry ethanol (0.5 mL) was treated with hydrazine (2.5 mg, 0.05 mmol) and stirred 1 h at 80 °C before being cooled to rt and concentrate under reduced pressure to get (3-((1R,4R)-4-(aminomethyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-cyclopropyl-5-(2- (phenylsulfonyl)acetamido)phenyl)carbamoyl)amide (10 mg, 0.011 mmol, 44% Yield) as a white solid which was used as a crude. A solution of the obtained (3-((1R,4R)-4-(aminomethyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5- yl)((3-cyclopropyl-5-(2-(phenylsulfonyl)acetamido)phenyl)carbamoyl)amide (10 mg, 0.018 mmol) in dry MeOH (0.4 mL) was treated with formaldehyde (97 mg, 1.2 mmol) followed by the addition of 1 drop of AcOH. Then, NaBH(OAc)3(23 mg, 0.11 mmol) was added and the resulting mixture was stirred at room temperature for 1 h before being concentrated in vacuo to give a residue which was purified by automated RP-HPLC using H2O (+ 0.1% TFA) and CH3CN (+ 0.1% TFA) as eluents (C18 column). Fractions containing product were lyophilized to give the title compound as a white powder (0.6 mg, 6%).1H NMR (400 MHz, DMSO-d6) δ 10.10 (s, 1H), 9.28 (s, 1H), 8.12 (s, 1H), 7.92 (d, J = 7.8 Hz, 2H), 7.77 (t, J = 7.5 Hz, 1H), 7.67 (t, J = 7.7 Hz, 2H), 7.55 (s, 1H), 7.12 (s, 1H), 6.86 (s, 1H), 6.53 (s, 1H), 4.71 (br s, 1H), 4.46 (s, 2H), 2.87-2.69 (m, 3H), 2.31-2.17 (m, 3H), 2.08 (s, 5H), 2.02-1.88 (m, 5H), 1.87-1.71 (m, 2H), 0.91 (br d, J = 8.1 Hz, 2H), 0.54 (br d, J = 5.4 Hz, 2H). LCMS (ES+) m / z calculated for C29H36N6O5S 580.25, found 581 (M+H)+. HPLC tR 1.12 min. Example 150: (3-((1R,4R)-4-((Dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5- yl)((3-(2-(phenylsulfonyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide The title compound was synthesized following the same synthetic procedure described for the synthesis of Example 149 using 3-nitro-5-(trifluoromethyl)aniline as starting material in Step 1.1H NMR (400 MHz, DMSO-d6) δ 10.60 (s, 1H), 9.77 (s, 1H), 8.18 (s, 1H), 7.96-7.88 (m, 3H), 7.84 (s, 1H), 7.77 (br t, J = 7.3 Hz, 1H), 7.68 (t, J = 7.6 Hz, 2H), 7.55 (s, 1H), 4.71 (br t, J = 11.4 Hz, 1H), 4.51 (s, 2H), 2.22 (br d, J = 10.1 Hz, 2H), 2.12 (s, 6H), 2.08-1.90 (m, 5H), 1.58 (br s, 1H), 1.24 (s, 1H), 1.13-1.00 (m, 2H).19F NMR (377 MHz, DMSO-d6) ^ -61.60 (s, 3F). LCMS (ES+) m / z calculated for C27H31F3N6O5S 608.20; found 609 (M-H)-. HPLC 1.25 min. Examples 147-148, 167, 172 and 193 were synthetized according to the conditions described for the synthesis of Example 149 using the appropriate aniline intermediate in Step 3. Example 147: (3-((1R,4R)-4-((Dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5- yl)((3-(2-phenylacetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide. The title compound was obtained as a white powder (11 mg, 38%) using N-(3-amino-5- (trifluoromethyl)phenyl)-2-phenylacetamide (Intermediate 1).1H NMR (400 MHz, DMSO-d6) δ 10.43 (s, 1H), 9.72 (s, 1H), 8.17 (s, 1H), 7.96 (s, 1H), 7.83 (s, 1H), 7.66 (s, 1H), 7.34 (d, J = 4.4 Hz, 4H), 7.31-7.24 (m, 1H), 4.74-4.67 (m, 1H), 3.65 (s, 2H), 2.27-2.19 (m, 2H), 2.12 (s, 6H), 2.05- 1.90 (m, 6H), 1.63-1.56 (m, 1H), 1.15-1.04 (m, 2H).19F NMR (377 MHz, DMSO-d6) ^ -61.58 (s, 3H). LCMS (ES+) m / z calculated for C27H31F3N6O3544.24, found 545 (M+H)+. HPLC 1.35 min. Example 148: (3-((1R,4R)-4-((Dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5- yl)((3-(2-oxo-3-phenylpyrrolidin-1-yl)-5-(trifluoromethyl)phenyl)carbamoyl)amide. The title compound was obtained as a white powder (8.0 mg, 31%) using 1-(3-amino-5- (trifluoromethyl)phenyl)-3-phenylpyrrolidin-2-one (Intermediate 38).1H NMR (400 MHz, DMSO-d6) δ 9.75 (s, 1H), 8.25 (s, 1H), 8.07 (s, 1H), 7.92 (s, 1H), 7.81 (s, 1H), 7.39-7.21 (m, 5H), 4.73-4.66 (m, 1H), 4.00-3.88 (m, 3H), 2.63-2.57 (m, 1H), 2.26-2.18 (m, 3H), 2.12 (s, 6H), 2.05- 1.90 (m, 6H), 1.61-1.55 (m, 1H), 1.15-1.04 (m, 2H).19F NMR (377 MHz, DMSO-d6) ^ -61.41 (s, 3H). LCMS (ES+) m / z calculated for C29H33F3N6O3570.26, found 571 (M+H)+. HPLC 1.42 min. Example 167: (3-((1R,4R)-4-((Dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5- yl)((3-(N-methyl-2-phenylpropanamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide. The title compound was obtained as a white powder (1.2 mg, 3%) using N-(3-amino-5- (trifluoromethyl)phenyl)-N-methyl-2-phenylpropanamide (Intermediate 41).1H NMR (400 MHz, DMSO-d6) δ 9.79 (s, 1H), 9.22 (br s, 1H), 8.26 (s, 1H), 8.10 (s, 1H), 7.68 (s, 1H), 7.41-7.13 (m, 4H), 6.97-6.82 (m, 2H), 4.79-4.73 (m, 1H), 3.25-3.19 (m, 1H), 3.15 (s, 3H), 2.99 (t, J = 6.0 Hz, 2H), 2.81 (d, J = 4.8 Hz, 6H), 2.30-2.26 (m, 2H), 2.08-1.82 (m, 5H), 1.29 (d, J = 6.8 Hz, 3H), 1.23-1.17 (m, 2H).19F NMR (377 MHz, DMSO-d6) ^ -61.47 (s, 3H). LCMS (ES+) m / z calculated for C29H35F3N6O3572.27, found 573 1.38 min. Example 172: (3-((1R,4R)-4-((Dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5- yl)((3-(N-methyl-2-phenylacetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide. The title compound was obtained as a white powder (29.4 mg, 55%) using N-(3-amino-5- (trifluoromethyl)phenyl)-N-methyl-2-phenylacetamide (Intermediate 45).1H NMR (400 MHz, DMSO-d6) δ 9.80 (br s, 1H), 8.26 (s, 1H), 8.11 (br s, 1H), 7.77 (s, 1H), 7.26-7.20 (m, 4H), 7.13 (s, 1H), 7.06 (br s, 1H), 4.74-4.66 (m, 1H), 3.50 (br s, 2H), 3.20 (br s, 3H), 2.26-1.92 (m, 15H), 1.12-1.03 (m, 2H).19F NMR (377 MHz, DMSO-d6) ^ -61.35 (s, 3H). LCMS (ES+) m / z calculated for C28H33F3N6O3558.26, found 559 (M+H)+. HPLC 1.33 min. Example 193: ((2-(2-(2-Chlorophenyl)acetamido)-6-(trifluoromethyl)pyridin-4- yl)carbamoyl)(3-((1R,4R)-4-((dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5- yl)amide. The title compound was obtained as a white powder (1.5 mg, 23%) using N-(4-amino-6- (trifluoromethyl)pyridin-2-yl)-2-(2-chlorophenyl)acetamide.1H NMR (400 MHz, DMSO-d6) δ 10.91 (s, 1H), 10.13 (s, 1H), 9.08 (br s, 1H), 8.70 (s, 1H), 8.29 (s, 1H), 7.80 (d, J = 1.6 Hz, 1H), 7.48-7.42 (m, 2H), 7.33-7.30 (m, 2H), 4.78-4.72 (m, 1H), 3.93 (s, 2H), 2.98 (br t, J = 6.1 Hz, 2H), 2.80 (d, J = 4.9 Hz, 6H), 2.29-2.24 (m, 2H), 2.03-1.86 (m, 5H), 1.24-1.15 (m, 2H).19F NMR (377 MHz, DMSO-d6) ^ -66.98 (s, 3F). LCMS (ES+) m / z calculated for C26H29ClF3N7O3579.20, found 580 1.43 min. Intermediate 39: 1-(3-Amino-5-(trifluoromethyl)phenyl)-3-phenylpyrrolidin-2-one

[0003] Scheme 30 Step 1: N-(3-Nitro-5-(trifluoromethyl)phenyl)-2-phenylpent-4-enamide (Intermediate 36) Step A: a solution of 2-phenylpent-4-enoic acid (500 mg, 2.8 mmol, 1 eq.) in anhydrous DCM (7 mL) at rt under nitrogen atmosphere was treated with 2.0 M oxalyl chloride in DCM (1.7 mL, 3.41 mmol, 1.2 eq.) and a drop of DMF. The resulting mixture was stirred at rt for 1 h. The excess of solvent was removed under reduced pressure to obtain a crude product as an orange oil which was used in step B without furthermore purification. Step B: a solution of 3-amino-5-nitrobenzotrifluoride (526 mg, 2.5 mmol, 1eq.) in dry THF (8 mL) was treated with pyridine (0.25 mL,3.1 mmol, 1.1 eq.) and stirred at rt for 10 min. Then a solution acetyl chloride from step A (2.84 mmol, 1.0 eq.) in DCM (6 mL), was added to the solution previously cooled at 0 °C. The reaction mixture was warmed at rt and stirred for 20 min. The reaction mixture was quenched with H2O and diluted with DCM; the organic layer was separated, washed with brine, and dried under reduced pressure to get a residue which was purified by flash chromatography on silica gel (eluting with 0-50% EtOAc in petroleum ether) to get the title compound as an orange solid (83%).1H NMR (300 MHz, DMSO-d6) δ 10.93 (s, 1H), 8.77 (t, J = 1.9 Hz, 1H), 8.38 (s, 1H), 8.14 (s, 1H), 7.55-7.20 (m, 5H), 5.76 (tq, J = 10.3, 6.7 Hz, 1H), 5.17-5.06 (m, 1H), 5.05-4.97 (m, 1H), 3.80 (dd, J1= 8.7, J2= 6.4 Hz, 1H), 2.93-2.78(m, 1H), 2.49- 2.42 (m, 1H). LCMS (ES+) m / z calculated for C18H15F3N2O3365.35; found 366 (M+H)+. HPLC tR 2.39 min. Step2: 5-Hydroxy-1-(3-nitro-5-(trifluoromethyl)phenyl)-3-phenylpyrrolidin-2-one (Intermediate 37) A solution of N-(3-nitro-5-(trifluoromethyl)phenyl)-2-phenylpent-4-enamide (Intermediate 36, 888 mg, 2.44 mmol) in a mixture of THF (40 mL), H2O (8 mL) and tert-butanol (3 mL) was treated with OsO4En-Cat (5% wt; 1.24 g, 0.24 mmol) followed by sodium periodate (1.1 g, 4.87 mmol) and stirred at rt for 1.5 h before being filtered. A saturated aqueous solution of sodium thiosulfate was added to the filtered solution, and the resulting mixture was stirred for 10 min at rt before being poured onto a mixture of EtOAc and NaHCO3(sat. aqueous solution). The organic phase was washed with brine, dried over Na2SO4, filtered and concentrated under reduced pressure to get the title compound as light yellowish foam (862 mg, 97%) that was used as a crude. LCMS (ES+) m / z calculated for C17H13F3N2O4366.08, found 367 (M-H)-. HPLC tR2.01 min. Step 2: 1-(3-Nitro-5-(trifluoromethyl)phenyl)-3-phenylpyrrolidin-2-one (Intermediate 38) A solution of 5-hydroxy-1-(3-nitro-5-(trifluoromethyl)phenyl)-3-phenylpyrrolidin-2-one (Intermediate 37, 862 mg, 2.35 mmol) in DCM (30 mL) was treated with triethyl silane (1.13 mL, 7.06 mmol) followed by TFA (2.68 mL, 35 mmol) and the reaction mixture was stirred at rt for 3 h before being poured onto a mixture of NaHCO3 (sat. aqueous solution) and EtOAc. The organic layer was separated, washed with brine, dried over Na2SO4, filtered and concentrated in vacuo to afford the title compound as a yellow solid (825 mg, 99%) which was used as a crude. LCMS (ES+) m / z calculated for C17H13F3N2O3350.09, found 351 (M+H)+. HPLC tR 2.21 min. Step 3: 1-(3-Amino-5-(trifluoromethyl)phenyl)-3-phenylpyrrolidin-2-one (Intermediate 39) A suspension of 1-(3-nitro-5-(trifluoromethyl)phenyl)-3-phenylpyrrolidin-2-one (Intermediate 38, 880 mg, 2.51 mmol), NH4Cl (311 mg, 6.28 mmol) and iron (702 mg, 12.56 mmol) in a mixture of EtOH / H2O (2:1, 170 mL / 85mL) was refluxed at 80 °C for 1.5 h. After cooling the suspension was filtered and the filtrate was diluted with EtOAc and H2O. The aqueous phase was extracted with EtOAC and the combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated in vacuo to give a residue which was purified by flash chromatography on silica gel (eluting with 0-100% DCM + 1% MeOH in DCM) to get the title compound (368 mg, 46%).1H NMR (400 MHz, DMSO-d6) δ 7.43-7.21 (m, 6H), 7.10 (s, 1H), 6.65 (s, 1H), 5.67 (s, 2H), 4.04- 3.76 (m, 3H), 2.63-2.53 (m, 1H), 2.26-2.06 (m, 1H).19F NMR (377 MHz, DMSO-d6) ^^ -61.55 (s, 3F). LCMS (ES+) m / z calculated for C17H15F3N2O 320.11, found 321 (M+H)+. HPLC tR 1.88 min. Intermediate 42: N-(3-amino-5-(trifluoromethyl)phenyl)-N-methyl-2-phenylpropanamide Scheme 31 Step 1: N-(3-Nitro-5-(trifluoromethyl)phenyl)-2-phenylacetamide (Intermediate 40) The title compound was prepared using the same synthetic procedure reported in Step 1 for the synthesis of Example 149 starting from 3-nitro-5-(trifluoromethyl)aniline and obtained as an orange powder (380 mg, 97%). LCMS (ES+) m / z calculated for C15H11F3N2O3324.07, found 323 (M-H)-. HPLC tR2.01 min. Step 2: N-Methyl-N-(3-nitro-5-(trifluoromethyl)phenyl)-2-phenylpropanamide (Intermediate 41) NaH (60% wt; 15 mg, 0.37 mmol) was added to a stirring solution of N-[3-nitro-5- (trifluoromethyl)phenyl]-2-phenyl-acetamide (Intermediate 39, 80 mg, 0.25 mmol) in dry DMF (1.6 mL) at 0 °C and the mixture was stirred at rt for 30 minutes before being treated with MeI (39 mg, 0.27 mmol) and stirred at rt for 1 h. The reaction mixture was diluted with EtOAc, washed with H2O, brine, dried over Na2SO4 and concentrated in vacuo to afford a residue which was purified by flash chromatography on silica gel (eluting with 0-80% EtOAc in Petroleum ether) to get the title compound (70 mg, 81%). LCMS (ES+) m / z calculated for C17H15F3N2O3352.10, found 353 (M+H)+. HPLC tR 2.05 min. Step 3: N-(3-Amino-5-(trifluoromethyl)phenyl)-N-methyl-2-phenylpropanamide (Intermediate 42) The title compound was prepared using the same synthetic procedure reported in Step 2 for the synthesis of Example 149 and obtained as a white powder (44 mg, 69%).1H NMR (400 MHz, DMSO-d6) δ 7.36-7.25 (m, 6H), 6.69 (s, 1H), 6.62 (s, 1H), 3.25 (s, 3H), 1.87 (s, 3H).19F NMR (377 MHz, DMSO-d6) ^ -62.72 (s, 3F). LCMS (ES+) m / z calculated for C17H17F3N2O 322.13, found 323 1.85 min. Intermediate 45: N-(3-Amino-5-(trifluoromethyl)phenyl)-N-methyl-2-phenylacetamide Scheme 32 Step 1: N-Methyl-3-nitro-5-(trifluoromethyl)aniline (Intermediate 43) A suspension of 1-fluoro-3-nitro-5-(trifluoromethyl)benzene (125 mg, 0.60 mmol) and cesium carbonate (584 mg, 1.79 mmol) in dry DMF (2.0 mL) was treated with methylamine hydrochloride (61 mg, 0.90 mmol) and the mixture was stirred at 110 °C for 2 h. After cooling the mixture was concentrated in vacuo and the oily residue was diluted with H2O and extracted with EtOAc. The organic layer was washed with brine, dried over Na2SO4, filtered and concentrated in vacuo to get a residue which was purified by flash chromatography on silica gel (eluting with 0-100% EtOAc in Petroleum ether) to get the title compound as a yellow oil (117 mg, 89%).1H NMR (400 MHz, DMSO-d6) δ 7.54 (s, 1H), 7.52 (s, 1H), 7.19 (s, 1H), 6.95-6.90 (br m, 1H), 2.81 (d, J = 5.0 Hz, 3H).19F NMR (377 MHz, DMSO-d6) ^ -61.83 (s, 3F). LCMS (ES+) m / z calculated for C8H7F3N2O2220.05, found 221 (M+H)+. HPLC tR 1.89 min. Step 2: N-Methyl-N-(3-nitro-5-(trifluoromethyl)phenyl)-2-phenylacetamide (Intermediate 44) The title compound was prepared using the same synthetic procedure reported in Step 1 for the synthesis of Example 149 and obtained as a yellow powder (103 mg, 57%).1H NMR (400 MHz, DMSO-d6): δ 8.49 (br s, 1H), 8.41 (br s, 1H), 8.19 (s, 1H), 7.31-7.08 (m, 5H), 3.70 (br s, 2H), 3.35 (s, 3H).19F NMR (377 MHz, DMSO-d6) ^ -61.27 (s, 3F). LCMS (ES+) m / z calculated for C16H13F3N2O3338.09, found 339 (M+H)+. HPLC 1.95 min. Step 3: N-(3-Amino-5-(trifluoromethyl)phenyl)-N-methyl-2-phenylacetamide (Intermediate 45) The title compound was prepared using the same synthetic procedure reported in Step 2 for the synthesis of Example 149 and obtained as a white powder (94 mg, 99%). LCMS (ES+) m / z calculated for C16H15F3N2O 308.11, found 309 (M+H)+. HPLC 1.70 min. Intermediate 49: N-(4-Amino-6-(trifluoromethyl)pyridin-2-yl)-2-(2-chlorophenyl)- acetamide Scheme 33 Step 1: 2-Chloro-N-(4-methoxybenzyl)-6-(trifluoromethyl)pyridin-4-amine (Intermediate 46) A solution of 2-chloro-6-(trifluoromethyl)pyridin-4-amine (200 mg, 1.0 mmol), 4- methoxybenzaldehyde (416 mg, 3.1 mmol) and acetic acid (64 uL, 1.1 mmol) in DCM (2.0 mL) under N2was treated with sodium triacetoxyhydroborate (645 mg, 3.1 mmol) and the mixture was stirred at rt for 18 h before being diluted with EtOAc and H2O. The organic layer was washed with brine, dried over Na2SO4, filtered and concentrated in vacuo to give a residue which was purified by flash chromatography on silica gel (eluting with 5-100% EtOAc in Petroleum ether) to get the title compound as a yellow oil (274 mg, 85%).1H NMR (400 MHz, DMSO-d6) δ 7.93 (br t, J = 5.6 Hz, 1H), 7.28 (d, J = 8.8 Hz, 2H), 7.01 (br s, 1H), 6.93 (d, J = 8.9 Hz, 2H), 6.75 (br s, 1H), 4.34 (d, J = 5.8 Hz, 2H), 3.74 (s, 3H).19F NMR (377 MHz, DMSO-d6) ^ -67.44 (s, 3F). LCMS (ES+) m / z calculated for C14H12ClF3N2O1316.06, found 317 (M+H)+. HPLC tR 2.00 min. Step 2: N-4-(4-Methoxybenzyl)-6-(trifluoromethyl)pyridine-2,4-diamine (Intermediate 47) Pd2(dba)3(13.7 mg, 0.015 mmol) and SPhos (10.5 mg, 0.030 mmol) were charged in a degassed 20 mL Wheaton vial followed by a solution of 2-chloro-N-(4-methoxybenzyl)-6- (trifluoromethyl)pyridin-4-amine (Intermediate 45, 237 mg, 0.75 mmol) in THF (0.5 mL) and lithium bis(trimethylsilyl)amide (1.0 M in THF; 1.8 mL, 1.8 mmol) and the resulting mixture was stirred at 65 °C for 22 h. After cooling the reaction mixture was treated with HCl (1M) and the resulting suspension was stirred at rt for 10 min. EtOAc was then added and the organic phase was separated, dried over Na2SO4, filtered and concentrated in vacuo to give a residue which was purified by flash chromatography on silica gel (eluting with 5-100% EtOAc in Petroleum ether) to get the title compound as a yellow powder (61 mg, 27%).1H NMR (400 MHz, DMSO-d6) δ 7.24 (d, J = 8.8 Hz, 2H), 7.03 (t, J = 5.9 Hz, 1H), 6.91 (d, J = 8.9 Hz, 2H), 6.32 (d, J = 1.9 Hz, 1H), 5.87 (br s, 2H), 5.64 (br s, 1H), 4.19 (d, J = 5.9 Hz, 2H), 3.73 (s, 3H).19F NMR (377 MHz, DMSO- d6) ^ -67.50 (s, 3F). LCMS (ES+) m / z calculated for C14H14F3N3O 297.11, found 298 (M+H)+. HPLC tR1.11 min. Step 3 and 4: N-(4-Amino-6-(trifluoromethyl)pyridin-2-yl)-2-(2-chlorophenyl)acetamide (Intermediate 49) A solution of N-4-(4-methoxybenzyl)-6-(trifluoromethyl)pyridine-2,4-diamine (Intermediate 47, 69 mg, 0.23 mmol), 2-(2-chlorophenyl)acetic acid (44 mg, 0.26 mmol), HATU (265 mg, 0.70 mmol) in DMF (1.0 mL) was treated with DIPEA (33 mg, 0.26 mmol) and the resulting solution was stirred at rt for 2 h before being diluted with EtOAc and washed with NaHCO3 (sat. aqueous solution). The organic phase was washed with brine, then dried over Na2SO4, filtered and concentrated in vacuo to give a residue which was purified by flash chromatography on silica gel (eluting with 2-80% EtOAc in Petroleum ether) to get 2-(2-chlorophenyl)-N-[4-[(4- methoxyphenyl)methylamino]-6-(trifluoromethyl)-2-pyridyl]acetamide as a yellow oil (Intermediate 48, 26 mg, 22%) which was dissolved in TFA (0.5 mL). The reaction mixture was stirred at rt for 16 h before being concentrated in vacuo. The obtained residue was diluted with EtOAc and H2O. The separated organic phase was dried over Na2SO4, filtered and concentrated in vacuo to give a residue which was purified by flash chromatography on silica gel (eluting with 2-100% EtOAc in Petroleum ether) to get the title compound as a yellow powder (16 mg, 92%). LCMS (ES+) m / z calculated for C14H11ClF3N3O 329.05, found 330 (M+H)+. HPLC tR 1.76 min. Examples 151-158, 160-161 and 275-276 were prepared using the synthetic procedure described below in Scheme 34 part using the appropriate carboxylic acids in Step 4. Scheme 34 Step 1: (3-((1R,4R)-4-((1,3-Dioxoisoindolin-2-yl)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5- yl)((3-nitro-5-(trifluoromethyl)phenyl)carbamoyl)amide (Intermediate 50) The title compound was obtained using the procedure described in Step 3 for the synthesis of Example 149 using 3-nitro-5-(trifluoromethyl)aniline and obtained as a yellow powder (284 mg, 49%). LCMS (ES+) m / z calculated for C25H21F3N6O6558.15, found 559 (M+H)+. HPLC tR 2.11 min. Step 2: (3-((1R,4R)-4-((Dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-nitro- 5-(trifluoromethyl)phenyl)carbamoyl)amide (Intermediate 51) The title compound was obtained using the procedure described in Step 4 for the synthesis of Example 149 as a yellow powder (259 mg, 99%). LCMS (ES+) m / z calculated for C19H23F3N6O4456.17, found 457 (M+H)+. HPLC 1.37 min. Step 3: ((3-Amino-5-(trifluoromethyl)phenyl)carbamoyl)(3-((1R,4R)-)-4-((dimethylamino)- methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)amide (Intermediate 52) A solution of (3-((1R,4R)-4-((dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5- yl)((3-nitro-5-(trifluoromethyl)phenyl)carbamoyl)amide (Intermediate 51, 265 mg, 0.58 mmol) and NH4Cl (311 mg, 5.81 mmol) in a mixture of H2O (5 mL) and EtOH (20 mL) was treated with iron (162 mg, 2.9 mmol) and stirred at 100 °C for 1 h before being cooled and filtered on a pad of cellulose. The filtrate was concentrated in vacuo to give an oily residue which was purified by flash chromatography on silica gel (eluting with 0-100% CH3CN in H2O) to get a residue which was suspended in MeOH and filtered to afford after removal of the solvent under reduced pressure the title compound (201 mg, 81%). LCMS (ES+) m / z calculated for C19H25F3N6O2426.20, found 427 (M+H)+. HPLC tR 0.94 min. Step 4: General procedure A solution of ((3-amino-5-(trifluoromethyl)phenyl)carbamoyl)(3-((1R,4R)-4-((dimethylamino)- methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)amide (Intermediate 52, 0.035 mmol, 1.0 eq.) and HATU (0.11 mmol, 3.0 eq.) in DMF (0.35 mL) was treated with DIPEA (0.07 mmol, 2.0 eq.) and the selected carboxylic acid (0.11 mmol, 3.0 eq.) and stirred at rt for 18 h before being diluted with H2O and extracted with EtOAc (2x). The organic layer was washed with brine, dried over Na2SO4, filtered and concentrated in vacuo to give a residue which was purified by automated RP- HPLC using water (+ 0.1% TFA) and CH3CN (+ 0.1% TFA) as eluents (C18 column). Fractions containing product were lyophilized to give the desired compound. Example 151: (3-((1R,4R)-4-((Dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5- yl)((3-(2-(3-methoxyphenyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide. The title compound was obtained as a pale-yellow powder (2.2 mg, 11%).1H NMR (400 MHz, DMSO-d6) δ 10.41 (s, 1H), 9.72 (s, 1H), 8.17 (s, 1H), 7.96 (s, 1H), 7.83 (s, 1H), 7.65 (s, 1H), 7.28 - 7.19 (m, 1H), 6.91 (br s, 1H), 6.85 - 6.80 (m, 3H), 4.71 (m, 1H), 3.75 (s, 2H), 3.74 (s, 3H), 3.53 (s, 2H), 2.26 (m, 8H), 2.01-1.87 (m, 4H), 1.64 (m, 1H), 1.15-1.03 (m, 2H).19F NMR (377 MHz, DMSO-d6) ^ -61.57 (s, 3F). LCMS (ES+) m / z calculated for C28H33F3N6O4574.25, found 575 1.34 min. Example 152: (3-((1R,4R)-4-((Dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5- yl)((3-(2-(2-methoxyphenyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide. The title compound was obtained as a pale-yellow powder (2.5 mg, 15%).1H NMR (400 MHz, DMSO-d6) δ 10.32 (s, 1H), 9.73 (s, 1H), 9.12 (br s, 1H), 8.20 (s, 1H), 7.97 (s, 1H), 7.86 (s, 1H), 7.63 (s, 1H), 7.26 (t, J = 7.5 Hz, 1H), 7.21 (dd, J = 7.4, 1.6 Hz, 1H), 6.98 (d, J = 8.2 Hz, 1H), 6.91 (td, J = 7.4, 1.0 Hz, 1H), 4.80-4.69 (m, 1H), 3.83-3.71 (m, 3H), 3.64 (br s, 2H), 2.99 (br t, J = 6.1 Hz, 2H), 2.80 (d, J = 4.8 Hz, 6H), 2.33-2.23 (m, 2H), 2.08-1.84 (m, 5H), 1.30-1.11 (m, 2H).19F NMR (377 MHz, DMSO-d6) ^ -61.56 (s, 3F). LCMS (ES+) m / z calculated for C28H33F3N6O4574.25, found 575 (M+H)+. HPLC tR 1.34 min. Example 153: (3-(2-(Benzo[d][1,3]dioxol-5-yl)acetamido)-5-(trifluoromethyl)phenyl)- carbamoyl)(3-((1R,4R)-4-((dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl) amide. The title compound was obtained as a pale-yellow powder (2.2 mg, 12%).1H NMR (400 MHz, DMSO-d6) δ 10.35 (s, 1H), 9.74 (s, 1H), 9.11 (br s, 1H), 8.20 (s, 1H), 7.96 (s, 1H), 7.86 (s, 1H), 7.62 (s, 1H), 6.91 (d, J = 1.5 Hz, 1H), 6.87 (d, J = 7.0 Hz, 1H), 6.78 (dd, J = 7.9 and 1.6 Hz, 1H), 4.81-4.69 (m, 1H), 4.12 (q, J = 7.1 Hz, 1H), 3.19 (br d, J = 8.0 Hz, 1H), 3.08-2.90 (m, 3H), 2.80 (d, J = 4.9 Hz, 6H), 2.33-2.23 (m, 2H), 2.09-1.85 (m, 5H), 1.31-1.13 (m, 2H).19F NMR (377 MHz, DMSO-d6) ^-61.58 (s, 3F). LCMS (ES+) m / z calculated for C28H31F3N6O5588.23, found 589 (M+H)+. HPLC tR1.31 min. Example 154: (3-(2-(3-(Carboxymethyl)phenyl)acetamido)-5-(trifluoromethyl)- phenyl)carbamoyl)(3-((1R,4R)-4-((dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3- ium-5-yl)amide. The title compound was obtained as a white powder (1.2 mg, 7%).1H NMR (400 MHz, DMSO- d6) δ 10.42 (s, 1H), 9.74 (s, 1H), 9.10 (br s, 1H), 8.20 (s, 1H), 7.96 (s, 1H), 7.87 (s, 1H), 7.63 (s, 1H), 7.31-7.24 (m, 1H), 7.22 (br d, J = 1.8 Hz, 2H), 7.15 (br d, J = 7.4 Hz, 1H), 4.82-4.67 (m, 1H), 3.68-3.59 (m, 3H), 2.99 (br t, J = 6.1 Hz, 3H), 2.80 (d, J = 4.8 Hz, 6H), 2.33-2.23 (m, 2H), 2.05-1.86 (m, 5H), 1.29-1.12 (m, 2H).19F NMR (377 MHz, DMSO-d6) ^ -61.58 (s, 3F). LCMS (ES+) m / z calculated for C29H33F3N6O5602.25, found 603 1.16 min. Example 155: (3-((1R,4R)-4-((Dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5- yl)((3-(2-(pyridazin-4-yl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide. The title compound was obtained as a pale-yellow powder (1.1 mg, 7%).1H NMR (400 MHz, DMSO-d6) δ 10.57 (s, 1H), 9.76 (s, 1H), 9.22-9.16 (m, 2H), 8.19 (s, 1H), 7.98 (s, 1H), 7.88 (s, 1H), 7.65 (dd, J = 5.3, 2.2 Hz, 1H), 7.61 (s, 1H), 4.75 (br t, J = 12.2 Hz, 1H), 3.82 (s, 2H), 2.99 (br t, J = 6.0 Hz, 2H), 2.80 (d, J = 4.8 Hz, 6H), 2.33-2.23 (m, 2H), 2.08-1.85 (m, 5H), 1.29-1.13 (m, 2H).19F NMR (377 MHz, DMSO-d6) ^ -61.61 (s, 3F). LCMS (ES+) m / z calculated for C25H29F3N8O3546.23, found 547 (M+H)+. HPLC tR0.98 min. Example 156: (3-((1R,4R)-4-((Dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5- yl)((3-(3-(1-methyl-1H-indol-3-yl)propanamido)-5-(trifluoromethyl)phenyl)- carbamoyl)amide. The title compound was obtained as a powder (3.1 mg, 14%).1H NMR (400 MHz, DMSO-d6) δ 10.17 (s, 1H), 9.73 (s, 1H), 9.09 (br s, 1H), 8.20 (s, 1H), 7.92 (s, 1H), 7.87 (s, 1H), 7.66 (s, 1H), 7.59 (d, J = 7.8 Hz, 1H), 7.38 (d, J = 8.3 Hz, 1H), 7.17-7.09 (m, 2H), 7.05-6.99 (m, 1H), 4.86- 4.64 (m, 1H), 3.73 (s, 3H), 3.08-2.92 (m, 4H), 2.81 (d, J = 4.9 Hz, 6H), 2.73-2.63 (m, 2H), 2.39- 2.25 (m, 2H), 2.05-1.88 (m, 5H), 1.32-1.12 (m, 2H).19F NMR (377 MHz, DMSO-d6) ^ -61.53 (s, 3F). LCMS (ES+) m / z calculated for C31H36F3N7O3611.28, found 612 (M+H)+. HPLC tR 1.57 min. Example 157: (3-((1R,4R)-4-((Dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5- yl)((3-(3-(pyrazin-2-yl)propanamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide. The title compound was obtained as a pale-yellow powder (1.0 mg, 6%).1H NMR (400 MHz, DMSO-d6): δ 10.24 (s, 1H), 9.72 (s, 1H), 9.06 (br s, 1H), 8.61 (d, J = 1.4 Hz, 1H), 8.56 (dd, J = 2.6, 1.6 Hz, 1H), 8.48 (d, J = 2.6 Hz, 1H), 8.19 (s, 1H), 7.91 (s, 1H), 7.87 (s, 1H), 7.60 (s, 1H), 4.80-4.70 (m, 1H), 3.16-3.06 (m, 2H), 3.05-2.93 (m, 2H), 2.87-2.76 (m, 8H), 2.33-2.26 (m, 2H), 2.09-1.89 (m, 5H), 1.29-1.19 (m, 2H).19F NMR (377 MHz, DMSO-d6) ^ -61.56 (s, 3F). LCMS (ES+) m / z calculated for C26H31F3N8O3560.25, found 561 1.05 min. Example 158: ((3-(2-(2-Carboxyphenyl)acetamido)-5-(trifluoromethyl)phenyl)- carbamoyl)(3-((1R,4R)-4-((dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl) amide. The title compound was obtained as a white powder (1.9 mg, 9%).1H NMR (400 MHz, DMSO- d6) δ 9.84 (s, 1H), 9.09 (br s, 1H), 8.28-8.23 (m, 2H), 8.10 (s, 1H), 7.84 (d, J = 7.5 Hz, 1H), 7.80- 7.73 (m, 1H), 7.72-7.61 (m, 2H), 7.47 (s, 1H), 4.80-4.70 (m, 1H), 3.30 (s, 2H), 2.99 (br t, J = 6.1 Hz, 2H), 2.80 (d, J = 4.8 Hz, 6H), 2.39-2.24 (m, 2H), 2.10-1.89 (m, 5H), 1.30-1.14 (m, 2H)19F NMR (377 MHz, DMSO-d6) ^ -61.41 (s, 3F). LCMS (ES+) m / z calculated for C28H31F3N6O5 588.23, found 589 (M+H)+. HPLC 1.00 min. Example 160: (3-(2,2-Difluoro-3-(pyrrolidin-1-yl)propanamido)-5-(trifluoromethyl)- phenyl)carbamoyl)(3-((1R,4R)-4-((dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3- ium-5-yl)amide. The title compound was obtained as a powder (1.0 mg, 5%).1H NMR (400 MHz, DMSO-d6): δ 10.83 (s, 1H), 9.79 (s, 1H), 8.21 (s, 1H), 8.16 (s, 1H), 7.98 (s, 1H), 7.59 (s, 1H), 4.74-4.70 (m, 1H), 3.29-3.16 (m, 4H), 2.63 (br s, 6H), 2.32-2.15 (m, 4H), 2.03-1.87 (m, 5H), 1.70-1.65 (m, 4H), 1.24-1.12 (m, 4H).19F NMR (377 MHz, DMSO-d6) ^ -61.59 (s, 3F), -106.80 (s, 2F). LCMS (ES+) m / z calculated for C26H34F5N7O3587.26, found 588 (M+H)+. HPLC tR0.89 min. Example 161: (3-((1R,4R)-4-((Dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5- yl)((3-(2-(1-methyl-1H-indol-3-yl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)-amide. The title compound was obtained as a powder (1.3 mg, 6%).1H NMR (400 MHz, DMSO-d6) δ 10.37 (s, 1H), 9.73 (s, 1H), 9.13 (br s, 1H), 8.19 (s, 1H), 7.96 (s, 1H), 7.85 (s, 1H), 7.65-7.60 (m, 2H), 7.41-7.39 (m, 1H), 7.25 (s, 1H), 7.19-7.14 (m, 1H), 7.05-7.02 (m, 1H), 4.77-4.71 (m, 1H), 3.82-3.72 (m, 5H), 2.99 (br t, J = 6.1 Hz, 2H), 2.80 (d, J = 4.9 Hz, 6H), 2.30-2.25 (m, 2H), 2.02- 1.89 (m, 5H), 1.24-1.16 (m, 2H).19F NMR (377 MHz, DMSO-d6) ^ -61.56 (s, 3F). LCMS (ES+) m / z calculated for C30H34F3N7O3597.27, found 598 (M+H)+. HPLC 1.45 min. Example 275: (3-((1R,4R)-4-((Dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5- yl)((3-((R)-3-methyl-2-phenylbutanamido)-5-(trifluoromethyl)phenyl)-carbamoyl)amide The title compound was obtained as white powder (9.0 mg, 19%).1H NMR (400 MHz, DMSO- d6) δ 10.34 (s, 1H), 9.71 (s, 1H), 9.19 - 9.08 (m, 1H), 8.20 (s, 1H), 7.97 (s, 1H), 7.82 (s, 1H), 7.62 (s, 1H), 7.42-7.38 (m, 2H), 7.36-7.31 (m, 2H), 7.30-7.22 (m, 1H), 4.81-4.69 (m, 1H), 3.27 (d, J = 10.8 Hz, 1H), 2.99 (br t, J = 6.2 Hz, 2H), 2.81 (d, J = 4.9 Hz, 6H), 2.39-2.23 (m, 3H), 2.05-1.86 (m, 5H), 1.29-1.15 (m, 1H), 1.02 (d, J = 6.5 Hz, 3H), 0.67 (d, J = 6.8 Hz, 3H).19F NMR (377 MHz, DMSO-d6) δ -61.59 (s, 3F). LCMS (ES+) m / z calculated for C30H37F3N6O3586.65, found 609 (M+Na)+. HPLC tR 1.52 min. Example 276: (3-((1R,4S)-4-((Dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5- yl)((3-((S)-3-methyl-2-phenylbutanamido)-5-(trifluoromethyl)phenyl)-carbamoyl)amide The title compound was obtained as white powder (12.2 mg, 27%).1H NMR (400 MHz, DMSO- d6) δ 10.38 (s, 1H), 9.90 (br s, 1H), 9.18 (br s, 1H), 8.42-8.33 (m, 1H), 8.00 (s, 1H), 7.80 (s, 1H), 7.64 (s, 1H), 7.42-7.38 (m, 2H), 7.36-7.31 (m, 2H), 7.28-7.23 (m, 1H), 4.86-4.75 (m, 1H), 3.27 (d, J = 10.8 Hz, 1H), 3.00 (br t, J = 6.1 Hz, 2H), 2.81 (d, J = 4.8 Hz, 6H), 2.39-2.26 (m, 3H), 2.07- 1.84 (m, 5H), 1.29-1.16 (m, 1H), 1.02 (d, J = 6.4 Hz, 3H), 0.67 (d, J = 6.8 Hz, 3H).19F NMR (377 MHz, DMSO-d6) δ -61.59 (s, 3F). LCMS (ES+) m / z calculated for C30H37F3N6O3586.65, found 609 1.65 min. Example 162: (3-(2-(3-(2-Amino-2-oxoethyl)phenyl)acetamido)-5-(trifluoromethyl)- phenyl)carbamoyl)(3-((1R,4R)-4-((dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3- ium-5-yl)amide.

[0004] Scheme 35 Step 1: [3-[[2-[3-(2-Amino-2-oxo-ethyl)phenyl]acetyl]amino]-5-(trifluoromethyl)-phenyl] carbamoyl-[3-[4-[(1,3-dioxoisoindolin-2-yl)methyl]-cyclohexyl]oxadiazol-3-ium-5-yl]azanide (Intermediate 53) The title compound was prepared following the conditions reported for the synthesis of Example 3 in scheme 11 using intermediate 35 (47 mg, 0.13 mmol) and the appropriate aniline and obtained as a white powder (5 mg, 5%).1H NMR (400 MHz, CDCl3) δ 7.95-7.84 (m, 3H), 7.82 (s, 1H), 7.80-7.71 (m, 3H), 7.56 (s, 1H), 7.46 (s, 1H), 7.447.36 (m, 1H), 7.32-7.29 (m, 2H), 4.51-4.39 (m, 1H), 3.79-3.63 (m, 6H), 3.85-3.61 (m, 1H), 2.31 (br d, J = 10.4 Hz, 2H), 2.06-2.00 (m, 2H), 1.97- 1.79 (m, 5H), 1.44 - 1.30 (m, 2H), 1.24 - 1.13 (m, 1H), 1.04 - 0.80 (m, 1H). LCMS (ES+) m / z calculated for C35H32F3N7O6703.67, found 704 (M+H)+. HPLC tR1.97 min. Step 2: (3-(2-(3-(2-Amino-2-oxoethyl)phenyl)acetamido)-5-(trifluoromethyl)-phenyl)carbamoyl)- (3-((1R,4R)-4-((dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)amide (Example 162) The title compound was prepared following the conditions reported for the synthesis of Example 151 in scheme 34, Step 2 and obtained as a white powder (2.5 mg, 57%).1H NMR (400 MHz, DMSO-d6) δ 10.45 (s, 1H), 9.74 (s, 1H), 8.19 (s, 1H), 7.96 (s, 1H), 7.87 (s, 1H), 7.64 (s, 1H), 7.37- 7.23 (m, 5H), 6.54 (br s, 2H), 4.79-4.71 (m, 1H), 4.05 (br s, 2H), 3.68 (br s, 2H), 2.99 (br t, J = 6.2 Hz, 2H), 2.80 (d, J = 4.9 Hz, 6H), 2.29-2.25 (m, 2H), 2.00-1.92 (m, 5H), 1.26-1.19 (m, 2H).19F NMR (377 MHz, DMSO-d6) ^ -61.59 (s, 3F). LCMS (ES+) m / z calculated for C29H34F3N7O4 601.26, found 602 (M+H)+. HPLC 1.30 min. Examples 163-166 and 168-171 were prepared using the synthetic procedure described above in Scheme 35 part using the appropriate aniline in Step 1. Example 163: (3-(2-(3-(Aminomethyl)phenyl)acetamido)-5-(trifluoromethyl)-phenyl)- carbamoyl)(3-((1R,4R)-4-((dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5- yl)amide. The title compound was obtained as a pale-yellow powder (9.6 mg, 26%).1H NMR (400 MHz, DMSO-d6) δ 10.47 (s, 1H), 9.77 (s, 1H), 9.16 (br s, 1H), 8.18 (s, 1H), 8.14 (br s, 1H), 7.95 (s, 1H), 7.83 (s, 1H), 7.70 (s, 1H), 7.43-7.34 (m, 4H), 4.78-4.72 (m, 1H), 4.04 (q, J = 5.8 Hz, 2H), 3.70 (s, 2H), 2.99 (br t, J = 6.2 Hz, 2H), 2.81 (d, J = 4.9 Hz, 6H), 2.29-2.25 (m, 2H), 2.03-1.89 (m, 5H), 1.24-1.16 (m, 2H).19F NMR (377 MHz, DMSO-d6) ^ -61.60 (s, 3F). LCMS (ES+) m / z calculated for C28H34F3N7O3573.27, found 574 (M+H)+. HPLC tR 0.88 min. Example 164: (3-((1R,4R)-4-((Dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5- yl)((3-(2-phenylpropanamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide. The title compound was obtained as a white powder (3.7 mg, 30%).1H NMR (400 MHz, DMSO- d6) δ 10.31 (s, 1H), 9.71 (s, 1H), 9.05 (br s, 1H), 8.19 (s, 1H), 7.98 (br s, 1H), 7.83 (s, 1H), 7.63 (s, 1H), 7.40-7.32 (m, 4H), 7.29-7.23 (m, 1H), 4.77-4.74 (m, 1H), 3.85 (q, J = 6.6 Hz, 1H), 2.99 (br t, J = 6.3 Hz, 2H), 2.81 (d, J = 4.9 Hz, 6H), 2.30-2.25 (m, 2H), 2.03-1.89 (m, 5H), 1.42 (d, J = 7.0 Hz, 3H), 1.25-1.18 (m, 2H).19F NMR (377 MHz, DMSO-d6) ^ -61.59 (s, 3F). LCMS (ES+) m / z calculated for C28H33F3N6O3558.26, found 559 (M+H)+. HPLC 1.37 min. Example 165: (3-((1R,4R)-4-((Dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5- yl)((3-(2-phenylbutanamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide. The title compound was obtained as a white powder (3.5 mg, 25%).1H NMR (400 MHz, DMSO- d6) δ 10.34 (s, 1H), 9.71 (s, 1H), 9.08 (br s, 1H), 8.19 (s, 1H), 7.98 (br s, 1H), 7.83 (s, 1H), 7.63 (s, 1H), 7.40-7.31 (m, 4H), 7.29-7.23 (m, 1H), 4.78-4.72 (m, 1H), 3.61-3.57 (m, 1H), 2.99 (br t, J = 6.2 Hz, 2H), 2.81 (d, J = 4.9 Hz, 6H), 2.29-2.25 (m, 2H), 2.06-1.89 (m, 6H), 1.74-1.67 (m, 1H), 1.24-1.16 (m, 2H), 0.86 (t, J = 7.3 Hz, 3H).19F NMR (377 MHz, DMSO-d6) ^ -61.59 (s, 3F). LCMS (ES+) m / z calculated for C29H35F3N6O3572.27, found 573 (M+H)+. HPLC tR 1.53 min. Example 166: (3-((1R,4R)-4-((Dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5- yl)((3-(trifluoromethyl)-5-(2-(2-(trifluoromethyl)phenyl)acetamido)phenyl)-carbamoyl) amide. The title compound was obtained as a white powder (17.9 mg, 34%).1H NMR (400 MHz, DMSO- d6) δ 10.48 (s, 1H), 9.72 (s, 1H), 8.17 (s, 1H), 7.97 (br s, 1H), 7.83 (s, 1H), 7.72 (d, J = 7.8 Hz, 1H), 7.68-7.65 (m, 2H), 7.54-7.48 (m, 2H), 4.74-4.67 (m, 1H), 3.94 (s, 2H), 2.24-2.17 (m, 2H), 2.12 (s, 6H), 2.05-1.90 (m, 6H), 1.62-1.56 (m, 1H), 1.12-1.02 (m, 2H).19F NMR (377 MHz, DMSO-d6) ^ -58.58 (s, 3F), -61.61 (s, 3F). LCMS (ES+) m / z calculated for C28H30F6N6O3612.23, found 613 1.47 min. Example 168: ((3-(2-(2-Chlorophenyl)acetamido)-5-(trifluoromethyl)phenyl)-carbamoyl)(3- ((1R,4R)-4-((dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)amide. The title compound was obtained as a white powder (7.1 mg, 17%).1H NMR (400 MHz, DMSO- d6) δ 10.49 (s, 1H), 9.72 (s, 1H), 8.17 (s, 1H), 7.98 (s, 1H), 7.83 (s, 1H), 7.66 (s, 1H), 7.47-7.42 (m, 2H), 7.35-7.29 (m, 2H), 4.71-4.67 (m, 1H), 3.86 (s, 2H), 2.23-2.20 (m, 2H), 2.12 (s, 6H), 2.05- 1.91 (m, 6H), 1.60-1.56 (m, 1H), 1.12-1.01 (m, 2H).19F NMR (377 MHz, DMSO-d6) ^ -61.59 (s, 3F). LCMS (ES+) m / z calculated for C27H30ClF3N6O3578.20, found 579 (M+H)+. HPLC 1.40 min. Example 169: (3-(2-(2,3-Difluorophenyl)acetamido)-5-(trifluoromethyl)phenyl)-carbamoyl) (3-((1R,4R)-4-((dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)amide. The title compound was obtained as a powder (7.5 mg, 18%).1H NMR (400 MHz, DMSO-d6): δ 10.52 (s, 1H), 9.73 (s, 1H), 8.17 (s, 1H), 7.98 (s, 1H), 7.84 (s, 1H), 7.65 (s, 1H), 7.38-7.32 (m, 1H), 7.24-7.16 (m, 2H), 4.74-4.67 (m, 1H), 3.82 (s, 2H), 2.24-2.19 (m, 2H), 2.12 (s, 6H), 2.08- 1.90 (m, 6H), 1.60-1.55 (m, 1H), 1.12-1.04 (m, 2H).19F NMR (377 MHz, DMSO-d6) ^ -61.60 (s, 3F), -139.70 (s, 1F), -142.78 (s, 1F). LCMS (ES+) m / z calculated for C27H29F5N6O3580.22, found 581 1.36 min. Example 170: (3-((1R,4S)-4-((Dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5- yl)((3-((S)-2-phenylpropanamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide. The title compound was obtained as a white powder (4.5 mg, 10%).1H NMR (400 MHz, DMSO- d6): δ 10.31 (s, 1H), 9.69 (s, 1H), 8.17 (s, 1H), 7.98 (s, 1H), 7.79 (s, 1H), 7.66 (s, 1H), 7.40-7.32 (m, 4H), 7.27-7.23 (m, 1H), 4.79-4.66 (m, 1H), 3.85 (q, J = 7.1 Hz, 1H), 2.24-2.20 (m, 9H), 2.00- 1.92 (m, 5H), 1.63-1.58 (m, 1H), 1.43-1.41 (m, 3H), 1.11-1.05 (m, 2H).19F NMR (377 MHz, DMSO-d6) ^ -61.58 (s, 3F). LCMS (ES+) m / z calculated for C28H33F3N6O3558.26, found 559 (M+H)+. HPLC tR 1.42 min. Example 171: (3-((1R,4R)-4-((Dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5- yl)((3-(2-(o-tolyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide. The title compound was obtained as a white powder (2.3 mg, 19%).1H NMR (400 MHz, DMSO- d6): δ 10.40 (s, 1H), 9.73 (s, 1H), 9.04 (br s, 1H), 8.19 (s, 1H), 7.99 (s, 1H), 7.86 (s, 1H), 7.62 (s, 1H), 7.27-7.22 (m, 1H), 7.19-7.14 (m, 3H), 4.79-4.72 (m, 1H), 3.70 (s, 2H), 2.99 (br t, J = 5.9 Hz, 2H), 2.81 (d, J = 4.9 Hz, 6H), 2.30 (s, 3H), 2.28-2.24 (m, 2H), 2.00-1.91 (m, 5H), 1.24-1.19 (m, 2H).19F NMR (377 MHz, DMSO-d6) ^ -61.58 (s, 3F). LCMS (ES+) m / z calculated for C28H33F3N6O3558.26, found 559 (M+H)+. HPLC 1.40 min. Example 175: (3-((1R,4R)-4-((Dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5- yl)((3-(3-phenyloxetane-3-carboxamido)-5-(trifluoromethyl)phenyl)-carbamoyl)amide Scheme 36 Step 1: ((3-Amino-5-(trifluoromethyl)phenyl)carbamoyl)(3-((1R,4R)-4-((1,3-dioxoisoindolin-2- yl)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)amide (trifluoroacetate salt)(Intermediate 54) The title compound was prepared following the conditions reported for the synthesis of Example 3 in scheme 11 using Intermediates 5 and 35 as starting materials. The compound was obtained as a white powder (122 mg, 16%).1H NMR (400 MHz, DMSO-d6) δ 9.44 (s, 1H), 8.19 (s, 1H), 7.91- 7.84 (m, 4H), 7.37 (s, 1H), 7.04 (s, 1H), 6.48 (s, 1H), 4.73-4.67 (m, 1H), 3.50 (d, J = 6.6 Hz, 2H), 2.20 (br d, J = 14.6 Hz, 2H), 2.03-1.82 (m, 6H), 1.36-1.25 (m, 3H).19F NMR (377 MHz, DMSO- d6) δ -61.60 (s, 3F) and -74.52 (s, 3F). LCMS (ES+) m / z calculated for C25H23F3N6O4528.17, found 529 1.72 min. Step 2: (3-((1R,4R)-4-((1,3-Dioxoisoindolin-2-yl)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5- yl)((3-((R)-2-phenylpropanamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide (Intermediate 55) The title compound was prepared following the conditions reported for the synthesis of Example 151 in Scheme 34, Step 4 and obtained as a white powder (22 mg, 51%). LCMS (ES+) m / z calculated for C34H31F3N6O5660.64, found 661 (M+H)+. HPLC tR 2.12 min. Step 3: 3-((1R,4R)-4-((Dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-((R)-2- phenylpropanamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide (Example 175) The title compound was prepared following the conditions reported for the synthesis of Example 173 in Scheme 35, Step 3A using Intermediate 71 as starting material. The compound was obtained as a white powder (5.1 mg, 26%).1H NMR (400 MHz, DMSO-d6) δ 10.16 (s, 1H), 9.73 (s, 1H), 9.12-9.05 (m, 1H), 8.20 (s, 1H), 8.08 (s, 1H), 7.83 (s, 1H), 7.62 (s, 1H), 7.51-7.47 (m, 2H), 7.46 - 7.41 (m, 2H), 7.36-7.31 (m, 1H), 5.20 (d, J = 6.5 Hz, 2H), 4.87 (d, J = 6.5 Hz, 2H), 4.75 (br t, J = 11.8 Hz, 1H), 2.99 (t, J = 6.1 Hz, 2H), 2.81 (d, J = 4.9 Hz, 6H), 2.28 (br d, J = 11.6 Hz, 2H), 2.04- 1.88 (m, 5H), 1.24-1.15 (m, 2H).19F NMR (376 MHz, DMSO-d6) δ -61.58 (s, 3F) and -74.03 (s, 3F). LCMS (ES+) m / z calculated for C29H33F3N6O4586.61, found 587 (M+H)+. HPLC tR 1.26 min. Examples 176-177, 191, 194-199, 205, 208, 212, 243, 255, 258, and 297 were prepared using the synthetic procedure described above in Scheme 36 part using the appropriate carboxylic acid in Step 2. Example 176: (3-(2-(3-Chlorophenyl)acetamido)-5-(trifluoromethyl)phenyl)-carbamoyl)(3- ((1R,4R)-4-((dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)amide. The title compound was obtained as a white powder (2.0 mg, 8%).1H NMR (400 MHz, DMSO- d6) δ 10.44 (s, 1H), 9.73 (s, 1H), 9.09 (br s, 1H), 8.19 (s, 1H), 7.98 (s, 1H), 7.86 (s, 1H), 7.61 (s, 1H), 7.41-7.28 (m, 4H), 4.78-4.72 (m, 1H), 3.69 (s, 2H), 2.99 (br t, J = 6.0 Hz, 2H), 2.80 (d, J = 4.8 Hz, 6H), 2.29-2.25 (m, 2H), 2.03-1.90 (m, 5H), 1.28-1.19 (m, 2H).19F NMR (377 MHz, DMSO-d6) ^ -61.59 (s, 3F). LCMS (ES+) m / z calculated for C27H30ClF3N6O3578.20, found 579 1.44 min. Example 177: (3-((1R,4R)-4-((Dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5- yl)((3-(1,2,3,4-tetrahydronaphthalene-1-carboxamido)-5-(trifluoromethyl)phenyl)-carba- moyl)amide. The title compound was obtained as a white powder (5.8 mg, 18%).1H NMR (400 MHz, DMSO- d6) δ 10.47 (s, 1H), 9.74 (s, 1H), 9.08 (br s, 1H), 8.20 (s, 1H), 8.04 (s, 1H), 7.88 (s, 1H), 7.66 (s, 1H), 7.16-7.09 (m, 4H), 4.78-4.72 (m, 1H), 3.91-3.88 (m, 1H), 2.99 (br t, J = 6.1 Hz, 2H), 2.80 (d, J = 4.9 Hz, 6H), 2.78-2.74 (m, 2H), 2.28-2.25 (m, 2H), 2.04-1.97 (m, 9H), 1.24-1.16 (m, 2H).19F NMR (377 MHz, DMSO-d6) ^ -61.56 (s, 3F). LCMS (ES+) m / z calculated for C30H35F3N6O3584.27, found 585 (M+H)+. HPLC 1.46 min. Example 191: (3-((1R,4R)-4-((Dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5- yl)((3-(2-(2-hydroxyphenyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide. The title compound was obtained as a white powder (1.2 mg, 4%).1H NMR (400 MHz, DMSO- d6) δ 10.31 (s, 1H), 9.73 (s, 1H), 9.47 (s, 1H), 9.08 (br s, 1H), 8.20 (s, 1H), 7.98 (s, 1H), 7.86 (s, 1H), 7.64 (s, 1H), 7.15-7.05 (m, 2H), 6.81-6.74 (m, 2H), 4.78-4.72 (m, 1H), 3.61 (s, 2H), 2.99 (br t, J = 6.3 Hz, 2H), 2.80 (d, J = 4.8 Hz, 6H), 2.29-2.25 (m, 2H), 2.03-1.90 (m, 5H), 1.24-1.16 (m, 2H).19F NMR (377 MHz, DMSO-d6) ^ -61.57 (s, 3F). LCMS (ES+) m / z calculated for C27H31F3N6O4560.24, found 561 1.21 min. Example 194: (3-((1R,4R)-4-((Dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5- yl)((3-(2-fluoro-2-(2-fluorophenyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)- amide. The title compound was obtained as a powder (4.4 mg, 41%).1H NMR (400 MHz, DMSO-d6) δ 10.64 (s, 1H), 9.76 (s, 1H), 9.11 (br s, 1H), 8.21 (s, 1H), 8.16 (s, 1H), 7.93 (s, 1H), 7.63 (s, 1H), 7.59-7.52 (m, 2H), 7.36-7.30 (m, 2H), 4.79-4.71 (m, 1H), 2.99 (br t, J = 6.3 Hz, 2H), 2.80 (d, J = 4.8 Hz, 6H), 2.29-2.25 (m, 2H), 2.04-1.95 (m, 5H), 1.92 (s, 1H), 1.24-1.19 (m, 2H).19F NMR (377 MHz, DMSO-d6) ^ -61.56 (s, 3F), -116.75 (s, 1F), -174.94 (s, 1F). LCMS (ES+) m / z calculated for C27H29F5N6O3580.22, found 581 1.35 min. Example 195: (3-(Bicyclo[4.2.0]octa-1(6),2,4-triene-7-carboxamido)-5-(trifluoromethyl)- phenyl)carbamoyl)(3-((1R,4R)-4-((dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3- ium-5-yl)amide. The title compound was obtained as a powder (4.8 mg, 38%).1H NMR (400 MHz, DMSO-d6) δ 10.47 (s, 1H), 9.74 (s, 1H), 9.07 (br s, 1H), 8.20 (s, 1H), 8.03 (s, 1H), 7.88 (s, 1H), 7.64 (s, 1H), 7.25-7.16 (m, 4H), 4.79-4.72 (m, 1H), 4.46-4.44 (m, 1H), 3.42-3.36 (m, 2H), 2.99 (br t, J = 6.3 Hz, 2H), 2.81 (d, J = 4.9 Hz, 6H), 2.29-2.25 (m, 2H), 2.05-1.89 (m, 5H), 1.24-1.19 (m, 2H).19F NMR (377 MHz, DMSO-d6) ^ -61.57 (s, 3F). LCMS (ES+) m / z calculated for C28H31F3N6O3 556.24, found 555 1.35 min. Example 196: (3-((1R,4R)-4-((Dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5- yl)((3-(2-(6-hydroxypyridin-2-yl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)-amide. The title compound was obtained as a powder (4.8 mg, 38%).1H NMR (400 MHz, DMSO-d6) δ 11.56 (br s, 1H), 10.40 (s, 1H), 9.75 (s, 1H), 9.13 (br s, 1H), 8.19 (s, 1H), 8.00 (s, 1H), 7.86 (s, 1H), 7.59 (s, 1H), 7.40-7.36 (m, 1H), 6.22 (br d, J = 8.4 Hz, 1H), 6.11 (br s, 1H), 4.79-4.72 (m, 1H), 3.62 (s, 2H), 2.99 (br t, J = 6.3 Hz, 2H), 2.80 (d, J = 4.8 Hz, 6H), 2.29-2.25 (m, 2H), 2.04- 1.89 (m, 8H), 1.25-1.18 (m, 2H).19F NMR (377 MHz, DMSO-d6) ^ -61.60 (s, 3F). LCMS (ES+) m / z calculated for C26H30F3N7O4561.23, found 562 (M+H)+. HPLC tR0.90 min. Example 197: (3-((1R,4R)-4-((Dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5- yl)((3-(2-(3,5-dimethylisoxazol-4-yl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)- amide. The title compound was obtained as a colorless oil (4.1 mg, 25%).1H NMR (400 MHz, DMSO- d6) δ 10.39 (s, 1H), 9.74 (s, 1H), 9.10 (br s, 1H), 8.19 (s, 1H), 7.98 (s, 1H), 7.87 (s, 1H), 7.60 (s, 1H), 4.78-4.72 (m, 1H), 3.46 (s, 2H), 2.99 (br t, J = 6.2 Hz, 2H), 2.81 (d, J = 4.9 Hz, 6H), 2.34 (s, 3H), 2.29-2.25 (m, 2H), 2.17 (s, 3H), 2.04-1.89 (m, 5H), 1.25-1.18 (m, 2H).19F NMR (377 MHz, DMSO-d6) ^ -61.58 (s, 3F). LCMS (ES+) m / z calculated for C26H32F3N7O4563.25, found 564 (M+H)+. HPLC tR 1.14 min. Example 198: ((3-(2-(2-Chloro-6-fluorophenyl)acetamido)-5-(trifluoromethyl)phenyl)- carbamoyl)(3-((1R,4R)-4-((dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5- yl)amide. The title compound was obtained as a white powder (1.5 mg, 23%).1H NMR (400 MHz, DMSO- d6) δ 10.58 (s, 1H), 9.77-9.66 (s, 1H), 8.17 (s, 1H), 7.99 (s, 1H), 7.83 (s, 1H), 7.66-7.60 (m, 2H), 7.44-7.33 (m, 2H), 7.29 - 7.22 (m, 1H), 4.75-4.64 (m, 1H), 3.91 (d, J = 1.3 Hz, 2H), 3.00 (s, 2H), 2.12 (s, 6H), 2.03 - 2.05 (m, 3H), 1.98-1.90 (m, 6H).19F NMR (377 MHz, DMSO-d6) ^ -61.61 (s, 3F), -112.41 (s, 1F). LCMS (ES+) m / z calculated for C27H29ClF4N6O3596.19, found 597 (M+H)+. HPLC tR1.40 min. Example 199: (3-(2-(2,6-Difluorophenyl)acetamido)-5-(trifluoromethyl)phenyl)- carbamoyl)(3-((1R,4R)-4-((dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5- yl)amide. The title compound was obtained as a white powder (1.5 mg, 23%).1H NMR (400 MHz, DMSO- d6) δ 10.56 (s, 1H), 9.73 (s, 1H), 8.18 (s, 1H), 7.98 (s, 1H), 7.84 (s, 1H), 7.63 (br s, 1H), 7.44-7.33 (m, 1H), 7.14-7.10 (m, 2H), 4.73-4.67 (m, 1H), 3.79 (s, 2H), 2.24-2.20 (m, 2H), 2.12 (s, 6H), 2.05-1.90 (m, 7H), 1.23-1.18 (m, 2H).19F NMR (377 MHz, DMSO-d6) ^ -61.61 (s, 3F), -114.64 (s, 2F). LCMS (ES+) m / z calculated for C27H29F5N6O3580.22, found 581 (M+H)+. HPLC 1.34 min. Example 205: ((3-(2-(2-Chlorophenyl)propanamido)-5-(trifluoromethyl)phenyl)- carbamoyl)(3-((1R,4R)-4-((dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5- yl)amide. The title compound was obtained as a powder (3.5 mg, 24%).1H NMR (400 MHz, DMSO-d6) δ 10.42 (s, 1H), 9.73 (s, 1H), 9.16 (br s, 1H), 8.20 (s, 1H), 8.02 (s, 1H), 7.83 (s, 1H), 7.65 (s, 1H), 7.48-7.45 (m, 2H), 7.38-7.27 (m, 2H), 4.78-4.72 (m, 1H), 4.23 (q, J = 6.9 Hz, 1H), 2.99 (br t, J = 6.1 Hz, 2H), 2.80 (d, J = 4.8 Hz, 6H), 2.29-2.26 (m, 2H), 2.03-1.89 (m, 5H), 1.45 (d, J = 7.0 Hz, 3H), 1.25-1.16 (m, 2H).19F NMR (377 MHz, DMSO-d6) ^ -61.58 (s, 3F). LCMS (ES+) m / z calculated for C28H32ClF3N6O3592.22, found 593 (M+H)+. HPLC 1.47 min. Example 208: (3-((1R,4R)-4-((Dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5- yl)((3-(2-methyl-2-phenylpropanamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide. The title compound was obtained as a powder (5.6 mg, 27%).1H NMR (400 MHz, DMSO-d6) δ 9.66 (s, 1H), 9.36 (s, 1H), 9.15 (br s, 1H), 8.21 (s, 1H), 8.16 (s, 1H), 7.78 (s, 1H), 7.55 (s, 1H), 7.37-7.35 (m, 4H), 7.28-7.25 (m, 1H), 4.77-4.71 (m, 1H), 2.99 (br t, J = 6.1 Hz, 2H), 2.81 (d, J = 4.9 Hz, 6H), 2.29-2.26 (m, 2H), 2.03-1.89 (m, 5H), 1.57 (s, 6H), 1.25-1.16 (m, 2H).19F NMR (377 MHz, DMSO-d6) ^ -61.49 (s, 3F). LCMS (ES+) m / z calculated for C29H35F3N6O3572.27, found 573 1.47 min. Example 212: (3-((1R,4R)-4-((Dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5- yl)((3-(2-(2,3-dimethylphenyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)-amide. The title compound was obtained as a powder (15.6 mg, 41%).1H NMR (400 MHz, DMSO-d6) δ 10.38 (s, 1H), 9.73 (s, 1H), 9.12 (br s, 1H), 8.19 (s, 1H), 7.98 (s, 1H), 7.85 (s, 1H), 7.63 (s, 1H), 7.09-7.01 (m, 3H), 4.78-4.72 (m, 1H), 3.72 (s, 2H), 2.99 (br t, J = 6.2 Hz, 2H), 2.80 (d, J = 4.8 Hz, 6H), 2.33-2.26 (m, 2H), 2.25 (s, 3H), 2.18 (s, 3H), 2.03-1.89 (m, 5H), 1.25-1.16 (m, 2H).19F NMR (377 MHz, DMSO-d6) ^ -61.58 (s, 3F). LCMS (ES+) m / z calculated for C29H35F3N6O3 572.27, found 573 (M+H)+. HPLC tR1.41 min. Example 243 and Example 268: (3-((1R,4S)-4-((Dimethylamino)methyl)cyclohexyl)-1,2,3- oxadiazol-3-ium-5-yl)((3-((S)-2-fluoro-2-(2-fluorophenyl)acetamido)-5-(trifluoromethyl)- phenyl)carbamoyl)amide and (3-((1R,4R)-4-((Dimethylamino)methyl)cyclohexyl)-1,2,3- oxadiazol-3-ium-5-yl)((3-((R)-2-fluoro-2-(2-fluorophenyl)acetamido)-5-(trifluoromethyl)- phenyl)carbamoyl)amide. (3-((1R,4R)-4-((Dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-fluoro-2- (2-fluorophenyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)-amide (Example 194, I- 1015460) was subjected to SFC purification (Column: Chiralpak OJ (cellulose) - Run time 20 min - Eluent: 20% MeOH + 0.2% DEA using an isocratic method) to get (3-((1R,4S)-4- ((Dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-((S)-2-fluoro-2-(2-fluoro- phenyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide (Example 243) (1steluted compound) as a white powder (3.5 mg, 6%). LCMS (ES+) m / z calculated for C27H29F5N6O3 580.51; found 581 (M+H)+. HPLC 1.47 min. and (3-((1R,4R)-4- ((Dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-((R)-2-fluoro-2-(2-fluoro- phenyl)-acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide (Example 268) (2ndeluted compound) as a white powder (2.4 mg, 4%). LCMS (ES+) m / z calculated for C27H29F5N6O3 580.51; found 581 (M+H)+. HPLC tR 1.47 min. Example 255: (3-((1R,4R)-4-(Dimethylamino)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- (o-tolyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide (trifluoroacetate salt). The title compound was obtained as a white powder (6.8 mg, 32%).1H NMR (400 MHz, DMSO- d6) δ 10.41 (s, 1H), 9.74 (s, 1H), 9.52 (br s, 1H), 8.24 (s, 1H), 7.98 (s, 1H), 7.86 (s, 1H), 7.63 (s, 1H), 7.26-7.22 (m, 1H), 7.20-7.12 (m, 3H), 4.80-4.72 (m, 1H), 3.70 (s, 2H), 3.28 (dt, J = 4.1, 8.2 Hz, 1H), 2.78 (d, J = 5.0 Hz, 6H), 2.39 (br d, J = 9.4 Hz, 2H), 2.30 (s, 3H), 2.23-2.15 (m, 2H), 2.11-1.98 (m, 2H), 1.72-1.62 (m, 2H).19F NMR (377 MHz, DMSO-d6) δ -61.58 (s, 3F), -74.27 (s, 3F). LCMS (ES+) m / z calculated for C27H31F3N6O3544.57, found 567 (M+Na)+. HPLC 1.35 min. Example 297: (3-((1R,4R)-4-((Dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5- yl)((3-(3-phenyloxetane-3-carboxamido)-5-(trifluoromethyl)phenyl)-carbamoyl)amide (trifluoroacetate salt). The title compound was obtained as a white powder (5.1 mg, 26%).1H NMR (400 MHz, DMSO- d6) δ 10.16 (s, 1H), 9.73 (s, 1H), 9.12 - 9.05 (m, 1H), 8.20 (s, 1H), 8.08 (s, 1H), 7.83 (s, 1H), 7.62 (s, 1H), 7.51-7.47 (m, 2H), 7.46-7.41 (m, 2H), 7.36-7.31 (m, 1H), 5.20 (d, J = 6.5 Hz, 2H), 4.87 (d, J = 6.5 Hz, 2H), 4.75 (br t, J = 11.8 Hz, 1H), 2.99 (t, J = 6.1 Hz, 2H), 2.81 (d, J = 4.9 Hz, 6H), 2.28 (br d, J = 11.6 Hz, 2H), 2.04 - 1.88 (m, 5H), 1.24 - 1.15 (m, 2H).19F NMR (376 MHz, DMSO- d6) δ -61.58 (s, 3F) and -74.03 (s, 3F). LCMS (ES+) m / z calculated for C29H33F3N6O4586.61, found 587 1.26 min. Example 173: (3-((1R,3R)-3-(Dimethylamino)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- phenylacetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide. Step 1: 5-Amino-3-((1R,3R)-3-(1,3-dioxoisoindolin-2-yl)cyclohexyl)-1,2,3-oxadiazol-3-ium chloride (Intermediate 55) A suspension of 2-((1R,3R)-3-aminocyclohexyl)isoindoline-1,3-dione (246 mg, 0.88 mmol) and 2-bromoacetonitrile (115mg, 0.96 mmol) in CH3CN (1.75 mL) was treated with DIPEA (340 mg, 2.63 mmol) at 0 °C. The reaction mixture was stirred at 60°C for 2h before being concentrated under reduced pressure. The obtained oily residue was treated with H2O and extracted with EtOAc which was washed with H2O, brine, dried over Na2SO4, filtered and concentrated under reduced pressure to obtain a colorless oil (245 mg, 99%) which was dissolved in THF (0.85 mL), treated with tBuNO2 (315 mg, 2.6 mmol) and stirred at rt for 30 min. The mixture was concentrated in vacuo to give a crude material (254 mg, 94%) which was dissolved in 1,4-dioxane (1.0 mL) and treated with HCl (4 N, 0.4 mL, 1.6 mmol) at rt for 15 min until a white precipitate appeared which was filtered, washed with Et2O and dried in vacuo give the title compound as a white powder (179 mg, 63%). LCMS (ES+) m / z calculated for C16H17ClN4O3313.13, found 313 (M)+. 0.92 min. Step 2: (3-((1R,3R)-3-(1,3-Dioxoisoindolin-2-yl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- phenylacetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide (Intermediate 56) The title compound was prepared following the procedure reported for the synthesis of Example 149 in Step 3 and obtained as a white powder (54 mg, 75%). LCMS (ES+) m / z calculated for C32H27F3N6O5632.20, found 633 (M+H)+. HPLC tR2.02 min. Step 3A: (3-((1R,3R)-3-(Dimethylamino)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- phenylacetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide (Example 173). The title compound was prepared following the procedure reported for the synthesis of Example 149 in Step 4 and obtained as a white powder (15.9 mg, 36%).1H NMR (400 MHz, DMSO-d6) δ 10.42 (s, 1H), 9.72 (s, 1H), 8.19 (s, 1H), 7.97 (s, 1H), 7.82 (s, 1H), 7.66 (s, 1H), 7.34 (d, J = 4.4 Hz, 4H), 7.30-7.26 (m, 1H), 4.80-4.58 (m, 2H), 3.65 (s, 2H), 2.33-2.07 (m, 10H), 1.81-1.70 (m, 2H), 1.61-1.54 (m, 2H).19F NMR (377 MHz, DMSO-d6) ^ -61.57 (s, 3F). LCMS (ES+) m / z calculated for C26H29F3N6O3530.23, found 531 (M+H)+. HPLC tR1.30 min. Step 3B: (3-((1R,2S)-2-(dimethylamino)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-(o- tolyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide (Example 283) A solution of [3-[[2-(o-tolyl)acetyl]amino]-5-(trifluoromethyl)phenyl]carbamoyl-[3-[rac-(1R,2S)- 2-(tert-butoxycarbonylamino)cyclohexyl]oxadiazol-3-ium-5-yl]azanide (ortho regioisomer (3- ((1R,2R)-3-(1,3-Dioxoisoindolin-2-yl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- phenylacetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide synthesis using the synthetic procedure described in the scheme 37 for Intermediate 56, 72 mg, 0.12 mmol) in dry dichloromethane (2 mL) was treated with trifluoroacetic acid (0.095 mL, 1.17 mmol) and stirred 4 h at room temperature before being concentrate under reduced pressure to get [3-[[2-(o- tolyl)acetyl]amino]-5-(trifluoromethyl)phenyl]carbamoyl-[3-[rac-(1R,2S)-2-aminocyclohexyl]- oxadiazol-3-ium-5-yl]azanide;2,2,2-trifluoroacetic acid (90 mg, 0.12 mmol) as a yellow oil which was used as a crude which was transformed into the corresponding Example 283, following the experimental procedure described for Example 117 in Scheme 20. The title compound was obtained as a white powder (8.0 mg, 22%).1H NMR (400 MHz, DMSO- d6) δ 10.43 (s, 1H), 9.71 (s, 1H), 8.20 (s, 1H), 8.02 (s, 1H), 7.73 (d, J = 8.1 Hz, 2H), 7.28-7.22 (m, 1H), 7.20-7.07 (m, 3H), 5.42 (q, J = 3.4 Hz, 1H), 3.70 (s, 2H), 2.30 (s, 3H), 2.19 (s, 7H), 2.03- 1.83 (m, 3H), 1.65-1.51 (m, 3H), 1.47-1.32 (m, 1H), 1.26 (br d, J = 17.0 Hz, 1H).19F NMR (377 MHz, DMSO-d6) δ -61.55 (s, 3F). LCMS (ES+) m / z calculated for C27H31F3N6O3544.57, found 545 1.42 min. Examples 174, 202, 204, 244, 288 and 294 were prepared using the synthetic procedure described in scheme 37 step 3A for example 173 using the appropriate starting materials. Example 174: (3-((1R,3S)-3-(Dimethylamino)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- phenylacetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide. The title compound was obtained as a white powder (18.5 mg, 59%).1H NMR (400 MHz, DMSO- d6) δ 10.42 (s, 1H), 9.72 (s, 1H), 8.24 (s, 1H), 7.95 (s, 1H), 7.86 (s, 1H), 7.65 (s, 1H), 7.34 (d, J = 4.4 Hz, 4H), 7.30-7.24 (m, 1H), 4.80-4.66 (m, 1H), 3.65 (s, 2H), 2.31-2.09 (m, 9H), 1.96-1.74 (m, 4H), 1.43-1.24 (m, 2H).19F NMR (377 MHz, DMSO-d6) ^ -61.58 (s, 3F). LCMS (ES+) m / z calculated for C26H29F3N6O3530.23, found 531 (M+H)+. HPLC tR1.30 min. Example 202: (3-((1R,3S)-3-(Dimethylamino)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- (o-tolyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide. The title compound was obtained as a powder (9.3 mg, 27%).1H NMR (400 MHz, DMSO-d6) δ 10.41 (s, 1H), 9.76 (br s, 2H), 8.33 (s, 1H), 7.99 (s, 1H), 7.89 (s, 1H), 7.60 (s, 1H), 7.25-7.22 (m, 1H), 7.20-7.12 (m, 3H), 4.90-4.82 (m, 1H), 3.70 (s, 2H), 2.80-2.77 (m, 6H), 2.60-2.55 (m, 2H), 2.30 (s, 3H), 2.25-2.18 (m, 2H), 2.05-1.96 (m, 3H), 1.55-1.46 (m, 2H).19F NMR (377 MHz, DMSO-d6) ^ -61.59 (s, 3F). LCMS (ES+) m / z calculated for C27H31F3N6O3544.24, found 545 (M+H)+. HPLC tR1.35 min. Example 204: (3-((1R,3S)-3-(Dimethylamino)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((2- (trifluoromethyl)pyridin-4-yl)carbamoyl)amide. The title compound was obtained as a powder (4.1 mg, 9%).1H NMR (400 MHz, DMSO-d6) δ 10.19 (s, 1H), 9.67 (br s, 1H), 8.47 (d, J = 5.5 Hz, 1H), 8.45 (s, 1H), 8.29 (d, J = 1.9 Hz, 1H), 7.66 (dd, J = 5.7, 1.8 Hz, 1H), 4.94-4.88 (m, 1H), 2.81-2.77 (m, 6H), 2.60-2.55 (m, 2H), 2.29-2.20 (m, 2H), 2.04-1.88 (m, 3H), 1.54-1.46 (m, 2H).19F NMR (377 MHz, DMSO-d6) ^ -66.93 (s, 3F). LCMS (ES+) m / z calculated for C17H21F3N6O2398.17, found 399 (M+H)+. HPLC tR 0.88 min. Example 244: (3-((1R,2S)-2-(Dimethylamino)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- (o-tolyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide The title compound was obtained as a white powder (8.0 mg, 22%).1H NMR (400 MHz, DMSO- d6) δ 10.43 (s, 1H), 9.71 (s, 1H), 8.20 (s, 1H), 8.02 (s, 1H), 7.73 (d, J = 8.1 Hz, 2H), 7.27-7.22 (m, 1H), 7.20-7.12 (m, 3H), 5.42 (br d, J = 3.3 Hz, 1H), 3.70 (s, 2H), 2.30 (s, 3H), 2.19 (s, 7H), 1.96- 1.83 (m, 3H), 1.6 -1.51 (m, 3H), 1.40 (br d, J = 8.3 Hz, 1H), 1.32-1.21 (m, 1H).19F NMR (377 MHz, DMSO-d6) ^ -61.55 (s, 3F). LCMS (ES+) m / z calculated for C27H31F3N6O3545.57, found 545 (M+H)+. HPLC tR1.42 min. Example 288: (3-((1R,4R)-4-(Dimethylamino)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- (o-tolyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide (trifluoroacetate salt) The title compound was obtained as a white powder (6.8 mg, 21%).1H NMR (400 MHz, DMSO- d6) δ 10.41 (s, 1H), 9.74 (s, 1H), 9.52 (br s, 1H), 8.24 (s, 1H), 7.98 (s, 1H), 7.86 (s, 1H), 7.63 (s, 1H), 7.26-7.22 (m, 1H), 7.20-7.12 (m, 3H), 4.81-4.74 (m, 1H), 3.70 (s, 2H), 3.33-3.26 (m, 1H), 2.78 (d, J = 5.0 Hz, 6H), 2.39 (br d, J = 9.4 Hz, 2H), 2.30 (s, 3H), 2.18 (br d, J = 10.9 Hz, 2H), 2.11-1.98 (m, 2H), 1.75-1.62 (m, 2H).19F NMR (377 MHz, DMSO-d6) δ -61.58 (s, 3F), -74.27 (s, 6F). LCMS (ES+) m / z calculated for C27H31F3N6O3544.57, found 567 (M+Na)+. HPLC 1.35 min. Example 294: (3-((1R,4R)-4-((Dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5- yl)((4-(2-phenylacetamido)-3-(trifluoromethyl)phenyl)carbamoyl)amide (trifluoroacetate salt) The title compound was obtained as a white powder (3.7 mg, 7%).1H NMR (400 MHz, DMSO- d6) δ 9.70 (s, 1H), 9.59 (s, 1H), 9.09 (br s, 1H), 8.24 (s, 2H), 7.69 (br d, J = 8.5 Hz, 1H), 7.35-7.30 (m, 4H), 7.29 - 7.23 (m, 2H), 4.81 - 4.68 (m, 1H), 3.65 (s, 2H), 2.99 (br t, J = 6.1 Hz, 2H), 2.80 (d, J = 4.8 Hz, 6H), 2.31-2.23 (m, 2H), 2.03 - 1.89 (m, 4H), 1.28-1.14 (m, 3H).19F NMR (377 MHz, DMSO-d6) δ -59.55 (s, 3F) and -73.96 (s, 3F). LCMS (ES+) m / z calculated for C27H31F3N6O3544.24, found 545 (M+H)+. HPLC 1.18 min. Examples 213, 245-246, 271, 274, 281, 286 and 296 were prepared using the synthetic procedure described in scheme 37 step 3B for example 283 using the appropriate starting materials. Example 213: (3-((1R,3R)-3-((Dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5- yl)((3-(2-(o-tolyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide The title compound was obtained as a powder (16.0 mg, 80%).1H NMR (400 MHz, DMSO-d6) δ 10.40 (s, 1H), 9.74 (s, 1H), 9.12 (br s, 1H), 8.22 (s, 1H), 8.01 (s, 1H), 7.86 (s, 1H), 7.60 (s, 1H), 7.26-7.22 (m, 1H), 7.20-7.13 (m, 3H), 4.83-4.77 (m, 1H), 3.70 (s, 2H), 3.04-2.99 (m, 2H), 2.82- 2.80 (m, 6H), 2.35-2.24 (m, 5H), 2.09-1.66 (m, 5H), 1.55-1.44 (m, 1H), 1.10-1.00 (m, 1H).19F NMR (377 MHz, DMSO-d6) ^ -61.58 (s, 3F). LCMS (ES+) m / z calculated for C28H33F3N6O3558.26, found 559 (M+H)+. HPLC 1.41 min. Example 245 and example 246: (3-((1S,3R)-3-((dimethylamino)methyl)cyclohexyl)-1,2,3- oxadiazol-3-ium-5-yl)((3-(2-(o-tolyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)- amide and (3-((1R,3S)-3-((dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5- yl)((3-(2-(o-tolyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide. (3-((1R,3R)-3-((Dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-(o-tolyl)- acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide (Example 213) was subjected to SFC purification (Column: Chiralpak OJ (cellulose) - Run time 40 min - Eluent: 12% MeOH+0.2% DEA using an isocratic method) to get (3-((1S,3R)-3-((dimethylamino)methyl)cyclohexyl)-1,2,3- oxadiazol-3-ium-5-yl)((3-(2-(o-tolyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)-amide (Example 245) (1steluted compound) as a white powder (3.2 mg, 16%). LCMS (ES+) m / z calculated for C28H33F3N6O3558.60; found 590 (M+H)+. HPLC tR 1.44 min. and (3-((1R,3S)-3- ((dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-(o-tolyl)acetamido)-5- (trifluoromethyl)phenyl)carbamoyl)amide (Example 246) (2ndeluted compound) as a white powder (4.5 mg, 22%). LCMS (ES+) m / z calculated for C28H33F3N6O3558.60; found 590 (M+H)+. HPLC tR 1.44 min. Example 271: (3-(6-Methyl-6-azabicyclo[3.2.1]octan-3-yl)-1,2,3-oxadiazol-3-ium-5-yl)((3- ((S)-2-phenylpropanamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide (trifluoroacetate salt) The title compound was obtained as a white powder (2.0 mg, 23%).1H NMR (400 MHz, DMSO- d6) δ 10.30 (s, 1H), 9.79-9.73 (m, 1H), 9.35 (br s, 1H), 8.31 (s, 1H), 8.00 (s, 1H), 7.86 (s, 1H), 7.62-7.56 (m, 1H), 7.41-7.31 (m, 5H), 7.28-7.23 (m, 1H), 5.16-5.05 (m, 1H), 3.92 (br s, 1H), 3.85 (q, J = 6.8 Hz, 1H), 3.76 (br dd, J = 6.3, 11.6 Hz, 1H), 3.06-2.98 (m, 1H), 2.89 (d, J = 5.1 Hz, 3H), 2.80-2.69 (m, 2H), 2.65-2.53 (m, 1H), 2.43 (br dd, J = 7.8, 16.2 Hz, 1H), 2.17-2.04 (m, 2H), 1.42 (d, J = 7.0 Hz, 3H).19F NMR (377 MHz, DMSO-d6) δ -61.60 (s, 3F) and -74.07 (s, 6F). LCMS (ES+) m / z calculated for C27H30F3N6O3542.55, found 543 (M+H)+. HPLC tR1.35 min. Example 274: (3-(2-Methyl-2-azaspiro[4.5]decan-8-yl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-(o- tolyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide (trifluoroacetate salt) The title compound was obtained as a white powder (5.8 mg, 99%).1H NMR (400 MHz,DMSO- d6) δ 10.40 (s, 1H), 9.76-9.66 (m, 2H), 8.31 (d, J = 8.6 Hz, 1H), 7.96 (s, 1H), 7.90 (br d, J = 7.9 Hz, 1H), 7.61 (br d, J = 5.9 Hz, 1H), 7.26-7.22 (m, 1H), 7.21-7.12 (m, 3H), 4.80-4.68 (m, 1H), 3.81-3.74 (m, 1H), 3.67-3.54 (m, 1H), 3.44-3.36 (m, 1H), 3.22-3.09 (m, 1H), 2.86 (dd, J = 4.9, 7.4 Hz, 4H), 2.30 (s, 3H), 2.18-1.89 (m, 7H), 1.86-1.75 (m, 2H), 1.70-1.52 (m, 2H).19F NMR (377 MHz, DMSO-d6) δ -61.57 (s, 3F), -74.16 (s, 3F). LCMS (ES+) m / z calculated for C29H33F3N6O3570.61, found 571 (M+H)+. HPLC tR 1.40 min. Example 281: 3-((1R,3S,4R)-4-(Dimethylamino)-3-fluorocyclohexyl)-5-(3-(3-((S)-2- phenylpropanamido)-5-(trifluoromethyl)phenyl)ureido)-1,2,3-oxadiazol-3-ium (trifluoroacetate salt) The title compound was obtained as a white powder (36 mg, 53%).1H NMR (400 MHz, DMSO- d6) δ 10.31 (s, 1H), 9.85 (br dd, J = 1.2, 5.2 Hz, 1H), 9.73 (s, 1H), 8.31 (s, 1H), 7.98 (s, 1H), 7.83 (s, 1H), 7.63 (s, 1H), 7.41-7.31 (m, 4H), 7.28-7.24 (m, 1H), 5.60 (d, J = 56 Hz, 1H), 5.04-4.94 (m, 1H), 3.85 (q, J = 6.8 Hz, 2H), 3.62-3.45 (m, 1H), 2.89 (t, J = 5.6 Hz, 6H), 2.83-2.73 (m, 1H), 2.47- 2.43 (m, 1H), 2.40-2.25 (m, 2H), 2.18-2.04 (m, 1H), 1.99-1.87 (m, 1H), 1.42 (d, J = 7.0 Hz, 3H).19F NMR (377 MHz, DMSO-d6) δ -61.60 (s, 3F), -74.13 (s, 3F), -198.16 (s, 1F). LCMS (ES+) m / z calculated for C27H31F4N6O3563.57, found 564 (M+H)+. HPLC tR 1.37 min. Example 286: (S)-(3-(2-Methyl-2-azaspiro[3.5]nonan-7-yl)-1,2,3-oxadiazol-3-ium-5-yl)((3- (2-phenylpropanamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide (trifluoroacetate salt) The title compound was obtained as a white powder (9.0 mg, 25%).1H NMR (400 MHz, DMSO- d6) δ 10.30 (s, 1H), 9.71 (s, 2H), 8.28 (s, 1H), 7.94 (s, 1H), 7.88 (s, 1H), 7.61 (s, 1H), 7.41-7.33 (m, 4H), 7.28-7.23 (m, 1H), 4.71 (br t, J = 10.9 Hz, 1H), 4.13-4.06 (m, 1H), 3.94-3.74 (m, 4H), 2.87 (d, J = 5.1 Hz, 3H), 2.19-2.05 (m, 4H), 1.96-1.85 (m, 1H), 1.74-1.63 (m, 2H), 1.42 (d, J = 7.0 Hz, 3H).19F NMR (377 MHz, DMSO-d6) δ -61.59 (s, 3F), -73.93 (s, 3F). LCMS (ES+) m / z calculated for C28H31F3N6O3556.58, found 557 (M+H)+. HPLC tR 1.35 min. Example 296: (3-((1R,4S)-4-(Dimethylamino)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3- ((S)-2-phenylpropanamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide (trifluoroacetate salt) The title compound was obtained as a white powder (8.6 mg, 48%).1H NMR (400 MHz, DMSO-d6) δ 10.31 (s, 1H), 9.72 (s, 1H), 9.54 (br s, 1H), 8.23 (s, 1H), 7.98 (s, 1H), 7.83 (s, 1H), 7.63 (s, 1H), 7.4-7.32 (m, 4H), 7.30-7.22 (m, 1H), 4.82-4.72 (m, 1H), 3.88-3.84 (m, 2H), 3.32- 3.24 (m, 1H), 2.79 (d, J = 5.0 Hz, 6H), 2.39 (br d, J = 10.4 Hz, 2H), 2.22-2.14 (m, 2H), 2.07- 1.99 (m, 2H), 1.73-1.62 (m, 2H), 1.42 (d, J = 7.0 Hz, 3H).19F NMR (377 MHz, DMSO-d6) δ - 61.59 (s, 3F), -74.10 (s, 3F). LCMS (ES+) m / z calculated for C27H31F3N6O3544.57, found 567 1.36 min. Example 203: (3-((1R,2R)-2-Hydroxycyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-(o- tolyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide Scheme 38 Step 1: 5-Amino-3-((1R,2R)-2-hydroxycyclohexyl)-1,2,3-oxadiazol-3-ium chloride (Intermediate 57) The title compound was prepared following the procedure reported for the synthesis of Example 173 in Step 1 and obtained as a light-yellow powder (203 mg, 90%). LCMS (ES+) m / z calculated for C8H14ClN3O2+184.11, found 184 (M)+. HPLC tR 0.49 min. Step 2: (3-((1R,2R)-2-Hydroxycyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-(o-tolyl)- acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide (Example 203). The title compound was prepared following the procedure reported for the synthesis of Example 149 in Step 3 and obtained as a white powder (14 mg, 19%).1H NMR (400 MHz, DMSO-d6) δ 10.41 (s, 1H), 9.71 (s, 1H), 8.20 (s, 1H), 7.97 (s, 1H), 7.84 (s, 1H), 7.66 (s, 1H), 7.27-7.22 (m, 1H), 7.20-7.11 (m, 3H), 4.43-4.37 (m, 1H), 3.97-3.86 (m, 1H), 3.70 (s, 2H), 2.30 (s, 3H), 2.17- 2.10 (m, 1H), 2.05-1.98 (m, 2H), 1.79-1.65 (m, 2H), 1.46-1.30 (m, 3H).19F NMR (377 MHz, DMSO-d6) ^ -61.56 (s, 3F). LCMS (ES+) m / z calculated for C25H26F3N5O4517.19, found 518 1.83 min. Examples 178, 181, 192, 200, 206, 214-215, 217-218, 223-224, 227-230, 240, 278, 287, 291-292 and 300-302 were prepared using the synthetic procedure described in Scheme 38 for the synthesis of Example 203 using the appropriate starting materials. Example 178: (3-((1-Methyl-1,2,3,4-tetrahydroquinolin-2-yl)methyl)-1,2,3-oxadiazol-3-ium- 5-yl)((2-(trifluoromethyl)pyridin-4-yl)carbamoyl)amide. The title compound was obtained as a powder (0.6 mg, 2%).1H NMR (400 MHz, DMSO-d6) δ 10.19 (s, 1H), 8.50-8.45 (m, 2H), 8.25-8.23 (m, 1H), 7.71-7.68 (m, 1H), 7.09-7.03 (m, 1H), 7.00- 6.97 (m, 1H), 6.64-6.57 (m, 2H), 4.77-4.58 (m, 2H), 4.09-4.05 (m, 1H), 2.91 (s, 3H), 2.34-2.33 (m, 4H).19F NMR (377 MHz, DMSO-d6) ^ -66.93 (s, 3F). LCMS (ES+) m / z calculated for C20H19F3N6O2432.15, found 433 1.85 min. Example 181: (3-((2-Methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)methyl)-1,2,3-oxadiazol-3- ium-5-yl)((2-(trifluoromethyl)pyridin-4-yl)carbamoyl)amide. The title compound was obtained as a powder (2.8 mg, 8%).1H NMR (400 MHz, DMSO-d6) δ 10.13 (s, 1H), 8.46 (d, J = 4.6 Hz, 1H), 8.23 (s, 1H), 8.20 (d, J = 1.8 Hz, 1H), 7.70 (dd, J = 5.6, 1.8 Hz, 1H), 7.41-7.35 (m, 1H), 7.25-7.19 (m, 2H), 7.15-7.12 (m, 1H), 4.91 (d, J = 6.1 Hz, 2H), 4.24 (t, J = 6.1 Hz, 1H), 3.25-3.19 (m, 1H), 2.87-2.79 (m, 1H), 2.71-2.65 (m, 1H), 2.57-2.54 (m, 1H), 2.42 (s, 3H).19F NMR (377 MHz, DMSO-d6) ^ -66.89 (s, 3F). LCMS (ES+) m / z calculated for C20H19F3N6O2432.15, found 433 (M+H)+. HPLC tR 1.24 min. Example 192: (3-((2-Methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)methyl)-1,2,3-oxadiazol-3- ium-5-yl)((3-(2-phenylacetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide. The title compound was obtained as a white powder (17 mg, 15%).1H NMR (400 MHz, DMSO- d6) δ 10.44 (s, 1H), 9.69 (s, 1H), 8.11 (s, 1H), 8.01 (s, 1H), 7.72 (d, J = 7.8 Hz, 2H), 7.40-7.35 (m, 1H), 7.34 (d, J = 4.5 Hz, 4H), 7.30-7.18 (m, 3H), 7.15-7.10 (m, 1H), 4.88 (d, J = 5.9 Hz, 2H), 4.21 (t, J = 5.9 Hz, 1H), 3.66 (s, 2H), 3.24-3.18 (m, 1H), 2.85-2.78 (m, 1H), 2.70-2.65 (m, 1H), 2.58- 2.53 (m, 1H), 2.43 (s, 3H).19F NMR (377 MHz, DMSO-d6) ^ -61.56 (s, 3F). LCMS (ES+) m / z calculated for C29H27F3N6O3564.21, found 565 (M+H)+. HPLC tR1.64 min. Example 200: (3-((1,2,3,4-Tetrahydronaphthalen-1-yl)methyl)-1,2,3-oxadiazol-3-ium-5- yl)((2-(trifluoromethyl)pyridin-4-yl)carbamoyl)amide. The title compound was obtained as a white powder (22 mg, 30%).1H NMR (400 MHz, DMSO- d6) δ 10.18 (s, 1H), 8.48 (s, 1H), 8.46 (s, 1H), 8.25 (s, 1H), 7.71-7.69 (m, 1H), 7.39-7.36 (m, 1H), 7.20-7.12 (m, 3H), 4.90-4.69 (m, 2H), 3.63-3.55 (m, 1H), 2.81-2.68 (m, 2H), 1.93-1.68 (m, 3H), 1.60-1.54 (m, 1H).19F NMR (377 MHz, DMSO-d6) ^ -66.93 (s, 3F). LCMS (ES+) m / z calculated for C20H18F3N5O2417.14, found 418 (M+H)+. HPLC tR1.97 min. Example 206: (3-((1R,4R)-4-(2-Hydroxypropan-2-yl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5- yl)((3-(2-(o-tolyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide. The title compound was obtained as a white powder (12 mg, 14%).1H NMR (400 MHz, DMSO- d6) δ 10.42 (s, 1H), 9.71 (s, 1H), 8.16 (s, 1H), 7.98 (s, 1H), 7.81 (s, 1H), 7.67 (s, 1H), 7.27-7.23 (m, 1H), 7.20-7.12 (m, 3H), 4.71-4.65 (m, 1H), 4.19 (br s, 1H), 3.70 (s, 2H), 2.30 (s, 3H), 2.29- 2.24 (m, 2H), 1.97-1.85 (m, 4H), 1.38-1.20 (m, 3H), 1.07 (s, 6H).19F NMR (377 MHz, DMSO- d6) ^ -61.56 (s, 3F). LCMS (ES+) m / z calculated for C28H32F3N5O4559.24, found 560 (M+H)+. HPLC tR 1.87 min. Example 214: (3-((1R,3S)-3-Hydroxycyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-(o- tolyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide. The title compound was obtained as a powder (4 mg, 14%).1H NMR (400 MHz, DMSO-d6) δ 10.43 (s, 1H), 9.73 (s, 1H), 8.20 (s, 1H), 7.98 (s, 1H), 7.82 (s, 1H), 7.68 (s, 1H), 7.28-7.22 (m, 1H), 7.20-7.15 (m, 3H), 4.80-4.74 (m, 1H), 3.70 (s, 2H), 2.39-2.34 (m, 1H), 2.30 (s, 3H), 2.15- 2.10 (m, 1H), 1.90-1.75 (m, 4H), 1.41-1.36 (m, 1H), 1.26-1.20 (m, 2H).19F NMR (377 MHz, DMSO-d6) ^ -61.57 (s, 3F). LCMS (ES+) m / z calculated for C25H26F3N5O4517.19, found 518 1.70 min. Example 215: (3-((1R,3R)-3-Hydroxycyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-(o- tolyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide. The title compound was obtained as a powder (3.1 mg, 11%).1H NMR (400 MHz, DMSO-d6) δ 10.42 (s, 1H), 9.72 (s, 1H), 8.19 (s, 1H), 7.98 (s, 1H), 7.82 (s, 1H), 7.67 (s, 1H), 7.28-7.22 (m, 1H), 7.20-7.12 (m, 3H), 4.97-4.92 (m, 1H), 4.11 (br s, 1H), 3.70 (s, 2H), 2.30 (s, 3H), 2.18-2.09 (m, 3H), 2.02-1.75 (m, 2H), 1.66-1.24 (m, 4H).19F NMR (377 MHz, DMSO-d6) ^ -61.56 (s, 3F). LCMS (ES+) m / z calculated for C25H26F3N5O4517.19, found 518 (M+H)+. HPLC 1.75 min. Example 217: (3-(((1S,2S)-2-Hydroxycyclohexyl)methyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- (o-tolyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide. The title compound was obtained as a white powder (20 mg, 15%).1H NMR (400 MHz, DMSO- d6) δ 10.42 (s, 1H), 9.73 (s, 1H), 8.05 (s, 1H), 8.01 (s, 1H), 7.78 (s, 1H), 7.69 (s, 1H), 7.28-7.22 (m, 1H), 7.20-7.13 (m, 3H), 4.77-4.72 (m, 1H), 4.50-4.44 (m, 1H), 3.70 (s, 2H), 3.22-3.15 (m, 1H), 2.30 (s, 3H), 1.92-1.80 (m, 2H), 1.67-1.55 (m, 3H), 1.26-1.04 (m, 5H).19F NMR (377 MHz, DMSO-d6) ^ -61.56 (s, 3F). LCMS (ES+) m / z calculated for C26H28F3N5O4531.21, found 532 1.87 min. Example 218: (3-(((1R,2S)-2-Hydroxycyclohexyl)methyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- (o-tolyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide. The title compound was obtained as a white powder (27mg, 20%).1H NMR (400 MHz, DMSO- d6) δ 10.42 (s, 1H), 9.73 (s, 1H), 8.13 (s, 1H), 8.00 (s, 1H), 7.79 (s, 1H), 7.68 (s, 1H), 7.27-7.20 (m, 1H), 7.18-7.13 (m, 3H), 4.57-4.52 (m, 1H), 4.40-4.35 (m, 1H), 3.70 (s, 2H), 2.30 (s, 3H), 2.15- 2.10 (m, 1H), 1.76-1.54 (m, 3H), 1.43-1.30 (m, 4H), 1.29-1.21 (m, 2H).19F NMR (377 MHz, DMSO-d6) ^ -61.57 (s, 3F). LCMS (ES+) m / z calculated for C26H28F3N5O4531.21, found 532 1.90 min. Example 223: (3-((1R,3S)-3-(Methoxycarbonyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3- (2-(o-tolyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide. The title compound was obtained as a white powder (16 mg, 2.4%).1H NMR (400 MHz, DMSO- d6) δ 10.41 (s, 1H), 9.73 (s, 1H), 8.25 (s, 1H), 7.97 (s, 1H), 7.84 (s, 1H), 7.67 (s, 1H), 7.28-7.23 (m, 1H), 7.20-7.13 (m, 3H), 4.87-4.81 (m, 1H), 3.70 (s, 2H), 3.64 (s, 3H), 2.68-2.62 (m, 1H), 2.45- 2.40 (m, 1H), 2.30 (s, 3H), 2.22-2.18 (m, 1H), 2.06-1.89 (m, 4H), 1.53-1.37 (m, 2H).19F NMR (377 MHz, DMSO-d6) ^ -61.57 (s, 3F). LCMS (ES+) m / z calculated for C27H28F3N5O5559.20, found 560 (M+H)+. HPLC tR1.96 min. Example 224: (3-((1R,3R)-3-(Methoxycarbonyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3- (2-(o-tolyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide. The title compound was obtained as a white powder (10 mg, 1.5%).1H NMR (400 MHz, DMSO- d6) δ 10.41 (s, 1H), 9.74 (s, 1H), 8.22 (s, 1H), 7.98 (s, 1H), 7.83 (s, 1H), 7.67 (s, 1H), 7.27-7.22 (m, 1H), 7.20-7.13 (m, 3H), 5.01-4.93 (m, 1H), 3.70 (s, 2H), 3.64 (s, 3H), 3.01-2.93 (m, 1H), 2.38- 2.31 (m, 2H), 2.30 (s, 3H), 2.14-2.04 (m, 2H), 1.89-1.81 (m, 1H), 1.75-1.66 (m, 2H), 1.57-1.45 (m, 1H).19F NMR (377 MHz, DMSO-d6) ^ -61.57 (s, 3F). LCMS (ES+) m / z calculated for C27H28F3N5O5559.20, found 560 (M+H)+. HPLC tR 1.98 min. Example 227: (3-(4-(Methoxycarbonyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-(o- tolyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide. The title compound was obtained as a yellow powder (8.5 mg, 1.4%).1H NMR (400 MHz, DMSO- d6) δ 10.42 (s, 1H), 9.77 (s, 1H), 8.22 (s, 1H), 7.99 (s, 1H), 7.82 (s, 1H), 7.66 (s, 1H), 7.28-7.22 (m, 1H), 7.20-7.13 (m, 3H), 4.83-4.75 (m, 1H), 3.70 (s, 2H), 3.63 (s, 3H), 2.47-2.45 (m, 1H), 2.30 (s, 3H), 2.28-2.22 (m, 2H), 2.12-1.98 (m, 4H), 1.63-1.53 (m, 2H).19F NMR (377 MHz, DMSO- d6) ^ -61.59 (s, 3F). LCMS (ES+) m / z calculated for C27H28F3N5O5559.20, found 560 (M+H)+. HPLC tR1.94 min. Example 228: (3-((1R,4R)-4-(Hydroxymethyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- (o-tolyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide. The title compound was obtained as a powder (5.4 mg, 28%).1H NMR (400 MHz, DMSO-d6) δ 10.42 (s, 1H), 9.75 (s, 1H), 8.23 (s, 1H), 7.99 (s, 1H), 7.82 (s, 1H), 7.67 (s, 1H), 7.28-7.22 (m, 1H), 7.20-7.12 (m, 3H), 4.78-4.67 (m, 1H), 4.29 (d, J = 5.9 Hz, 1H), 3.70 (s, 2H), 3.27 (d, J = 6.1 Hz, 2H), 2.30 (s, 3H), 2.26-2.22 (m, 2H), 1.98-1.85 (m, 4H), 1.50-1.09 (m, 3H).19F NMR (377 MHz, DMSO-d6) ^ -61.58 (s, 3F). LCMS (ES+) m / z calculated for C26H28F3N5O4531.21, found 532 (M+H)+. HPLC tR 1.73 min. Example 229: (3-((1R,4R)-4-Carboxycyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-(o- tolyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide. The title compound was obtained as a powder (6.2 mg, 6%).1H NMR (400 MHz, DMSO-d6) δ 12.27 (br s, 1H), 10.42 (s, 1H), 9.73 (s, 1H), 8.19 (s, 1H), 7.99 (s, 1H), 7.82 (s, 1H), 7.66 (s, 1H), 7.28-7.23 (m, 1H), 7.20-7.13 (m, 3H), 4.80-4.73 (m, 1H), 3.70 (s, 2H), 2.39-2.32 (m, 1H), 2.30 (s, 3H), 2.26-2.23 (m, 2H), 2.10-1.97 (m, 4H), 1.60-1.33 (m, 2H).19F NMR (377 MHz, DMSO-d6) ^ -61.57 (s, 3F). LCMS (ES+) m / z calculated for C26H26F3N5O5545.19, found 546 (M+H)+. HPLC tR 1.74 min. Example 230: (3-(-3-(Hydroxymethyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-(o- tolyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide. The title compound was obtained as a beige powder (6.9 mg, 13%).1H NMR (400 MHz, DMSO- d6) δ 10.41 (s, 1H), 9.72 (s, 1H), 8.17 (s, 1H), 7.98 (s, 1H), 7.83 (s, 1H), 7.67 (s, 1H), 7.28-7.22 (m, 1H), 7.20-7.13 (m, 3H), 5.01-4.73 (m, 1H), 3.70 (s, 2H), 3.38-3.26 (m, 4H), 2.30 (s, 3H), 2.26- 2.18 (m, 2H), 1.92-1.43 (m, 6H).19F NMR (377 MHz, DMSO-d6) ^ -61.57 (s, 3F). LCMS (ES+) m / z calculated for C26H28F3N5O4531.21, found 532 (M+H)+. HPLC tR1.76 min. Example 240: (3-((1S,2R)-2-Hydroxycyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-(o- tolyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide (trifluoroacetate salt) The title compound was obtained as a powder (9.0 mg, 15%).1H NMR (400 MHz, DMSO-d6) δ 10.43 (s, 1H), 9.75 (s, 1H), 8.08 (s, 1H), 8.06 - 8.01 (m, 1H), 7.75 (s, 1H), 7.73-7.69 (m, 1H), 7.27-7.22 (m, 1H), 7.20-7.12 (m, 3H), 4.84 (td, J = 3.2, 11.9 Hz, 1H), 4.18 (br s, 1H), 3.70 (s, 2H), 2.30 (s, 3H), 2.29-2.08 (m, 1H), 2.02-1.87 (m, 1H), 1.86-1.76 (m, 2H), 1.70-1.56 (m, 2H), 1.43 (br s, 3H).19F NMR (377 MHz, DMSO-d6) δ -61.57 (s, 3F), -74.82 (s, 3F). LCMS (ES+) m / z calculated for C25H26F3N5O4517.50, found 518 (M+H)+. HPLC tR 1.81 min. Example 278: (S)-(3-(4-(Dimethylamino)-4-(trifluoromethyl)cyclohexyl)-1,2,3-oxadiazol-3- ium-5-yl)((3-(2-phenylpropanamido)-5-(trifluoromethyl)phenyl)carbamoyl)-amide (trifluoroacetate salt) The title compound was obtained as white powder (6.6 mg, 6%).1H NMR (400 MHz, DMSO-d6) δ 10.32 (s, 1H), 9.71 (s, 1H), 8.08 (s, 1H), 8.00 (s, 1H), 7.76 (s, 1H), 7.69 (s, 1H), 7.41-7.31 (m, 4H), 7.29-7.22 (m, 1H), 4.95-4.87 (m, 1H), 3.85 (q, J = 7.0 Hz, 1H), 2.45 (d, J = 1.9 Hz, 6H), 2.30-2.22 (m, 2H), 2.18-2.01 (m, 4H), 1.76-1.63 (m, 2H), 1.42 (d, J = 6.9 Hz, 3H).19F NMR (377 MHz, DMSO-d6) δ -61.57 (s, 3F), -70.49 (s, 3F), -74.55 (s, 3F). LCMS (ES+) m / z calculated for C28H30F6N6O3612.57, found 613 (M+H)+. HPLC tR2.26 min. Example 287: (S)-(3-(1,4-Dioxaspiro[4.5]decan-8-yl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- phenylpropanamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide The title compound was obtained as a yellow powder (268 mg, 45%).1H NMR (400 MHz, DMSO- d6)1H NMR (400 MHz, DMSO-d6) δ 10.32 (s, 1H), 9.70 (s, 1H), 8.11 (s, 1H), 7.98 (s, 1H), 7.76 (s, 1H), 7.69 (s, 1H), 7.41-7.31 (m, 4H), 7.31-7.22 (m, 1H), 4.93-4.83 (m, 1H), 3.96-3.83 (m, 5H), 2.29-2.21 (m, 2H), 2.10 (dq, J = 3.6, 12.1 Hz, 2H), 1.86-1.78 (m, 2H), 1.72 (br dd, J = 4.0, 13.0 Hz, 2H), 1.42 (d, J = 7.0 Hz, 3H).19F NMR (377 MHz, DMSO-d6) δ -61.58 (s, 3F). LCMS (ES+) m / z calculated for C27H28F3N5O5559.53, found 560 (M+H)+. HPLC tR 1.90 min. Example 291: (3-((1R,4S)-4-Morpholinocyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-((S)-2- phenylpropanamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide (trifluoroacetate salt) The title compound was obtained as white powder (4.3 mg, 8%).1H NMR (400 MHz, DMSO-d6) δ 10.31 (s, 1H), 9.72 (s, 1H), 9.64 (s, 1H), 8.24 (s, 1H), 7.98 (s, 1H), 7.84 (s, 1H), 7.63 (s, 1H), 7.40-7.32 (m, 4H), 7.28-7.23 (m, 1H), 4.84-4.75 (m, 1H), 4.04 (br d, J = 11.8 Hz, 2H), 3.85 (q, J = 7.0 Hz, 1H), 3.74-3.64 (m, 2H), 3.45 (br d, J = 10.6 Hz, 2H), 3.36-3.28 (m, 1H), 3.17 (br d, J = 11.8 Hz, 2H), 2.44-2.37 (m, 2H), 2.31-2.25 (m, 2H), 2.10-2.02 (m, 2H), 1.75-1.62 (m, 2H), 1.42 (d, J = 7.0 Hz, 3H).19F NMR (377 MHz, DMSO-d6) δ -61.60 (s, 3F), -74.08 (s, 6F). LCMS (ES+) m / z calculated for C29H33F3N6O4586.61, found 609 (M+Na)+. HPLC tR1.37 min. Example 292: (S)-(3-(4-(4,4-Difluoropiperidin-1-yl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5- yl)((3-(2-phenylpropanamido)-5-(trifluoromethyl)phenyl)carbamoyl)-amide (trifluoroacetate salt) The title compound was obtained as white powder (1.8 mg, 2%).1H NMR (400 MHz, DMSO-d6) δ 10.31 (s, 1H), 9.72 (s, 1H), 8.24 (s, 1H), 8.03-7.96 (m, 1H), 7.85-7.80 (m, 1H), 7.62 (s, 1H), 7.42-7.31 (m, 4H), 7.28-7.23 (m, 1H), 4.93-4.80 (m, 1H), 3.85 (d, J = 6.9 Hz, 1H), 3.69-3.60 (m, 1H), 3.57-3.42 (m, 1H), 3.31-3.12 (m, 2H), 2.46-2.23 (m, 7H), 2.15-1.99 (m, 3H), 1.82-1.67 (m, 2H), 1.42 (d, J = 7.0 Hz, 4H).19F NMR (377 MHz, DMSO-d6) δ -61.60 (s, 3F), -74.16 (s, 6F). LCMS (ES+) m / z calculated for C30H33F5N6O3620.61, found 621 (M+H)+. HPLC tR 1.44 min. Example 300: ((3-(2-Fluoro-2-(2-fluorophenyl)acetamido)-5-(trifluoromethyl)phenyl)- carbamoyl)(3-((1R,4S)-4-(2-hydroxypropan-2-yl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5- yl)amide The title compound was obtained as white powder (34 mg, 23%).1H NMR (400 MHz, DMSO- d6) δ 10.66 (s, 1H), 9.75 (s, 1H), 8.21 (s, 1H), 8.16 (s, 1H), 7.90 (s, 1H), 7.66 (s, 1H), 7.61-7.52 (m, 2H), 7.37-7.29 (m, 2H), 6.37-6.23 (d, J = 60 Hz, 1H), 4.68 (br t, J = 12.1 Hz, 1H), 2.26 (br d, J = 11.4 Hz, 2H), 2.00-1.85 (m, 4H), 1.38-1.17 (m, 4H), 1.07 (s, 6H).19F NMR (376 MHz, DMSO- d6) δ -61.55 (s, 3F), -74.61 (s, 3F), -116.77 (s, 1F), -174.93 (s, 1F). LCMS (ES+) m / z calculated for C27 H28 F5 N5O4581.53, found 582 (M+H)+. HPLC tR 1.91 min. ((3-((S)-2-Fluoro-2-(2-fluorophenyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)(3- ((1R,4S)-4-(2-hydroxypropan-2-yl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)amide (Example 301) and ((3-((R)-2-Fluoro-2-(2-fluorophenyl)acetamido)-5-(trifluoromethyl)phenyl)- carbamoyl)(3-((1R,4S)-4-(2-hydroxypropan-2-yl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5- yl)amide (Example 302). ((3-(2-Fluoro-2-(2-fluorophenyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)(3-((1R,4S)-4- (2-hydroxypropan-2-yl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)amide (Example 300) (31 mg, 0.05 mmol) was subjected to SFC purification (Column: Chiralpak OJ (cellulose) - Run time 18 min - Eluent: MeOH – Method: 20% MeOH (3 min), 20-40% MeOH (10 min), 40-55% MeOH (3 min), 55-20% MeOH (1 min), 20% MeOH (1 min) to get ((3-((S)-2-fluoro-2-(2- fluorophenyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)(3-((1R,4S)-4-(2-hydroxypropan- 2-yl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)amide (Example 301) (1steluted compound) as a white powder (4.8 mg, 3%). LCMS (ES+) m / z calculated for C27H28F5N5O4581.53; found 582 (M+H)+. HPLC tR 1.91 min. And (3-((S)-2-fluoro-2-(2-fluorophenyl)acetamido)-5- (trifluoromethyl)phenyl)carbamoyl)(3-((1R,4S)-4-(2-hydroxypropan-2-yl)cyclohexyl)-1,2,3- oxadiazol-3-ium-5-yl)amide (Example 302) (2ndeluted compound) as a white powder (4.5 mg, 3%). LCMS (ES+) m / z calculated for C27H28F5N5O4581.53; found 582 (M+H)+. HPLC tR1.91 min. Example 180: (1,1-Difluorospiro[2.4]heptan-5-yl)carbamoyl)(3-((5-(4,6-dimethyl- pyrimidin-5-yl)pyridin-2-yl)methyl)-1,2,3-oxadiazol-3-ium-5-yl)amide. Scheme 39 A solution of 4,6-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine (17.5 mg, 0.07 mmol), (3-((5-bromopyridin-2-yl)methyl)-1,2,3-oxadiazol-3-ium-5-yl)((1,1-difluorospiro- [2.4]heptan-5-yl)carbamoyl)amide (Intermediate 58, prepared as reported in Scheme 21 using the corresponding commercially available starting material, 16 mg, 0.037 mmol) and K3PO4 (24 mg, 0.11 mmol) in 1,4-dioxane (1.0 mL) and H2O (0.1 mL) was treated with Pd(dppf)Cl2(2.7 mg, 0.004 mmol), degassed and heated at 75 °C for 1 h. After cooling the mixture was treated with EtOAc and H2O and the organic phase was washed with brine, dried over Na2SO4, filtered and concentrated in vacuo to give a residue which was purified by automated RP-HPLC using H2O (+ 0.1% TFA) and CH3CN (+ 0.1% TFA) as eluents (C18 column). Fractions containing product were lyophilized to give the title compound as a powder (3.2 mg, 15%).1H NMR (400 MHz, DMSO-d6) δ 8.94 (s, 1H), 8.60-8.56 (m, 1H), 8.15-8.09 (m, 1H), 7.99-7.93 (m, 1H), 7.76 (d, J = 8.3 Hz, 1H), 7.22-7.15 (m, 1H), 6.01 (s, 2H), 4.00-3.93 (m, 1H), 2.20 (s, 6H), 2.07-2.00 (m, 2H), 1.73-1.68 (m, 2H), 1.63-1.54 (m, 2H), 1.41-1.33 (m, 2H).19F NMR (377 MHz, DMSO-d6) ^ - 135.88 (s, 2F). LCMS (ES+) m / z calculated for C22H23F2N7O2455.19, found 456 (M+H)+. HPLC tR1.16 min. Example 254: rac-(3-(4-(4,6-Dimethylpyrimidin-5-yl)benzyl)-1,2,3-oxadiazol-3-ium-5- yl)(((1S,3S)-3-(trifluoromethyl)cyclopentyl)carbamoyl)amide. The title compound was prepared using the same synthetic procedure described for Example 180 in Scheme 39 using the appropriated starting material and obtained as a white powder (16mg, 30%).1H NMR (400 MHz, DMSO-d6) δ 8.90 (s, 1H), 8.00 (s, 1H), 7.66 (d, J = 8.3 Hz, 2H), 7.43- 7.39 (m, 2H), 7.09 (d, J = 7.4 Hz, 1H), 5.80 (s, 2H), 4.04-3.96 (m, 1H), 3.00-2.87 (m, 1H), 2.54- 2.54 (m, 1H), 2.01-1.79 (m, 4H), 1.76-1.68 (m, 2H), 1.61-1.48 (m, 4H).19F NMR (377 MHz, DMSO-d6) ^ -70.01 (s, 3F). LCMS (ES+) m / z calculated for C22H23F3N6O2460.18, found 461 (M+H)+. HPLC tR 1.31 min. Examples 231 & 232: (3-((1S,3R)-3-(Methylcarbamoyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5- yl)((3-(2-(o-tolyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide & (3-((1S,3S)-3- (methylcarbamoyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-(o-tolyl)-acetamido)-5- (trifluoromethyl)phenyl)carbamoyl)amide. Scheme 40 A solution of (3-(3-carboxycyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-(o-tolyl)acetamido)- 5-(trifluoromethyl)phenyl)carbamoyl)amide (Intermediate 59, prepared as reported in Scheme 39, 55 mg, 0.10 mmol), methylamine hydrochloride (20mg, 0.30 mmol), HATU (115 mg, 0.30 mmol) and triethylamine (30.6 mg, 0.30 mmol) in DMF (1.0 mL) was stirred at rt for 18 h before being diluted with EtOAc and NaHCO3(sat. aqueous solution) The organic phase was washed with brine, dried over Na2SO4, filtered and concentrated in vacuo to give a residue which was purified by automated RP-HPLC using H2O (+ 0.1% TFA) and CH3CN (+ 0.1% TFA) as eluents (C18 column). Fractions containing products were lyophilized to give Example 231 as a white powder (12.6 mg, 21%).1H NMR (400 MHz, DMSO-d6) ^ 10.42 (s, 1H), 9.73 (s, 1H), 8.17 (s, 1H), 7.98 (s, 1H), 7.84-7.82 (m, 2H), 7.67 (s, 1H), 7.26-7.23 (m, 1H), 7.20-7.13 (m, 3H), 5.22-5.12 (m, 1H), 3.70 (s, 2H), 2.65-2.60 (m, 1H), 2.59 (d, J = 4.6 Hz, 3H), 2.30 (s, 3H), 2.25-2.18 (m, 2H), 2.09- 2.03 (m, 2H), 1.77-1.58 (m, 4H).19F NMR (377 MHz, DMSO-d6) ^ -61.56 (s, 3F). LCMS (ES+) m / z calculated for C27H29F3N6O4558.22, found 559 (M+H)+. HPLC tR 1.73 min. Example 232 as a powder (15.3 mg, 27%).1H NMR (400 MHz, DMSO-d6) ^ 10.41 (s, 1H), 9.73 (s, 1H), 8.23 (s, 1H), 7.97 (s, 1H), 7.83 (s, 1H), 7.82-7.78 (m, 1H), 7.67 (s, 1H), 7.26-7.23 (m, 1H), 7.20-7.13 (m, 3H), 4.84-4.78 (m, 1H), 3.70 (s, 2H), 2.58 (d, J = 4.5 Hz, 3H), 2.39-2.35 (m, 1H), 2.30 (s, 3H), 2.29-2.22 (m, 2H), 2.10-1.77 (m, 4H), 1.48-1.35 (m, 2H).19F NMR (377 MHz, DMSO-d6) ^ - 61.57 (s, 3F). LCMS (ES+) m / z calculated for C27H29F3N6O4558.22, found 559 (M+H)+. HPLC tR1.69 min. Examples 234-235, 247, 250-253 and 264 were prepared using the synthetic procedure described in Scheme 40 for the synthesis of Examples 231 and 232 using the appropriate amines. Example 234: (3-((1S,3S)-3-(Dimethylcarbamoyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5- yl)((3-(2-(o-tolyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide. The title compound was obtained as a white powder (22.4 mg, 39%).1H NMR (400 MHz, DMSO- d6) ^ 10.41 (s, 1H), 9.73 (s, 1H), 8.25 (s, 1H), 7.96 (s, 1H), 7.84 (s, 1H), 7.67 (s, 1H), 7.27-7.23 (m, 1H), 7.20-7.13 (m, 3H), 4.89-4.82 (m, 1H), 3.70 (s, 2H), 3.05 (s, 3H), 2.94-2.88 (m, 1H), 2.82 (s, 3H), 2.30 (s, 3H), 2.22-2.16 (m, 2H), 2.06-1.90 (m, 3H), 1.74-1.71 (m, 1H), 1.57-1.54 (m, 1H), 1.41-1.35 (m, 1H).19F NMR (377 MHz, DMSO-d6) ^ -61.57 (s, 3F). LCMS (ES+) m / z calculated for C28H31F3N6O4572.24, found 573 1.77 min. Example 235: (3-((1S,3R)-3-Carbamoylcyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-(o- tolyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide. The title compound was obtained as a white powder (7.1 mg, 28%).1H NMR (400 MHz, DMSO- d6) ^ 10.42 (s, 1H), 9.72 (s, 1H), 8.18 (s, 1H), 7.98 (s, 1H), 7.82 (s, 1H), 7.68 (s, 1H), 7.38 (s, 1H), 7.26-7.22 (m, 1H), 7.19-7.14 (m, 3H), 6.91 (s, 1H), 5.19-5.14 (m, 1H), 3.70 (s, 2H), 2.68-2.63 (m, 1H), 2.30 (s, 3H), 2.28-2.16 (m, 2H), 2.08-2.03 (m, 2H), 1.79-1.61 (m, 4H).19F NMR (377 MHz, DMSO-d6) ^ -61.56 (s, 3F). LCMS (ES+) m / z calculated for C26H27F3N6O4544.20, found 545 1.66 min. Example 247: (3-((1R,4R)-4-(Dimethylcarbamoyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5- yl)((3-(2-(o-tolyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide. The title compound was obtained as a white powder (15.2 mg, 58%).1H NMR (400 MHz, DMSO- d6) δ 10.41 (s, 1H), 9.72 (s, 1H), 8.17 (s, 1H), 7.99 (s, 1H), 7.83 (s, 1H), 7.65 (s, 1H), 7.26-7.13 (m, 4H), 4.79 (tt, J = 4.0, 12.0 Hz, 1H), 3.70 (s, 2H), 3.04 (s, 3H), 2.82 (s, 3H), 2.81-2.74 (m, 1H), 2.30 (s, 3H), 2.28-2.21 (m, 2H), 2.21-1.99 (m, 2H), 1.85 (br d, J = 11.9 Hz, 2H), 1.65-1.49 (m, 2H).19F NMR (377 MHz, DMSO-d6) ^ -61.58 (s, 3F). LCMS (ES+) m / z calculated for C28H31F3N6O4572.58, found 573 (M+H)+. HPLC tR 1.75 min. Example 250: (3-((1R,4R)-4-(Methylcarbamoyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3- (2-(o-tolyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide. The title compound was obtained as a white powder (14.6 mg, 57%).1H NMR (400 MHz, DMSO- d6) δ 10.41 (s, 1H), 9.71 (s, 1H), 8.20 (s, 1H), 7.98 (s, 1H), 7.83 (s, 1H), 7.82-7.76 (m, 1H), 7.66 (s, 1H), 7.26-7.12 (m, 4H), 4.74 (tt, J = 3.7, 11.9 Hz, 1H), 3.70 (s, 2H), 2.58 (d, J = 4.6 Hz, 3H), 2.30 (s, 3H), 2.28-2.14 (m, 3H), 2.01-1.86 (m, 4H), 1.58 (dq, J = 3.1, 13.0 Hz, 2H).19F NMR (377 MHz, DMSO-d6) ^ -61.57 (s, 3F). LCMS (ES+) m / z calculated for C28H31F3N6O4558.55, found 559 (M+H)+. HPLC tR 1.66 min. Example 251: (3-((1R,3S)-3-(Dimethylcarbamoyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5- yl)((3-(2-(o-tolyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide The title compound was obtained as a white powder (22.4 mg, 39%).1H NMR (400 MHz, DMSO- d6) δ 10.41 (s, 1H), 9.73 (s, 1H), 8.25 (s, 1H), 7.96 (s, 1H), 7.84 (s, 1H), 7.67 (s, 1H), 7.27-7.22 (m, 1H), 7.20-7.13 (m, 3H), 4.91-4.79 (m, 1H), 4.08-3.97 (m, 2H), 3.05 (s, 3H), 2.98-2.85 (m, 1H), 2.82 (s, 3H), 2.30 (s, 3H), 2.25-2.14 (m, 2H), 2.09-2.02 (m, 1H), 1.96-1.87 (m, 2H), 1.78- 1.68 (m, 1H), 1.65-1.49 (m, 1H), 1.43-1.33 (m, 1H), 0.90-0.81 (m, 1H).19F NMR (377 MHz, DMSO-d6) δ -61.57 (s, 3F), -74.28 (s, 3F). LCMS (ES+) m / z calculated for C28H31F3N6O4572.58, found 573 (M+H)+. HPLC tR 1.77 min. Example 252: (3-((1R,4R)-4-(Pyrrolidine-1-carbonyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5- yl)((3-(2-(o-tolyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide. The title compound was obtained as a white powder (10.9 mg, 39%).1H NMR (400 MHz, DMSO- d6) δ 10.41 (s, 1H), 9.72 (s, 1H), 8.18 (s, 1H), 7.98 (s, 1H), 7.83 (s, 1H), 7.66 (s, 1H), 7.27-7.22 (m, 1H), 7.20-7.13 (m, 3H), 4.79 (tt, J = 4.0, 12.0 Hz, 1H), 3.70 (s, 2H), 3.49 (t, J = 6.7 Hz, 2H), 3.28 (t, J = 6.9 Hz, 2H), 2.62-2.53 (m, 1H), 2.30 (s, 3H), 2.282.21 (m, 2H), 2.02 (dq, J = 3.1, 12.5 Hz, 2H), 1.93-1.86 (m, 4H), 1.82-1.74 (m, 2H), 1.64-1.52 (m, 2H).19F NMR (377 MHz, DMSO- d6) ^ -61.57 (s, 3F). LCMS (ES+) m / z calculated for C30H33F3N6O4598.62, found 599 (M+H)+. HPLC tR1.82 min. Example 253: (3-((1R,3S)-3-Carbamoylcyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-(o- tolyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide (trifluoroacetate salt). The title compound was obtained as a white powder (8.8 mg, 35%).1H NMR (400 MHz, DMSO- d6) δ 10.41 (s, 1H), 9.73 (s, 1H), 8.21 (s, 1H), 7.97 (s, 1H), 7.83 (s, 1H), 7.67 (s, 1H), 7.32 (br s, 1H), 7.27-7.22 (m, 1H), 7.20-7.12 (m, 3H), 6.86 (br s, 1H), 4.85-4.75 (m, 1H), 3.70 (s, 2H), 2.40 - 2.33 (m, 1H), 2.30 (s, 3H), 2.27-2.15 (m, 2H), 2.07-1.81 (m, 4H), 1.53-1.29 (m, 2H).19F NMR (377 MHz, DMSO-d6) δ -61.57 (s, 3F), -74.07 (s, 3F). LCMS (ES+) m / z calculated for C26H27F3N6O4544.53, found 545 1.83 min. Example 264: (3-((1R,3R)-3-Carbamoylcyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-(o- tolyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide. The title compound was obtained as a white powder (7.0 mg, 28%).1H NMR (400 MHz, DMSO- d6) δ 10.42 (s, 1H), 9.72 (s, 1H), 8.18 (s, 1H), 7.98 (s, 1H), 7.82 (s, 1H), 7.68 (s, 1H), 7.38 (s, 1H), 7.27-7.22 (m, 1H), 7.20-7.12 (m, 3H), 6.91 (s, 1H), 5.16 (br d, J = 4.8 Hz, 1H), 3.70 (s, 2H), 2.70- 2.60 (m, 1H), 2.30 (s, 3H), 2.27-2.13 (m, 2H), 2.08-2.02 (m, 1H), 1.83-1.72 (m, 1H), 1.71-1.57 (m, 3H).19F NMR (377 MHz, DMSO-d6) δ -61.56 (s, 3F), -73.98 (s, 3F). LCMS (ES+) m / z calculated for C26H27F3N6O4544.53, found 545 (M+H)+. HPLC tR 1.66 min. Examples 182 & 187: (3-(((1S,4S)-4-(Pyrimidin-5-yl)cyclohexyl)methyl)-1,2,3-oxadiazol-3- ium-5-yl)((2-(trifluoromethyl)pyridin-4-yl)carbamoyl)amide & (3-(((1R,4R)-4-(pyrimidin- 5-yl)cyclohexyl)methyl)-1,2,3-oxadiazol-3-ium-5-yl)((2-(trifluoromethyl)-pyridine-4-yl)- carbamoyl)amide. Scheme 41 Step 1: 1,3-Dioxoisoindolin-2-yl (1R,4R)-4-(((tert-butoxycarbonyl)amino)methyl-)cyclohexane- 1-carboxylate A mixture of (1R,4R)-4-(((tert-butoxycarbonyl)amino)methyl)cyclohexane-1-carboxylic acid (103 mg, 0.4 mmol) and 2-hydroxyisoindoline-1,3-dione (81 mg, 0.5 mmol) was charged in a 4 mL Wheaton vial previously oven dried overnight. Air was removed, the vial was filled with N2and THF (0.5 mL) was added to the mixture followed by N,N-diisopropylcarbodiimide (56 mg, 0.4 mmol). The mixture was stirred at rt for 3 h at rt and used as such in the following step. Step 2: tert -Butyl ((4-(pyrimidin-5-yl)cyclohexyl)methyl)carbamate (Intermediate 60) A 4 mL wheaton vial previously oven dried overnight was charged with dichloronickel hexahydrate (19 mg, 0.08 mmol), 5-bromopyrimidine (95 mg, 0.6 mmol) and 2,2'-dipyridine (12 mg, 0.08 mmol). Air was removed, the vial was filled with N2 and the reaction was stirred at rt for 20 minutes before adding the suspension coming from Step 1. The reaction mixture was transferred to a 5 mL ElectraSyn 2.0 vial previously filled with AgNO3 (34 mg, 0.2 mmol) in NMP (2.5 mL), containing a magnesium anode and a RVC cathode (6 x 36 x 5 mm). The electrochemical reaction is performed under constant current conditions, with no reference electrode, 12 mA irradiation, for 0.4 mmol of substrate, using 2.5 F / mol and with no alternation of the polarity. Reaction was completed after 2.5 F in 2.5 h. The reaction mixture was transferred in a separating funnel, diluted with EtOAc and H2O, and the electrodes were rinsed with EtOAc. The organic layer was washed with H2O and brine, dried over Na2SO4, filtered and concentrated in vacuo to get a residue which was purified by flash chromatography on C18 RP (eluting with 0-100% CH3CN in H2O) to get the title compound as a colorless oil (82 mg, 70%) (trans / cis isomers 80:20). LCMS (ES+) m / z calculated for C16H25N3O2291.19, found 292 (M+H)+. 1.56 min. Step 3: (4-(Pyrimidin-5-yl)cyclohexyl)methanamine (Intermediate 61) TFA (0.77 mL, 10.3 mmol) was added to a stirring solution of tert-butyl ((4-(pyrimidin-5- yl)cyclohexyl)methyl)carbamate (Intermediate 60, 300 mg, 1.03 mmol) in DCM (2.1 mL) and the mixture was stirred at rt for 18 h. Solvent was removed under reduced pressure and the residue treated with a mixture of CH3CN / H2O and lyophilized to get the title compound, used as such in the following step. Step 4: 5-Amino-3-((4-(pyrimidin-5-yl)cyclohexyl)methyl)-1,2,3-oxadiazol-3-ium chloride (Intermediate 62) The title compound was prepared as reported for the synthesis of Example 173 in Step 1 and obtained as an oil (270 mg, 99%). LCMS (ES+) m / z calculated for C13H18N5O+260.15, found 260 (M)+. HPLC tR 0.58 min. Step 5: (3-(((1S,4S)-4-(Pyrimidin-5-yl)cyclohexyl)methyl)-1,2,3-oxadiazol-3-ium-5-yl)((2- (trifluoromethyl)pyridin-4-yl)carbamoyl)amide (Example 182) & (3-(((1R,4R)-4-(pyrimidin-5- yl)cyclohexyl)methyl)-1,2,3-oxadiazol-3-ium-5-yl)((2-(trifluoromethyl)pyridin-4-yl)-carbamoyl- amide (Example 187). Title compounds were prepared as reported for the synthesis of Example 149 in Step 3. Example 182 was obtained as a white powder (1.5 mg, 2%).1H NMR (400 MHz, DMSO-d6) ^ 10.18 (s, 1H), 9.06 (s, 1H), 8.83 (s, 2H), 8.46 (d, J = 5.6 Hz, 1H), 8.36 (s, 1H), 8.23 (d, J = 1.8 Hz, 1H), 7.70 (dd, J = 5.6, 1.9 Hz, 1H), 4.80 (d, J = 8.1 Hz, 2H), 2.73-2.71 (m, 1H), 1.91-1.82 (m, 2H), 1.72-1.65 (m, 4H), 1.62-1.55 (m, 2H), 1.30-1.22 (m, 1H).19F NMR (377 MHz, DMSO-d6) ^ - 66.93 (s, 3F). LCMS (ES+) m / z calculated for C20H20F3N7O2447.16, found 448 (M+H)+. HPLC tR1.43 min. Example 187 as a white powder (5.6 mg, 7%).1H NMR (400 MHz, DMSO-d6) ^ 10.18 (s, 1H), 9.03 (s, 1H), 8.72 (s, 2H), 8.47 (d, J = 5.6 Hz, 1H), 8.30 (s, 1H), 8.23 (d, J = 1.9 Hz, 1H), 7.71 (dd, J = 5.6, 1.9 Hz, 1H), 4.54 (d, J = 7.1 Hz, 2H), 2.62-2.58 (m, 1H), 2.13-2.08 (m, 1H), 1.90-1.77 (m, 4H), 1.60-1.51 (m, 2H), 1.30-1.21 (m, 2H).19F NMR (377 MHz, DMSO-d6) ^ - 66.92 (s, 3F). LCMS (ES+) m / z calculated for C20H20F3N7O2447.16, found 448 (M+H)+. HPLC tR 1.40 min. Examples 179, 183, 185-186, 219-222 and 241 were prepared using the same synthetic procedure described for the synthesis of Examples 182 and 187 in Scheme 41 part using the appropriate starting materials. Example 179: (3-(((1S,4S)-4-(Pyrimidin-5-yl)cyclohexyl)methyl)-1,2,3-oxadiazol-3-ium-5- yl)((3-(trifluoromethyl)phenyl)carbamoyl)amide. The title compound was obtained as a white powder (1.5 mg, 2%).1H NMR (400 MHz, DMSO- d6) ^ 9.73 (s, 1H), 9.05 (s, 1H), 8.83 (s, 2H), 8.28 (s, 1H), 8.24 (s, 1H), 7.73 (br d, J = 8.1 Hz, 1H), 7.44 (t, J = 8.0 Hz, 1H), 7.22 (d, J = 7.8 Hz, 1H), 4.77 (d, J = 8.3 Hz, 2H), 2.73-2.69 (m, 1H), 1.90-1.82 (m, 2H), 1.73-1.65 (m, 4H), 1.62-1.53 (m, 2H), 1.27-1.20 (m, 1H).19F NMR (377 MHz, DMSO-d6) ^ -61.29 (s, 3F). LCMS (ES+) m / z calculated for C21H21F3N6O2446.17, found 447 1.68 min. Example 183: (3-((3-(Pyrimidin-5-yl)bicyclo[1.1.1]pentan-1-yl)methyl)-1,2,3-oxadiazol-3- ium-5-yl)((3-(trifluoromethyl)phenyl)carbamoyl)amide. The title compound was obtained as a light-yellow powder (5.9 mg, 4%).1H NMR (400 MHz, DMSO-d6) ^ 9.75 (s, 1H), 9.08 (s, 1H), 8.72 (s, 2H), 8.24 (s, 1H), 8.17 (s, 1H), 7.74 (d, J = 8.8 Hz, 1H), 7.45 (t, J = 7.9 Hz, 1H), 7.23 (d, J = 7.8 Hz, 1H), 4.85 (s, 2H), 2.16 (s, 6H).19F NMR (377 MHz, DMSO-d6) ^ -61.27 (s, 3F). LCMS (ES+) m / z calculated for C20H17F3N6O2430.14, found 431 (M+H)+. HPLC tR 1.59 min. Example 185: (3-((4-(Pyrimidin-5-yl)bicyclo[2.2.1]heptan-1-yl)methyl)-1,2,3-oxadiazol-3- ium-5-yl)((2-(trifluoromethyl)pyridin-4-yl)carbamoyl)amide. The title compound was obtained as a white powder (11.9 mg, 8%).1H NMR (400 MHz, DMSO- d6) ^ 10.18 (br s, 1H), 9.04 (s, 1H), 8.77 (s, 2H), 8.46 (d, J = 5.6 Hz, 1H), 8.24 (s, 1H), 8.23 (d, J = 1.8 Hz, 1H), 7.71 (dd, J = 5.8, 1.9 Hz, 1H), 4.89 (s, 2H), 1.93-1.75 (m, 8H), 1.59-1.50 (m, 2H).19F NMR (377 MHz, DMSO-d6) ^ -66.91 (s, 3F). LCMS (ES+) m / z calculated for C21H20F3N7O2459.16, found 460 (M+H)+. HPLC 1.43 min. Example 186: (3-(((1R,4R)-4-(Pyrimidin-5-yl)cyclohexyl)methyl)-1,2,3-oxadiazol-3-ium-5- yl)((3-(trifluoromethyl)phenyl)carbamoyl)amide. The title compound was obtained as a white powder (14.2 mg, 15%).1H NMR (400 MHz, DMSO- d6) ^ 9.73 (s, 1H), 9.03 (s, 1H), 8.72 (s, 2H), 8.25 (s, 1H), 8.22 (s, 1H), 7.73 (d, J = 8.5 Hz, 1H), 7.45 (t, J = 7.9 Hz, 1H), 7.23 (d, J = 7.6 Hz, 1H), 4.51 (d, J = 7.0 Hz, 2H), 2.67-2.55 (m, 1H), 2.14-2.10 (m, 1H), 1.93-1.85 (m, 2H), 1.83-1.75 (m, 2H), 1.60-1.51 (m, 2H), 1.29-1.21 (m, 2H).19F NMR (377 MHz, DMSO-d6) ^ -61.28 (s, 3F). LCMS (ES+) m / z calculated for C21H21F3N6O2 446.17, found 447 (M+H)+. HPLC 1.64 min. Example 219: (3-((1R,3R)-3-(Pyrimidin-5-yl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((2- (trifluoromethyl)pyridin-4-yl)carbamoyl)amide. The title compound was obtained as a white powder (3.5 mg, 8%).1H NMR (400 MHz, DMSO- d6) ^ 10.16 (s, 1H), 9.07 (s, 1H), 8.79 (s, 2H), 8.46 (d, J = 5.6 Hz, 1H), 8.34 (s, 1H), 8.24 (d, J = 1.8 Hz, 1H), 7.69 (dd, J = 5.5, 1.9 Hz, 1H), 5.21 (br t, J = 3.9 Hz, 1H), 3.06-2.99 (m, 1H), 2.58- 2.36 (m, 3H), 2.08-2.02 (m, 1H), 1.92-1.85 (m, 1H), 1.77-1.67 (m, 3H).19F NMR (377 MHz, DMSO-d6) ^ -66.90 (s, 3F). LCMS (ES+) m / z calculated for C19H18F3N7O2433.15, found 434 1.33 min. Example 220: (3-((1R,3S)-3-(Pyrimidin-5-yl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((2- (trifluoromethyl)pyridin-4-yl)carbamoyl)amide. Title compound was obtained as a white powder (17.5 mg, 40%).1H NMR (400 MHz, DMSO-d6) ^ 10.16 (s, 1H), 9.08 (s, 1H), 8.80 (s, 2H), 8.46 (d, J = 5.6 Hz, 1H), 8.39 (s, 1H), 8.26 (d, J = 1.9 Hz, 1H), 7.67 (dd, J = 5.4, 1.8 Hz, 1H), 5.03-4.95 (m, 1H), 2.97-2.89 (m, 1H), 2.41-2.25 (m, 3H), 2.05-1.87 (m, 3H), 1.66-1.57 (m, 2H).19F NMR (377 MHz, DMSO-d6) ^ -66.92 (s, 3F). LCMS (ES+) m / z calculated for C19H18F3N7O2433.15, found 434 1.36 min. Example 221: (3-((1R,3R)-3-(Pyrimidin-5-yl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- (o-tolyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide. Title compound was obtained as a white powder (3.6 mg, 5%).1H NMR (400 MHz, DMSO-d6) ^ 10.42 (s, 1H), 9.74 (s, 1H), 9.07 (s, 1H), 8.79 (s, 2H), 8.21 (s, 1H), 7.99 (s, 1H), 7.81 (s, 1H), 7.68 (s, 1H), 7.26-7.21 (m, 1H), 7.18-7.14 (m, 3H), 5.19-5.17 (m, 1H), 3.70 (s, 2H), 3.05-3.00 (m, 1H), 2.41-2.35 (m, 3H), 2.30 (s, 3H), 2.08-2.00 (m, 1H), 1.92-1.85 (m, 1H), 1.77-1.70 (m, 3H).19F NMR (377 MHz, DMSO-d6) ^ -61.56 (s, 3F). LCMS (ES+) m / z calculated for C29H28F3N7O3579.22, found 580 (M+H)+. HPLC 1.78 min. Example 222: (3-((1R,3S)-3-(Pyrimidin-5-yl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- (o-tolyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide. Title compound was obtained as a white powder (14.1 mg, 19%).1H NMR (400 MHz, DMSO-d6) ^ 10.41 (s, 1H), 9.74 (s, 1H), 9.08 (s, 1H), 8.80 (s, 2H), 8.28 (s, 1H), 7.98 (s, 1H), 7.86 (s, 1H), 7.64 (s, 1H), 7.26-7.23 (m, 1H), 7.19-7.13 (m, 3H), 4.96-4.92 (m, 1H), 3.70 (s, 2H), 2.95-2.92 (m, 1H), 2.39-2.31 (m, 3H), 2.30 (s, 3H), 2.05-1.84 (m, 3H), 1.66-1.56 (m, 2H).19F NMR (377 MHz, DMSO-d6) ^ -61.58 (s, 3F). LCMS (ES+) m / z calculated for C29H28F3N7O3579.22, found 580 1.80 min. Example 241: (3-(((1R,4R)-4-(4-Methylpyrimidin-5-yl)cyclohexyl)methyl)-1,2,3-oxadiazol- 3-ium-5-yl)((2-(trifluoromethyl)pyridin-4-yl)carbamoyl)amide. The title compound was obtained as a white powder (8.7 mg, 16%).1H NMR (400 MHz, DMSO- d6) δ 10.17 (s, 1H), 8.85 (s, 1H), 8.58 (s, 1H), 8.47 (d, J = 5.6 Hz, 1H), 8.30 (s, 1H), 8.23 (d, J = 1.9 Hz, 1H), 7.71 (dd, J = 1.9, 5.5 Hz, 1H), 4.58-4.52 (m, 2H), 2.76-2.66 (m, 1H), 2.50 (br s, 3H), 1.88-1.78 (m, 4H), 1.62-1.49 (m, 2H), 1.36 - 1.21 (m, 3H).19F NMR (377 MHz, DMSO-d6) ^ - 66.92 (s, 3F). LCMS (ES+) m / z calculated for C21H22F3N7O2461.44, found 462 (M+H)+. HPLC tR1.40 min. Examples 188 & 190: (3-(4-(3-Methylpyridazin-4-yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)((2- (trifluoromethyl)pyridin-4-yl)carbamoyl)amide & (3-(4-(4-Methoxy-6-methylpyrimidin-5- yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)((2-(trifluoromethyl)pyridin-4-yl)carbamoyl)amide. Scheme 42 Step 1: (3-(4-Bromobenzyl)-1,2,3-oxadiazol-3-ium-5-yl)((2-(trifluoromethyl)pyridin-4- yl)carbamoyl)amide (Intermediate 64) The title compound was prepared following the conditions reported for the synthesis of Example 149 in Step 3 using Intermediate 61 as starting material. The compound was obtained as a yellow powder (190 mg, 62%).1H NMR (400 MHz, DMSO-d6) ^ 10.17 (s, 1H), 8.46 (d, J = 5.6 Hz, 1H), 8.31 (s, 1H), 8.20 (d, J = 1.8 Hz, 1H), 7.70-7.67 (m, 3H), 7.57-7.53 (m, 2H), 5.81 (s, 2H). LCMS (ES+) m / z calculated for C16H11BrF3N5O2441.00, found 440-442 (M-H)-. HPLC 1.81 min. Step 2A: (3-(4-(3-Methylpyridazin-4-yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)((2-(trifluoromethyl)- pyridin-4-yl)carbamoyl)amide (Example 188) A suspension of (3-(4-bromobenzyl)-1,2,3-oxadiazol-3-ium-5-yl)((2-(trifluoromethyl)pyridin-4- yl)carbamoyl)amide (Intermediate 64, 30 mg, 0.07 mmol), 3-methyl-4-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)pyridazine (25.4 mg, 0.12 mmol), Pd(dppf)Cl2 (5 mg, 0.01 mmol) and K3PO4 (43.2 mg, 0.2 mmol) in a mixture of 1,4-dioxane (0.8 mL) and H2O (0.1 mL) was heated at 75 °C for 1h before being diluted with EtOAc and washed with H2O and brine. The organic layer was dried over Na2SO4, filtered, and concentrated in vacuo to get a residue which was purified by flash chromatography on C18 RP (eluting with 0-100% CH3CN in H2O) to get the title compound as a white powder (6.8 mg, 22%).1H NMR (400 MHz, DMSO-d6) ^ 10.18 (s, 1H), 9.20 (s, 1H), 9.07 (s, 1H), 8.46 (d, J = 5.6 Hz, 1H), 8.39 (s, 1H), 8.21 (d, J = 1.9 Hz, 1H), 7.75 (d, J = 8.3 Hz, 2H), 7.69 (dd, J = 5.6, 1.8 Hz, 1H), 7.64 (d, J = 8.3 Hz, 2H), 5.92 (s, 2H), 2.33 (s, 3H).19F NMR (377 MHz, DMSO-d6) ^ -66.92 (s, 3F). LCMS (ES+) m / z calculated for C21H16F3N7O2455.13, found 456 (M+H)+. HPLC tR 1.31 min. Step 2B: (3-(4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)-1,2,3-oxadiazol-3-ium-5- yl)((2-(trifluoromethyl)pyridin-4-yl)carbamoyl)amide (Intermediate 65) A suspension of (3-(4-bromobenzyl)-1,2,3-oxadiazol-3-ium-5-yl)((2-(trifluoromethyl)pyridin-4- yl)carbamoyl)amide (Intermediate 64, 192 mg, 0.43 mmol), bis(pinacolate)diboron (221 mg, 0.87 mmol), Pd(dppf)Cl2 (32mg, 0.04 mmol) and KOAc (128 mg, 1.3 mmol) in 1,4-dioxane (4.0 mL) was heated at 75 °C for 8 h before being diluted with EtOAc and washed with H2O and brine. The organic layer was dried over Na2SO4, filtered, and concentrated in vacuo to get a residue which was purified by flash chromatography (eluting with 0-100% EtOAc in petroleum ether) to get the title compound as an orange powder (112 mg, 53%).1H NMR (400 MHz, DMSO-d6) ^ 10.17 (s, 1H), 8.46 (d, J = 5.6 Hz, 1H), 8.28 (s, 1H), 8.19 (d, J = 1.8 Hz, 1H), 7.75 (d, J = 8.1 Hz, 2H), 7.69 (dd, J = 5.6, 1.9 Hz, 1H), 7.57 (d, J = 8.1 Hz, 2H), 5.86 (s, 2H), 1.30 (s, 12H). LCMS (ES+) m / z calculated for C22H23BF3N5O4489.18, found 490 (M+H)+. HPLC tR 2.02 min. Step 3: (3-(4-(4-Methoxy-6-methylpyrimidin-5-yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)((2- (trifluoromethyl)pyridin-4-yl)carbamoyl)amide (Example 190) The title compound was prepared following the conditions reported for the synthesis of Example 188 in Step 2A using (3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)-1,2,3-oxadiazol- 3-ium-5-yl)((2-(trifluoromethyl)pyridin-4-yl)carbamoyl)amide (Intermediate 65) and 5-bromo-4- methoxy-6-methylpyrimidine as starting materials. The compound was obtained as a white powd...

Claims

CLAIMS 1) A compound of general formula (I):wherein: n is 0, 1 or 2; R1 and R2 are independently selected from H and C1-6alkyl optionally substituted with one or more substituents selected from: hydroxy, OC1-3alkyl, halogen, NH2, NHCOC1-6alkyl, NHCOOC1-6alkyl, NHC(=O)NHC1-6alkyl, NHSO2C1-6alkyl, NHC1-3alkyl, N(C1-3alkyl)2, or a cyclic amine selected from aziridine, azetidine, pyrrolidine, pyperidine, morpholine, piperazine, N- methylpyperazine; or R1 and R2 are linked together to form a C3-10-cycloalkyl ring or a C4-12-heterocycloalkyl ring; R3 is selected from: - saturated or unsaturated C3-10cycloalkyl ring, saturated or unsaturated C3-10cycloheteroalkyl ring, each of said ring being optionally substituted with one or more substituents independently selected from halogen, hydroxy, NH2, NHC1-3alkyl, N(C1- 3alkyl)2, NHC1-3haloalkyl, N(C1-3alkyl)(C1-3haloalkyl), C1-6alkylNH2, C1-6alkylNHC1- 3alkyl, C1-6alkylN(C1-3alkyl)2, C1-6alkylNHC1-3haloalkyl, C1-6alkylC(O)OC1-3alkyl, NHCOC1-6alkyl, NHCOOC1-6alkyl, NHC(=O)NHC1-6alkyl, NHSO2C1-6alkyl, C1-6alkyl, C1-6haloalkyl, C1-6alkylOH, C(O)OH, C(O)OC1-3alkyl, C(O)NH2, C(O)NH(C1-3alkyl), C(O)N(C1-3alkyl)2, optionally substituted aziridine, optionally substituted azetidine, optionally substituted pyrrolidine, optionally substituted pyperidine, optionally substituted morpholine, optionally substituted piperazine, optionally substituted N-methylpyperazine, optionally substituted aryl, optionally substituted heteroaryl wherein each of said optional substituent is selected from halogen, methyl and trifluoromethyl; or - aromatic or heteroaromatic ring optionally substituted with one or more substituents independently selected from halogen, hydroxy, NH2, NHCOC1-6alkyl, NHCOOC1-6alkyl, NHC(=O)NHC1-6alkyl, NHSO2C1-6alkyl, NHC1-3alkyl, N(C1-3alkyl)2, C1-6alkyl, C1-6alkylC(O)OH, C1-6alkylC(O)OC1-3alkyl, hydroxyC1-6alkyl C3-6cycloalkyl, haloC1-6alkyl, C1-6alkoxy, cyano, aryl, heteroaryl wherein said aryl or heteroaryl ring are optionallysubstituted with one or more substituents each independently selected from halogen, hydroxy, cyano, NH2, NHCOC1-6alkyl, NHCOOC1-6alkyl, NHC1-3alkyl, N(C1-3alkyl)2, C3- 6cycloalkyl, aziridine, azetidine, pyrrolidine, pyperidine, morpholine, piperazine, N- methylpyperazine, C1-6alkyl, C1-6alkoxy, wherein said C1-6alkyl, C1-6alkoxy are optionally substituted with one or more halogen, hydroxy, NH2, NHCOCH3, NHCOOC1-6alkyl, NHC1-3alkyl, N(C1-3alkyl)2, aziridine, azetidine, pyrrolidine, pyperidine, morpholine, piperazine and N-methylpyperazine; R4 is selected from: a) a ring of formula (IIa) or (IIb):wherein - R6is selected from NHC(O)R8, N(C1-6alkyl)C(O)R8, NHSO2R8, NH(C1-6alkyl), NH(C1-6haloalkyl), hydroxy-C1-6alkyl, CN, C(O)OC1-6alkyl, C(O)NHR8, C2-6alkynyl, C1- 6alkylNHC(O)R8, C1-6alkylN(C1-6alkyl)C(O)R8, and- R6 is H and R7 is selected from NHC(O)R8, N(C1-6alkyl)C(O)R8, NHSO2R8, NH(C1- 6alkyl), NH(C1-6haloalkyl), hydroxy-C1-6alkyl, CN, C(O)OC1-6alkyl, C(O)NHR8C2-6alkynyl, C1-6alkylNHC(O)R8, C1-6alkylN(C1-6alkyl)C(O)R8, and- R6and R7are H, with the proviso that when R6and R7are H, R3is selected from saturated or unsaturated C3-10cycloalkyl ring, saturated or unsaturated C3-10heterocycloalkyl ring, each of said ring being optionally substituted with halogen, C1-6alkyl, haloC1-6alkyl, halogen, CN, OH, C1-6alkoxy, amine, optionally substituted aryl, optionally substituted heteroaryl; or when R6 and R7 are H, R3 is (4,6-dimethylpyrimidin-5-yl)pyridazin-3-yl; or - R6 is OCH3 or OH and R7 is H, or R6 is H and R7 is OCH3 or C(O)OCH3, or R6 and R7 are joined to form together with the ring of formula (IIa) a 8-(trifluoromethyl)quinoline-6-yl ring, with the proviso that R3 is 4-(4,6-dimethylpyrimidin-5-yl)phenyl;- R8 is C1-6alkyl, C1-6haloalkyl, C1-6alkyl-aryl, C1-6alkyl-heteroaryl, C1-6alkyl-C3- 10cycloalkyl, C1-6alkyl-C3-10heterocycloalkyl, C1-6haloalkyl-aryl, C1-6haloalkyl-heteroaryl, C1-6haloalkyl-C3-10cycloalkyl, C1-6haloalkyl-C3-10heterocycloalkyl, C1-6alkylSO2aryl, C1-6alkylSO2heterocycloalkyl, C2-6alkynyl-aryl, aryl, heteroaryl, C3-10cycloalkyl ring, C3- 10heterocycloalkyl ring, wherein each of said cycloalkyl and heterocycloalkyl ring is saturated or unsaturated and wherein each of said aryl, heteroaryl, cycloalkyl and herocycloalkyl ring is optionally substituted with one or more substituents independently selected from C1-6alkyl, C1-6alkoxy, C3-10cycloalkyl, C3-10heteroycloalkyl, amine, CN, C1- 3alkyl-aryl, C1-3alkyl-heteroaryl, C1-3alkyl-C3-10cycloalkyl, C1-3alkyl-C3-10heterocycloalkyl, C1-6alkylCOOH, C1-6alkylCOOCH3, C1-6alkylCONH2COOH, C(O)OC1-3alkyl, NHC(O)C1-6alkyl, NHC(O)C3-6cycloalkyl, C1-6haloalkyl, halogen, C1- 6alkylamine, OH, optionally substituted C1-3alkylaryl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heteroaryloxy, optionally substituted aryloxy optionally substituted heteroaryl-alkoxy, heterocycloalkoxy, C1- 6alkyl-SO2NH2, C1-6alkyl-OC1-3alkylheteroaryl wherein said heteroaryl is optionally substituted with CH3, halogen or OH; - R9 is C1-6alkyl, halogen, C3-6cycloalkyl or C3-6heterocycloalkyl each of said cycloalkyl or heterocycloalkyl being optionally substituted with C1-3alkyl, haloC1-3alkyl, halogen; b) saturated or unsaturated C3-10cycloalkyl ring, saturated or unsaturated C3-10cycloheteroalkyl ring, each of said ring being optionally substituted with one or more substituents each independently selected from C1-6alkyl, haloC1-6alkyl, halogen, CN, OH, C1-6alkoxy, NHC(O)R8, N(C1-6alkyl)C(O)R8, NHSO2R8, NH(C1-6alkyl), NH(C1-6haloalkyl), hydroxy-C1-6alkyl, C(O)OC1-6alkyl, C(O)NHR8, C2-6alkynyl, C1-6alkylNHC(O)R8, C1-6alkylN(C1-6alkyl)C(O)R8, and; c) a ring of formula (III):wherein R10is CF3, OCH3, t-butyl; and wherein when R4is a ring of formula (III), R3is selected from:- C3-10cycloalkyl ring, C3-10cycloalkenyl ring, C3-10cycloheteroalkyl ring, each of said ring being optionally substituted with halogen, C1-6alkyl, haloC1-6alkyl, halogen, CN, OH, C1- 6alkoxy, amine, optionally substituted aryl, optionally substituted heteroaryl; or - (1-methyl-1,2,3,4-tetrahydroquinolin-2-yl), 2-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl, (3-methylpyridazin-4-yl)phenyl, 4-(4-(trifluoromethyl)pyrimidin-5-yl)phenyl, 4-(4- methoxy-6-methylpyrimidin-5-yl)phenyl, 4-(1,4-dimethyl-1H-pyrazol-5-yl)phenyl, (2- methylthiazol-4-yl)phenyl, (3,5-dimethylisothiazol-4-yl)phenyl, (4-methylpyrimidin-5- yl)phenyl, (1,3-dimethyl-1H-pyrazol-4-yl)phenyl, 4-(4-methyl-1-(oxetan-3-yl)-1H- pyrazol-5yl)phenyl, 4-(4-methyl-1-(oxetan-3-yl)-1H-pyrazol-3-yl)phenyl, 4-(2- methylpyridin-3-yl)phenyl, 4-(2,5-dimethylthiazol-4-yl)phenyl, 4-(2-amino-4- methylpyrimidin-5-yl)phenyl, 4-(2,4-dimethylpyridin-3-yl)phenyl, 4-(pyrimidin-5- yl)phenyl, 4-(1,3,5-trimethyl-1H-pyrazol-4-yl)phenyl, 4-(4,6-dimethylpyrimidin-5- yl)phenyl, 4-(4-Methyl-2-(oxetan-3-yl)pyrazol-3-yl]phenyl); and R5 is H, C1-6alkyl, C1-6haloalkyl or halogen; or a pharmaceutically acceptable salt, tautomer, solvate, or stereoisomer thereof. 2) The compound according to claim 1 wherein: - n is 0 or 1; - R1and R2are H; and / or - R5is H; and / or - R9 is cyclopropyl, methyl-cyclopropyl, trifluoromethyl-cyclopropyl, fluorocyclopropyl, difluorocyclopropyl, oxetane. 3) The compound according to any one of previous claims wherein R3 is phenyl, pyridinyl, pyrazynyl, trifluoromethylphenyl, cyclobutyl, cyclohexyl, pyperidine, oxabicyclo[3.3.1]nonanyl, oxazepanyl, bicyclo[1.1.1]pentanyl, tetrahydroquinolinyl, bicyclo[2.2.1]heptanyl, tetrahydronaphtalenyl, azabicyclo[3.2.1]octane, 2-azaspiro[3.5]nonane, 3-azaspiro[5.5]undecane, wherein each of said ring is optionally substituted with one or more substituents independently selected from optionally substituted heteroaryl, optionally substituted aryl, C1-3alkyl, halogen, hydroxy, isoindoline, NH2, NHCH3, N(CH3)2, N(C1-3alkyl)(haloC1-3alkyl), C1-3alkyl-NH2, C1-3alkyl-N(CH3)2, (1,3-dioxoisoindolin-2-yl)methyl, C1-3alkyl-NHCH3, C1-3alkyl-N(CH3)2, C1-3alkyl-NHC(O)CH3, COOH, C(O)NH2, C(O)NH(C1-3alkyl), C(O)N(C1-3alkyl)2, cycloamino-C(O) C1-3alkyl-C(O)O(C1-3alkyl), C1-3alkyl-OH, C(O)OC1-3alkyl, NHCH2CF3, CH2NHCH2CF3, C1- 3alkyl-OH, haloC1-3alkyl, NH(CO)CF3.4) The compound according to any one of previous claims wherein R4 is a ring of formula (IIa) or (IIb):wherein - R6 is selected from NHC(O)R8, N(C1-3alkyl)C(O)R8, NHSO2R8, NH(C1-3alkyl), NH(C1- 3haloalkyl), hydroxy-C1-3alkyl, CN, C(O)OC1-3alkyl, C(O)NHR8, C2-6alkynyl, C1- 3alkylNHC(O)R8, C1-3alkylN(C1-3alkyl)C(O)R8, and- R6is H and R7is selected from NHC(O)R8, N(C1-3alkyl)C(O)R8, NHSO2R8, NH(C1-3alkyl), NH(C1-3haloalkyl), hydroxy-C1-3alkyl, CN, C(O)OC1-3alkyl, C(O)NHR8C2-6alkynyl, C1-3alkylNHC(O)R8, C1-3alkylN(C1-3alkyl)C(O)R8, and- R6 and R7 are H, with the proviso that when R6 and R7 are H, R3 is selected from saturated or unsaturated C3-10cycloalkyl ring, saturated or unsaturated C3-10heterocycloalkyl ring, each of said ring being optionally substituted with halogen, C1-6alkyl, haloC1-6alkyl, halogen, CN, OH, C1-6alkoxy, amine, optionally substituted aryl, optionally substituted heteroaryl; or when R6 and R7 are H, R3 is (4,6-dimethylpyrimidin-5-yl)pyridazin-3-yl; or - R6is OCH3or OH and R7is H, or R6is H and R7is OCH3or C(O)OCH3, or R6and R7are joined to form together with the ring of formula (IIa) a 8-(trifluoromethyl)quinoline-6-yl ring, with the proviso that R3 is 4-(4,6-dimethylpyrimidin-5-yl)phenyl; - R8is C1-6alkyl, C1-6haloalkyl, C1-6alkyl-aryl, C1-3alkyl-heteroaryl, C1-3alkyl-C3-6cycloalkyl, C1-3alkyl-C3-8heterocycloalkyl, C1-3haloalkyl-aryl, C1-3haloalkyl-heteroaryl, C1-3haloalkyl-C3-6cycloalkyl, C1-3haloalkyl-C3-8heterocycloalkyl, C1-3alkylSO2aryl, C1- 3alkylSO2heterocycloalkyl, C2-6alkynyl-aryl, aryl, heteroaryl, C3-6cycloalkyl ring, C3- 10heterocycloalkyl ring, wherein each of said cycloalkyl and heterocycloalkyl ring is saturated or unsaturated and wherein each of said aryl, heteroaryl, cycloalkyl and herocycloalkyl ring is optionally substituted with one or more substituents independentlyselected from C1-3alkyl, C1-3alkoxy, C3-6cycloalkyl, C3-8heteroycloalkyl, amine, CN, C1- 3alkyl-aryl, C1-3alkyl-heteroaryl, C1-3alkyl-C3-6cycloalkyl, C1-3alkyl-C3-8heterocycloalkyl, C1-3alkylCOOH, C1-3alkylCOOCH3, C1-3alkylCONH2COOH, C(O)OC1-3alkyl, NHC(O)C1-3alkyl, NHC(O)C3-6cycloalkyl, C1-3haloalkyl, halogen, C1-3alkylamine, OH, optionally substituted C1-3alkylaryl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heteroaryloxy, optionally substituted aryloxy optionally substituted heteroaryl-alkoxy, heterocycloalkoxy, C1-3alkyl-SO2NH2, C1-3alkyl-OC1- 3alkylheteroaryl wherein said heteroaryl is optionally substituted with CH3, halogen or OH; or R4is saturated or unsaturated C3-10cycloalkyl ring, saturated or unsaturated C3-10cycloheteroalkyl ring, each of said ring being optionally substituted with one or more substituents each independently selected from C1-6alkyl, haloC1-6alkyl, halogen, CN, OH, C1- 6alkoxy, NHC(O)R8, N(C1-6alkyl)C(O)R8, NHSO2R8, NH(C1-6alkyl), NH(C1-6haloalkyl), hydroxy-C1-6alkyl, C(O)OC1-6alkyl, C(O)NHR8, C2-6alkynyl, C1-6alkylNHC(O)R8, C1-6alkylN(C1-6alkyl)C(O)R8. 5) The compound according to any one of previous claims having formula (Ia), or formula (Ib) or formula (Ic) or formula (Id):Wherein R1, R2, R3, R5, R8and n are as defined in any one of previous claims. 6) A compound of general formula (I) according to claim 1 selected from the following list: - (3-(4-(2-Methoxy-4-methylpyrimidin-5-yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- phenylacetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide- ((3-((Cyclohexylmethyl)sulfonamido)-5-(trifluoromethyl)phenyl)carbamoyl)(3-(4-(2- methoxy-4-methylpyrimidin-5-yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - ((3-Amino-5-(trifluoromethyl)phenyl)-carbamoyl)(3-(4-(2-methoxy-4- methylpyrimidin-5-yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - (3-((5-(2-(Aminomethyl)phenyl)pyridin-2-yl)methyl)-1,2,3-oxadiazol-3-ium-5-yl)((3- (2-phenylacetamido)-5-(trifluoromethyl)phenyl-)carbamoyl)amide - (3-((5-(1-Methyl-1H-imidazol-5-yl)pyridin-2-yl)methyl)-1,2,3-oxadiazol-3-ium-5- yl)((3-(2-phenylacetamido)-5-(trifluoromethyl)-phenyl)carbamoyl)amide - ((3-(2-Phenylacetamido)-5-(trifluoromethyl)-phenyl)carbamoyl)(3-(pyridin-2- ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - ((3-(2-Cyclohexylacetamido)-5-(trifluoro-methyl)phenyl)carbamoyl)(3-(4-(2- methoxy-4-methylpyrimidin-5-yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - (3-(4-(2-Methoxy-4-methylpyrimidin-5-yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(3- phenylpropanamido)-5-(trifluoro-methyl)phenyl)carbamoyl)amide - (3-(4-(2-Methoxy-4-methylpyrimidin-5-yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)((3- ((phenylmethyl)sulfonamido)-5-(trifluoro-methyl)phenyl)carbamoyl)amide - ((3-Acetamido-5-(trifluoromethyl)phenyl)-carbamoyl)(3-(4-(2-methoxy-4- methylpyrimidin-5-yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - (3-((5-Bromopyridin-2-yl)methyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- phenylacetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - (3-((5-(2-Methoxy-4-methylpyrimidin-5-yl)-pyridin-2-yl)methyl)-1,2,3-oxadiazol-3- ium-5-yl)((3-(2-phenylacetamido)-5-(trifluoromethyl)-phenyl)carbamoyl)amide - (3-((5-(Isoindolin-4-yl)pyridin-2-yl)methyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- phenyla-cetamido)-5-(trifluoromethyl)phenyl)carbamoyl)-amide - ((3-Benzamido-5-(trifluoromethyl)phenyl)-carbamoyl)(3-(4-(2-methoxy-4- methylpyrimidin-5-yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - (3-(4-(2-Methoxy-4-methylpyrimidin-5-yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- (4-methoxyphenyl)acetamido)-5-(trifluoromethyl)-phenyl)carbamoyl)amide - ((3-(2-(4-Chlorophenyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)(3-(4-(2- methoxy-4-methylpyrimidin-5-yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - ((3-(Cyclopentanecarboxamido)-5-(trifluoromethyl)phenyl)carbamoyl)(3-(4-(2- methoxy-4-methylpyrimidin-5-yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - (3-(4-(2-Methoxy-4-methylpyrimidin-5-yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- (pyridin-3-yl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide- ((3-(2-(Benzo[d]isoxazol-3-yl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)(3-(4- (2-methoxy-4-methylpyrimidin-5-yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - ((3-(2-(2-Chlorophenyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)(3-(4-(2- methoxy-4-methylpyrimidin-5-yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - ((3-(2-(4-(Aminomethyl)phenyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)(3- (4-(2-methoxy-4-methylpyrimidin-5-yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - (R)-(3-(2-Amino-1-(4-(3,5-dimethylisoxazol-4-yl)phenyl)ethyl)-1,2,3-oxadiazol-3- ium-5-yl)((3-(2-phenylacetamido)-5-(trifluoromethyl)phenyl)-carbamoyl)amide - (S)-(3-(2-Amino-1-(4-(3,5-dimethylisoxazol-4-yl)phenyl)ethyl)-1,2,3-oxadiazol-3- ium-5-yl)((3-(2-phenylacetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - (3-((5-(2-Amino-4-methylpyrimidin-5-yl)pyridin-2-yl)methyl)-1,2,3-oxadiazol-3-ium- 5-yl)((3-(2-phenylacetamido)-5-(trifluoromethyl)-phenyl)carbamoyl)amide - (3-((1R,3R)-3-Aminocyclobutyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- phenylacetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - ((3-(2-(4-(Aminomethyl)phenyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)(3- (pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - (3-Benzyl-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-phenylacetamido)-5- (trifluoromethyl)phenyl)-carbamoyl)amide - ((3-(1H-Benzo[d]imidazole-5-carboxamido)-5-(trifluoromethyl)phenyl)carbamoyl)(3- (pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - 5-(3-(3-(5-(Morpholinomethyl)furan-2-carboxamido)-5- (trifluoromethyl)phenyl)ureido)-3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium - ((3-(3-Phenoxybenzamido)-5-(trifluoromethyl)-phenyl)carbamoyl)(3-(pyridin-2- ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - ((3-(2-Phenylpropanamido)-5-(trifluoromethyl)-phenyl)carbamoyl)(3-(pyridin-2- ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - ((3-(2-(5-Methyl-2-phenyloxazol-4-yl)acetamido)-5-(trifluoromethyl)phenyl)- carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - ((3-(1-Phenyl-1H-pyrazole-5-carboxamido)-5-(trifluoromethyl)phenyl)carbamoyl)(3- (pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - ((3-(1-Benzyl-1H-pyrazole-4-carboxamido)-5-(trifluoromethyl)phenyl)carbamoyl)(3- (pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - ((3-(2-(1H-Pyrrolo[3,2-b]pyridin-3-yl)acetamido)-5-(trifluoromethyl)phenyl)- carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide- ((3-(6-Cyanoimidazo[1,2-a]pyridine-2-carboxamido)-5-(trifluoromethyl)- phenyl)carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - (3-(Pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(4,5,6,7-tetrahydro-1H- indazole-7-carboxamido)-5-(trifluoromethyl)phenyl)-carbamoyl)amide - ((3-(5-Methyl-5,6-dihydro-4H-thieno[2,3-c]pyrrole-2-carboxamido)-5- (trifluoromethyl)phenyl)carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5- yl)amide - ((3-(2-(1-Methyl-1H-pyrazol-3-yl)acetamido)-5- (trifluoromethyl)phenyl)carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5- yl)amide - ((3-(2-(2-Methylthiazol-4-yl)acetamido)-5-(trifluoromethyl)phenyl)-carbamoyl)(3- (pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - ((3-(2-(6-Aminopyridin-3-yl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)(3- (pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - ((3-(2-(Phenylsulfonyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)(3-(pyridin- 2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - ((3-(Isoxazole-3-carboxamido)-5-(trifluoromethyl)-phenyl)carbamoyl)(3-(pyridin-2- ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - ((3-(Pyrazine-2-carboxamido)-5-(trifluoromethyl)-phenyl)carbamoyl)(3-(pyridin-2- ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - ((3-(3-Phenylpropiolamido)-5-(trifluoromethyl)-phenyl)carbamoyl)(3-(pyridin-2- ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - ((3-(Bicyclo[4.2.0]octa-1(6),2,4-triene-7-carboxamido)-5-(trifluoromethyl)phenyl)- carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - ((3-(1-Isopropyl-1H-pyrazole-3-carboxamido)-5- (trifluoromethyl)phenyl)carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5- yl)amide - ((3-(1-Methylazetidine-3-carboxamido)-5-(trifluoromethyl)phenyl)carbamoyl)(3- (pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - ((3-(2-Phenylcyclopropane-1-carboxamido)-5-(trifluoromethyl)phenyl)carbamoyl)(3- (pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - ((3-(3-(Methoxycarbonyl)bicyclo[1.1.1]pentane-1-carboxamido)-5- (trifluoromethyl)phenyl)-carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5- yl)amide- ((3-(3-Carboxybicyclo[1.1.1]pentane-1-carboxamido)-5-(trifluoromethyl)phenyl)- carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - ((3-(Phenethylamino)-5-(trifluoromethyl)-phenyl)carbamoyl)(3-(pyridin-2-ylmethyl)- 1,2,3-oxadiazol-3-ium-5-yl)amide - ((3-(2-Cyclobutylacetamido)-5-(trifluoromethyl)phenyl)carbamoyl)(3-(pyridin-2- ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - (3-((1R3R)-3-(Dimethylamino)cyclobutyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-phenyl- acetamido)-5-(trifluoromethyl)phenyl)-carbamoyl)amide - (3-(4-(Aminomethyl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-phenylacetamido)-5- (trifluoromethyl)phenyl)carbamoyl)amide - ((3-Methyl-5-(2-phenylacetamido)phenyl)-carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3- oxadiazol-3-ium-5-yl)amide - ((3-Chloro-5-(2-phenylacetamido)phenyl)-carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3- oxadiazol-3-ium-5-yl)amide - (3-((1S,4S)-4-(Aminomethyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-phenyl- acetamido)-5-(trifluoromethyl)phenyl)-carbamoyl)amide - (3-((1S,4S)- 4-((1,3-Dioxoisoindolin-2-yl)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium- 5-yl)((3-(2-phenylacetamido)-5-(trifluoromethyl)-phenyl)carbamoyl)amide - (3-((1S,4S)- -4-((Dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3- (2-phenylacetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - (3-((1S,4S)-4-(Acetamidomethyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- phenylacetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - ((3-(2-(Bicyclo[2.1.1]hexan-2-yl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)(3- (pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - ((3-(5,5-Dioxido-6,7-dihydro-4H-pyrazolo[5,1-c][1,4]thiazine-2-carboxamido)-5- (trifluoromethyl)phenyl)carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5- yl)amide - ((3-(2-(2-(Difluoromethyl)-1H-benzo[d]imidazol-1-yl)acetamido)-5- (trifluoromethyl)phenyl)carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5- yl)amide - ((3-(4-Hydroxybicyclo[2.2.1]heptane-1-carboxamido)-5-(trifluoromethyl)phenyl)- carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - ((3-(7-Methyl-2,3-dihydrobenzofuran-3-carboxamido)-5-(trifluoromethyl)phenyl)- carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide- ((3-(3-Benzylcyclobutane-1-carboxamido)-5-(trifluoromethyl)phenyl)carbamoyl)(3- (pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - ((3-((1S,3S)-3-hydroxy-3-(pyridin-2-yl)cyclobutane-1-carboxamido)-5- (trifluoromethyl)phenyl)carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5- yl)amide - ((3-(1-((5-Methylfuran-2-yl)methyl)piperidine-4-carboxamido)-5- (trifluoromethyl)phenyl)-carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5- yl)amide - ((3-(1-(3-Cyano-1H-pyrazol-1-yl)cyclopropane-1-carboxamido)-5- (trifluoromethyl)phenyl)carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5- yl)amide - ((3-(2-((4-Methyl-4H-1,2,4-triazol-3-yl)methoxy)acetamido)-5-(trifluoromethyl)- phenyl)carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - ((3-(3-(Cyclopentyloxy)propanamido)-5-(trifluoromethyl)phenyl)carbamoyl)(3- (pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - ((3-((1S,4R,5R)-4-(3-Methoxyphenyl)-2-oxabicyclo[2.1.1]hexane-5-carboxamido)-5- (trifluoromethyl)phenyl)carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5- yl)amide - ((3-(1-Cyclopropyl-1H-imidazole-5-carboxamido)-5-(trifluoromethyl)phenyl)- carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - ((3-(2,2-Difluoro-3-(pyrrolidin-1-yl)propanamido)-5-(trifluoromethyl)phenyl)- carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - ((3-(1-Cyclopropylazetidine-3-carboxamido)-5-(trifluoromethyl)phenyl)carbamoyl)(3- (pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - (3-(Pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(4-(1- sulfamoylethyl)benzamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - ((3-(2,3-Dihydrofuro[3,2-b]pyridine-5-carboxamido)-5-(trifluoromethyl)phenyl)- carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - (3-(Pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(5,6,7,8- tetrahydroimidazo[1,5-a]pyridine-7-carboxamido)-5-(trifluoromethyl) - phenyl)carbamoyl)amide - ((3-(3,4-Dihydro-1H-pyrrolo[2,1-c][1,4]oxazine-8-carboxamido)-5-(trifluoromethyl)- phenyl)carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide- ((3-(5-(Piperidin-1-ylsulfonyl)pentanamido)-5-(trifluoromethyl)phenyl)carbamoyl)(3- (pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - ((3-(3-(4-Chlorophenoxy)oxetane-3-carboxamido)-5-(trifluoromethyl)phenyl)- carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - ((3-(2,6-Dioxaspiro[4.5]decane-7-carboxamido)-5- (trifluoromethyl)phenyl)carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5- yl)amide - ((3-(3,3-Difluorospiro[3.3]heptane-1-carboxamido)-5-(trifluoromethyl)phenyl)- carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - (3-(Pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-(3-(pyrrolidin-1-yl)oxetan- 3-yl)acetamido)-5-(trifluoromethyl)phenyl) - carbamoyl)amide - (3-(Pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2,4,5,6- tetrahydrocyclopenta[c]pyrrole-1-carboxamido)-5-(trifluoromethyl)phenyl)- carbamoyl)amide - ((3-(4,4-Dioxido-1,4-oxathiane-2-carboxamido)-5- (trifluoromethyl)phenyl)carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5- yl)amide - ((3-Cyclopropyl-5-(2-phenylacetamido)phenyl)-carbamoyl)(3-(pyridin-2-ylmethyl)- 1,2,3-oxadiazol-3-ium-5-yl)amide - ((3-(2-(Benzylamino)-2-oxoethyl)-5-(trifluoromethyl)phenyl)carbamoyl)(3-(pyridin- 2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - (3-((1S,4S)-4-Aminocyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- phenylacetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - (3-((1R,4R)-4-Aminocyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- phenylacetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - (3-((1R,4R)-4-(Aminomethyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-phenyl- acetamido)-5-(trifluoromethyl)phenyl)-carbamoyl)amide - (3-((1R,4R)-4-((Dimethylamino)methyl)-cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3- (2-phenylacetamido)-5-(trifluoromethyl)phenyl)-carbamoyl)amide - (3-((1S,4S)-4-(Dimethylamino)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- phenylacetamido)-5-(trifluoromethyl)phenyl)-carbamoyl)amide - (3-((1R,4R)-4-(dimethylamino)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- phenylacetamido)-5-(trifluoromethyl)phenyl)-carbamoyl)amide- (3-(4-(Methoxycarbonyl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- phenylacetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - ((3-(2-Phenylacetamido)-5-(trifluoromethyl)-phenyl)carbamoyl)(3-(piperidin-4-yl)- 1,2,3-oxadiazol-3-ium-5-yl)amide - (3-(1-Methylpiperidin-4-yl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-phenylacetamido)-5- (trifluoromethyl)phenyl)carbamoyl)amide - (3-(4-Carboxybenzyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-phenylacetamido)-5- (trifluoromethyl)-phenyl)carbamoyl)amide - (3-(4-(Hydroxymethyl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-phenylacetamido)- 5-(trifluoromethyl)phenyl)carbamoyl)amide - (3-(4-(Aminomethyl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-phenylacetamido)-5- (trifluoromethyl)phenyl)carbamoyl)amide - (3-(4-Carbamoylbenzyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-phenylacetamido)-5- (trifluoromethyl)phenyl)carbamoyl)amide - (3-((1-Methylpiperidin-2-yl)methyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- phenylacetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - (3-((1-Methylpiperidin-4-yl)methyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- phenylacetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - (3-(3-((1,3-Dioxoisoindolin-2-yl)methyl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- phenylacetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - (3-(3-(Aminomethyl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-phenylacetamido)-5- (trifluoromethyl)phenyl)carbamoyl)amide - (3-(4-(2-Methoxy-2-oxoethyl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- phenylacetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - ((3-(2-Phenylacetamido)-5-(trifluoromethyl)-phenyl)carbamoyl)(3-(piperidin-3- ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - (3-(4-(2-Hydroxyethyl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-phenylacetamido)- 5-(trifluoromethyl)phenyl)carbamoyl)amide - (3-(9-Amino-3-oxabicyclo[3.3.1]nonan-7-yl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- phenylacetamido)-5-(trifluoromethyl)phenyl)-carbamoyl)amide - (3-((5-(Methoxycarbonyl)pyridin-2-yl)methyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- phenylacetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - (3-(2-(Aminomethyl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-phenylacetamido)-5- (trifluoromethyl)phenyl)carbamoyl)amide- (3-((1,4-Oxazepan-2-yl)methyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-phenylacetamido)- 5-(trifluoromethyl)phenyl)carbamoyl)amide - (3-((5-(Hydroxymethyl)pyridin-2-yl)methyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- phenylacetamido)-5-(trifluoromethyl)phenyl)-carbamoyl)amide - (3-((1-Methylpiperidin-3-yl)methyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- phenylacetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - (3-((3-Aminocyclobutyl)methyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- phenylacetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - (3-((1S,4S)-4-(Aminomethyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-oxo-3- phenyl-pyrrolidin-1-yl)-5-(trifluoromethyl)phenyl)-carbamoyl)amide - ((3-(2-Phenylacetamido)-5-(trifluoromethyl)-phenyl)carbamoyl)(3-(piperidin-4- ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - (3-((5-(Isopropoxycarbonyl)pyridin-2-yl)methyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- phenylacetamido)-5-(trifluoromethyl)phenyl)-carbamoyl)amide - ((3-(2-Oxo-4-phenylpyrrolidin-1-yl)-5-(trifluoromethyl)phenyl)carbamoyl)(3- (pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - ((3-(2-(6-Oxo-1,6-dihydropyridin-3-yl)acetamido)-5-(trifluoromethyl)phenyl)- carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - ((3-(2-(1H-Benzo[d]imidazol-6-yl)acetamido)-5- (trifluoromethyl)phenyl)carbamoyl)(3-(pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5- yl)amide - ((3-(2-Phenylacetamido)-5-(trifluoromethyl)-phenyl)carbamoyl)(3-(piperidin-2- ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - ((3-(2-(1H-Indazol-7-yl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)(3-(pyridin- 2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - ((3-Cyclopropyl-5-(2-phenylacetamido)phenyl)-carbamoyl)(3-((1-methylpiperidin-2- yl)methyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - ((3-Cyclopropyl-5-(2-phenylacetamido)phenyl)-carbamoyl)(3-((5- (methoxycarbonyl)pyridin-2-yl)methyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - ((3-Cyclopropyl-5-(2-phenylacetamido)phenyl)-carbamoyl)(3-((5- (hydroxymethyl)pyridin-2-yl)methyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - ((3-((1R,2R)-2-Methylcyclopropyl)-5-(2-phenylacetamido)phenyl)carbamoyl)(3- (pyridin-2-ylmethyl)-1,2,3-oxadiazol-3-ium-5-yl)amide- (3-(((1S,4S)-4-Aminocyclohexyl)methyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-oxo-3- phenylpyrrolidin-1-yl)-5-(trifluoromethyl)-phenyl)carbamoyl)amide - (3-(((1R,4R)-4-Aminocyclohexyl)methyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-oxo-3- phenylpyrrolidin-1-yl)-5-(trifluoromethyl)-phenyl)carbamoyl)amide - (3-(((1S,4S)-4-(Aminomethyl)cyclohexyl)-methyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- oxo-3-phenylpyrrolidin-1-yl)-5-(trifluoromethyl)-phenyl)carbamoyl)amide - (3-((3-(((5-Hydroxypyridin-2-yl)methyl)amino)-cyclobutyl)methyl)-1,2,3-oxadiazol- 3-ium-5-yl)((3-(2-phenylacetamido)-5-(trifluoromethyl)-phenyl)carbamoyl)amide - ((3-(2-Oxo-3-phenylpyrrolidin-1-yl)-5-(trifluoromethyl)phenyl)carbamoyl)(3- ((1S,4S)-4-(((2,2,2-trifluoroethyl)amino)methyl)-cyclohexyl)-1,2,3-oxadiazol-3-ium- 5-yl)amide - ((3-(2-Oxo-3-phenylpyrrolidin-1-yl)-5-(trifluoromethyl)phenyl)carbamoyl)(3- (((1s,4s)-4-((2,2,2-trifluoroethyl)amino)cyclohexyl)methyl)-1,2,3-oxadiazol-3-ium-5- yl)amide - ((3-(2-Oxo-3-phenylpyrrolidin-1-yl)-5-(trifluoromethyl)phenyl)carbamoyl)(3- (((1R,4R)-4-((2,2,2-trifluoroethyl)amino)-cyclohexyl)methyl)-1,2,3-oxadiazol-3-ium- 5-yl)amide - (3-((1S,4S)-4-((Dimethylamino)methyl)-cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3- (2-oxo-3-phenylpyrrolidin-1-yl)-5-(trifluoromethyl)-phenyl)carbamoyl)amide - ((3-(2-Oxo-3-phenylpyrrolidin-1-yl)-5-(trifluoromethyl)phenyl)carbamoyl)(3- (((1s,4s)-4-(((2,2,2-trifluoroethyl)amino)methyl)cyclohexyl)-methyl)-1,2,3-oxadiazol- 3-ium-5-yl)amide - (3-((1-(2-Ethoxy-2-oxoethyl)piperidin-4-yl)methyl)-1,2,3-oxadiazol-3-ium-5-yl)((3- (2-phenylacetamido)-5-(trifluoromethyl)phenyl)-carbamoyl)amide - (3-((1-(2-Hydroxyethyl)piperidin-4-yl)methyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- phenylacetamido)-5-(trifluoromethyl)phenyl)-carbamoyl)amide - ((3-(2-Phenylacetamido)-5-(trifluoromethyl)-phenyl)carbamoyl)(3-((1-(2,2,2- trifluoroethyl)-piperidin-2-yl)methyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - (3-(((1R,4R)-4-Aminocyclohexyl)methyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-((R)-2-oxo- 3-phenylpyrrolidin-1-yl)-5-(trifluoromethyl)-phenyl)carbamoyl)amide - ((3-((R)-2-Oxo-3-phenylpyrrolidin-1-yl)-5-(trifluoromethyl)phenyl)carbamoyl)(3- (((1r,4r)-4-((2,2,2-trifluoroethyl)amino)cyclohexyl)-methyl)-1,2,3-oxadiazol-3-ium-5- yl)amide- ((3-((R)-2-Oxo-3-phenylpyrrolidin-1-yl)-5-(trifluoromethyl)phenyl)carbamoyl)(3- (((1R,4R)-4-(2,2,2-trifluoroacetamido)cyclohexyl)methyl)-1,2,3-oxadiazol-3-ium-5- yl)amide - (3-(((1R,4R)-4-(Methyl(2,2,2-trifluoroethyl)-amino)cyclohexyl)methyl)-1,2,3- oxadiazol-3-ium-5-yl)((3-((R)-2-oxo-3-phenylpyrrolidin-1-yl)-5- (trifluoromethyl)phenyl)carbamoyl)amide - (3-((1R,4R)-4-((Dimethylamino)methyl)-cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3- (2-phenylacetamido)-5-(trifluoromethyl)phenyl)-carbamoyl)amide - (3-((1R,4R)-4-((Dimethylamino)methyl)-cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3- (2-oxo-3-phenylpyrrolidin-1-yl)-5-(trifluoromethyl)-phenyl)carbamoyl)amide - (3-((5-(4,6-Dimethylpyrimidin-5-yl)pyridin-2-yl)methyl)-1,2,3-oxadiazol-3-ium-5- yl)((3-(2-phenylacetamido)-5-(trifluoromethyl)phenyl)-carbamoyl)amide - ((3-Cyclopropyl-5-(2-(phenylsulfonyl)-acetamido)phenyl)carbamoyl)(3-((1R,4R)-4- ((dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - (3-((1R,4R)-4-((Dimethylamino)methyl)-cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3- (2-(phenylsulfonyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - (3-((1R,4R)-4-((Dimethylamino)methyl)-cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3- (2-(3-methoxyphenyl)acetamido)-5-(trifluoromethyl)-phenyl)carbamoyl)amide - (3-((1R,4R)-4-((Dimethylamino)methyl)-cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3- (2-(2-methoxyphenyl)acetamido)-5-(trifluoromethyl)-phenyl)carbamoyl)amide - ((3-(2-(Benzo[d][1,3]dioxol-5-yl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)(3- ((1R,4R)-4-((dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - ((3-(2-(3-(Carboxymethyl)phenyl)acetamido)-5- (trifluoromethyl)phenyl)carbamoyl)(3-((1R,4R)-4- ((dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - ((3-(2-(4-Carboxyphenyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)(3- ((1R,4R)-4-((dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - (3-((1R,4R)-4-((Dimethylamino)methyl)-cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3- (3-(1-methyl-1H-indol-3-yl)propanamido)-5- (trifluoromethyl)phenyl)carbamoyl)amide - (3-((1R,4R)-4-((Dimethylamino)methyl)-cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3- (3-(pyrazin-2-yl)propanamido)-5-(trifluoromethyl-)phenyl)carbamoyl)amide - ((3-(2-(2-Carboxyphenyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)(3- ((1R,4R)-4-((dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)amide- ((3-(2,2-Difluoro-3-(pyrrolidin-1-yl)propanamido)-5-(trifluoromethyl)phenyl)- carbamoyl)(3-((1R,4R)-4-((dimethylamino)-methyl)cyclohexyl)-1,2,3-oxadiazol-3- ium-5-yl)amide - (3-((1R,4R)-4-((dimethylamino)methyl)-cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3- (2-(1-methyl-1H-indol-3-yl)acetamido)-5-(trifluoro-methyl)phenyl)carbamoyl)amide - ((3-(2-(3-(2-Amino-2-oxoethyl)phenyl)-acetamido)-5-(trifluoromethyl)phenyl)- carbamoyl)(3-((1R,4R)-4-((dimethylamino)-methyl)cyclohexyl)-1,2,3-oxadiazol-3- ium-5-yl)amide - ((3-(2-(3-(Aminomethyl)phenyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)(3- ((1R,4R)-4-((dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - (3-((1R,4R)-4-((Dimethylamino)methyl)-cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3- (2-phenylpropanamido)-5-(trifluoromethyl)phenyl)-carbamoyl)amide - (3-((1R,4R)-4-((Dimethylamino)methyl)-cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3- (2-phenylbutanamido)-5-(trifluoromethyl)phenyl)-carbamoyl)amide - (3-((1R,4R)-4-((Dimethylamino)methyl)-cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3- (trifluoromethyl)-5-(2-(2-(trifluoromethyl)- phenyl)acetamido)phenyl)carbamoyl)amide - (3-((1R,4R)-4-((Dimethylamino)methyl)-cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3- (N-methyl-2-phenylpropanamido)-5-(trifluoro-methyl)phenyl)carbamoyl)amide - ((3-(2-(2-Chlorophenyl)acetamido)-5-(trifluoro-methyl)phenyl)carbamoyl)(3- ((1R,4R)-4-((dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - ((3-(2-(2,3-Difluorophenyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)(3- ((1R,4R)-4-((dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - (3-((1R,4S)-4-((Dimethylamino)methyl)-cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3- ((S)-2-phenylpropanamido)-5-(trifluoromethyl)-phenyl)carbamoyl)amide - (3-((1R,4R)-4-((Dimethylamino)methyl)-cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3- (2-(o-tolyl)acetamido)-5-(trifluoromethyl)phenyl)-carbamoyl)amide - (3-((1R,4R)-4-((Dimethylamino)methyl)-cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3- (N-methyl-2-phenylacetamido)-5-(trifluoromethyl)-phenyl)carbamoyl)amide - (3-((1R,3R)-3-(Dimethylamino)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- phenylacetamido)-5-(trifluoromethyl)phenyl)-carbamoyl)amide - (3-((1R,3S)-3-(Dimethylamino)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- phenyl-acetamido)-5-(trifluoromethyl)phenyl)-carbamoyl)amide- (3-((1R,4R)-4-((Dimethylamino)methyl)-cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3- ((R)-2-phenylpropanamido)-5-(trifluoromethyl)-phenyl)carbamoyl)amide - ((3-(2-(3-Chlorophenyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)(3- ((1R,4R)-4-((dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - (3-((1R,4R)-4-((Dimethylamino)methyl)-cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3- (1,2,3,4-tetrahydronaphthalene-1-carboxamido)-5- (trifluoromethyl)phenyl)carbamoyl)amide - rac-(3-((1-Methyl-1,2,3,4-tetrahydroquinolin-2-yl)methyl)-1,2,3-oxadiazol-3-ium-5- yl)((2-(trifluoromethyl)pyridin-4-yl)carbamoyl)amide - (3-(((1S,4S)-4-(Pyrimidin-5-yl)cyclohexyl)-methyl)-1,2,3-oxadiazol-3-ium-5-yl)((3- (trifluoromethyl)phenyl)carbamoyl)amide - rac-(((3R,5S)-1,1-Difluorospiro[2.4]heptan-5-yl)carbamoyl)(3-((5-(4,6- dimethylpyrimidin-5-yl)pyridin-2-yl)methyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - rac-(3-((2-Methyl-1,2,3,4-tetrahydroisoquinolin -1-yl)methyl)-1,2,3-oxadiazol-3-ium- 5-yl)((2-(trifluoromethyl)pyridin-4-yl)carbamoyl)amide - (3-(((1S,4S)-4-(Pyrimidin-5-yl)cyclohexyl) methyl)-1,2,3-oxadiazol-3-ium-5-yl)((2- (trifluoro methyl)pyridin-4-yl)carbamoyl)amide - (3-((3-(Pyrimidin-5-yl)bicyclo[1.1.1]pentan-1-yl)methyl)-1,2,3-oxadiazol-3-ium-5- yl)((3-(trifluoromethyl)phenyl)carbamoyl)amide - (3-((6-(4,6-Dimethylpyrimidin-5-yl)pyridazin-3-yl)methyl)-1,2,3-oxadiazol-3-ium-5- yl)((3-(trifluoromethyl)phenyl)carbamoyl)amide - (3-((4-(Pyrimidin-5-yl)bicyclo[2.2.1]heptan-1-yl)methyl)-1,2,3-oxadiazol-3-ium-5- yl)((2-(trifluoromethyl)pyridin-4-yl)carbamoyl)amide - (3-(((1R,4R)-4-(Pyrimidin-5-yl)cyclohexyl) methyl)-1,2,3-oxadiazol-3-ium-5-yl)((3- (trifluoro methyl)phenyl)carbamoyl)amide - (3-(((1R,4R)-4-(Pyrimidin-5-yl)cyclohexyl)-methyl)-1,2,3-oxadiazol-3-ium-5-yl)((2- (trifluoromethyl)pyridin-4-yl)carbamoyl)amide - (3-(4-(3-Methylpyridazin-4-yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)((2- (trifluoromethyl)-pyridin-4-yl)carbamoyl)amide - ((2-(Trifluoromethyl)pyridin-4-yl)carbamoyl)(3-(4-(4-(trifluoromethyl)pyrimidin-5- yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - (3-(4-(4-Methoxy-6-methylpyrimidin-5-yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)((2- (trifluoromethyl)pyridin-4-yl)carbamoyl)amide- (3-((1R,4R)-4-((Dimethylamino)methyl)-cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3- (2-(2-hydroxyphenyl)acetamido)-5-(trifluoromethyl)-phenyl)carbamoyl)amide - rac-(3-((2-Methyl-1,2,3,4-tetrahydro isoquinolin-1-yl)methyl)-1,2,3-oxadiazol-3-ium- 5-yl)((3-(2-phenylacetamido)-5-(trifluoromethyl) phenyl)carbamoyl)amide - ((2-(2-(2-Chlorophenyl)acetamido)-6-(trifluoromethyl)pyridin-4-yl)carbamoyl)(3- ((1R,4R)-4-((dimethylamino)methyl)-cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - (3-((1R,4R)-4-((Dimethylamino)methyl)-cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3- (2-fluoro-2-(2-fluorophenyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - ((3-(Bicyclo[4.2.0]octa-1(6),2,4-triene-7-carboxamido)-5-(trifluoromethyl)phenyl)- carbamoyl)(3-((1R,4R)-4-((dimethylamino-methyl)cyclohexyl)-1,2,3-oxadiazol-3- ium-5-yl)amide - (3-((1R,4R)-4-((Dimethylamino)methyl)-cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3- (2-(6-hydroxypyridin-2-yl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - (3-((1R,4R)-4-((Dimethylamino)methyl)-cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3- (2-(3,5-dimethylisoxazol-4-yl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - ((3-(2-(2-Chloro-6-fluorophenyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)(3- ((1R,4R)-4-((dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - ((3-(2-(2,6-Difluorophenyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)(3- ((1R,4R)-4-((dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - Rac-(3-((1,2,3,4-Tetrahydronaphthalen-1-yl)methyl)-1,2,3-oxadiazol-3-ium-5-yl)((2- (trifluoromethyl)pyridin-4-yl)carbamoyl)amide - (3-(4-(1,4-Dimethyl-1H-pyrazol-5-yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)((2- (trifluoromethyl)-pyridin-4-yl)carbamoyl)amide - (3-((1R,3S)-3-(Dimethylamino)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-(o- tolyl)acetamido)-5-(trifluoromethyl)phenyl)-carbamoyl)amide - (3-((1R,2R)-2-Hydroxycyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-(o- tolyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - (3-((1R,3S)-3-(Dimethylamino)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((2- (trifluoromethyl)-pyridin-4-yl)carbamoyl)amide - ((3-(2-(2-Chlorophenyl)propanamido)-5-(trifluoromethyl)phenyl)carbamoyl)(3- ((1R,4R)-4-((dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - (3-((1R,4R)-4-(2-Hydroxypropan-2-yl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- (o-tolyl)acetamido)-5-(trifluoromethyl)phenyl)-carbamoyl)amide- ((4-Cyano-3-(trifluoromethyl)phenyl)-carbamoyl)(3-(4-(4,6-dimethylpyrimidin-5- yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - (3-((1R,4R)-4-((Dimethylamino)methyl)-cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3- (2-methyl-2-phenylpropanamido)-5-(trifluoro-methyl)phenyl)carbamoyl)amide - (3-(4-(4,6-Dimethylpyrimidin-5-yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)((2- methoxypyridin-4-yl)carbamoyl)amide - (3-(4-(2-Methylthiazol-4-yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)((2- (trifluoromethyl)pyridin -4-yl)carbamoyl)amide - (3-(4-(3,5-Dimethylisothiazol-4-yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)((2- (trifluoromethyl)-pyridin-4-yl)carbamoyl)amide - (3-((1R,4R)-4-((Dimethylamino)methyl)-cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3- (2-(2,3-dimethylphenyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - (3-((1S,3R)-3-((Dimethylamino)methyl)-cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3- (2-(o-tolyl)acetamido)-5-(trifluoromethyl)phenyl) carbamoyl)amide - (3-((1R,3S)-3-Hydroxycyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-(o- tolyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - (3-((1R,3R)-3-Hydroxycyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-(o- tolyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - (3-((4-(4,6-Dimethylpyrimidin-5-yl)cyclohex-3-en-1-yl)methyl)-1,2,3-oxadiazol-3- ium-5-yl)((2-(trifluoromethyl)pyridin-4-yl)carbamoyl)amide - (3-(((1R,2R)-2Hydroxycyclohexyl)methyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-(o- tolyl)acetamido)-5-(trifluoromethyl)phenyl)-carbamoyl)amide - (3-(((1S,2R)-2-Hydroxycyclohexyl)methyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-(o- tolyl)acetamido)-5-(trifluoromethyl)phenyl)-carbamoyl)amide - (3-((1S,3S)-3-(Pyrimidin-5-yl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((2- (trifluoromethyl)pyridin -4-yl)carbamoyl)amide - (3-((1S,3R)-3-(Pyrimidin-5-yl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((2- (trifluoromethyl)-pyridin-4-yl)carbamoyl)amide - (3-((1S,3S)-3-(Pyrimidin-5-yl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-(o- tolyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - (3-((1S,3R)-3-(Pyrimidin-5-yl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-(o- tolyl)acetamido)-5-(trifluoromethyl)phenyl)-carbamoyl)amide - (3-((1R,3S)-3-(Methoxycarbonyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-(o- tolyl)acetamido)-5-(trifluoromethyl)phenyl)-carbamoyl)amide- (3-((1R,3R)-3-(Methoxycarbonyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-(o- tolyl)-acetamido)-5-(trifluoromethyl)phenyl)-carbamoyl)amide - (3-(4-(4-Methylpyrimidin-5-yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)((2- (trifluoromethyl)pyridin -4-yl)carbamoyl)amide - ((2-(tert-Butyl)pyridin-4-yl)carbamoyl)(3-(4-(4,6-dimethylpyrimidin-5-yl)benzyl)- 1,2,3-oxadiazol-3-ium-5-yl)amide - (3-((1R,4R)-4-(Methoxycarbonyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-(o- tolyl)-acetamido)-5-(trifluoromethyl)phenyl)carbamoyl) - amide - (3-((1R,4R)-4-(Hydroxymethyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-(o- tolyl)acetamido)-5-(trifluoromethyl)phenyl) carbamoyl)amide - (3-((1R,4R)-4-Carboxycyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-(o- tolyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - (3-((1R)-3-(Hydroxymethyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-(o- tolyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - (3-((1R,3R)-3-(Methylcarbamoyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-(o- tolyl)acetamido)-5-(trifluoromethyl)phenyl)-carbamoyl)amide - (3-((1R,3S)-3-(Methylcarbamoyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-(o- tolyl)acetamido)-5-(trifluoromethyl)phenyl)-carbamoyl)amide - (3-(4-(4,6-Dimethylpyrimidin-5-yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)(((1S,3S)-3- (trifluoromethyl)cyclopentyl)carbamoyl)amide - (3-((1R,3S)-3-(Dimethylcarbamoyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-(o- tolyl)-acetamido)-5-(trifluoromethyl)phenyl)-carbamoyl)amide - (3-((1R,3R)-3-Carbamoylcyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-(o- tolyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - (3-(4-(Pyrimidin-5-yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)((2- (trifluoromethyl)pyridin-4-yl)-carbamoyl)amide - (3-(4-(1,3-Dimethyl-1H-pyrazol-4-yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)((2- (trifluoromethyl)-pyridin-4-yl)carbamoyl)amide - ((4-Cyano-3-(trifluoromethyl)phenyl)-carbamoyl)(3-(4-(1,4-dimethyl-1H-pyrazol-5- yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - (3-((4-(4-Methyl-2-(oxetan-3-yl)pyrazol-3-yl]phenyl)methyl)oxadiazol-3-ium-5-yl)- ((2-(trifluoromethyl)pyridin-4-yl)carbamoyl)-azanide- (3-((1S,2R)-2-Hydroxycyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-(o- tolyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - (3-(((1R,4S)-4-(4-Methylpyrimidin-5-yl)cyclohexyl)methyl)-1,2,3-oxadiazol-3-ium-5- yl)((2-(trifluoromethyl)pyridin-4-yl)carbamoyl)-amide - (3-(4-(1,4-Dimethyl-1H-pyrazol-5-yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)((2- (trifluoromethyl)-pyridin-4-yl)carbamoyl)amide - (3-((1R,4S)-4-((Dimethylamino)methyl)-cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3- ((S)-2-fluoro-2-(2-fluorophenyl)acetamido)-5- (trifluoromethyl)phenyl)carbamoyl)amide - rac-(3-((1R,2S)-2-(Dimethylamino)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-(o- tolyl)acetamido)-5-(trifluoromethyl)phenyl)-carbamoyl)amide - rac-(3-((1R,3S)-3-(Methylcarbamoyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- (o-tolyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - rac-(3-((1S,3R)-3-((Dimethylamino)methyl)-cyclohexyl)-1,2,3-oxadiazol-3-ium-5- yl)((3-(2-(o-tolyl)acetamido)-5-(trifluoromethyl)phenyl)-carbamoyl)amide - rac-(3-((1R,3S)-3-((Dimethylamino)methyl)-cyclohexyl)-1,2,3-oxadiazol-3-ium-5- yl)((3-(2-(o-tolyl)acetamido)-5-(trifluoromethyl)phenyl)-carbamoyl)amide - (3-((1R,4R)-4-(Dimethylcarbamoyl)-cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- (o-tolyl)acetamido)-5-(trifluoromethyl)phenyl)-carbamoyl)amide - (3-(4-(4,6-Dimethylpyrimidin-5-yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)((4-methoxy- 3-(trifluoromethyl)phenyl)carbamoyl)amide - (3-(4-(4-Methyl-1-(oxetan-3-yl)-1H-pyrazol-3-yl)benzyl)-1,2,3-oxadiazol-3-ium-5- yl)((2-(trifluoromethyl)pyridin-4-yl)carbamoyl)amide - rac-(3-((1R,4R)-4-(Methylcarbamoyl)-cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- (o-tolyl)acetamido)-5-(trifluoromethyl)phenyl)-carbamoyl)amide - rac-(3-((1R,3R)-3-(Methylcarbamoyl)-cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- (o-tolyl)-acetamido)-5-(trifluoromethyl)phenyl)-carbamoyl)amide - rac-(3-((1R,3S)-3-(Dimethylcarbamoyl)-cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3- (2-(o-tolyl)-acetamido)-5-(trifluoromethyl)phenyl)-carbamoyl)amide - (3-((1R,4R)-4-(Pyrrolidine-1-carbonyl)-cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3- (2-(o-tolyl)acetamido)-5-(trifluoromethyl)phenyl)-carbamoyl)amide - (3-((1R,3S)-3-Carbamoylcyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-(o- tolyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide- (3-((4-(4,6-Dimethylpyrimidin-5-yl)phenyl)methyl)oxadiazol-3-ium-5-yl)-((rac- (1R,3R)-3-(trifluoromethyl)cyclopentyl)-carbamoyl)azanide - (3-((1R,4R)-4-(Dimethylamino)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-(o- tolyl)-acetamido)-5-(trifluoromethyl)phenyl)-carbamoyl)amide - (3-(4-(2-Methylpyridin-3-yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)((2- (trifluoromethyl)pyridin -4-yl)carbamoyl)amide - (3-(4-(2,5-Dimethylthiazol-4-yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)((2- (trifluoromethyl)pyridin -4-yl)carbamoyl)amide - (3-(4-(2-Amino-4-methylpyrimidin-5-yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)((2- (trifluoromethyl)pyridin-4-yl)carbamoyl)amide - (3-(4-(4,6-Dimethylpyrimidin-5-yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)((4-hydroxy- 3-(trifluoromethyl)phenyl)carbamoyl)amide - (3-(4-(4,6-Dimethylpyrimidin-5-yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)((4-(methoxy- carbonyl)-3-(trifluoromethyl)phenyl)carbamoyl) amide - (3-(4-(2,4-Dimethylpyridin-3-yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)((2- (trifluoromethyl)pyridin -4-yl)carbamoyl)amide - ((4-Acetamido-3-(trifluoromethyl)phenyl)-carbamoyl)(3-(4-(4,6-dimethylpyrimidin-5- yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - (3-(3-(Hydroxymethyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-(o- tolyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - (3-(4-(Pyrimidin-5-yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)((2- (trifluoromethyl)pyridin-4-yl)carbamoyl)amide - (3-((1R,3R)-3-Carbamoylcyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-(o- tolyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - ((2-(Trifluoromethyl)pyridin-4-yl)carbamoyl)(3-(4-(1,3,5-trimethyl-1H-pyrazol-4- yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - (3-(4-(4-Methoxy-6-methylpyrimidin-5-yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)((2- (trifluoromethyl)pyridin-4-yl)carbamoyl)amide - ((2-(Trifluoromethyl)pyridin-4-yl)carbamoyl)(3-(4-(4-(trifluoromethyl)pyrimidin-5- yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - (3-((1R,4R)-4-((Dimethylamino)methyl)-cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3- ((R)-2-fluoro-2-(2-fluorophenyl)acetamido)-5- (trifluoromethyl)phenyl)carbamoyl)amide- (3-(4-(4,6-Dimethylpyrimidin-5-yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)((8- (trifluoromethyl)-quinolin-6-yl)carbamoyl)amide - (3-(4-(4,6-Dimethylpyrimidin-5-yl)benzyl)-1,2,3-oxadiazol-3-ium-5-yl)((4-(methyl- carbamoyl)-3-(trifluoromethyl)phenyl)carbamoyl) amide - (3-(6-methyl-6-azabicyclo[3.2.1]octan-3-yl)-1,2,3-oxadiazol-3-ium-5-yl)((3-((S)-2- phenylpropanamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - (3-((1R,4R)-4-((dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3- (7-hydroxy-2-phenylhept-4-ynamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - ((3-((S)-2-phenylpropanamido)-5-(trifluoromethyl)phenyl)carbamoyl)(3-((1r,4S)-4- (pyrrolidin-1-yl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - (3-(2-methyl-2-azaspiro[4.5]decan-8-yl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-(o- tolyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - (3-((1R,4R)-4-((dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3- ((R)-3-methyl-2-phenylbutanamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - (3-((1R,4S)-4-((dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3- ((S)-3-methyl-2-phenylbutanamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - (3-((1R,4S)-4-(methyl(2,2,2-trifluoroethyl)amino)cyclohexyl)-1,2,3-oxadiazol-3-ium- 5-yl)((3-((S)-2-phenylpropanamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - (S)-(3-(4-(dimethylamino)-4-(trifluoromethyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5- yl)((3-(2-phenylpropanamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - (3-((1S,4R)-4-(3,3-difluoroazetidin-1-yl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3- ((S)-2-phenylpropanamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - (S)-(3-(4-oxocyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-phenylpropanamido)-5- (trifluoromethyl)phenyl)carbamoyl)amide - 3-((1R,3S,4R)-4-(dimethylamino)-3-fluorocyclohexyl)-5-(3-(3-((S)-2- phenylpropanamido)-5-(trifluoromethyl)phenyl)ureido)-1,2,3-oxadiazol-3-ium - ((3-((S)-2-phenylpropanamido)-5-(trifluoromethyl)phenyl)carbamoyl)(3-((1s,4R)-4- ((1,1,1-trifluoropropan-2-yl)amino)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - (3-((1R,2S)-2-(dimethylamino)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-(o- tolyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - (3-((1R,4R)-4-((dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3- (6-hydroxy-2-phenylhex-4-ynamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - 5-(3-(3-((S)-2-phenylpropanamido)-5-(trifluoromethyl)phenyl)ureido)-3-((1r,4S)-4- ((2,2,2-trifluoroethyl)amino)cyclohexyl)-1,2,3-oxadiazol-3-ium- (S)-(3-(2-methyl-2-azaspiro[3.5]nonan-7-yl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- phenylpropanamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - (S)-(3-(1,4-dioxaspiro[4.5]decan-8-yl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- phenylpropanamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - (3-((1R,4R)-4-(dimethylamino)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-(o- tolyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - ((3-((S)-2-phenylpropanamido)-5-(trifluoromethyl)phenyl)carbamoyl)(3-((1r,4S)-4- ((1,1,1-trifluoropropan-2-yl)amino)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - (3-((1R,4R)-4-(pyrrolidin-1-yl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2-(o- tolyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - (3-((1R,4S)-4-morpholinocyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-((S)-2- phenylpropanamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - (S)-(3-(4-(4,4-difluoropiperidin-1-yl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-(2- phenylpropanamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - (3-(4-(methyl(1,1,1-trifluoropropan-2-yl)amino)cyclohexyl)-1,2,3-oxadiazol-3-ium-5- yl)((3-((S)-2-phenylpropanamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - (3-((1R,4R)-4-((dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((4- (2-phenylacetamido)-3-(trifluoromethyl)phenyl)carbamoyl)amide - (3-((1S,4R)-4-(methyl(2,2,2-trifluoroethyl)amino)cyclohexyl)-1,2,3-oxadiazol-3-ium- 5-yl)((3-((S)-2-phenylpropanamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - (3-((1R,4S)-4-(dimethylamino)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-((S)-2- phenylpropanamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - (3-((1R,4R)-4-((dimethylamino)methyl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3- (3-phenyloxetane-3-carboxamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - (3-((1R,4S)-4-(3,3-difluoroazetidin-1-yl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3- ((S)-2-phenylpropanamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - (3-((1R,4S)-4-hydroxycyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)((3-((S)-2- phenylpropanamido)-5-(trifluoromethyl)phenyl)carbamoyl)amide - ((3-(2-fluoro-2-(2-fluorophenyl)acetamido)-5-(trifluoromethyl)phenyl)carbamoyl)(3- ((1r,4r)-4-(2-hydroxypropan-2-yl)cyclohexyl)-1,2,3-oxadiazol-3-ium-5-yl)amide - ((3-((S)-2-fluoro-2-(2-fluorophenyl)acetamido)-5- (trifluoromethyl)phenyl)carbamoyl)(3-((1r,4S)-4-(2-hydroxypropan-2-yl)cyclohexyl)- 1,2,3-oxadiazol-3-ium-5-yl)amide- ((3-((R)-2-fluoro-2-(2-fluorophenyl)acetamido)-5- (trifluoromethyl)phenyl)carbamoyl)(3-((1r,4R)-4-(2-hydroxypropan-2-yl)cyclohexyl)- 1,2,3-oxadiazol-3-ium-5-yl)amide. 7) The compound according to any one of claims 1 to 6 being an inhibitor of NS2B-NS3 protease of a Flavivirus, preferably an inhibitor of the NS2B-NS3 protease of Zika and / or Dengue and / or West Nile and / or Japan Encephalitis virus. 8) The compound according to any one of previous claims for medical use. 9) The compound according to claim 8 for use in treatment and / or prevention of a Flavivirus infection, preferably wherein the Flavivirus is selected from the group consisting of Dengue, West Nile, Zika and Japan Encephalitis virus. 10) A pharmaceutical composition comprising the compound according to any one of claims 1 to 6, either alone or in combination with one further therapeutic agent, and at least one pharmaceutically acceptable excipient. 11) The pharmaceutical composition of claim 10 for use in the treatment and / or prevention of a Flavivirus infection, preferably wherein the Flavivirus is selected from the group consisting of Dengue, West Nile, Zika and Japan Encephalitis virus.

Images